Production of cannabinoids in modified yeast using a fatty acid feedstock

ABSTRACT

Strains of yeasts are provided containing the genes for the production of cannabinoids from fatty acids. The enzymes that mediate cannabinoid production are localized to the cytosol, peroxisome or different compartments within the secretory pathway (e.g., endoplasmic reticulum, Golgi, vacuole) to ensure efficient production. The engineered microorganisms produce cannabinoids in a controlled fermentation process.

INCORPORATION BY REFERENCE TO RELATED APPLICATIONS

Any and all priority claims identified in the Application Data Sheet, orany correction thereto, are hereby incorporated by reference under 37CFR 1.57. This application is a continuation of PCT InternationalApplication No. PCT/US2019/051357, filed Sep. 16, 2019, designating theUnited States and published in English, which claims the benefit of U.S.Provisional Application No. 62/731,978, filed Sep. 17, 2018. and U.S.Provisional Application No. 62/731,980, filed, filed Sep. 17, 2018. Eachof the aforementioned applications is incorporated by reference hereinin its entirety, and each is hereby expressly made a part of thisspecification.

FIELD OF THE INVENTION

Strains of yeasts are provided containing the genes for the productionof cannabinoids from fatty acids. The enzymes that mediate cannabinoidproduction are localized to the cytosol, peroxisome or differentcompartments within the secretory pathway (e.g., endoplasmic reticulum,Golgi, vacuole) to ensure efficient production. The engineeredmicroorganisms produce cannabinoids in a controlled fermentationprocess.

REFERENCE TO SEQUENCE LISTING

This application is filed with an electronic sequence listing entitledLBI00003C1SEQLIST.txt, created on Mar. 3, 2020, which is 490 KB in size.The information in the electronic sequence listing is herebyincorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Microorganisms employ various enzyme-driven biological pathways tosupport their own metabolism and growth. A cell synthesizes nativeproteins, including enzymes, in vivo from deoxyribonucleic acid (DNA).DNA first is transcribed into a complementary ribonucleic acid (RNA)that comprises a ribonucleotide sequence encoding the protein. RNA thendirects translation of the encoded protein by interaction with variouscellular components, such as ribosomes. The resulting enzymesparticipate as biological catalysts in pathways involved in productionof molecules by the organism.

SUMMARY OF THE INVENTION

These pathways can be exploited for the harvesting of the naturallyproduced products. The pathways also can be altered to increaseproduction or to produce different products that may be commerciallyvaluable. Advances in recombinant molecular biology methodology allowresearchers to isolate DNA from one organism and insert it into anotherorganism, thus altering the cellular synthesis of enzymes or otherproteins. Advances in recombinant molecular biology methodology alsoallow endogenous genes, carried in the genomic DNA of a microorganism,to be increased in copy number, thus altering the cellular synthesis ofenzymes or other proteins. Such genetic engineering can change thebiological pathways within the host organism, causing it to produce adesired product.

Microorganic industrial production instead of plant production canincrease the availability of natural products while reducing themanufacturing and environmental cost.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts production of cannabinoids by producing hexanoic acid inthe peroxisome. A fatty acid (FA) enters the peroxisome and is activatedby a fatty acyl-CoA synthetase/fatty acyl activating enzyme (FAA) tobecome a fatty acyl-CoA (FA-CoA). It undergoes multiple rounds of betaoxidation, with each round producing one acetyl-CoA. Eventually, amolecule of hexanoyl-CoA is produced. An acyl-CoA thioesterase (TES)acts on the hexanoyl-CoA to produce hexanoic acid (hexanoate). Thehexanoic acid leaves the peroxisome and is activated by a hexanoyl-CoAsynthetase (HXS) to become hexanoyl-CoA, which is then acted upon by apolyketide synthase (TKS) and olivetolic acid cyclase (OAC) to produceolivetolic acid. A prenyltransferase (PTS) adds a geranyl moiety toolivetolic acid to produce cannabigerolic acid, which is converted toone of several cannabinoids as described in FIG. 4.

FIG. 2 depicts production of cannabinoids by producing olivetolic acidin the peroxisome. A fatty acid (FA) enters the peroxisome and isactivated by a fatty acyl-CoA synthetase/fatty acyl activating enzyme(FAA) to become a fatty acyl-CoA (FA-CoA). It undergoes multiple roundsof beta oxidation, with each round producing one acetyl-CoA. Eventually,a molecule of hexanoyl-CoA is produced, which is then acted upon by apolyketide synthase (TKS) and olivetolic acid cyclase (OAC) to produceolivetolic acid. If necessary, an acetyl-CoA carboxylase (ACC) will belocalized to the peroxisome to produce additional malonyl-CoA. Theolivetolic acid leaves the peroxisome and enters the cytosol. Aprenyltransferase (PTS) adds a geranyl moiety to olivetolic acid toproduce cannabigerolic acid, which is converted to one of severalcannabinoids as described in FIG. 4.

FIG. 3 depicts production of cannabinoids by producing cannabigerolicacid in the peroxisome. A fatty acid (FA) enters the peroxisome and isactivated by a fatty acyl-CoA synthetase/fatty acyl activating enzyme(FAA) to become a fatty acyl-CoA (FA-CoA). It undergoes multiple roundsof beta oxidation, with each round producing one acetyl-CoA. Eventually,a molecule of hexanoyl-CoA is produced, which is then acted upon by apolyketide synthase (TKS) and olivetolic acid cyclase (OAC) to produceolivetolic acid. If necessary, an acetyl-CoA carboxylase (ACC) will belocalized to the peroxisome to produce additional malonyl-CoA. Aprenyltransferase (PTS) adds a geranyl moiety to olivetolic acid toproduce cannabigerolic acid, which is converted to one of severalcannabinoids as described in FIG. 4.

FIG. 4 depicts compartmentalization of enzymes for cannabinoidproduction. Cannabidiolic acid (CBDA) synthase, tetrahydrocannabidiolicacid (THCA) synthase or cannabichromenic acid (CBCA) synthase will belocalized to: A) the cytoplasm, B) the peroxisome, C) compartments ofthe secretory pathway, such as the endoplasmic reticulum (ER) or Golgior D) the vacuole. The enzymes will be localized to differentcompartments through the use of signal sequences.

FIG. 5 provides a map of plasmid pLD1.

FIG. 6 provides a map of plasmid pLD10.

FIG. 7 provides a map of plasmid pLD12.

FIG. 8 provides a map of plasmid pLD14.

FIG. 9 provides a map of plasmid pLD16.

FIG. 10 provides a map of plasmid pLD20.

FIG. 11 provides a map of plasmid pLD22.

FIG. 12 provides a map of plasmid pLD24.

FIG. 13 provides a map of plasmid pLD56.

FIG. 14 provides a map of plasmid pLD87.

FIG. 15 provides a map of plasmid pLD101.

FIG. 16 provides a map of plasmid pLD102.

FIG. 17 provides a map of plasmid pLD111.

FIG. 18 provides a map of plasmid pLD112.

FIG. 19 provides a map of plasmid pLD113.

FIG. 20 provides a map of plasmid pLD125.

FIG. 21 provides a map of plasmid pLD127.

FIG. 22 provides a map of plasmid pLD131.

FIG. 23 provides a map of plasmid pLD132.

FIG. 24 provides a map of plasmid pLD135.

FIG. 25 provides a map of plasmid pLD137.

FIG. 26 provides a map of plasmid pLD138.

FIG. 27 provides a map of plasmid pLD139.

FIG. 28 provides a map of plasmid pLD19.

FIG. 29 provides a map of plasmid pLD26.

FIG. 30 depicts the use of a fatty acid ester where the fatty acid esteris transported to the cytoplasm. In the cytoplasm a native or introducefatty acid esterase cleaves the fatty acid ester to release the fattyacid. This fatty acid is then the substrate for a acyl-CoA synthaseforming the corresponding fatty acid CoA. This fatty acid CoA is thenthe substrate of a polyketide synthase to crease a polyketide.

FIG. 31 depicts the use of a fatty acid ester where the fatty acid esteris cleaved outside of the cell by a native or introduced fatty acidesterase to release the fatty acid. This fatty acid is then transportedinto the cytoplasm where it is the substrate for a acyl-CoA synthaseforming the corresponding fatty acid CoA. This fatty acid CoA is thenthe substrate of a polyketide synthase to crease a polyketide.

DETAILED DESCRIPTION

Cannabis is the dried preparation of the Cannabis sativa plant and hasbeen widely used to treat disease or alleviate disease symptoms. Theflowers of the plant are used to produce Cannabis, but other parts ofthe plant can be used as well. According to some accounts, Cannabis iscomposed of at least 483 known chemical compounds, which includecannabinoids, terpenoids, flavonoids, nitrogenous compounds, aminoacids, proteins, glycoproteins, enzymes, sugars and related compounds,hydrocarbons, alcohols, aldehydes, ketones, acids, fatty acids, esters,lactones, steroids, terpenes, non-cannabinoid phenols, vitamins, andpigments.

The cannabinoids are believed to mediate the medical and recreationalproperties of the plant. Cannabinoids act by binding to cannabinoidreceptors found in the brain to mediate many of the effects of Cannabis.The efficacy of cannabinoids for treating specific ailments is thesubject of ongoing research with either a purified cannabinoid, asynthetic cannabinoid or Cannabis.

For medical applications, the use of a purified cannabinoid is preferredto a mixture of molecules extracted from Cannabis. One option for theproduction of cannabinoids is synthetic biology: the construction ofspecific strains of bacteria, yeast or filamentous fungi that willproduce cannabinoids in a fermentation process. Producing cannabinoidswith a genetically modified organism in fermentation has multipleadvantages.

A fermentation-based process is more controlled and economical than thecurrent process of isolating cannabinoids from Cannabis sativa plants,which requires expensive indoor facilities and cloning of plant strainsunder sterile conditions to ensure consistent distribution ofcannabinoids in the final plant material.

Usually, cannabinoids are extracted from the Cannabis plant as part of acrude mixture, combined with other chemical compounds found in theCannabis plant. Most extractions of Cannabis plant matter aim to extractcannabinoids, particularly tetrahydrocannabinol (THC). THC is useful forrelieving pain, treating glaucoma, and relieving nausea. THC is alsogaining immense popularity as a recreational drug substance. Othercannabinoids of interest include, Cannabigerol (CBG), CannabigerolicAcid (CBGA), Cannabidiol (CBD), Cannabinol (CBN), Cannabichromene (CBC),Tetrahydrocannabivarin (THCV), Cannabigerovarin (CBGV), andCannabigerovarinic Acid (CBGVA).

A variety of growing and cultivating techniques have been developed forincreasing the production of secondary compounds within plants of genusCannabis. These techniques include outdoor cultivation, indoorcultivation, hydroponics, fertilization, atmospheric manipulation,cloning, crossbreeding, Screen of Grow (SCROG), Sea of Green (SOG),pinching, training, topping, etc.

While breeding and farming techniques yield plants with highconcentrations of cannabinoids, these techniques fail to provide thelevel of control and production needed. In addition, the production timeis measured in multiple weeks if not months.

Production of a single cannabinoid by fermentation with a microorganism,will provide the cannabinoid of interest in less complex chemical matrixfacilitating the isolation of purified cannabinoid. This will result inless equipment needed and lower cost of purification. In addition, afermentation-based process timeline will be measured in days and notweeks, allowing production to quickly adapt to changing market needs.Finally, a fermentation-based process footprint will allow production ofcannabinoids in a smaller facility that those required for plant-basedprocess where big greenhouses are required.

Microorganisms

A microorganism selected often is suitable for genetic manipulation andoften can be cultured at cell densities useful for industrial productionof a target fatty dicarboxylic acid product. A microorganism selectedoften can be maintained in a fermentation device.

The term “engineered microorganism” as used herein refers to a modifiedmicroorganism that includes one or more activities distinct from anactivity present in a microorganism utilized as a starting point(hereafter a “host microorganism”). An engineered microorganism includesa heterologous polynucleotide in some embodiments, and in certainembodiments, an engineered organism has been subjected to selectiveconditions that alter an activity, or introduce an activity, relative tothe host microorganism. Thus, an engineered microorganism has beenaltered directly or indirectly by a human being. A host microorganismsometimes is a native microorganism, and at times is a microorganismthat has been engineered to a certain point.

In some embodiments an engineered microorganism is a single cellorganism, often capable of dividing and proliferating. A microorganismcan include one or more of the following features: aerobe, anaerobe,filamentous, non-filamentous, monoploid, dipoid, auxotrophic and/ornon-auxotrophic. In certain embodiments, an engineered microorganism isa prokaryotic microorganism (e.g., bacterium), and in certainembodiments, an engineered microorganism is a non-prokaryoticmicroorganism. In some embodiments, an engineered microorganism is aeukaryotic microorganism (e.g., yeast, fungi, amoeba). In someembodiments, an engineered microorganism is a fungus. In someembodiments, an engineered organism is a yeast.

Any suitable yeast may be selected as a host microorganism, engineeredmicroorganism, genetically modified organism or source for aheterologous or modified polynucleotide. Yeast include, but are notlimited to, Yarrowia yeast (e.g., Y. lipolytica (formerly classified asCandida lipolytica)), Candida yeast (e.g., C. revkaufi, C. viswanathii,C. pulcherrima, C. tropicalis, C. utilis), Rhodotorula yeast (e.g., R.glutinus, R. graminis), Rhodosporidium yeast (e.g., R. toruloides),Saccharomyces yeast (e.g., S. cerevisiae, S. bayanus, S. pastorianus, S.carlsbergensis), Cryptococcus yeast, Trichosporon yeast (e.g., T.pullans, T. cutaneum), Pichia yeast (e.g., P. pastoris) and Lipomycesyeast (e.g., L. starkeyii, L. lipoferus). In some embodiments, asuitable yeast is of the genus Arachniotus, Aspergillus, Aureobasidium,Auxarthron, Blastomyces, Candida, Chrysosporuim, ChrysosporuimDebaryomyces, Coccidiodes, Cryptococcus, Gymnoascus, Hansenula,Histoplasma, Issatchenkia, Kluyveromyces, Lipomyces, Lssatchenkia,Microsporum, Myxotrichum, Myxozyma, Oidiodendron, Pachysolen,Penicillium, Pichia, Rhodosporidium, Rhodotorula, Rhodotorula,Saccharomyces, Schizosaccharomyces, Scopulariopsis, Sepedonium,Trichosporon, or Yarrowia. In some embodiments, a suitable yeast is ofthe species Arachniotus flavoluteus, Aspergillus flavus, Aspergillusfumigatus, Aspergillus niger, Aureobasidium pullulans, Auxarthronthaxteri, Blastomyces dermatitidis, Candida albicans, Candidadubliniensis, Candida famata, Candida glabrata, Candida guilliermondii,Candida kefyr, Candida krusei, Candida lambica, Candida lipolytica,Candida lustitaniae, Candida parapsilosis, Candida pulcherrima, Candidarevkaufi, Candida rugosa, Candida tropicalis, Candida utilis, Candidaviswanathii, Candida xestobii, Chrysosporuim keratinophilum, Coccidiodesimmitis, Cryptococcus albidus var. diffluens, Cryptococcus laurentii,Cryptococcus neofomans, Debaryomyces hansenii, Gymnoascus dugwayensis,Hansenula anomala, Histoplasma capsulatum, Issatchenkia occidentalis,lsstachenkia orientalis, Kluyveromyces lactis, Kluyveromyces marxianus,Kluyveromyces thermotolerans, Kluyveromyces waltii, Lipomyces lipoferus,Lipomyces starkeyii, Microsporum gypseum, Myxotrichum deflexum,Oidiodendron echinulatum, Pachysolen tannophilis, Penicillium notatum,Pichia anomala, Pichia pastoris, Pichia stipitis, Rhodosporidiumtoruloides, Rhodotorula glutinus, Rhodotorula graminis, Saccharomycescerevisiae, Saccharomyces kluyveri, Schizosaccharomyces pombe,Scopulariopsis acremonium, Sepedonium chrysospermum, Trichosporoncutaneum, Trichosporon pullans, Yarrowia lipolytica, or Yarrowialipolytica (formerly classified as Candida lipolytica). In someembodiments, a yeast is a Y. lipolytica strain that includes, but is notlimited to, ATCC20362, ATCC8862, ATCC18944, ATCC20228, ATCC76982 andLGAM S(7)1 strains (Papanikolaou S., and Aggelis G., Bioresour. Technol.82(1):43-9 (2002)). In certain embodiments, a yeast is a Candida species(i.e., Candida spp.) yeast. Any suitable Candida species can be usedand/or genetically modified for production of a fatty dicarboxylic acid(e.g., octanedioic acid, decanedioic acid, dodecanedioic acid,tetradecanedioic acid, hexadecanedioic acid, octadecanedioic acid,eicosanedioic acid). In some embodiments, suitable Candida speciesinclude, but are not limited to Candida albicans, Candida dubliniensis,Candida famata, Candida glabrata, Candida guilliermondii, Candida kefyr,Candida krusei, Candida lambica, Candida lipolytica, Candidalustitaniae, Candida parapsilosis, Candida pulcherrima, Candidarevkaufi, Candida rugosa, Candida tropicalis, Candida utilis, Candidaviswanathii, Candida xestobii and any other Candida spp. yeast describedherein. Non-limiting examples of Candida spp. strains include, but arenot limited to, sAA001 (ATCC20336), sAA002 (ATCC20913), sAA003(ATCC20962), sAA496 (US2012/0077252), sAA106 (US2012/0077252), SU-2(ura3-/ura3-), H5343 (beta oxidation blocked; U.S. Pat. No. 5,648,247)strains. Any suitable strains from Candida spp. yeast may be utilized asparental strains for genetic modification.

Yeast genera, species and strains are often so closely related ingenetic content that they can be difficult to distinguish, classifyand/or name. In some cases, strains of C. lipolytica and Y. lipolyticacan be difficult to distinguish, classify and/or name and can be, insome cases, considered the same organism. In some cases, various strainsof C. tropicalis and C. viswanathii can be difficult to distinguish,classify and/or name (for example see Arie et. al., J. Gen. Appl.Microbiol., 46, 257-262 (2000). Some C. tropicalis and C. viswanathiistrains obtained from ATCC as well as from other commercial or academicsources can be considered equivalent and equally suitable for theembodiments described herein. In some embodiments, some parental stainsof C. tropicalis and C. viswanathii are considered to differ in nameonly.

Any suitable fungus may be selected as a host microorganism, engineeredmicroorganism or source for a heterologous polynucleotide. Non-limitingexamples of fungi include, but are not limited to, Aspergillus fungi(e.g., A. parasiticus, A. nidulans), Thraustochytrium fungi,Schizochytrium fungi and Rhizopus fungi (e.g., R. arrhizus, R. oryzae,R. nigricans). In some embodiments, a fungus is an A. parasiticus strainthat includes, but is not limited to, strain ATCC24690, and in certainembodiments, a fungus is an A. nidulans strain that includes, but is notlimited to, strain ATCC38163.

Any suitable prokaryote may be selected as a host microorganism,engineered microorganism or source for a heterologous polynucleotide. AGram negative or Gram positive bacteria may be selected. Examples ofbacteria include, but are not limited to, Bacillus bacteria (e.g., B.subtilis, B. megaterium), Acinetobacter bacteria, Norcardia bacteria,Xanthobacter bacteria, Escherichia bacteria (e.g., E. coli (e.g.,strains DH10B, Stb12, DH5-alpha, DB3, DB3.1), DB4, DB5, JDP682 andccdA-over (e.g., U.S. application Ser. No. 09/518,188)), Streptomycesbacteria, Erwinia bacteria, Klebsiella bacteria, Serratia bacteria(e.g., S. marcessans), Pseudomonas bacteria (e.g., P. aeruginosa),Salmonella bacteria (e.g., S. typhimurium, S. typhi), Megasphaerabacteria (e.g., Megasphaera elsdenii). Bacteria also include, but arenot limited to, photosynthetic bacteria (e.g., green non-sulfurbacteria, Choroflexus bacteria (e.g., C. aurantiacus), Chloronemabacteria (e.g., C. gigateum)), green sulfur bacteria (e.g., Chlorobiumbacteria (e.g., C. limicola)), Pelodictyon bacteria (e.g., P. luteolum),purple sulfur bacteria (e.g., Chromatium bacteria (e.g., C. okenii)),and purple non-sulfur bacteria (e.g., Rhodospirillum bacteria (e.g., R.rubrum), Rhodobacter bacteria (e.g., R. sphaeroides, R. capsulatus), andRhodomicrobium bacteria (e.g., R. vanellii)).

Cells from non-microbial organisms can be utilized as a hostmicroorganism, engineered microorganism or source for a heterologouspolynucleotide. Examples of such cells, include, but are not limited to,insect cells (e.g., Drosophila (e.g., D. melanogaster), Spodoptera(e.g., S. frugiperda Sf9 or Sf21 cells) and Trichoplusa (e.g., High-Fivecells); nematode cells (e.g., C. elegans cells); avian cells; amphibiancells (e.g., Xenopus laevis cells); reptilian cells; mammalian cells(e.g., NIH3T3, 293, CHO, COS, VERO, C127, BHK, Per-C6, Bowes melanomaand HeLa cells); and plant cells (e.g., Arabidopsis thaliana, Nicotaniatabacum, Cuphea acinifolia, Cuphea aequipetala, Cuphea angustifolia,Cuphea appendiculata, Cuphea avigera, Cuphea avigera var. pulcherrima,Cuphea axilliflora, Cuphea bahiensis, Cuphea baillonis, Cupheabrachypoda, Cuphea bustamanta, Cuphea calcarata, Cuphea calophylla,Cuphea calophylla subsp. mesostemon, Cuphea carthagenensis, Cupheacircaeoides, Cuphea confertiflora, Cuphea cordata, Cuphea crassiflora,Cuphea cyanea, Cuphea decandra, Cuphea denticulata, Cuphea disperma,Cuphea epilobiifolia, Cuphea ericoides, Cuphea flava, Cupheaflavisetula, Cuphea fuchsiifolia, Cuphea gaumeri, Cuphea glutinosa,Cuphea heterophylla, Cuphea hookeriana, Cuphea hyssopifolia(Mexican-heather), Cuphea hyssopoides, Cuphea ignea, Cuphea ingrata,Cuphea jorullensis, Cuphea lanceolata, Cuphea linarioides, CupheaIlavea, Cuphea lophostoma, Cuphea lutea, Cuphea lutescens, Cupheamelanium, Cuphea melvilla, Cuphea micrantha, Cuphea micropetala, Cupheamimuloides, Cuphea nitidula, Cuphea palustris, Cuphea parsonsia, Cupheapascuorum, Cuphea paucipetala, Cuphea procumbens, Cuphea pseudosilene,Cuphea pseudovaccinium, Cuphea pulchra, Cuphea racemosa, Cuphea repens,Cuphea salicifolia, Cuphea salvadorensis, Cuphea schumannii, Cupheasessiliflora, Cuphea sessilifolia, Cuphea setosa, Cuphea spectabilis,Cuphea spermacoce, Cuphea splendida, Cuphea splendida var. viridiflava,Cuphea strigulosa, Cuphea subuligera, Cuphea teleandra, Cupheathymoides, Cuphea tolucana, Cuphea urens, Cuphea utriculosa, Cupheaviscosissima, Cuphea watsoniana, Cuphea wrightii, Cuphea lanceolata)).

Microorganisms or cells used as host organisms or source for aheterologous polynucleotide are commercially available. Microorganismsand cells described herein, and other suitable microorganisms and cellsare available, for example, from Invitrogen Corporation (Carlsbad,Calif.), American Type Culture Collection (Manassas, Va.), andAgricultural Research Culture Collection (NRRL; Peoria, Ill.).

Host microorganisms and engineered microorganisms may be provided in anysuitable form. For example, such microorganisms may be provided inliquid culture or solid culture (e.g., agar-based medium), which may bea primary culture or may have been passaged (e.g., diluted and cultured)one or more times. Microorganisms also may be provided in frozen form ordry form (e.g., lyophilized). Microorganisms may be provided at anysuitable concentration.

Important Pathways for Cannabinoid Production—Beta Oxidation

Cellular fatty acid degradation occurs via the β-oxidation pathway inall organisms. See, e.g., European Published Application No.EP2502932A1. So far it has been established that there are two differentβ-oxidation systems in eukaryotes: the β-oxidation located inmitochondria for mammals and some filamentous fungi and the β-oxidationsystem located in peroxisomes for plants, fungi and animals.

Fatty acid beta-oxidation begins with the addition of coenzyme A to afatty acid, and occurs by successive cycles of reactions during each ofwhich the fatty acid is shortened by a two-carbon fragment removed asacetyl coenzyme A, generating trans-2,3 hydroxyl, and 3-ketointermediates, until only two or three carbons remain (as acetyl-CoA orpropionyl-CoA respectively). The proteins involved in the mitochondrialβ-oxidation and in the peroxisomal β-oxidation are however different.Multifunctional proteins (MFPs) or multifunctional enzymes (MFEs) areinvolved in the peroxisomal β-oxidation pathway, whereas β-oxidationconsists of monofunctional enzymes.

The peroxisomal β-oxidation process begins with oxidation of theacyl-CoA substrate into trans-2-enoyl-CoA by Acyl-CoA oxidase, namelyFox 1p/Pox 1p. It has been demonstrated that Pox 1Δ yeasts are unable togrow on fatty acids as sole carbon atoms. Then the peroxisomalβ-oxidation proceeds from trans-2-enoyl-CoA to 3-ketoacyl-CoA via the(3R)-hydroxyacyl-CoA ester intermediates. In the yeast oxidation system,the second and third reactions of the β-oxidation cycle are catalyzed bythe same enzymes called Mfe2p, Fox2p or again Pox2p, which contains boththe 3-hydroxyacyl-CoA and 2-enoyl-CoA hydratase activities. The2-enoyl-CoA hydratase converts the trans-2-enoyl CoA esters into(3R)-hydroxyacyl-CoA esters, whereas the hydratase 2 produces the3-ketoacyl-CoA. This enzyme was first isolated from Candida tropicalisand comprise a duplicated domain organization in its N-terminal region,which contains two deshydrogenase active domains A and B. Domain A wasdemonstrated to have highest activity with long and medium chainsubstrates, whereas domain B has the highest activity with short-chainsubstrates. The C-terminal region of the Fox2p enzyme contains the2-enoyl-CoA hydratase 2 activity. Hiltunen et al. (JBC, Vol. 267, No.10, Apr. 5, 1992, pp 6646-6653) showed that fatty acid catabolism inyeast was mainly based on the activity of Fox2p and that disruption ofFOX2 resulted in the inability of yeast cells to grow on fatty acids astheir sole carbon source. At the next reaction of the β-oxidation cyclethe ketoacyl-CoA intermediate undergoes thiolytic cleavage by a3-ketoacyl-CoA thiolase, namely Pot1p/Fox3p. The Pot1p/Fox3p is adimeric protein with a subunit size of 45 kDa. A single subunitcomprises three domains: two core domains, and a loop domain of 120residues. The active site of yeast thiolase is shaped by residues fromthe two core domains and surrounded by the loop domain. The products ofthis last step are acetyl-CoA and a C2-shortened acyl-CoA, which acts assubstrate for Pox1 p/Fox1 p for an additional cycle. The acetyl-CoAwhich is produced by peroxisomal beta oxidation is then used in theglyoxilic cycle, thereby allowing the transformation of acetyl-CoA intooxaloacetate. These reactions are catalyzed by two enzymes: isocitratelyase (Ic11p) and malate synthase (M1s1p) which permits the use of twocarbon atoms such as acetate, in the neoglucogenese.

Cannabinoid Production

Acyl-CoA oxidase (EC 1.3.3.6) is the first reported enzyme of the fattyacid β-oxidation pathway. See, e.g., U.S. Pat. No. 6,518,488. Thisenzyme catalyzes the desaturation of acyl-CoAs longer than eight carbonsto 2-trans-enoyl-CoAs, by donating electrons directly to molecularoxygen and releasing H₂O₂ (Lazarow et al., 1976). There are multipleisozymes of acyl-CoA oxidase and these isozymes show specificity towardsshort, medium and long chain fatty acyl-CoAs (Hooks et al., Biochem J.,320:607-614 (1996); Hooks et al., Plant J., 20:1-13 (1999)). Forexample, Arabidopsis thaliana acyl-CoA oxidase isoform 1 (ACX1) hasoptimal activity on an acyl-CoA substrate that is fourteen carbons longand minimal activity on substrates shorter than six carbons. However,ACX2 has optimal activity on an acyl-CoA substrate that is eighteencarbons long and minimal activity on substrates shorter than tencarbons. In Y. lipolytica, there are five acyl-CoA oxidase isoforms thathave different activities on acyl-CoA substrates of different lengths.For example, the protein encoded by POX3 has maximal activity on C6 andC8 acyl-CoA substrates.

Cannabinoids have their biosynthetic origins in both polyketide andterpenoid metabolism and are termed terpenophenolics or prenylatedpolyketides (See, e.g., US Patent Publication No. US20190169661; PageJ., Nagel J. (2006) Biosynthesis of terpenophenolics in hop andCannabis. In J T Romeo, ed, Integrative Plant Biochemistry, Vol. 40.Elsevier, Oxford, pp 179-210).

Polyketides represent a large family of diverse compounds ultimatelysynthesized from 2-carbon units through a series of Claisen-typecondensations and subsequent modifications. See, e.g., US PatentPublication No. US20050032176. Members of this group include antibioticssuch as tetracyclines, anticancer agents such as daunomycin, andimmunosuppressants such as FK506 and rapamycin. Polyketides occur inmany types of organisms including fungi and mycelial bacteria, inparticular, the actinomycetes.

The structural diversity of polyketides is achieved through the seriesof reactions catalyzed by polyketide synthases (PKS), with features thatcontribute to diversity including the selection of various starter andextender units, final chain length, cyclization, degree of reduction,and the like. See, e.g., US20120122180. Downstream reactions such asglycosylation, hydroxylation, halogenation, prenylation, acylation, andalkylation can add additional diversity to the resulting products. Thisgroup of enzymatically active proteins is considered in a differentcategory from the fatty acid synthases which also catalyze condensationof 2-carbon units to result in, for example, fatty acids andprostaglandins. Two major types of PKS are known which are vastlydifferent in their construction and mode of synthesis. These arecommonly referred to as Type I or “modular” and Type II, “aromatic.”

There is a third class of PKS enzymes, the Type III PKS synthases, whichconsist of a small homodimer containing one active site where both chainextension and cyclization take place (See. e.g., US20190078098; Austin,M. B. and J. P. Noel. Natural Product Reports, 2002.20(1): p. 79-110;Lim, Y., et al. Molecules, 2016.21(6): p. 806; Yu, D., et al. IUBMBLife, 2012. 64(4): p. 285-295). Type III PKSs are able to produce a widediversity of polyketide products by using a variety of larger,CoA-containing precursors as a starting unit. These starters range fromsmall aliphatic molecules, such as acetyl-CoA, to larger ring-containingcompounds derived from the phenylpropanoid pathway, such as4-coumaroyl-CoA. Often, these CoA molecules are formed through thefunction of acid CoA ligases that convert carboxylic acids intocorresponding CoA molecules.

Cannabinoid biosynthesis occurs primarily in glandular trichomes thatcover female flowers at a high density. See, e.g., US20190169661.Cannabinoids are formed by a three-step biosynthetic process: polyketideformation, aromatic prenylation and cyclization (see FIG. 1).

The first enzymatic step in cannabinoid biosynthesis is the formation ofolivetolic acid by a putative polyketide synthase enzyme that catalyzesthe condensation of hexanoyl coenzyme A (CoA) and malonyl CoA. A TypeIII polyketide synthase, termed “olivetol synthase” and referred toherein as polyketide synthase/olivetol synthase (CsPKS/olivetolsynthase), from Cannabis sativa has recently been shown to form olivetoland several pyrone products but not olivetolic acid (Taura F, Tanaka S,Taguchi C, Fukamizu T, Tanaka H, Shoyama Y, Morimoto, S. (2009)Characterization of olivetol synthase, Type III a polyketide synthaseputatively involved in cannabinoid biosynthetic pathway. FEBS Lett. 583:2061-2066). The nucleotide sequence of the gene encoding CsPKS/olivetolsynthase is found in GenBank under accession number AB164375 with thepolypeptide as accession BAG14339. The aforementioned products includethe pyrones hexanoytriacetic lactone (HTAL) and pentyldiacetic lactone(PDAL). The reason for the inability of this enzyme to form olivetolicacid, which is clearly a pathway intermediate based on the carboxylatestructure of the cannabinoids, is not known. The lack of olivetolic acidformation by this polyketide synthase from Cannabis was confirmed by theinventors, as further described herein and also by Marks et al. (Marks MD, Tian L, Wenger J P, Omburo S N, Soto-Fuentes W, He J, Gang D R,Weiblen G D, Dixon R A. (2009) Identification of candidate genesaffecting Delta9-tetrahydrocannabinol biosynthesis in Cannabis sativa. JExp Bot. 60, 3715-3726).

The second enzymatic step is the prenylation of olivetolic acid to formcannabigerolic acid (CBGA) by the enzymegeranylpyrophosphate:olivetolate geranyltransferase. This enzyme is anaromatic prenyltransferase and is the subject of commonly owned U.S.Provisional patent applications U.S. Ser. No. 61/272,057 filed Aug. 12,2009 and U.S. Ser. No. 61/272,117 filed Aug. 18, 2009. CBGA is a centralbranch-point intermediate for the biosynthesis of the different classesof cannabinoids. Cyclization of CBGA yields Δ9-tetrahydrocannabinolicacid (THCA) or its isomers cannabidiolic acid (CBDA) or cannabichromenicacid (CBCA) (see FIG. 1). The Shoyama group has previously published theidentification and purification of the three enzymes responsible forthese cyclizations (Morimoto S, Komatsu K, Taura F, Shoyama, Y. (1998)Purification and characterization of cannabichromenic acid synthase fromCannabis sativa. Phytochemistry. 49: 1525-1529; Taura F, Morimoto S,Shoyama Y. (1996) Purification and characterization ofcannabidiolic-acid synthase from Cannabis sativa L. Biochemical analysisof a novel enzyme that catalyzes the oxidocyclization of cannabigerolicacid to cannabidiolic acid. J Biol Chem. 271: 17411-17416; and Taura F,Morimoto S, Shoyama Y, Mechoulam R. (1995) First direct evidence for themechanism of 1-tetrahydrocannabinolic acid biosynthesis. J Am Chem Soc.117: 9766-9767). Cloning of THCA and CBDA synthases has also beenpreviously published (Sirikantaramas S, Taura F, Tanaka Y, Ishikawa Y,Morimoto S, Shoyama Y. (2005) Tetrahydrocannabinolic acid synthase, theenzyme controlling marijuana psychoactivity, is secreted into thestorage cavity of the glandular trichomes. Plant Cell Physiol. 46:1578-1582; Taura F, Sirikantaramas S, Shoyama Y, Yoshikai K, Shoyama Y,Morimoto S. (2007) Cannabidiolic-acid synthase, thechemotype-determining enzyme in the fiber-type Cannabis sativa. FEBSLett. 581: 2929-2934. The genes for THCA synthase and CBDA synthase havebeen reported in Japan (Japanese Patent Publication 2000-078979;Japanese Patent Publication 2001-029082).

Beta-Oxidation Activities

The term “beta oxidation pathway” as used herein, refers to a series ofenzymatic activities utilized to metabolize fatty alcohols, fatty acids,or dicarboxylic acids. The activities utilized to metabolize fattyalcohols, fatty acids, or dicarboxylic acids include, but are notlimited to, acyl-CoA ligase activity, acyl-CoA oxidase activity,acyl-CoA hydrolase activity, acyl-CoA thioesterase activity, enoyl-CoAhydratase activity, 3-hydroxyacyl-CoA dehydrogenase activity andacetyl-CoA C-acyltransferase activity. The term “beta oxidationactivity” refers to any of the activities in the beta oxidation pathwayutilized to metabolize fatty alcohols, fatty acids or dicarboxylicacids.

Beta-Oxidation—Acyl-CoA Ligase

An acyl-CoA ligase enzyme sometimes is encoded by the host organism andcan be added to generate an engineered organism. In some embodiments,host acyl-CoA ligase activity can be increased by increasing the numberof copies of an acyl-CoA ligase gene, by increasing the activity of apromoter that regulates transcription of an acyl-CoA ligase gene, or byincreasing the number copies of the gene and by increasing the activityof a promoter that regulates transcription of the gene, therebyincreasing production of target due to increased carbon flux through thepathway. In certain embodiments, the acyl-CoA ligase gene can beisolated from any suitable organism. Non-limiting examples of organismsthat include, or can be used as donors for, acyl-CoA ligase enzymesinclude Arxula, Candida, Saccharomyces, or Yarrowia.

Beta-Oxidation—Enoyl-CoA Hydratase

An enoyl-CoA hydratase enzyme catalyzes the addition of a hydroxyl groupand a proton to the unsaturated β-carbon on a fatty-acyl CoA andsometimes is encoded by the host organism and sometimes can be added togenerate an engineered organism. In certain embodiments, the enoyl-CoAhydratase activity is unchanged in a host or engineered organism. Insome embodiments, the host enoyl-CoA hydratase activity can be increasedby increasing the number of copies of an enoyl-CoA hydratase gene, byincreasing the activity of a promoter that regulates transcription of anenoyl-CoA hydratase gene, or by increasing the number copies of the geneand by increasing the activity of a promoter that regulatestranscription of the gene, thereby increasing the production of targetproduct (due to increased carbon flux through the pathway. In certainembodiments, the enoyl-CoA hydratase gene can be isolated from anysuitable organism. Non-limiting examples of organisms that include, orcan be used as donors for, enoyl-CoA hydratase enzymes include Arxula,Candida, Saccharomyces, or Yarrowia.

Beta-Oxidation—3-Hydroxyacyl-CoA Dehydrogenase

3-hydroxyacyl-CoA dehydrogenase enzyme catalyzes the formation of a3-ketoacyl-CoA by removal of a hydrogen from the newly formed hydroxylgroup created by the activity of enoyl-CoA hydratase. In someembodiments, the activity is encoded by the host organism and sometimescan be added or increased to generate an engineered organism. In certainembodiments, the 3-hydroxyacyl-CoA activity is unchanged in a host orengineered organism. In some embodiments, the host 3-hydroxyacyl-CoAdehydrogenase activity can be increased by increasing the number ofcopies of a 3-hydroxyacyl-CoA dehydrogenase gene, by increasing theactivity of a promoter that regulates transcription of a3-hydroxyacyl-CoA dehydrogenase gene, or by increasing the number copiesof the gene and by increasing the activity of a promoter that regulatestranscription of the gene, thereby increasing production of targetproduct (e.g., sebacic or dodecanedioic acid) due to increased carbonflux through the pathway. In certain embodiments, the 3-hydroxyacyl-CoAdehydrogenase gene can be isolated from any suitable organism.Non-limiting examples of organisms that include, or can be used asdonors for, 3-hydroxyacyl-CoA dehydrogenase enzymes include Arxula,Candida, Saccharomyces, or Yarrowia.

Beta-Oxidation—Acetyl-CoA C-Acyltransferase

An Acetyl-CoA C-acyltransferase (e.g., beta-ketothiolase) enzymecatalyzes the formation of a fatty acyl-CoA shortened by 2 carbons bycleavage of the 3-ketoacyl-CoA by the thiol group of another molecule ofCoA. The thiol is inserted between C-2 and C-3, which yields an acetylCoA molecule and an acyl CoA molecule that is two carbons shorter. AnAcetyl-CoA C-acyltransferase sometimes is encoded by the host organismand sometimes can be added to generate an engineered organism. Incertain embodiments, the acetyl-CoA C-acyltransferase activity isunchanged in a host or engineered organism. In some embodiments, thehost acetyl-CoA C-acyltransferase activity can be increased byincreasing the number of copies of an acetyl-CoA C-acyltransferase gene,or by increasing the activity of a promoter that regulates transcriptionof an acetyl-CoA C-acyltransferase gene, thereby increasing theproduction of target product due to increased carbon flux through thepathway. In certain embodiments, the acetyl-CoA C-acyltransferase genecan be isolated from any suitable organism. Non-limiting examples oforganisms that include, or can be used as donors for, acetyl-CoAC-acyltransferase enzymes include Arxula, Candida, Saccharomyces, orYarrowia.

Altered Activities and Engineering Pathways

In one embodiment, which is represented by FIG. 1, the microorganism isengineered to consume fatty acids through peroxisomal beta-oxidation byinsertion of a gene encoding an acyl-CoA oxidase. The acyl-CoA oxidaseis targeted to the peroxisome by the addition of a peroxisomal targetingsequence (PTS) to the carboxyl-terminus to the protein. A PTS sequencecan be GRRAKL or a smaller subset of those amino acids based on theconsensus sequence [S/A/H/C/E/P/Q/V]-[K/R/H/QHL/F]. Alternatively, amicroorganism that naturally consumes fatty acids can be used. Themicroorganism will be constructed to express a hexanoate-acyl activatingenzyme (HXS), an olivetol synthase (TKS), an olivetol cyclase (OAC), acannabigerolic acid synthase (PTS), and either a cannabidiolic synthase(CBDAS) to produce cannabidiolic acid, a tetrahydrocannabinolic acidsynthase (THCAS) to produce tetrahydrocannabinolic acid, or acannabichromenic acid synthase (CBCAS) to produce cannabichromenic acid.The CBDAS, THCAS or CBCAS may be localized to either the cytosol, theperoxisome, a secretory traffic compartment such as the ER or Golgi orthe vacuole through the use of signal sequences as described in FIG. 4.Other genetic manipulations may be performed that are known to increasethe carbon flux into the isoprenoid pathway.

In one embodiment, which is represented by FIG. 2, the microorganism isengineered to consume fatty acids through peroxisomal beta-oxidation byinsertion of a gene encoding an acyl-CoA oxidase. The acyl-CoA oxidaseis targeted to the peroxisome by the addition of a peroxisomal targetingsequence (PTS) to the carboxyl-terminus of the protein. A PTS sequencecan be GRRAKL or a smaller subset of those amino acids based on theconsensus sequence [S/A/H/C/E/P/Q/V]-[K/R/H/QHL/F]. Alternatively, amicroorganism that naturally consumes fatty acids can be used. Themicroorganism will be constructed to express an olivetol synthase (TKS),an olivetol cyclase (OAC), a cannabigerolic acid synthase (PTS), andeither a cannabidiolic synthase (CBDAS) to produce cannabidiolic acid, atetrahydrocannabinolic acid synthase (THCAS) to producetetrahydrocannabinolic acid, or a cannabichromenic acid synthase (CBCAS)to produce cannabichromenic acid. The TKS and OAC enzymes will betargeted to the peroxisome by the addition of a PTS sequence, such asGRRAKL or a smaller subset of those amino acids based on the consensussequence of [S/A/H/C/E/P/Q/V]-[K/R/H/QHL/F], which will be added to thecarboxyl terminus of the proteins. An alternative mechanism of targetingto the peroxisome is the use of a PTS2 sequence near the N-terminus ofthe protein, which is defined by the consensus sequence-(R/K)(L/V/I/Q)XX(L/V/I/H/Q)(L/S/G/A/K)X(H/Q)(L/A/F)-. An example couldbe RRMLSSKQL as found in Pcd1p from S. cerevisiae. The CBDAS, THCAS orCBCAS may be localized to either the cytosol, the peroxisome, asecretory traffic compartment such as the ER or Golgi or the vacuolethrough the use of signal sequences as described in FIG. 4. Othergenetic manipulations may be performed that are known to increase thecarbon flux into the isoprenoid pathway.

In one embodiment, which is represented by FIG. 3, the microorganism isengineered to consume fatty acids through peroxisomal beta-oxidation byinsertion of a gene encoding an acyl-CoA oxidase. The acyl-CoA oxidaseis targeted to the peroxisome by the addition of a peroxisomal targetingsequence (PTS) to the carboxyl-terminus of the protein. A PTS sequencecan be GRRAKL or a smaller subset of those amino acids based on theconsensus sequence of [S/A/H/C/E/P/Q/V]-[K/R/H/QHL/F]. Alternatively, amicroorganism that naturally consumes fatty acids can be used. Themicroorganism will be constructed to express an olivetol synthase (TKS),an olivetol cyclase (OAC), a cannabigerolic acid synthase (PTS), andeither a cannabidiolic synthase (CBDAS) to produce cannabidiolic acid, atetrahydrocannabinolic acid synthase (THCAS) to producetetrahydrocannabinolic acid, or a cannabichromenic acid synthase (CBCAS)to produce cannabichromenic acid. The TKS, OAC and PTS enzymes will betargeted to the peroxisome by the addition of a PTS sequence, such asGRRAKL or a smaller subset of those amino acids based on the consensussequence of [S/A/H/C/E/P/Q/V]-[K/R/H/QHL/F], which will be added to thecarboxyl terminus of the proteins. An alternative mechanism of targetingto the peroxisome is the use of a PTS2 sequence near the N-terminus ofthe protein, which is defined by the consensus sequence-(R/K)(L/V/I/Q)XX(L/V/I/H/Q)(L/S/G/A/K)X(H/Q)(L/A/F)-. An example couldbe RRMLSSKQL as found in Pcd1p from S. cerevisiae. If necessary, anacetyl-CoA carboxylase will be expressed and targeted to the peroxisomethrough a PTS1 or PTS2. The CBDAS, THCAS or CBCAS may be localized toeither the cytosol, the peroxisome, a secretory traffic compartment suchas the ER or Golgi or the vacuole through the use of signal sequences asdescribed in FIG. 4. Other genetic manipulations may be performed thatare known to increase the carbon flux into the isoprenoid pathway.

In one embodiment, which is represented by “A” of FIG. 4, the THCAsynthase, CBDA synthase or CBCA synthase enzyme is expressed in thecytoplasm or cytosol as the native form of the enzyme.

In one embodiment, which is represented by “B” of FIG. 4, the THCAsynthase, CBDA synthase or CBCA synthase enzyme is targeted to thevacuole by the addition of a KFERQ motif to the enzyme or the additionof an N-terminal QRPL motif found on carboxypeptidase Y fromSaccharomyces cerevisiae. An alternative vacuolar targeting sequence isthe hydrophobic 22 amino acid signal sequence, or pre sequence(MFSLKALLPLALLLVSANQVAA) (SEQ ID NO: 1), and 54 amino acid propeptide(KVHKAKIYKHELSDEMKEVTFEQHLAHLGQKYLTQFEKANPEVVFSREHPFFTE) (SEQ ID NO: 2)of pre-pro Proteinase A from Saccharomyces cerevisiae or of theparticular yeast that will be engineered for cannabinoid production.Deletions in proteinases, such as PEP4, may be performed to ensure thetargeted enzyme is not degraded in the vacuole.

In one embodiment, which is represented by “C” of FIG. 4, the THCAsynthase, CBDA synthase or CBCA synthase enzyme is targeted to theendoplasmic reticulum (ER), Golgi or generally to the secretory pathwayby the addition of some or all of the pre-pro region of alpha-factorfrom Saccharomyces cerevisiae or the Ost1p signal sequence fromSaccharomyces cerevisiae. The alpha-factor or Ost1p secretion signalfrom the non-conventional yeast that will be engineered will beidentified and considered as well. Other possible secretion signalsinclude the 22 amino acid pre sequence of Proteinase A fromSaccharomyces cerevisiae, MVRMVPVLLSLLLLLGPA (SEQ ID NO: 3) from humanzinc-binding alpha-2-glycoprotein, MLFSNTLLIAAASALLAEA (SEQ ID NO: 4)from Kluyveromyces marxianus polygalacturonase, and MKFGVLFSVFAAIVSALPA(SEQ ID NO: 5) from Saccharomycopsis fibuligera glucoamylase. An HDELmotif can be added to the C-terminus of a protein to ensure retention inthe ER.

In one embodiment, which is represented by “D” FIG. 4, the THCAsynthase, CBDA synthase or CBCA synthase enzyme is targeted to theperoxisome by the addition of some or all of the PTS sequence GRRAKL(SEQ ID NO: 6) or a smaller subset of those amino acids based on theconsensus sequence of [S/A/H/C/E/P/Q/V]-[K/R/H/QHL/F] (SEQ ID NO: 7) tothe C-terminus of each protein. An alternative mechanism of targeting tothe peroxisome is the use of a PTS2 sequence near the N-terminus of theprotein, which is defined by the consensus sequence-(R/K)(L/V/I/Q)XX(L/V/I/H/Q)(L/S/G/A/K)X(H/Q)(L/A/F)- (SEQ ID NO: 8). Anexample could be RRMLSSKQL (SEQ ID NO: 9) as found in Pcd1p from S.cerevisiae.

One of the intermediates for the production of some polyketides a fattyis acid. For example, an intermediate for cannabinoids is hexanoic acid.This six-carbon liner carboxylic acid is toxic to yeast at lowconcentration. This lipophilic weak acid crosses the plasma membrane bypassive diffusion and dissociate in the neutral cytosol leading to adecrease in the intracellular pH and accumulating. This cause inhibitionof growth and death. For example, at pH 5, the specific growth ofSaccharomyces cerevisiae in minimum media drops from 0.4 hr-1 to 0.22hr-1 at a hexanoic concentration of 2 mm (0.3 g/L). The inhibition andtoxicity of hexanoic acid and some other short fatty acids makes it achallenge to run a fermentation with it. The fermentation will need tobe run in a fed batch form adding hexanoic acid at a very low rate toavoid accumulating and causing toxicity. The fermentation will be neededto run at a higher pH where the toxicity of fatty acids are less. Thiswill make the fermentation more prone to contamination. Some short fattyacids such as hexanoic acid can be corrosive to metals so specialmetallurgy needs to be used for the piping of the feedstock.

Herein, also disclosed is the use of fatty acid esters for theproduction of polyketides by fermentation. Some suitable fatty acidesters include methyl, ethyl, butyl, allyl, isobutyl, hexyl, propyl, andgeranyl fatty acid esters. Of special interest are ethyl esters, as theethyl group can be used to produce acetyl coA as a carbon source, andgeraryl caproate as it will provide two intermediates for thecannabinoid pathway. In addition, this process may require theexpression of an esterase to slowly cleave the fatty acid ester if thereis not an endogenous esterase being produced.

In one embodiment as illustrated in FIG. 30 for the production of thepolyketides, a strain from yeast that had been modified to producepolyketides from a fatty and dextrose, is modified to express anesterase or it has an endogenous cytoplasmic fatty acid esterase.

In another embodiment as illustrated in FIG. 31, a strain from a yeastthat had been modified to produce cannabinoids from hexanoic acid anddextrose is modified to express a hexanoate esterase or it has anendogenous secreted hexanoate esterase. The hexanoate esterase has beentargeted for secretion by a terminal fusion with a secretion motif suchas the leader sequence of the yeast mating pheromone alpha-factor orinvertase. In addition to the motifs mention here, other motifs could beused.

Some potential sources for the hexanoate ester are as follows:Lactobacillus casei EstB, Lactobacillus plantarum Lp_0796, Acinetobactersp. ADP1 AreA, and Lactococcus lactis EstA.

The methods used to construct these strains are commonly known, havebeen used extensively to engineer S. cerevisiae and non-conventionalyeasts and are described in numerous scientific publications andpatents. Promoters will be used that are active during the preferredfermentation conditions. Some examples of promoters that could be usedare those of the genes encoding glyceraldehyde 3-phosphate dehydrogenaseand the translational elongation factor EF-1 alpha. Genes will beinserted in intergenic regions or non-essential genes.

Sources for Enzymes

Expressing one of these proteins in a acyl-CoA oxidase null mutant mayresult in the production of hexanoate CoA.

ACO1P Protein (Source Anthrobacter) (SEQ ID NO: 10)MTEVVDRASSPASPGSTTAAADGAKVAVEPRVDVAALGEQLLGRWADIRLHARDLAGREVVQKVEGLTHTEHRSRVFGQLKYLVDNNAVHRAFPSRLGGSDDHGGNIAGFEELVTADPSLQIKAGVQWGLFGSAVMHLGTREHHDKWLPGIMSLEIPGCFAMTETGHGSDVASIATTATYDEETQEFVIDTPFRAAWKDYIGNAANDGLAAVVFAQLITRKVNHGVHAFYVDLRDPATGDFLPGIGGEDDGIKGGLNGIDNGRLHFTNVRIPRTNLLNRYGDVAVDGTYSSTIESPGRRFFTMLGTLVQGRVSLDGAAVAASKVALQSAIHYAAERRQFNATSPTEEEVLLDYQRHQRRLFTRLATTYAASFAHEQLLQKFDDVFSGAHDTDADRQDLETLAAALKPLSTWHALDTLQECREACGGAGFLIENRFASLRADLDVYVTFEGDNTVLLQLVAKRLLADYAKEFRGANFGVLARYVVDQAAGVALHRTGLRQVAQFVADSGSVQKSALALRDEEGQRTLLTDRVQSMVAEVGAALKGAGKLPQHQAAALFNQHQNELIEAAQAHAELLQWEAFTEALAKVDDAGTKEVLTRLRDLFGLSLIEKHLSWYLMNGRLSMQRGRTVGTYINRLLVKIRPHALDLVDAFGYGAEHLRAAIATGAEATRQDEARTYFRQQRASGSAPADEKTLLAIKAG KSRGRRAKLACO2 Protein (Source Yarrowia lipolytica) (SEQ ID NO: 11)MNPNNTGTIEINGKEYNTFTEPPVAMAQERAKTSFPVREMTYFLDGGEKNTLKNEQIMEEIERDPLFNNDNYYDLNKEQIRELTMERVAKLSLFVRDQPEDDIKKRFALIGIADMGTYTRLGVHYGLFFGAVRGTGTAEQFGHWISKGAGDLRKFYGCFSMTELGHGSNLAGLETTAIYDEETDEFIINTPHIAATKWWIGGAAHTATHTVVFARLIVKGKDYGVKTFVVQLRNINDHSLKVGISIGDIGKKMGRDGIDNGWIQFTNVRIPRQNLLMKYTKVDREGNVTQPPLAQLTYGSLITGRVSMASDSHQVGKRFITIALRYACIRRQFSTTPGQPETKIIDYPYHQRRLLPLLAYVYALKMTADEVGALFSRTMLKMDDLKPDDKAGLNEVVSDVKELFSVSAGLKAFSTWACADVIDKTRQACGGHGYSGYNGFGQAYADWVVQCTWEGDNNILTLSAGRALIQSAVALRKGEPVGNAVSYLKRYKDLANAKLNGRSLTDPKVLVEAWEVAAGNIINRATDQYEKLIGEGLNADQAFEVLSQQRFQAAKVHTRRHLIAAFFSRIDTEAGEAIKQPLLNLALLFALWSIEEDSGLFLREGFLEPKDIDTVTELVNKYCTTVREEVIGYTDAFNLSDYFINAPIGCYDGDAYRHYFQKVNEQNPARDPRPPYYASTLKPFLFREEEDDDICELDEEACO3 Protein (Source Rattus norvegicus) (SEQ ID NO: 12)MNPDLRKERASATFNPELITHILDGSPENTRRRREIENLILNDPDFQHEDYNFLTRSQRYEVAVKKSATMVKKMREYGISDPEEIMWFKKLYLANFVEPVGLNYSMFIPTLLNQGTTAQQEKWMRPSQELQIIGTYAQTEMGHGTHLRGLETTATYDPKTQEFILNSPTVTSIKWWPGGLGKTSNHAIVLAQLITQGECYGLHAFVVPIREIGTHKPLPGITVGDIGPKFGYEEMDNGYLKMDNYRIPRENMLMKYAQVKPDGTYVKPLSNKLTYGTMVFVRSFLVGNAAQSLSKACTIAIRYSAVRRQSEIKQSEPEPQILDFQTQQYKLFPLLATAYAFHFVGRYMKETYLRINESIGQGDLSELPELHALTAGLKAFTTWTANAGIEECRMACGGHGYSHSSGIPNIYVTFTPACTFEGENTVMMLQTARFLMKIYDQVRSGKLVGGMVSYLNDLPSQRIQPQQVAVWPTMVDINSLEGLTEAYKLRAARLVEIAAKNLQTHVSHRKSKEVAWNLTSVDLVRASEAHCHYVVVKVFSDKLPKIQDKAVQAVLRNLCLLYSLYGISQKGGDFLEGSIITGAQLSQVNARILELLTLIRPNAVALVDAFDFKDMTLGSVLGRYDGNVYENLFEWAKKSPLNKTEVHESY HKHLKPLQSKLACO4 Protein (Source Rattus norvegicus) (SEQ ID NO: 13)MNPDLRKERASATFNPELITHILDGSPENTRRRREIENLILNDPDFQHEDYNFLTRSQRYEVAVKKSATMVKKMREYGISDPEEIMWFKNSVHRGHPEPLDLHLGMFLPTLLHQATAEQQERFFMPAWNLEITGTYAQTEMGHGTHLRGLETTATYDPKTQEFILNSPTVTSIKWWPGGLGKTSNHAIVLAQLITQGECYGLHAFVVPIREIGTHKPLPGITVGDIGPKFGYEEMDNGYLKMDNYRIPRENMLMKYAQVKPDGTYVKPLSNKLTYGTMVFVRSFLVGNAAQSLSKACTIAIRYSAVRRQSEIKQSEPEPQILDFQTQQYKLFPLLATAYAFHFVGRYMKETYLRINESIGQGDLSELPELHALTAGLKAFTTWTANAGIEECRMACGGHGYSHSSGIPNIYVTFTPACTFEGENTVMMLQTARFLMKIYDQVRSGKLVGGMVSYLNDLPSQRIQPQQVAVWPTMVDINSLEGLTEAYKLRAARLVEIAAKNLQTHVSHRKSKEVAWNLTSVDLVRASEAHCHYVVVKVFSDKLPKIQDKAVQAVLRNLCLLYSLYGISQKGGDFLEGSIITGAQLSQVNARILELLTLIRPNAVALVDAFDFKDMTLGSVLGRYDGNVYENLFEWAKKSPLNKTEVHESY HKHLKPLQSKLACO5 Protein (Glycine max) (SEQ ID NO: 14)MEDGVDHLAFERNKAQFDVEDMKIIWAGSRQDFELSDRISRLVASDPAFRKDDRTRLIGRLFKNTLRKAAYAWKRINELRLNEQEAYKLRSFVDQPAFTDLHWGMFVPAIQGQGTDEQQQKWLPLAYGMQIIGCYAQTELGHGSNVQGLETTATFDPKTDEFVIHSPTLTSSKWWPGGLGKISTHAVAYARLIIGGEDHGVHGFIVQLRSLDDHLPLPGITIGDIGMKFGNAAYNTMDNGVLRFDHVRIPRNQMLMRVSQVTREGRYVSSNVPRQLVYGTMVNVRQKIVADASVALSRAVCIATRYSAVRRQFGSHNGGLETQVIDYKTQQARLFPLLASAYAFRFVGGWLKWLYMDVTERLQANDFSTLPEAHACTAGLKSLTTTATADGIEECRKLCGGHGYLCSSGLPELFAVYVPACTYEGDNVVLLLQVARHLMKTVSQLGSGNKPVGTTAYMARVEQLMQYHSDVEKAEDWLKPNVVLEAFEARASRMSVACAQNLSKFANPEEGFQELAADLVDAAVAHCQLIVVSKFIEKLQQDIPGKGVKKQLEVLCSIYALFLLHKHLGDFLSTGCINPKQGSLASEQLRNLYSQVRPNAIALVDAFNYTDHYLGSILGRYDGNVYPKMNEEAWKDPLNDSVVPDGFKEY IQPMLKQQLRNARLACO6 Protein (Glycine Max) (SEQ ID NO: 15)MEGMVDHLAFERNNSQFDVDEMKIVWAGSRHAFEVSDKMARLVASDPAFRKDDRVVLDRKALFKNTLRKAAYAWKRIIELRLSEEEAAMLRSFVDQPAFTDLHWGMFVPAIKGQGTEEQQKKWLPLAHKMQIIGCYAQTELGHGSNVQGLETTATFDPRTDEFVIHSPTLTSSKWWPGGLGKVSTHAVVYARLITDGQDHGVHGFIVQLRSLDDHLPLPGITVGDIGMKFGNGAYNSMDNGMLRFDHVRIPRNQMLMRVSQVTREGKYVQSSVPRQLVYGTMVYVRQTIVSDASVALSRAVCIATRYSAVRRQFGSKEGGLETQVIDYKTQQARLFPLLASAYAFRFVGEWLKWLYMDVMKRLQASDFSTLPEAHACTAGLKSLTTSATADGIEECRKLCGGHGYLCSSGLPELFAVYIPTCTYEGDNTVLLLQVARHLIKTISQLGSRNKPVGTTSYIGRVEQLMQYRSDVQKVEDWLKPNAVLGAFEARAAKKVVACAQNLSKFTNPEEGFQELSVDLVEAAVAHCQLIVVSKFIEKLQQDIPGKGVKQQLELLCSIYALFLLHKHLGDFLATGCITPKQGSLANELLRSLYSQVRPNAIALVDAFNYTDHYLGSVLGRYDGDVYPKLYEEAWKDPLNDSVVPDGFQE YIRPMLKQQLRNARLACO7 Protein (Source Beuvaria bassiana) (SEQ ID NO: 16)MSFPDNLKPKEPSGSSLLEKERRQSPVDVDALGKHIFAGTSFLERQARVLRAIEQEPLFDKSRQQQLSRVERVKLGLARGKLMRRLQDRHGWDMDDYHMAAYLVGEQSPYRLHVGMFRTTVEEQSSDAQRAYWMPRVNGWEVSGAYSQTELGHGSNVRGVELEARWDPAAREFVVHSPTLTAAKWWNGSLGRTANHAILMAQLMVPDPKREGQYISHGPQAFIAQIRDLKTNLPLEGVVIGDIGVKIGFTSMDNGYMLFNQFRIPHSALLSRYVQLDPETGVFSKSPNPALAYGTMTSIRTMLVEEAGTHLARAVTIAIRYTAIRQQFRDKDSQDPSSAELQVLDYPTVQVRLFPLLAAAFALQYTGKVMRQDYAKTRGEVEKGNLEGLAVMHSNSSGLKSLSTEITNAGIETCRRAMGGHGYGSGSGLVEMQKDYQAKPILEGDNWMITQQTSSFLIKRMTAAAKTRNEPPKDQIDAQLKTFLHQKDKGRTFDILNSDSDIEESFKWRAASMTYDAYEARVIKKKRHNDLLIQFHKLSHAHSQSIMVSSFLTTLTSSNDLAHETKEIVFDLYRLFAYTTIQAESYEFLRCGAASSKDLDALPERIQALLTRIRPHAVKLVDAWKIPDYLLDSALGRYDGNVYEDLFNRAHRLNPLNDIVFNPDYKDDEIVKGSGERKPLSPKLACO8 Protein (Source Aspergillus nidulans) (SEQ ID NO: 17)MPNPPPAWVQALKPASPQGTELLTQERAQSNIDVDTLGDLLHTKEALKKQDEILSVLKSEKVFDKSRNHVLGRTEKIQLALARGKRLQQLKKAHNWSDEDVHVANDLVSEPTPYGLHASMFLVTLREQGTPEQHKLFYERARNYEIIGCYAQTELGHGSNVRGLETTATWDPSDQTFIIHSPTLTASKWWIGSLGRTANHAVVMAQLYIGGKNYGPHPFVVQIRDMETHQPLENVYVGDIGPKFGYNTMDNGFLLFNKLKIPHVNMLARFAQVDKATNKYIRPASPSLMYGTMTWVRSNIVLQAGGVLARGVTIAVRYCAVRRQFQDRDAKANAEENQVLNYKMVQIRLLPLLAAMYALHFTGRGMMRLYEENQERMKAAAQADQEKRGAGPEQLRAGSDLLADLHATSCGLKALASTTAGEGLEVCRRACGGHGYSNYSGIGPWYADYLPTLTWEGDNYMLTQQVARYLLKSARAVLAGKGTANDTSRILQAYLARRDKGASFDILGNDADIVAAFAWRTAHLTFETLKYRDVEKRSWNSLLINFWRLSTALSQYLVVKNFYEAVNSPEIRSSLDKDTASTLRSLFRLHALHTLDREASEFFSSAAVTVRQIGLTQTSEVPKLLDEIRPHAVRLVDSWKIPDWQLDSALGRSDGDVYPDLFKRASMQNPVNDLVFDPYPWNENVLKNAGEIKSKLACO9 Protein (Source Arabidopsis thaliana) (SEQ ID NO: 18)MESRREKNPMTEEESDGLIAARRIQRLSLHLSPSLTPSPSLPLVQTETCSARSKKLDVNGEALSLYMRGKHIDIQEKIFDFFNSRPDLQTPIEISKDDHRELCMNQLIGLVREAGVRPFRYVADDPEKYFAIMEAVGSVDMSLGIKMGVQYSLWGGSVINLGTKKHRDKYFDGIDNLDYTGCFAMTELHHGSNVQGLQTTATFDPLKDEFVIDTPNDGAIKWWIGNAAVHGKFATVFARLILPTHDSKGVSDMGVHAFIVPIRDMKTHQTLPGVEIQDCGHKVGLNGVDNGALRFRSVRIPRDNLLNRFGDVSRDGTYTSSLPTINKRFGATLGELVGGRVGLAYASVGVLKISATIAIRYSLLRQQFGPPKQPEVSILDYQSQQHKLMPMLASTYAYHFATVYLVEKYSEMKKTHDEQLVADVHALSAGLKSYVTSYTAKALSVCREACGGHGYAAVNRFGSLRNDHDIFQTFEGDNTVLLQQVAADLLKRYKEKFQGGTLTVTWSYLRESMNTYLSQPNPVTARWEGEDHLRDPKFQLDAFRYRTSRLLQNVAARLQKHSKTLGGFGAWNRCLNHLLTLAESHIETVILAKFIEAVKNCPDPSAKAALKLACDLYALDRIWKDIGTYRNVDYVAPNKAKVCFLVACO10 Protein (Source Arabidopsis thaliana) (SEQ ID NO: 19)MESRREKNPMTEEESDGLIAARRIQRLSLHLSPSLTPSPSLPLVQTETCSARSKKLDVNGEALSLYMRGKHIDIQEKIFDFFNSRPDLQTPIEISKDDHRELCMNQLIGLVREAGVRPFRYVADDPEKYFAIMEAVGSVDMSLGIKMGVQYSLWGGSVINLGTKKHRDKYFDGIDNLDYTGCFAMTELHHGSNVQGLQTTATFDPLKDEFVIDTPNDGAIKWWIGNAAVHGKFATVFARLILPTHDSKGVSDMGVHAFIVPIRDMKTHQTLPGVEIQDCGHKVGLNGVDNGALRFRSVRIPRDNLLNRFGDVSRDGTYTSSLPTINKRFGATLGELVGGRVGLAYASVGVLKISATIAIRYSLLRQQFGPPKQPEVSILDYQSQQHKLMPMLASTYAYHFATVYLVEKYSEMKKTHDEQLVADVHALSAGLKSYVTSYTAKALSVCREACGGHGYAAVNRFGSLRNDHDIFQTFEGDNTVLLQQVAADLLKRYKEKFQGGTLTVTWSYLRESMNTYLSQPNPVTARWEGEDHLRDPKFQLDAFRYRTSRLLQNVAARLQKHSKTLGGFGAWNRCLNHLLTLAESHIETVILAKFIEAVKNCPDPSAKAALKLACDLYALDRIWKDIGTYRNVDYVAPNKAKAIHKLTEYLSFQVRNVAKELVDAFELPDHVTRAPIAMQSDAYSQYTQVVGF

Proteins involved in beta-oxidation that their encoding gene may bemodified, disrupted or replaced to produce a short-chain fatty acidintermediate.

POX4 Acyl-CoA Oxidase (Source Candida viswanathii) (SEQ ID NO: 20)MTFTKKNVSVSQGPDPRTSIQTERANSKFDPVTMNYFLEGSKERSELMKSLAQQIERDPILFTDGSYYDLTKDQQRELTVLKINRLSRYREGDSVDTFNKRLSIMGVVDPQVATRIGVNLGLFLSCISGNGTAEQFKYWAIDKGTHNIQGLYGCFGMTELGHGSNVAGVETTATFDKETDEFVINTPHIGATKWWIGGAAHSATHCSVYARLVVDGKDYGVKTFVVPLRDSNHDLMPGVTVGDIGAKMGRDGIDNGWIQFSNVRIPRFFMLQKFCKVSAEGEVVLPPLEQLSYSALLGGRVMMVLDSYRMLARVSTIALRYAIGRRQFKGDNVDQNDPNALETQLIDYPLHQKRLFPYLAAAYVVSTGALKVEHTIQSTLATLDAAVENNDTTAIFKSIDDMKSLFIDSGSLKATTTWLAAEAIDQCRQACGGHGYSSYNGFAKAFNDWVVQCTWEGDNNVLSLSVGKPIIKQIIGIEDNGKTVRGSTAFLNQVKDFTGSNASKVVLNNTSDLNDINKVIKSIEVAIIRLAHEAAISVRKESLDFAGAELVQISKLKAHHYLLTEFVKRVGEFEHKELVPFLNTIGRLYSATVVLDKFAGVFLTFNVASPQAITDLASTQIPKLCAEVRPNVVAYTDSFQQSDMVINSAIGKYDGDVYENYFDLVKQLNPPKNTKAPYTAALEGMLNRPSLEARERYEKS DETAAILSKPOX5POX5 Acyl-CoA Oxidase (Source Candida viswanathii) (SEQ ID NO: 21)MPTELQKERELTKFNPKELNYFLEGSQERSEIISNMVEQMQKDPILKVDASYYNLTKDQQREVTAKKIARLSRYFEHEYPDQQAQRLSILGVFDPQVFTRIGVNLGLFVSCVRGNGTNSQFFYWTINKGIDKLRGIYGCFGMTELAHGSNVQGIETTATFDEDTDEFVINTPHIGATKWWIGGAAHSATHCSVYARLKVKGKDYGVKTFVVPLRDSNHDLEPGVTVGDIGAKMGRDGIDNGWIQFSNVRIPRFFMLQKYCKVSRSGEVTMPPSEQLSYSALIGGRVTMMMDSYRMTSRFITIALRYAIHRRQFKKKDTDTIETKLIDYPLHQKRLFPFLAAAYLFSQGALYLEQTMNATNDKLDEAVSAGEKEAIDAAIVESKKLFVASGCLKSTCTWLTAEAIDEARQACGGHGYSSYNGFGKAYSDWVVQCTWEGDNNILAMNVAKPMVRDLLKEPEQKGLVLSSVADLDDPAKLVKAFDHALSGLARDIGAVAEDKGFDITGPSLVLVSKLNAHRFLIDGFFKRITPEWSEVLRPLGFLYADWILTNFGATFLQYGIITPDVSRKISSEHFPALCAKVRPNVVGLTDGFNLTDMMTNAAIGRYDGNVYEHYFETVKALNPPENTKAPYSKALEDMLNRPDLEVRERG EKSEEAAEILSSPOX1 Acyl-CoA Oxidase (Source Yarrowia lipolytica) (SEQ ID NO: 22)MTTNTFTDPPVEMAKERGKTQFTVRDVTNFLNGGEEETQIVEKIMSSIERDPVLSVTADYDCNLQQARKQTMERVAALSPYLVTDTEKLSLWRAQLHGMVDMSTRTRLSIHNNLFIGSIRGSGTPEQFKYWVKKGAVAVKQFYGCFAMTELGHGSNLKGLETTATYDQDSDQFIINTPHIGATKWWIGGAAHTSTHCVCFAKLIVHGKDYGTRNFVVPLRNVHDHSLKVGVSIGDIGKKMGRDGVDNGWIQFTNVRIPRQNMLMRYAKVSDTGVVTKPALDQLTYGALIRGRVSMIADSFHVSKRFLTIALRYACVRRQFGTSGDTKETKIIDYPYHQRRLLPLLAYCYAMKMGADEAQKTWIETTDRILALNPNDPAQKNDLEKAVTDTKELFAASAGMKAFTTWGCAKIIDECRQACGGHGYSGYNGFGQGYADWVVQCTWEGDNNVLCLSMGRGLVQSALQILAGKHVGASIQYVGDKSKISQNGQGTPREQLLSPEFLVEAFRTASRNNILRTTDKYQELVKTLNPDQAFEELSQQRFQCARIHTRQHLISSFYARIATAKDDIKPHLLKLANLFALWSIEEDTGIFLRENILTPGDIDLINSLVDELCVAVRDQVIGLTDAFGLSDFFINAPIGSYDGNVYEKYFAKVNQQNPATNPRPPYYESTLKPFLFREEEDDEICDLDEPOX2 Acyl-CoA Oxidase (Source Yarrowia lipolytica) (SEQ ID NO: 23)MNPNNTGTIEINGKEYNTFTEPPVAMAQERAKTSFPVREMTYFLDGGEKNTLKNEQIMEEIERDPLFNNDNYYDLNKEQIRELTMERVAKLSLFVRDQPEDDIKKRFALIGIADMGTYTRLGVHYGLFFGAVRGTGTAEQFGHWISKGAGDLRKFYGCFSMTELGHGSNLAGLETTAIYDEETDEFIINTPHIAATKWWIGGAAHTATHTVVFARLIVKGKDYGVKTFVVQLRNINDHSLKVGISIGDIGKKMGRDGIDNGWIQFTNVRIPRQNLLMKYTKVDREGNVTQPPLAQLTYGSLITGRVSMASDSHQVGKRFITIALRYACIRRQFSTTPGQPETKIIDYPYHQRRLLPLLAYVYALKMTADEVGALFSRTMLKMDDLKPDDKAGLNEVVSDVKELFSVSAGLKAFSTWACADVIDKTRQACGGHGYSGYNGFGQAYADWVVQCTWEGDNNILTLSAGRALIQSAVALRKGEPVGNAVSYLKRYKDLANAKLNGRSLTDPKVLVEAWEVAAGNIINRATDQYEKLIGEGLNADQAFEVLSQQRFQAAKVHTRRHLIAAFFSRIDTEAGEAIKQPLLNLALLFALWSIEEDSGLFLREGFLEPKDIDTVTELVNKYCTTVREEVIGYTDAFNLSDYFINAPIGCYDGDAYRHYFQKVNEQNPARDPRPPYYASTLKPFLFREEEDDDICELDEEPOX3 Acyl-CoA Oxidase (Source Yarrowia lipolytica) (SEQ ID NO: 24)MISPNLTANVEIDGKQYNTFTEPPKALAGERAKVKFPIKDMTEFLHGGEENVTMIERLMTELERDPVLNVSGDYDMPKEQLRETAVARIAALSGHWKKDTEKEALLRSQLHGIVDMGTRIRLGVHTGLFMGAIRGSGTKEQYDYWVRKGAADVKGFYGCFAMTELGHGSNVAGLETTATYIQDTDEFIINTPNTGATKWWIGGAAHSATHTACFARLLVDGKDYGVKIFVVQLRDVSSHSLMPGIALGDIGKKMGRDAIDNGWIQFTNVRIPRQNMLMKYAKVSSTGKVSQPPLAQLTYGALIGGRVTMIADSFFVSQRFITIALRYACVRRQFGTTPGQPETKIIDYPYHQRRLLPLLAFTYAMKMAADQSQIQYDQTTDLLQTIDPKDKGALGKAIVDLKELFASSAGLKAFTTWTCANIIDQCRQACGGHGYSGYNGFGQAYADWVVQCTWEGDNNVLCLSMGRGLIQSCLGHRKGKPLGSSVGYLANKGLEQATLSGRDLKDPKVLIEAWEKVANGAIQRATDKFVELTKGGLSPDQAFEELSQQRFQCAKIHTRKHLVTAFYERINASAKADVKPYLINLANLFTLWSIEEDSGLFLREGFLQPKDIDQVTELVNHYCKEVRDQVAGYTDAFGLSDWFINAPIGNYDGDVYKHYFAKVNQQNPAQNPRPPYYESTLRPFLFREDEDDDICELDEE*POX4 Acyl-CoA Oxidase (Source Yarrowia lipolytica) (SEQ ID NO: 25)MITPNPANDIVHDGKLYDTFTEPPKLMAQERAQLDFDPRDITYFLDGSKEETELLESLMLMYERDPLFNNQNEYDESFETLRERSVKRIFQLSKSIAMDPEPMSFRKIGFLGILDMGTYARLGVHYALFCNSIRGQGTPDQLMYWLDQGAMVIKGFYGCFAMTEMGHGSNLSRLETIATFDKETDEFIINTPHVGATKWWIGGAAHTATHTLAFARLQVDGKDYGVKSFVVPLRNLDDHSLRPGIATGDIGKKMGRDAVDNGWIQFTNVRVPRNYMLMKHTKVLRDGTVKQPPLAQLTYGSLITGRVQMTTDSHNVSKKFLTIALRYATIRRQFSSTPGEPETRLIDYLYHQRRLLPLMAYSYAMKLAGDHVRELFFASQEKAESLKEDDKAGVESYVQDIKELFSVSAGLKAATTWACADIIDKARQACGGHGYSAYNGFGQAFQDWVVQCTWEGDNTVLTLSAGRALIQSALVYRKEGKLGNATKYLSRSKELANAKRNGRSLEDPKLLVEAWEAVSAGAINAATDAYEELSKQGVSVDECFEQVSQERFQAARIHTRRALIEAFYSRIATADEKVKPHLIPLANLFALWSIEEDSALFLAEGYFEPEDIIEVTSLVNKYCGIVRKNVIGYTDAFNLSDYFINAAIGRYDGDVYKNYFEKVKQQYPPEGGKPHYYEDVMKPFLHRERIPDVPMEPEDI QPOX5 Acyl-CoA Oxidase (Source Yarrowia lipolytica) (SEQ ID NO: 26)MNNNPTNVILGGKEYDTFTEPPAQMELERAKTQFKVRDVTNFLTGSEQETLLTERIMREIERDPVLNVAGDYDADLPTKRRQAVERIGALARYLPKDSEKEAILRGQLHGIVDMGTRTRIAVHYGLFMGAIRGSGTKEQYDYWVAKGAATLHKFYGCFAMTELGHGSNVAGLETTATLDKDTDEFIINTPNSGATKWWIGGAAHSATHTACLARLIVDGKDYGVKIFIVQLRDLNSHSLLNGIAIGDIGKKMGRDAIDNGWIQFTDVRIPRQNMLMRYDRVSRDGEVTTSELAQLTYGALLSGRVTMIAESHLLSARFLTIALRYACIRRQFGAVPDKPETKLIDYPYHQRRLLPLLAYTYAMKMGADEAQQQYNSSFGALLKLNPVKDAEKFAVATADLKALFASSAGMKAFTTWAAAKIIDECRQACGGHGYSGYNGFGQAYADWVVQCTWEGDNNVLCLSMGRSLIQSCIAMRKKKGHVGKSVEYLQRRDELQNARVDNKPLTDPAVLITAWEKVACEAINRATDSFIKLTQEGLSPDQAFEELSQQRFECARIHTRKHLITSFYARISKAKARVKPHLTVLANLFAVWSIEEDSGLFLREGCFEPAEMDEITALVDELCCEAREQVIGFTDAFNLSDFFINAPIGRFDGDAYKHYMDEVKAANNPRNTHAPYYETKLRPFLFRPDEDEEICDLDEPOX6 Acyl-CoA Oxidase (Source Yarrowia lipolytica) (SEQ ID NO: 27)MLSQQSLNTFTEPPVEMARERNQTSFNPRLLTYFLDGGEKNTLLMDRLMQEYERDPVFRNEGDYDITDVAQSRELAFKRIAKLIEYVHTDDEETYLYRCMLLGQIDMGAFARYAIHHGVWGGAIRGAGTPEQYEFWVKKGSLSVKKFYGSFSMTELGHGSNLVGLETTATLDKNADEFVINTPNVAATKWWIGGAADTATHTAVFARLIVDGEDHGVKTFVVQLRDVETHNLMPGIAIGDCGKKMGRQGTDNGWIQFTHVRIPRQNMLMRYCHVDSDGNVTEPMMAQMAYGALLAGRVGMAMDSYFTSRKFLTIALRYATIRRAFAAGGGQETKLIDYPYHQRRLLPLMAQTYAIKCTADKVRDQFVKVTDMLLNLDVSDQEAVPKAIAEAKELFSVSAGVKATTTWACAHTIDQCRQACGGHGYSAYNGFGRAYSDWVIQCTWEGDNNILCLSAGRALVQSNRAVRAGKPIGGPTAYLAAPAGSPKLAGRNLYDPKVMIGAWETVSRALINRTTDEFEVLAKKGLSTAQAYEELSQQRFLCTRIHTRLYMVKNFYERIAEEGTEFTKEPLTRLANLYAFWSVEEEAGIFLREGYITPQELKYISAEIRKQLLEVRKDVIGYTDAFNVPDFFLNSAIGRADGDVYKNYFKVVNTQNPPQDPRPPYYESVIRPFLFRKDEDEEICSLEDEFOX2 Peroxisomal hydratase-dehydrogenase-epimerase(Source Candida viswanathii) (SEQ ID NO: 28)MSPVDFKDKVVIITGAGGGLGKYYSLEFAKLGAKVVVNDLGGALNGQGGNSKAADVVVDEIVKNGGVAVADYNNVLDGDKIVETAVKNFGTVHVIINNAGILRDASMKKMTEKDYKLVIDVHLNGAFAVTKAAWPYFQKQKYGRIVNTSSPAGLYGNFGQANYASAKSALLGFAETLAKEGAKYNIKANAIAPLARSRMTESILPPPMLEKLGPEKVAPLVLYLSSAENELTGQFFEVAAGFYAQIRWERSGGVLFKPDQSFTAEVVAKRFSEILDYDDSRKPEYLKNQYPFMLNDYATLTNEARKLPANDASGAPTVSLKDKVVLITGAGAGLGKEYAKWFAKYGAKVVVNDFKDATKTVDEIKAAGGEAWPDQHDVAKDSEAIIKNVIDKYGTIDILVNNAGILRDRSFAKMSKQEWDSVQQVHLIGTFNLSRLAWPYFVEKQFGRIINITSTSGIYGNFGQANYSSSKAGILGLSKTMAIEGAKNNIKVNIVAPHAETAMTLTIFREQDKNLYHADQVAPLLVYLGTDDVPVTGETFEIGGGWIGNTRWQRAKGAVSHDEHTTVEFIKEHLNEITDFTTDTENPKSTTESSMAILSAVGGDDDDDDEDEEEDEGDEEEDEEDEEEDDPVWRFDDRDVILYNIALGATTKQLKYVYENDSDFQVIPTFGHLITFNSGKSQNSFAKLLRNFNPMLLLHGEHYLKVHSWPPPTEGEIKTTFEPIATTPKGTNVVIVHGSKSVDNKSGELIYSNEATYFIRNCQADNKVYADRPAFATNQFLAPKRAPDYQVDVPVSEDLAALYRLSGDRNPLHIDPNFAKGAKFPKPILHGMCTYGLSAKALIDKFGMFNEIKARFTGIVFPGETLRVLAWKESDDTIVFQTHVVDRGTIAINNAAIKLV GDKAKI

Proteins with motifs or regions important for cellular localization areas follows.

OST1 (Source Candida viswanathii) (SEQ ID NO: 29)MMWKFLIAIGLIFSYCCNAQLLDSLSFDNNWVNTHYIRTIDLSKGFVKETDLIQIKNINDKPQDEYYFVVNDGFDSIDELSIFSAFVGDQALEVEVDEVVPDKVFKLKLPVPIAPNSDLELRINFVYIDSLVSVPSKIAMDATQQLLYKTNKFPFSPYVTQEYTLALSGMSKGQEMDLHIDVEDTPGLPDLKPRVESQVLKYGPIAEDIPAFALKPMGLMYDHNRPLTKAVSLNRSIWLPASDINKVSIEEYYELTNTGAELDKGFSRVDWMKGRFESTRNHWALSHLEIPLLERGFDDYYYTDKVGVVSTHKIFKNHLLLQPRYPVFGGWKYNFTLGWSEELSKFLHKLHDNQDEYIIKFPILNSLRDVTYQDVYLEFYLPENAEFQNISSPIAFESISIENELSYLDVSKGHTKITVHYTNLFDDLHKLDVFVKYQYTQVAFIYKIAKISGFVFLGLVSYYLLGLLDLSIGlU1 Glucoamylase (Source Saccharomyces fibuligera) (SEQ ID NO: 30)MKFGVLFSVFAAIVSALPLQEGPLNKRAYPSFEAYSNYKVDRTDLETFLDKQKEVSLYYLLQNIAYPEGQFNNGVPGTVIASPSTSNPDYYYQWTRDSAITFLTVLSELEDNNFNTTLAKAVEYYINTSYNLQRTSNPSGSFDDENHKGLGEPKFNTDGSAYTGAWGRPQNDGPALRAYAISRYLNDVNSLNEGKLVLTDSGDINFSSTEDIYKNIIKPDLEYVIGYWDSTGFDLWEENQGRHFFTSLVQQKALAYAVDIAKSFDDGDFANTLSSTASTLESYLSGSDGGFVNTDVNHIVENPDLLQQNSRQGLDSATYIGPLLTHDIGESSSTPFDVDNEYVLQSYYLLLEDNKDRYSVNSAYSAGAAIGRYPEDVYNGDGSSEGNPWFLATAYAAQVPYKLAYDAKSASNDITINKINYDFFNKYIVDLSTINSAYQSSDSVTIKSGSDEFNTVADNLVTFGDSFLQVILDHINDDGSLNEQLNRYTGYSTGAYSLTWSSGALLEAIRLRNKVKALASIAT1_RAT alpha-2,6-sialyltransferase (Source Rat norvegicus)(SEQ ID NO: 31)MIHTNLKKKFSLFILVFLLFAVICVWKKGSDYEALTLQAKEFQMPKSQEKVAMGSASQVVFSNSKQDPKEDIPILSYHRVTAKVKPQPSFQVWDKDSTYSKLNPRLLKIWRNYLNMNKYKVSYKGPGPGVKFSVEALRCHLRDHVNVSMIEATDFPFNTTEWEGYLPKENFRTKVGPWQRCAVVSSAGSLKNSQLGREIDNHDAVLRFNGAPTDNFQQDVGSKTTIRLMNSQLVTTEKRFLKDSLYTEGILIVWDPSVYHADIPKWYQKPDYNFFETYKSYRRLNPSQPFYILKPQMPWELWDIIQEISADLIQPNPPSSGMLGIIIMMTLCDQVDIYEFLPSKRKTDVCYYHQKFFDSACTMGAYDPLLFEKNMVKHLNEGTDEDIYLFGKATLSGFRNIRCB4galt1 Beta-1,4-galactosyltransferase 1 (Source Homo sapiens)(SEQ ID NO: 32)MRLREPLLSGSAAMPGASLQRACRLLVAVCALHLGVTLVYYLAGRDLSRLPQLVGVSTPLQGGSNSAAAIGQSSGELRTGGARPPPPLGASSQPRPGGDSSPVVDSGPGPASNLTSVPVPHTTALSLPACPEESPLLVGPMLIEFNMPVDLELVAKQNPNVKMGGRYAPRDCVSPHKVAIIIPFRNRQEHLKYWLYYLHPVLQRQQLDYGIYVINQISFDOA4 Ubiquitin carboxyl-terminal hydrolase 4 (Source Candida viswanathii)(SEQ ID NO: 33)MTLLLKPTSELDATSRKIIERIQSNSPTFQHLFDLLLNLLPFFDKTVSLLGSIGYCDYEVAYVTYQTCIQVVGLMKPKTNSLNQDIFKGVQLQTRKRASTFKAILSYFAEPETQEEDPLLNRFKSLSGGGSKTKSSQDEVFHEWITSSELQRELSSKKVLLIDFRPRKDYLNNHIKYKDLVHIEPTQLETLLDSASDQDLETLVKKSAPYDQYHIFLERHKYDLIVVYNYNYGSESTDRLLGIIDVVSKPNPFTKLITILMNNKYISSRLKVKPLFLSGGVLNWYKTFGIEYLERTLVQNGVAHTSDNQYLKSFNDYVSTSKETPKTQVKTQNGDYIRPSQRKVNQFDPVPVKSGPTVFASAKVDLPPTPGSPAVSTPSPPRAPAPPTKTTSLTHVPEKEAKSPSPVTKEVTVSSKKSQFLELYTTGLVNLGNSCYMNCVVQCLAAAPQLTSFFFPTITESFSDHSYRQHINSNNKLGTKGELTTSFVELILNMLNNNGKAFSPTKFKRTMGSLSPSQQFLTYDQQDCIEFLNFLLDALHEDLNNVTITDPSERKLITDLSPEQEKSRETLPVRLASTIEWERYLKLNFSVIVDYFQGQHLSQLKCLECGFTSTTYNAFSILSLPIPQKLNNLGKVLLKDCLEEFVTTELLDDNNKWYCPQCKRFTRLTKKIAITRLPQVLIVNFNRFKMTNTGGFNKLETFVTYPVNEELDMTPYWPDVGSRINENSTMSIEMEQDLLQSFPIRNQTPPFKYKLFGVANHFGNLTTGHYTSYVYKHSDSKKTRNWCYFDDSKITYNVSPSQVVNKNAYCLFFQRVAPR1 Vacuolar aspartic protease (Source Candida viswanathii)(SEQ ID NO: 34)MQLSLSVLSTVATALLSLTTAVDAKSHNIKLSKLSNEETLDASTFQEYTSSLANKYMNLFNAAHGNPTSFGLQHVLSNQEAEVPFVTPQKGGKYDAPLTNYLNAQYFTEIEIGTPGQPFKVILDTGSSNLWVPSQDCTSLACFLHSKYDHDASSTYKANGSEFSIQYGSGSMEGYISQDILTIGDLVIPKQDFAEATSEPGLAFAFGKFDGILGLAYDSISVNHIVPPVYNAINQGLLDKPQVSFYLGNTEKDENDGGLATFGGYDASLFQGKITWLPVRRKAYWEVSFEGIGLGDEYAELQKTGAAIDTGTSLITLPSSLAEIINAKIGATKSWSGQYQIDCAKRDELPDLTLTFAGHNFTLTAHDYILEVSGSCISVFTPMDFPKPIGDLAIIGDAFLRKYYSIYDLDKNAVGLAPSKAPHO8 (Source Candida viswanathii) (SEQ ID NO: 35)MGITNETQALLGGDSLSCLNKKKSNTKRNLSYLLNIITVSIIAYLCFFATHNHHNDSGIPKVDPHKKKNIIMMVTDGMGPASLSAARSFRQFRDKLAINDILTLDQYLIGSSRTRSSSSLVTDSAAGATAFSCALKSYNGAIGVSPDKSPCGTILEALKLQGYYTGLVVTTRITDATPAAFSAHVDYRFQEDLIAEHQLGEYPFGRAVDLILGGGRCHFLPTAQGGCRADDRNLIKESSDTWQYVGDRQQFDQLKGGKNVSLPLLGLLANTDIPYAIDRDEKEYPSLAEQVKVALTALSDATKDSDQGFFLLIEGSRIDHAGHHNDPTAQVREVLAYDEAFGEVIKFIDSTDVETVAISTSDHETGGLVVSRQVTPEYPDYIWYPEVLLNSTHSGDYLAHKIADYKNKDDTAKLTKFIKHEILETDLGVTDYTDKDVQAILDKVNDPANLLYVLNDIVSFRAQIGWTTHGHSAVDVNIYAHTNSPAIRAKLASAKAYHGLSGNHENIEIGAFMEEITGSNLSRVTELIKKTAHSPSLSKKEFSVDEFHGNV SNA4 (Source Saccharomyces cerevisiae) (SEQ ID NO: 36)MCCYCVCCTVSDFILYIVAFFFPPAAVLLRSGPCSSDFLLNVLLTLLGFLPGMLHAFYYITITSPLRNAEYVYYYQQGWVDSERNVPSNRPQNSQTPQNRPQQGSSARNVYPSVETPLLQGAAPHDNKQSLVESPPPYVP OCH1 (Source Candida viswanathii) (SEQ ID NO: 37)MRLKDIKLILIGILTISVTYFLISSFSGPRAYTTSDPNSSKMQFLRALESHPNWKETGLNFQPTKKLEVDDSSTPVRQQLAARFPYDPTQPFPKNIWQTWKVGIEDETFPKRYLKFQLSWDTKNPEYKHHVIPDDQCDELVAQLFEDVPDVARAYKVMPKSILKADFFRYLILFARGGVYTDIDTVGLKPIDTWMSNMELLWGEPNRAGLVVGIEADPDRPDWADWYARRIQFCQWTIQLKKGHPMLRELITKITDITLTREKRNELKKVLGKDEGGDIMNWTGPGIFTDTVFSYMNAILQAPEVITGKYKWDNIVDWKVFTGMQMPIAIDDVLVLPITSFSPDVSQMGSKSSTDPMAYAKHMFLGSWKDDGMPEME

Proteins for use in the cannabinoid pathway are as follows.

HXS1 Protein (Source Cannabis sativa) (SEQ ID NO: 38)MGKNYKSLDSVVASDFIALGITSEVAETLHGRLAEIVCNYGAATPQTWINIANHILSPDLPFSLHQMLFYGCYKDFGPAPPAWIPDPEKVKSTNLGALLEKRGKEFLGVKYKDPISSFSHFQEFSVRNPEVYWRTVLMDEMKISFSKDPECILRRDDINNPGGSEWLPGGYLNSAKNCLNVNSNKKLNDTMIVWRDEGNDDLPLNKLTLDQLRKRVWLVGYALEEMGLEKGCAIAIDMPMHVDAVVIYLAIVLAGYVVVSIADSFSAPEISTRLRLSKAKAIFTQDHIIRGKKRIPLYSRVVEAKSPMAIVIPCSGSNIGAELRDGDISWDYFLERAKEFKNCEFTAREQPVDAYTNILFSSGTTGEPKAIPWTQATPLKAAADGWSHLDIRKGDVIVWPTNLGWMMGPWLVYASLLNGASIALYNGSPLVSGFAKFVQDAKVTMLGVVPSIVRSWKSTNCVSGYDWSTIRCFSSSGEASNVDEYLWLMGRANYKPVIEMCGGTEIGGAFSAGSFLQAQSLSSFSSQCMGCTLYILDKNGYPMPKNKPGIGELALGPVMFGASKTLLNGNHHDVYFKGMPTLNGEVLRRHGDIFELTSNGYYHAHGRADDTMNIGGIKISSIEIERVCNEVDDRVFETTAIGVPPLGGGPEQLVIFFVLKDSNDTTIDLNQLRLSFNLGLQKKLNPLFKVTRVVPLSSLPRTATNKIMRRVL RQQFSHFETKS1 Protein (Source Cannabis sativa) (SEQ ID NO: 39)MNHLRAEGPASVLAIGTANPENILIQDEFPDYYFRVTKSEHMTQLKEKFRKICDKSMIRKRNCFLNEEHLKQNPRLVEHEMQTLDARQDMLVVEVPKLGKDACAKAIKEWGQPKSKITHLIFTSASTTDMPGADYHCAKLLGLSPSVKRVMMYQLGCYGGGTVLRIAKDIAENNKGARVLAVCCDIMACLFRGPSDSDLELLVGQAIFGDGAAAVIVGAEPDESVGERPIFELVSTGQTILPNSEGTIGGHIREAGLIFDLHKDVPMLISNNIEKCLIEAFTPIGISDWNSIFWITHPGGKAILDKVEEKLDLKKEKFVDSRHVLSEHGNMSSSTVLFVMDELRKRSLEEGKSTTGDGFEWGVLFGFGPGLTVERVVVRSVPIKY TKS1P Protein (Source Cannabis sativa)(SEQ ID NO: 40)MNHLRAEGPASVLAIGTANPENILIQDEFPDYYFRVTKSEHMTQLKEKFRKICDKSMIRKRNCFLNEEHLKQNPRLVEHEMQTLDARQDMLVVEVPKLGKDACAKAIKEWGQPKSKITHLIFTSASTTDMPGADYHCAKLLGLSPSVKRVMMYQLGCYGGGTVLRIAKDIAENNKGARVLAVCCDIMACLFRGPSDSDLELLVGQAIFGDGAAAVIVGAEPDESVGERPIFELVSTGQTILPNSEGTIGGHIREAGLIFDLHKDVPMLISNNIEKCLIEAFTPIGISDWNSIFWITHPGGKAILDKVEEKLDLKKEKFVDSRHVLSEHGNMSSSTVLFVMDELRKRSLEEGKSTTGDGFEWGVLFGFGPGLTVERVVVRSVPIKYGRRAKL OAC1 Protein (Source Cannabis sativa)(SEQ ID NO: 41)MAVKHLIVLKFKDEITEAQKEEFFKTYVNLVNIIPAMKDVYWGKDVTQKNKEEGYTHIVEVTFESVETIQDYIIHPAHVGFGDVYRSFWEKLLIFDYTPRKLKPKOAC1P Protein (Source Cannabis sativa) (SEQ ID NO: 42)MAVKHLIVLKFKDEITEAQKEEFFKTYVNLVNIIPAMKDVYWGKDVTQKNKEEGYTHIVEVTFESVETIQDYIIHPAHVGFGDVYRSFWEKLLIFDYTPRKLKPKGRRAKLPTS1 Protein (Source Cannabis sativa) (SEQ ID NO: 43)MGLSSVCTFSFQTNYHTLLNPHNNNPKTSLLCYRHPKTPIKYSYNNFPSKHTKS1FHLQNKCSESLSIAKNSIRAATTNQTEPPESDNHSVATKILNFGKACWKLQRPYTIIAFTSCACGLFGKELLHNTNLISWSLMFKAFFFLVAILCIASFTTTINQIYDLHIDRINKPDLPLASGEISVNTAWIMSIIVALFGLIITIKMKGGPLYIFGYCFGIFGGIVYSVPPFRWKQNPSTAFLLNFLAHIITNFTFYYASRAALGLPFELRPSFTFLLAFMKSMGSALALIKDASDVEGDTKFGISTLASKYGSRNLTLFCSGIVLLSYVAAILAGIIWPQAFNSNVMLLSHAILAFWLILQTRDFALTNYDPEAGRRFYEFMWKLYYAEYLVYVFI PTS1dN (Source Cannabis sativa)(SEQ ID NO: 44)MAATTNQTEPPESDNHSVATKILNFGKACWKLQRPYTIIAFTSCACGLFGKELLHNTNLISWSLMFKAFFFLVAILCIASFTTTINQIYDLHIDRINKPDLPLASGEISVNTAWIMSIIVALFGLIITIKMKGGPLYIFGYCFGIFGGIVYSVPPFRWKQNPSTAFLLNFLAHIITNFTFYYASRAALGLPFELRPSFTFLLAFMKSMGSALALIKDASDVEGDTKFGISTLASKYGSRNLTLFCSGIVLLSYVAAILAGIIWPQAFNSNVMLLSHAILAFWLILQTRDFALTNYDPEAGRRFYEFMWKLYYAEYLVYVFI PTS2 Protein (Source Cannabis sativa) (SEQ ID NO: 45)MGLSLVCTFSFQTNYHTLLNPHNKNPKNSLLSYQHPKTPIIKSSYDNFPSKYCLTKNFHLLGLNSHNRISSQSRSIRAGSDQIEGSPHHESDNSIATKILNFGHTCWKLQRPYVVKGMISIACGLFGRELFNNRHLFSWGLMWKAFFALVPILSFNFFAAIMNQIYDVDIDRINKPDLPLVSGEMSIETAWILSIIVALTGLIVTIKLKSAPLFVFIYIFGIFAGFAYSVPPIRWKQYPFTNFLITISSHVGLAFTSYSATTSALGLPFVWRPAFSFIIAFMTVMGMTIAFAKDISDIEGDAKYGVSTVATKLGARNMTFVVSGVLLLNYLVSISIGIIWPQVFKSNIMILSHAILAFCLIFQTRELALANYASAPSRQFFEFIWLLYYAEYFVYVFI PTS3 Protein (Source Cannabis sativa)(SEQ ID NO: 46)MGLSSVCTFSFQTNYHTLLNPHNNNPKTSLLYRHPKTPIKYSYNNFPSKHCSTKSFHLQNKCSESLSIAKNSIRAATTNQTEPPESDNHSVATKILNFGKACWKLQRPYTIIAFTSCACGLFGKELLHNTNLISWSLMFKAFFFLVAVLCIASFTTTINQIYDLHIDRINKPDLPLASGEISVNTAWIMSIIVALFGLIITIKMKGGPLYIFGYCFGIFGGTVYSVPPFRWKQNPSTAFLLNFLAHIITNFTFYHASRAALGLPFELRPSFTFLLAFMKSMGSALALIKDASDVEGDTKFGISTLASKYGSRNLTLFCSGIVLLSYVAAILAGIIWPQAFNSNVMLLSHAILAFWLILQTRDFALTNYDPEAGRRFYEFMWKLYYAEYLVYVFI PTS4 Protein (Source Cannabis sativa)(SEQ ID NO: 47)MELSSICNFSFQTNYHTLLNPHNKNPKSSLLSHQHPKTPIITSSYNNFPSNYCSNKNFHLQNRCSKSLLIAKNSIRTDTANQTEPPESNTKYSVVTKILSFGHTCWKLQRPYTFIGVISCACGLFGRELFHNTNLLSWSLMLKAFSSLMVILSVNLCTNIINQITDLDIDRINKPDLPLASGEMSIETAWIMSIIVALTGLILTIKLNCGPLFISLYCVSILVGALYSVPPFRWKQNPNTAFSSYFMGLVIVNFTCYYASRAAFGLPFEMSPPFTFILAFVKSMGSALFLCKDVSDIEGDSKHGISTLATRYGAKNITFLCSGIVLLTYVSAILAAIIWPQAFKSNVMLLSHATLAFWLIFQTREFALTNYNPEAGRKFYEFMWKLHYAEYLVYVFI PTS5 Protein (Source Cannabis sativa)(SEQ ID NO: 48)MVFSSVCSFPSSLGTNFKLVPRSNFKASSSHYHEINNFINNKPIKFSYFSSRLYCSAKPIVHRENKFTKSFSLSHLQRKSSIKAHGEIEADGSNGTSEFNVMKSGNAIWRFVRPYAAKGVLFNSAAMFAKELVGNLNLFSWPLMFKILSFTLVILCIFVSTSGINQIYDLDIDRLNKPNLPVASGEISVELAWLLTIVCTISGLTLTIITNSGPFFPFLYSASIFFGFLYSAPPFRWKKNPFTACFCNVMLYVGTSVGVYYACKASLGLPANWSPAFCLLFWFISLLSIPISIAKDLSDIEGDRKFGIITFSTKFGAKPIAYICHGLMLLNYVSVMAAAIIWPQFFNSSVILLSHAFMAIWVLYQAWILEKSNYATETCQKYYIFLWIIFSLEHAFYLFM PTS6 Protein (Source Cannabis sativa)(SEQ ID NO: 49)MELSLSLGGPTIFPRYRASYTSTKLTTHFSNFPSKFSTKNFHQTLSFYGPTRGSKSLLNTHQWRNSIRACAEAGAAGSNPVLNKVSDFRDACWRFLRPHTIRGTTLGSIALVARALIENPNLIKWSLLLKAFSGLLALICGNGYIVGINQIYDIGIDKVNKPYLPIAAGDLSVQSAWYLVILFAVAGLLTVGFNFGPFITSLYCLGLVLGTIYSVPPFRMKRFPVAAFLIIATVRGFLLNFGVYYATRAALGLTFEWSSAVAFITTFVTLFALVIAITKDLPDVEGDRKFQISTFATKLGVRNIAYLGSGLLLLNYIGAIAAAIYMPQAFKRNLMLPIHTILALSLVFQAWVLEQANYTKEAIAGFYRFIWNLFYVEYIIFPFI PTS7 Protein (Source Cannabis sativa)(SEQ ID NO: 50)MAIALWLPRISRSTTRRFLKPSSSLTLFSVSHSHNYIVTSNRSPIPRLFTVPNQSHGREWVSVSEVRLGYVSHISTAGKSDENRSRDAQVADVSWIDLYLPRQIHPYVRLARLDKPIGTWLLAWPCMWSISLAANPGHLPDIKMMTLFGCGALLLRGAGCTINDLLDRDIDTMVERTKLRPVASGIITPFQGICFLGFQLLLGLGILLQLNNYSRILGASSLLLVFSYPLMKRLTFWPQAYLGLTFNWGALLGWAAVKGNIDPAIVLPLYASGVFWTLVYDTIYAHQDKEDDVRVGIKSTALRFGDLTKQWNMGFGAACISSLALSGYNAEIGWPFYASLVAASGQLAWQISTVDLSSRDDCNKKFVSNKWFGAIIFSGIVLARISS PTS8 Protein (Source Cannabis sativa)(SEQ ID NO: 51)MSEAADVERVYAAMEEAAGLLGVACARDKIYPLLSTFQDTLVEGGSVVVFSMASGRHSTELDFSISVPTSHGDPYATVVEKGLFPATGHPVDDLLADTQKHLPVSMFAIDGEVTGGFKKTYAFFPTDNMPGVAELSAIPSMPPAVAENAELFARYGLDKVQMTSMDYKKRQVNLYFSELSAQTLEAESVLALVRELGLHVPNELGLKFCKRSFSVYPTLNWETGKIDRLCFAVISNDPTLVPSSDEGDIEKFHNYATKAPYAYVGEKRTLVYGLTLSPKEEYYKLGAYYHITDVQRGLLKAFDSLEDG PTS9 Protein (ScNphB) (Source Streptomyces)(SEQ ID NO: 52)MSEAADVERVYAAMEEAAGLLGVACARDKIYPLLSTFQDTLVEGGSVVVFSMASGRHSTELDFSISVPTSHGDPYATVVEKGLFPATGHPVDDLLADTQKHLPVSMFAIDGEVTGGFKKTYAFFPTDNMPGVAELSAIPSMPPAVAENAELFARYGLDKVQMTSMDYKKRQVNLYFSELSAQTLEAESVLALVRELGLHVPNELGLKFCKRSFSVYPTLNWETGKIDRLCFAVISNDPTLVPSSDEGDIEKFHNYATKAPYAYVGEKRTLVYGLTLSPKEEYYKLGAYYHITDVQRGLLKAFDSLEDGMKCSTFSFWFVCKIIFFFFSFNIQTSIANPRENFLKCFSQYIPNNATNLKLVYTQNNPLYMSVLNSTIHNLRFTSDTTPKPLVIVTPSHVSHIQGTILCSKKVGLQIRTRSGGHDSEGMSYISQVPFVIVDLRNMRSIKIDVHSQTAWVEAGATLGEVYYWVNEKNENLSLAAGYCPTVCAGGHFGGGGYGPLMRNYGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGAESFGIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKYDKDLLLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNKSFPELGIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQNGAFKIKLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMDEISESAIPFPHRAGILYELWYICSWEKQEDNEKHLNWIRNIYNFMTPYVSKNPRLAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDRLVKVKTLVDPNNFFRNEQSIPPLPRHRH CBD1dNS1 Protein (Source Cannabis sativa)(SEQ ID NO: 53)MFLKHIFVALAFALLADATPAQKRSPGFVALDFDIVKVQKNVTANDDAAAIVAKRQTNPRENFLKCFSQYIPNNATNLKLVYTQNNPLYMSVLNSTIHNLRFTSDTTPKPLVIVTPSHVSHIQGTILCSKKVGLQIRTRSGGHDSEGMSYISQVPFVIVDLRNMRSIKIDVHSQTAWVEAGATLGEVYYWVNEKNENLSLAAGYCPTVCAGGHFGGGGYGPLMRNYGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGAESFGIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKYDKDLLLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNKSFPELGIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQNGAFKIKLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMDEISESAIPFPHRAGILYELWYICSWEKQEDNEKHLNWIRNIYNFMTPYVSKNPRLAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDRLVKVKTLVDPNNFFRNEQSIPPLPRHRHCBD1dNS2 Protein (Source Cannabis sativa) (SEQ ID NO: 54)MQLSLSVLSTVATALLSLTTAVDAKSHNPRENFLKCFSQYIPNNATNLKLVYTQNNPLYMSVLNSTIHNLRFTSDTTPKPLVIVTPSHVSHIQGTILCSKKVGLQIRTRSGGHDSEGMSYISQVPFVIVDLRNMRSIKIDVHSQTAWVEAGATLGEVYYWVNEKNENLSLAAGYCPTVCAGGHFGGGGYGPLMRNYGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGAESFGIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKYDKDLLLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNKSFPELGIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQNGAFKIKLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMDEISESAIPFPHRAGILYELWYICSWEKQEDNEKHLNWIRNIYNFMTPYVSKNPRLAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDRLVKVKTLVDPNNFFRNEQ SIPPLPRHRHCBD1dNV1 Protein (Source Cannabis sativa) (SEQ ID NO: 55)MQLSLSVLSTVATALLSLTTAVDAKSHNIKLSKLSNEETLDASTFQEYTSSLANKYMNLFNAAHGNPTSFGLQHVLSNQEAEVPFVTPQKGGNPRENFLKCFSQYIPNNATNLKLVYTQNNPLYMSVLNSTIHNLRFTSDTTPKPLVIVTPSHVSHIQGTILCSKKVGLQIRTRSGGHDSEGMSYISQVPFVIVDLRNMRSIKIDVHSQTAWVEAGATLGEVYYWVNEKNENLSLAAGYCPTVCAGGHFGGGGYGPLMRNYGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGAESFGIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKYDKDLLLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNKSFPELGIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQNGAFKIKLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMDEISESAIPFPHRAGILYELWYICSWEKQEDNEKHLNWIRNIYNFMTPYVSKNPRLAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDRLVKVKTLVDPNNFFRNEQSIPPLPRHRH CBD1dNP1 Protein (Source Cannabis sativa)(SEQ ID NO: 56)MNPRENFLKCFSQYIPNNATNLKLVYTQNNPLYMSVLNSTIHNLRFTSDTTPKPLVIVTPSHVSHIQGTILCSKKVGLQIRTRSGGHDSEGMSYISQVPFVIVDLRNMRSIKIDVHSQTAWVEAGATLGEVYYWVNEKNENLSLAAGYCPTVCAGGHFGGGGYGPLMRNYGLAADNIIDAHLVNVHGKVLDRKSMGEDLFWALRGGGAESFGIIVAWKIRLVAVPKSTMFSVKKIMEIHELVKLVNKWQNIAYKYDKDLLLMTHFITRNITDNQGKNKTAIHTYFSSVFLGGVDSLVDLMNKSFPELGIKKTDCRQLSWIDTIIFYSGVVNYDTDNFNKEILLDRSAGQNGAFKIKLDYVKKPIPESVFVQILEKLYEEDIGAGMYALYPYGGIMDEISESAlPFPHRAGILYELWYICSWEKQEDNEKHLNWIRNIYNFMTPYVSKNPRLAYLNYRDLDIGINDPKNPNNYTQARIWGEKYFGKNFDRLVKVKTLVDPNNFFRNEQSIPPLPRHRHGRRAKLTHC1 Protein (Source Cannabis sativa) (SEQ ID NO: 57)MNCSAFSFWFVCKIIFFFLSFNIQISIANPQENFLKCFSEYIPNNPANPKFIYTQHDQLYMSVLNSTIQNLRFTSDTTPKPLVIVTPSNVSHIQASILCSKKVGLQIRTRSGGHDAEGMSYISQVPFVVVDLRNMHSIKIDVHSQTAWVEAGATLGEVYYWINEKNENFSFPGGYCPTVGVGGHFSGGGYGALMRNYGLAADNIIDAHLVNVDGKVLDRKSMGEDLFWAIRGGGGENFGIIAAWKIKLVAVPSKSTIFSVKKNMEIHGLVKLFNKWQNIAYKYDKDLVLMTHFITKNITDNHGKNKTTVHGYFSSIFHGGVDSLVDLMNKSFPELGIKKTDCKEFSWIDTTIFYSGVVNFNTANFKKEILLDRSAGKKTAFSIKLDYVKKPIPETAMVKILEKLYEEDVGVGMYVLYPYGGIMEEISESAIPFPHRAGIMYELWYTASWEKQEDNEKHINWVRSVYNFTTPYVSQNPRLAYLNYRDLDLGKTNPESPNNYTQARIWGEKYFGKNFNRLVKVKTKADPNNFFRNE QSIPPLPPHHHTHC1dNS1 Protein (Source Cannabis sativa) (SEQ ID NO: 58)MFLKHIFVALAFALLADATPAQKRSPGFVALDFDIVKVQKNVTANDDAAAIVAKRQTNPQENFLKCFSEYIPNNPANPKFIYTQHDQLYMSVLNSTIQNLRFTSDTTPKPLVIVTPSNVSHIQASILCSKKVGLQIRTRSGGHDAEGMSYISQVPFVVVDLRNMHSIKIDVHSQTAWVEAGATLGEVYYWINEKNENFSFPGGYCPTVGVGGHFSGGGYGALMRNYGLAADNIIDAHLVNVDGKVLDRKSMGEDLFWAIRGGGGENFGIIAAWKIKLVAVPSKSTIFSVKKNMEIHGLVKLFNKWQNIAYKYDKDLVLMTHFITKNITDNHGKNKTTVHGYFSSIFHGGVDSLVDLMNKSFPELGIKKTDCKEFSWIDTTIFYSGVVNFNTANFKKEILLDRSAGKKTAFSIKLDYVKKPIPETAMVKILEKLYEEDVGVGMYVLYPYGGIMEEISESAIPFPHRAGIMYELWYTASWEKQEDNEKHINWVRSVYNFTTPYVSQNPRLAYLNYRDLDLGKTNPESPNNYTQARIWGEKYFGKNFNRLVKVKTKADPNNFFRNEQSIPPLPPHHHTHC1dNS2 Protein (Source Cannabis sativa) (SEQ ID NO: 59)MQLSLSVLSTVATALLSLTTAVDAKSHNPQENFLKCFSEYIPNNPANPKFIYTQHDQLYMSVLNSTIQNLRFTSDTTPKPLVIVTPSNVSHIQASILCSKKVGLQIRTRSGGHDAEGMSYISQVPFVVVDLRNMHSIKIDVHSQTAWVEAGATLGEVYYWINEKNENFSFPGGYCPTVGVGGHFSGGGYGALMRNYGLAADNIIDAHLVNVDGKVLDRKSMGEDLFWAIRGGGGENFGIIAAWKIKLVAVPSKSTIFSVKKNMEIHGLVKLFNKWQNIAYKYDKDLVLMTHFITKNITDNHGKNKTTVHGYFSSIFHGGVDSLVDLMNKSFPELGIKKTDCKEFSWIDTTIFYSGVVNFNTANFKKEILLDRSAGKKTAFSIKLDYVKKPIPETAMVKILEKLYEEDVGVGMYVLYPYGGIMEEISESAIPFPHRAGIMYELWYTASWEKQEDNEKHINWVRSVYNFTTPYVSQNPRLAYLNYRDLDLGKTNPESPNNYTQARIWGEKYFGKNFNRLVKVKTKADPNNFFR NEQSIPPLPPHHHTHC1dNV1 Protein (Source Cannabis sativa) (SEQ ID NO: 60)MQLSLSVLSTVATALLSLTTAVDAKSHNIKLSKLSNEETLDASTFQEYTSSLANKYMNLFNAAHGNPTSFGLQHVLSNQEAEVPFVTPQKGGNPQENFLKCFSEYIPNNPANPKFIYTQHDQLYMSVLNSTIQNLRFTSDTTPKPLVIVTPSNVSHIQASILCSKKVGLQIRTRSGGHDAEGMSYISQVPFVVVDLRNMHSIKIDVHSQTAWVEAGATLGEVYYWINEKNENFSFPGGYCPTVGVGGHFSGGGYGALMRNYGLAADNIIDAHLVNVDGKVLDRKSMGEDLFWAIRGGGGENFGIIAAWKIKLVAVPSKSTIFSVKKNMEIHGLVKLFNKWQNIAYKYDKDLVLMTHFITKNITDNHGKNKTTVHGYFSSIFHGGVDSLVDLMNKSFPELGIKKTDCKEFSWIDTTIFYSGVVNFNTANFKKEILLDRSAGKKTAFSIKLDYVKKPIPETAMVKILEKLYEEDVGVGMYVLYPYGGIMEEISESAIPFPHRAGIMYELWYTASWEKQEDNEKHINWVRSVYNFTTPYVSQNPRLAYLNYRDLDLGKTNPESPNNYTQARIWGEKYFGKNFNRLVKVKTKADPNNFFRNEQSIPPLPPHHH THC1dNP1 Protein (Source Cannabis sativa)(SEQ ID NO: 61)MSNPQENFLKCFSEYIPNNPANPKFIYTQHDQLYMSVLNSTIQNLRFTSDTTPKPLVIVTPSNVSHIQASILCSKKVGLQIRTRSGGHDAEGMSYISQVPFVVVDLRNMHSIKIDVHSQTAWVEAGATLGEVYYWINEKNENFSFPGGYCPTVGVGGHFSGGGYGALMRNYGLAADNIIDAHLVNVDGKVLDRKSMGEDLFWAIRGGGGENFGIIAAWKIKLVAVPSKSTIFSVKKNMEIHGLVKLFNKWQNIAYKYDKDLVLMTHFITKNITDNHGKNKTTVHGYFSSIFHGGVDSLVDLMNKSFPELGIKKTDCKEFSWIDTTIFYSGVVNFNTANFKKEILLDRSAGKKTAFSIKLDYVKKPIPETAMVKILEKLYEEDVGVGMYVLYPYGGIMEEISESAIPFPHRAGIMYELWYTASWEKQEDNEKHINWVRSVYNFTTPYVSQNPRLAYLNYRDLDLGKTNPESPNNYTQARIWGEKYFGKNFNRLVKVKTKADPNNFFRNEQSIPPLPPHHHGRRAKLCBC1 Protein (Source Cannabis sativa) (SEQ ID NO: 62)MNCSTFSFWFVCKIIFFFLSFNIQISIANPQENFLKCFSEYIPNNPANPKFIYTQHDQLYMSVLNSTIQNLRFTSDTTPKPLVIVTPSNVSHIQASILCSKKVGLQIRTRSGGHDAEGLSYISQVPFAIVDLRNMHTVKVDIHSQTAWVEAGATLGEVYYWINEMNENFSFPGGYCPTVGVGGHFSGGGYGALMRNYGLAADNIIDAHLVNVDGKVLDRKSMGEDLFWAIRGGGGENFGIIAACKIKLVVVPSKATIFSVKKNMEIHGLVKLFNKWQNIAYKYDKDLMLTTHFRTRNITDNHGKNKTTVHGYFSSIFLGGVDSLVDLMNKSFPELGIKKTDCKELSWIDTTIFYSGVVNYNTANFKKEILLDRSAGKKTAFSIKLDYVKKLIPETAMVKILEKLYEEEVGVGMYVLYPYGGIMDEISESAIPFPHRAGIMYELWYTATWEKQEDNEKHINWVRSVYNFTTPYVSQNPRLAYLNYRDLDLGKTNPESPNNYTQARIWGEKYFGKNFNRLVKVKTKADPNNFFRNEQ SIPPLPPRHHPromoters for Use in Candida

Multiple promoters can be used including synthetic ones. The followingare some examples.

PEX11 Promoter Cv (SEQ ID NO: 63)GAGGATGAAGAAGACGAAGACGAATTGGATGAAGATGAAGCGTATGAGTATTATGAGTACTGTCGGACGTTGGAAGGTGGCAGAGTTAAGCCCGAGAAAGCAAGGAAGGAGTGGGAGATGATGAGTGATGCGGCCAAGAGGATGTGAAGGCTGCGTATCTGTTTTTGATAGCTGGTGGTAGCCGAATAGAGGAAGGCAAGCTTGTTCATATTGGATGATGATGGTAGATGGTGGCTGCCAAAGTGGTTGTAAATAGAAAAAAGTGGGTTTGGGTCTGTTGATAGTTAGTGGTGGCGGCTGTCTGTGATTACGTCAGCAAGTAGCACCTCGGCAGTTAAAACAGCAGCAACAGAAAAAAAATGTGTGAAAGTTTGATTCCCCCACAGTCTACCACACCCAGAGTTCCATTTATCCATAATATCACAAGCAATAGAAAAATAAAAAATTATCAACAAATCACAACGAAAAGATTCTGCAAAATTATTTTCACTTCTTCTTTTGACTTCCTCTTCTTCTTGTTAGGTTCTTTCCATATTTTCCCCTTAAACCCATACACAACGCAG CCATPoX4 Promoter CV (SEQ ID NO: 64)GAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTT CACGACATAAPOX2 Promoter CV (SEQ ID NO: 65)GTGCCGACGGAGTAACAAAAATGTTACAGTGCGCACTACTTATCCCGCTAAGGTGATAAACTGCAAAAACACACCGTCAAGGAGAAGTCGACGTTTTGCCGCCACTTGTGAAGGGAAGAAGAGTCGTTGAGTTGATGTAATTAAGCTGGCACGTAGATACCAGAAGGTTCTAGAGTAGAGCTTGGGTGGTGTTTGGCCCTGTTTGGACCACGGATAGAGATGGAGAATCCCTTGGTTAGAGCGGAGAGGAAAAAATTGAAACTTTGCATATCCCACTTCATTATCCTTGATGTAACCGTTTTATGGGGTAATTAAAGTGTGGAAAAATAATCAGGGAGACATATTCCCGATCAATTGGGTGGTGGTCGCTCAATTTCTGTGAGTAGTAGGCTCAGTGGTGTGTATTGGGATTGGTAGTAGTCTGTATAAGCAGTGTTATATAACCCATTGCTTGTTGATTCCTATTTTGCTGGCAAAAGTGACAACTGTAGTTGTGAGATAATCCTCGGTTATTACGCCTGGGGGGGCAGACAGCCAAAGTTGTGCCCGTGCGACAATGGCATCAGAAGAAACAGAAAAAAAAAACACAGGCATTTTTATCCACATGCACACTACCCCCACTATTCCTGTCTGCAGTGTGCTTGTGTGTGGCCCCCCGCAGAATCAACAGGGCAAACTCTGGAGCCTGAATCTTTATATAAACTTCAGGCATTGGCCCCCCTTTTCACAATTCTTCACATCCACCATTTTTTTTCTTCTTTCCTACCATATTAGTTTTTTTTTATTCTTTTCCTACCTATCTGATTATTATCAAACATCTGGTCATCCTCAAAAGAAAGAAAGAAACTATAACA ATCAATCFOX3 Promoter CV (SEQ ID NO: 66)TGGATTATGTAATCACAGGCTGTTTCTCCATTCCTGCATGTAGGCTGGCCCGCGGTATCAACCATCGTCCCGCTTCTTCTGGTTTTTTTTTTTTTTCCGCTATGATATTTTTGATCTCTTGGGGGATTTGGTGGGTCTGCCCCCCCCGCTACTACAAGCTCAAACACCCGAAACCTTACAACACACACACACACATCCCGCTTAGTTGCGGGTTGAAGAACGTGTATTCCCGTAGGGTTAATGGTGTGTCCCCCCCTAGTCACCCGCTTCTGCCATTCTGGGTTTGCCTTCAAAGCTGGCATAAATGACGAAAAAAAAGCACAGCATCCTGCACACAACCCTGCTCAGTGTGACAGGTGGTGGTGTAATAGAAAACCTCGGCTTAAAACCTCTGGTCAGAGCATCAACTGCAATCTTGTCTTTTTCTGCTGCCCTCACATTCTCCCCACACATTCCCACCCTCAAGATTTCACAGGCAAAAACTGCAAATATATATAAATCTACAACCAATTCTTTCCCCAGATGGAAAATCTAATTTTTGTTCACCCTTTTTCTTTCTCCTGCTATCACTGCTACTGCACATATTCAACACCACAACC TEF1 promoter CV (SEQ ID NO: 67)GACTGGGAGAACAGACCAAGGATGCCCATACACCATTAATAACAAGCACACCTTGATAAATCTCTAGTGTTGACAAATTGGTGATTTGAACATGACTGTAGAGAGAGAGACAAGTAACCACTGATGGATTGGTGGTGGCAAATAACCACTTTAAATAAAGACCAACTCACACACAAAGACAGCAGGTCGTGTTCCTATTTCCAATTTTCACAAGGAGAAGAATAAAAATTTTTCAATGAGATTAACTAAAGAAACAGACAGGCAGCCCACAAGAAGAAGAAGAAGAAGAGGAAGAGGAAGAAGAAGAAGAAGAAGAAGAAGAAGAGAAAAAAAATTTTTCCCTCTGCGTTGCGTTGGGCTTGGGTTGCCAGCACCCACCATATATAACTCTCATCAAATACCCAGTAGAGAAAAATTTTTCCTCCCTCTTTTTCTTTCTTTCTTCTCCTTCTTTTGCTACTCTTTCTGTTTTTCATCAAAAAGATATATATAATCAATCATG TDH3 Promoter CV(SEQ ID NO: 68)ACCAAACGTTACTTTTTTTTTGCAATCGGATGGTATGGGTCTGGGGTTCACCTGTTTTGTAAAGCTACAGAAGGTGGCATATTTCTCTGATCAGGTGTTTTTTTTTTCGGCTGCTGCTGCTCGTGGTGGTGTAGTGGTAGTGGTGTGTGTGTGTGTGTGTGCGTGCGTGTGGAAGGACGCTTTTTGCTCTCTGACTCCTCCCAATCAGAAGTTGCTATAGTGGTGAAACAACAATGGATGATAATGCCCCGGGCGGTGCGTGTCCGACACAAACCACTACATTTTTTAGCTGGGAGCCTACTGCCACTACGACCCACCCACCCATGGTCAACAAAAAAATTCTGACAAATTATAAAATAACCCTTGAATTCCCCCTTGGAAAAATTTTTGGTATTTCTCTCTCTCTTTTCCTTTCCCTCTTCTTTTTCTCTCCATCAATCAATTGACGTTCAGTAACTCAATTAATTACATCACATCCCTCAATTAAAGAATTTAAACAATGPromoters for Use in Yarrowia

Multiple promoters can be used including synthetic ones. The followingare some examples.

POX2 Promoter Yl (SEQ ID NO: 69)ACGATTCCGCCAAGTGAGACTGGCGATCGGGAGAAGGGTTGGTGGTCATGGGGGATAGAATTTGTACAAGTGGAAAAACCACTACGAGTAGCGGATTTGATACCACAAGTAGCAGAGATATACAGCAATGGTGGGAGTGCAAGTATCGGAATGTACTGTACCTCCTGTACTCGTACTCGTACGGCACTCGTAGAAACGGGGCAATACGGGGGAGAAGCGATCGCCCGTCTGTTCAATCGCCACAAGTCCGAGTAATGCTTGAGTATCGAAGTCTTGTACCTCCCTGTCAATCATGGCACCACTGGTCTTGACTTGTCTATTCATACTGGACAAGCGCCAGAGTTAAGCTTGTAGCGAATTTCGCCCTCGGACATCACCCCATACGACGGACACACATGCCCGACAAACAGCCTCTCTTATTGTAGCTGAAAGTATATTGAATGTGAACGTGTACAATATCAGGTACCAGCGGGAGGTTACGGCCAAGGTGATACCGGAATAACCCTGGCTTGGAGATGGTCGGTCCATTGTACTGAAGTGTCCGTGTCGTTTCCGTCACTGCCCCAATTGGACATGTTTGTTTTTCCGATCTTTCGGGCGCCCTCTCCTTGTCTCCTTGTCTGTCTCCTGGACTGTTGCTACCCCATTTCTTTGGCCTCCATTGGTTCCTCCCCGTCTTTCACGTCGTCTATGGTTGCATGGTTTCCCTTATACTTTTCCCCACAGTCACATGTTATGGAGGGGTCTAGATGGAGGCCTAATTTTGACGTGCAAGGGGCGAATTGGGGCGAGAAACACGTCGTGGACATGGTGCAAGGCCCGCAGGGTTGATTCGACGCTTTTCCGCGAAAAAAACAAGTCCAAATACCCCCGTTTATTCTCCCTCGGCTCTCGGTATTTCACATGAAAACTATAACCTAGACTACACGGGCAACCTTAACCCCAGAGTATACTTATATACCAAAGGGATGGGTCCTCAAAAATCACACAAGCAACGACGCCATGA LIP2 promoter Yl (SEQ ID NO: 70)AAACTTCTCCGAGTCTGTGCCTTCAGGTGGGCATAGTTGATGGGTGTTTTGAAGTTAATAGTGGGGAAGAACTATGGCAAACAAGCAGATGCAGGCACCTTGTAACTGCAGACCGGTTCTTGTCTACCGACTCCGCTGCACCTGTGCCGCGGTACATGTCGTCACAGGCTGCGGGGTTCGGAGGCCCCCTTGCAACCTCCTTTGATAGTTGCTATGGCCCCAAAGAGTTATACGAGATAGACCCACAGATCTACTTGACTGTTGTCACAGAACCTGCTAGGTTTGCTTATTGTACCCGCTTTGTAGCTACTGTACAACGACAACGTCAAAAATTGAGACGCGAACAAACTCCAGATGCAGAACCCAAACCTCTCTCTCAGAGTTTCGAGTGCTTCTACCTCACAGTAAAGTGGAGGTGGACCTGCAAGGGAATTCAGTCACAAGGCCCCGAATGTCTCCGAAACTCCAATCGGACCGTTTAAACAGACTAATATCACGTCATTGATTGATATTAGCATCCGGCAAGAGCCGCAAGGTTATCTCCTCACCAATGAGCCTGTTGTACGGCTCATTCCGCATCTGCGGCTGATTCAGTTTCGAGTGGGGATGGTAGACTTCATTGCAGCATTCCTAACCTTCTACTTGGTCCGTGGAGATGTCATGGACATCGATTTTGGGCTGAGAAGCCTTTTGACGATGTTGATATCACTGACCGCTAATTTACTCTGGCAGTTTCTCCGGCTCTCGAGGCATCGTCGATCACCAAACACTATCTGCTAGTCTAAATGTCCGACACGACAGCTTTTGATCGCCGTGAACGGCGCAGACCTCATGCACCATGCACCAGGGCCAAATCAATTACGGGTCGCTTAGCGTTGCAGTCGGGGCATTATGGTGGAAGTTCCGATACGGCACAGACACATTCCATAGTGGGGGGATTGGATTATAAAAGGGCCATAGAAAGCCCTCAATTGATACCCAAGTACCAGCTCTCCTCACTATGA ICL1 Promoter Yk (SEQ ID NO: 71)GACCCCCTCCTTTTGCCAGTATATCCACCGCAACACCCACCATGAGCGACATCTGATACCGTGCCGCGACCACTACCCCAAATAAGCTCCAACTAATATGCCGAGGCAGGTGGGAAACTATGCACTCCAGACGACGCTGTAGAAGCACATGGAAGGTGCGGAGGCGGTGGCAACGAGGGGCATGAGCCATCAACGAGTAACCACAGACAAGGCAAGGGGGGAAACGCGACCGGAATCTCTCGCGGTCACGTGACCCGCCCGGGTTCCACTCGTCCATGTTGTGTCTCTGGTGTCTTCGGCCGACTCGCATTGGTTAAACTTCCACCACCGCAATCACGTCCCACTGGCCAAACTTTTTCTGCTTTCTCTGACTTTTTCTGGCCAAAAGGCAACGTCGGAAAGGGTCGGGAGGATTCGGAACCGACGAAAATCGGCCGGCTCCAGCGGGGGTAGTTCGGCAGTCCTGGTGGGAGCTCTAGGGGAGCTGTGGTCTGTGTAGGGCGCGGGTCCGGGTTTGTTGGGTGTCAAATCACGTGTTTTTGCCCCCCCGCTGAGCCGGACTCCGACAACCGTGTCTCCAACGGCCTGACTAAGCTGCTCCCAGCACTCTGCCGTAGCGTTGGTCTGTCCTGTCGCACTCTGTTCAAAGACAGAAGAAAGAAAAAGCTAACCTCCACGTCAGAGACAATGGTAGAAGGCTTGTTCCTTGCAACCGAGGAGAGTGAGTGTTCTCGGCACGAGCATCATGGGCGATCTGGAGGGTATTTTTGAGGGGAAAAAACGGGATCAGGACAAACAGAGGCCACAGACCGGGAATCTGGGCCCCAAAACGGCCTTTTCCCGTCGCAAAACCGGTCTACATACACCCCTTCGGCCCGCCACAGGCCGGTGTGAAAAACCCTAAAGCTTGCTTCAAACCAGACGGACGCACAGCAAGACACATCATGAAGAGTCACCTGCAGTATATATAGATCTGGGGATTCCCAGTAGACTGACCAAGCATACAAAAGTGAGTATCCAACAGCGACACGTGAGATGGCAGAGACACAGAGACGTGTCTACATGGTTGGACAAGTCTCCACATTCGCCAGAGACGTATCCACATACAAACACAATCTCACAGCTGATCTGCTCCTGTGACAGCACAGTACATGTTAGTGGATGAGGTGTTGTGTAGTGGGTTAAATGGGTGGACTGATTCAGTGGCATCGGTGGCGACACCCTCTACTCTTCATGTCGTCACCTACCGTTCGGAATCCCAATTATCTGATGAACTAAACGATTTCTGGCCAAAACACAATTTTGCCAAAGAAGTCGTTCTCACCAATGCAAGTGTCACATCAAACATCTGTCCCGT ACTAACCCAGPOT1 Promoter Yl (SEQ ID NO: 72)CCACAATACCCCACAGTGTGCATATCAAACCTACCGGTTGTTGCTCTCTCCAGCCTTACTAAGAAGGAGGCGACGTGGCAGTGGCTCGCGGGAGGATCGGCGGGAAACTCCGGGATATCCGTCGAGAGTTTACACGTGAATGGGCAGCGCAATCCGTTGACGACGATACGACTGGCAAAGTAGCGACGATACCTGCCAGACAGGTGACATGTGCAGGCCGCACTAACAAGGAAACGGGCGCTGGGGGGGGCGGGCTTCTAGACTTTGCCCTTGAACAGGAATCTAGTGGGGGCTTGTCTTTCCGCCAATGGGGGAGCGCCTGTTGAGCGACCGTGCATGCTGGAACGCCAAGTGTATGTACAGCTGGTGTTCTCGCAGCGGTATGTGACGGGACTTACATCTCTCGTTTTTTCATGACCACGTTTTCACAGGCTCGGAGGTACGTTAAAGTTTTGAAGGCTGCATCTGAACCGAGGTATGGGGGAGTTTGAGGAGCAACAGTGTTGGGGCTGAGGGGGCCAAGATCGGGGCAAGCAGAGGTCTTAGATCAATTGTGGGAATCCCAAAGGGCTCGTTATCACCTTTTTCCACCCAATTCGGGTCCCAATTGATCCACTACTGGCTTGCCCAAGTTACCCCAGAAATGCCGCCCCGGATTTCTCCAAAAACCTAATAAGCTTCATGGAACTTGGTGGAAGTGACTTTCTACAGAGTGGAGAGAACCGTGGACACGTGGCAATGGCGCTGACCGTGTCCCCGAGCCGAATCGACGTGAGGGGAGAACGGAGTATCTGCGGTCATGTGACCTTCCAGAGCGGCGTCGCCAGTGTGCACGCGGTGACCCCCAGTTTGGTTCTCTGTCACACGCATACTACCTCGGCTCTCCACATGCTGAACTTTATCTTTCGTGGGGATCATACCGAAAGTTGCAACTACCAGGTGTATATAAAGCCTGGTAGACTCCCCCCACTTTGGACCTCATCCAACCAAGACACACAAAAATGTerminators to Use in Candida viswanathii

Multiple terminators can be used. The following are some examples.

POX4 Terminator Cv (SEQ ID NO: 73)GAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGAC PEX11 Terminator CV (SEQ ID NO: 74)AGCTCCAGGCTTGTTATGACTCTAGAGAGAAGTGTGTGTGTTTGCGTTTGTTTTACTATACATTCAACATGTTCTTTTTCTTTTTTGATATTTATTCCAACTATAATTATACACAGATTCGTATATACTTTACTTTACCCTCTTTCGTAGTTTTTTAATTTGATGATTTTTGAGTTTCATATCCAAGGTCAAAACCCGACTerminators to Use in Yarrowia lipolytica

Multiple terminators can be used. The following are some examples.

XPR2 Terminato Yl (SEQ ID NO: 75)TAGGCAATTAACAGATAGTTTGCCGGTGATAATTCTCTTAACCTCCCACACTCCTTTGACATAACGATTTATGTAACGAAACTGAAATTTGACCAGATATTGTTGTAAATAGAAAATCTGGCTTGTAGGTGGCAAAATGCGGCGTCTTTGTTCATCAATTCCCTCTGTGACTACTCGTCATCCCTTTATGTTCGACTGTCGTATTTCTTATTTTCCATACATATGCAAGTGAGATGCCCGTGTCCGAATTC TDH3 terminator YL (SEQ ID NO: 76)CTTCCGAGTAGCTATCCGAAGATCAAGAGCGAAGCAAGTTGTAAGTCCAGGACATGTTTCCCGCCCACGCGAGTGATTTATAACACCTCTCTTTTTTGACACCCGCTCGCCTTGAAATTCATGTCACATAAATTATAGTCAACGACGTTTGAATAACTTGTCTTGTAGTTCGATGATGATCATATGATTACATTAATAGTAATTACTGTATTTGATATATATACTAATTACAATAGTACATATTAGAACATACAATAGTTAGTGCCGTGAAGTGGCTTAAAATACCGCGAGTCGATTACGTAATATTA Markers for use in Yarrowia LEU2 Marker Yl(SEQ ID NO: 77)AACGTACCACTGTCCTCCACTACAAACACACCCAATCTGCTTCTTCTAGTCAAGGTTGCTACACCGGTAAATTATAAATCATCATTTCATTAGCAGGGCTGGGCCCTTTTTATAGAGTCTTATACACTAGCGGACCCTGCCGGTAGACCAACCCGCAGGCGCGTCAGTTTGCTCCTTCCATCAATGCGTCGTAGAAACGACTTACTCCTTCTTGAGCAGCTCCTTGACCTTGTTGGCAACAAAGTCTCCGACCTCGGAGGTGGAGGAGGAGCCTCCGATATCGGCGGTAGTGATACCAGCCTCGACGGACTCCTTGACGGCAGCCTCAACAGCGTCACCGGCGGGCTTCATGTTAAGAGAGAACTTGAGCATCATGGCGGCAGACAGAATGGTGGCAATGGGGTTGACCTTCTGCTTGCCGAGATCGGGGGCAGATCCGTGACAGGGCTCGTACAGACCGAACGCCTCGTTGGTGTCGGGCAGAGAAGCCAGAGAGGCGGAGGGCAGCAGACCCAGAGAACCGGGGATGACGGAGGCCTCGTCGGAGATGATATCGCCAAACATGTTGGTGGTGATGATGATACCATTCATCTTGGAGGGCTGCTTGATGAGGATCATGGCGGCCGAGTCGATCAGCTGGTGGTTGAGCTCCAGCTGGGGGAATTCGTCCTTGAGGACTCGGGTGACGGTCTTTCGCCAAAGTCGAGAGGAGGCCAGCACGTTGGCCTTGTCAAGGGACCACACGGGAAGAGGGGGGTTGTGCTGAAGGGCCAGGAAGGCGGCCATTCGGGCAATTCGCTCAACCTCAGGAACGGAGTAAGTCTCAGTGTCGGAAGCGACGCCAGATCCGTCATCCTCCTTTCGCTCTCCAAAGTAGATACCTCCGACGAGCTCTCGGACAATGATGAAGTCGGTGCCCTCAACGTTTCGGATGGGGGAGAGATCGGCGAGCTTGGGCGACAGCAGCTGGCAGGGTCGCAGGTTGGCGTACAGGTTCAGGTCCTTTCGCAGCTTGAGAAGACCCTGCTCGGGTCGCACGTCGGTTCGTCCGTCGGGAGTGGTCCATACGGTGTTGGCAGCGCCTCCGACAGCACCGAGCATAATAGAGTCAGCCTTTCGGCAGATGTCGAGAGTAGCGTCGGTGATGGGCTCGCCCTCCTTCTCAATGGCAGCTCCTCCAATGAGTCGGTCCTCAAACACAAACTCGGTGCCGGAGGCCTCAGCAACAGACTTGAGCACCTTGACGGCCTCGGCAATCACCTCGGGGCCACAGAAGTCGCCGCCGAGAAGAACAATCTTCTTGGAGTCAGTCTTGGTCTTCTTAGTTTCGGGTTCCATTGTGGATGTGTGTGGTTGTATGTGTGATGTGGTGTGTGGAGTGAAAATCTGTGGCTGGCAAACGCTCTTGTATATATACGCACTTTTGCCCGTGCTATGTGGAAGACTAAACCTCCGAAGATTGTGACTCAGGTAGTGCGGTATCGGCTAGGGACCCAAACCTTGTCGATGCCGATAGCGCTATCGAACGTACCCCAGCCGGCCGGGAGTATGTCGGAGGGGACATACGAGATCGTCAAGGGTTTGTGGCCAACTGGTAAATAAATGATGACTCAGGCGACGACGGAATTCGACAGCAACTACTCCTTTCACCAACCATGTGCATTTTAGCTCGAATAACATTCACAGGCTTGGTGATCTACATCCATGGTGTCTGGCCGATTACCGTGGTGTTTTGGCAGTAACGAGAATATTGAGTGAACTCTTCCCATCACCAATAAAGACTCATACTACAATCACGAGCGCTTCAGCTGCCACTATAGTGTTGGTGACACAATACCCCTCGATGCTGGGCATTACTGTAGCAAGAGATATTATTTCATGGCGCATTTTCCAGTCTACCTGACTTTTTAGTGTGATTTCTTCTCCACATTTTATGCTCAGTGTGAAAAGTTGGAGTGCACACTTAATTATCGCCGGTTTTCGGAAAGTACTATGTGCTCAAGGTTGCACCCCACGTTACGTATGCAGCACATTGAGCAGCCTTTGGACCGTGGAGATAACGGTGTGGAGATAGCAACGGGTAGTCTTCGTATTAATTCAATGCATTGTTAGTTTTATATGATATGGTGTCGA URA3 Marker Yl (SEQ ID NO: 78)TTTCTAATTTGGACCGATAGCCGTATAGTCCAGTCTATCTATAAGTTCAACTAACTCGTAACTATTACCATAACATATACTTCACTGCCCCAGATAAGGTTCCGATAAAAAGTTGTGCAGACTAAATTTATTTCAGTCTCCTCTTCACCACCAAAATGCCCTCCTACGAAGCGCGAGCTAACGTCCACAAGTCCGCCTTTGCCGCCCGAGTGCTCAAGCTCGTGGCAGCCAAGAAAACCAACCTGTGTGCTTCTCTGGATGTTACCACCACCAAGGAGCTCATTGAGCTTGCCGATAAGGTCGGACCTTATGTGTGCATGATCAAGACCCATATCGACATCATTGACGACTTCACCTACGCCGGAACTGTGCTCCCCCTCAAGGAACTTGCTCTTAAGCACGGTTTCTTCCTGTTCGAGGACAGAAAGTTCGCAGATATTGGCAACACTGTCAAGCACCAGTACAAGAACGGTGTCTACCGAATCGCCGAGTGGTCCGATATCACCAACGCCCACGGTGTACCCGGAACCGGAATCATTGCTGGCCTGCGAGCTGGTGCCGAGGAAACTGTCTCTGAACAGAAGAAGGAGGATGTCTCTGACTACGAGAACTCCCAGTACAAGGAGTTCCTGGTCCCCTCTCCCAACGAGAAGCTGGCCAGAGGTCTGCTCATGCTGGCCGAGCTGTCTTGCAAGGGCTCTCTGGCCACTGGCGAGTACTCCAAGCAGACCATTGAGCTTGCCCGATCCGACCCCGAGTTTGTGGTTGGCTTCATTGCCCAGAACCGACCTAAGGGCGACTCTGAGGACTGGCTTATTCTGACCCCCGGGGTGGGTCTTGACGACAAGGGAGATGCTCTCGGACAGCAGTACCGAACTGTTGAGGATGTCATGTCTACCGGAACGGATATCATAATTGTCGGCCGAGGTCTGTACGGCCAGAACCGAGATCCTATTGAGGAGGCCAAGCGATACCAGAAGGCTGGCTGGGAGGCTTACCAGAAGATTAACTGTTAGAGGTTAGACTATGGATATGTCATTTAACTGTGTATATAGAGAGCGTGCAAGTATGGAGCGCTTGTTCAGCTTGTATGATGGTCAGACGACCTGTCTGATCGAGTATGTATGATACTGCA CAACCTGPolynucleotides and Polypeptides

A nucleic acid (e.g., also referred to herein as nucleic acid reagent,target nucleic acid, target nucleotide sequence, nucleic acid sequenceof interest or nucleic acid region of interest) can be from any sourceor composition, such as DNA, cDNA, gDNA (genomic DNA), RNA, siRNA (shortinhibitory RNA), RNAi, tRNA or mRNA, for example, and can be in any form(e.g., linear, circular, supercoiled, single-stranded, double-stranded,and the like). A nucleic acid can also comprise DNA or RNA analogs(e.g., containing base analogs, sugar analogs and/or a non-nativebackbone and the like). It is understood that the term “nucleic acid”does not refer to or infer a specific length of the polynucleotidechain, thus polynucleotides and oligonucleotides are also included inthe definition. Deoxyribonucleotides include deoxyadenosine,deoxycytidine, deoxyguanosine and deoxythymidine. For RNA, the uracilbase is uridine.

A nucleic acid sometimes is a plasmid, phage, autonomously replicatingsequence (ARS), centromere, artificial chromosome, yeast artificialchromosome (e.g., YAC) or other nucleic acid able to replicate or bereplicated in a host cell. In certain embodiments a nucleic acid can befrom a library or can be obtained from enzymatically digested, shearedor sonicated genomic DNA (e.g., fragmented) from an organism ofinterest. In some embodiments, nucleic acid subjected to fragmentationor cleavage may have a nominal, average or mean length of about 5 toabout 10,000 base pairs, about 100 to about 1,000 base pairs, about 100to about 500 base pairs, or about 10, 15, 20, 25, 30, 35, 40, 45, 50,55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 200, 300, 400, 500, 600, 700,800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000 or 10000base pairs. Fragments can be generated by any suitable method in theart, and the average, mean or nominal length of nucleic acid fragmentscan be controlled by selecting an appropriate fragment-generatingprocedure by the person of ordinary skill. In some embodiments, thefragmented DNA can be size selected to obtain nucleic acid fragments ofa particular size range.

Nucleic acid can be fragmented by various methods known to the person ofordinary skill, which include without limitation, physical, chemical andenzymic processes. Examples of such processes are described in U.S.Patent Application Publication No. 20050112590 (published on May 26,2005, entitled “Fragmentation-based methods and systems for sequencevariation detection and discovery,” naming Van Den Boom et al.). Certainprocesses can be selected by the person of ordinary skill to generatenon-specifically cleaved fragments or specifically cleaved fragments.Examples of processes that can generate non-specifically cleavedfragment sample nucleic acid include, without limitation, contactingsample nucleic acid with apparatus that expose nucleic acid to shearingforce (e.g., passing nucleic acid through a syringe needle; use of aFrench press); exposing sample nucleic acid to irradiation (e.g., gamma,x-ray, UV irradiation; fragment sizes can be controlled by irradiationintensity); boiling nucleic acid in water (e.g., yields about 500 basepair fragments) and exposing nucleic acid to an acid and base hydrolysisprocess.

Nucleic acid may be specifically cleaved by contacting the nucleic acidwith one or more specific cleavage agents. The term “specific cleavageagent” as used herein refers to an agent, sometimes a chemical or anenzyme that can cleave a nucleic acid at one or more specific sites.Specific cleavage agents often will cleave specifically according to aparticular nucleotide sequence at a particular site. Examples of enzymicspecific cleavage agents include without limitation endonucleases (e.g.,DNase (e.g., DNase I, II); RNase (e.g., RNase E, F, H, P); Cleavase™enzyme; Taq DNA polymerase; E. coli DNA polymerase I and eukaryoticstructure-specific endonucleases; murine FEN-1 endonucleases; type I, IIor III restriction endonucleases such as Acc I, Afl III, Alu I, Alw44 I,Apa I, Asn I, Ava I, Ava II, BamH I, Ban II, Bcl I, Bgl I. Bgl II, BlnI, Bsa I, Bsm I, BsmBI, BssH II, BstE II, Cfo I, Cla I, Dde I, Dpn I,Dra I, EclX I, EcoR I, EcoR I, EcoR II, EcoR V, Hae II, Hae II, HindIII, Hind III, Hpa I, Hpa II, Kpn I, Ksp I, Mlu I, MluN I, Msp I, Nci I,Nco I, Nde I, Nde II, Nhe I, Not I, Nru I, Nsi I, Pst I, Pvu I, Pvu II,Rsa I, Sac I, Sap I, Sal I, Sau3A I, Sca I, ScrF I, Sfi I, Sma I, Spe I,Sph I, Ssp I, Stu I, Sty I, Swa I, Taq I, Xba I, Xho I); glycosylases(e.g., uracil-DNA glycolsylase (UDG), 3-methyladenine DNA glycosylase,3-methyladenine DNA glycosylase II, pyrimidine hydrate-DNA glycosylase,FaPy-DNA glycosylase, thymine mismatch-DNA glycosylase, hypoxanthine-DNAglycosylase, 5-Hydroxymethyluracil DNA glycosylase (HmUDG),5-Hydroxymethylcytosine DNA glycosylase, or 1,N6-etheno-adenine DNAglycosylase); exonucleases (e.g., exonuclease III); ribozymes, andDNAzymes. Sample nucleic acid may be treated with a chemical agent, orsynthesized using modified nucleotides, and the modified nucleic acidmay be cleaved. In non-limiting examples, sample nucleic acid may betreated with (i) alkylating agents such as methylnitrosourea thatgenerate several alkylated bases, including N3-methyladenine andN3-methylguanine, which are recognized and cleaved by alkyl purineDNA-glycosylase; (ii) sodium bisulfite, which causes deamination ofcytosine residues in DNA to form uracil residues that can be cleaved byuracil N-glycosylase; and (iii) a chemical agent that converts guanineto its oxidized form, 8-hydroxyguanine, which can be cleaved byformamidopyrimidine DNA N-glycosylase. Examples of chemical cleavageprocesses include without limitation alkylation, (e.g., alkylation ofphosphorothioate-modified nucleic acid); cleavage of acid lability ofP3′-N5′-phosphoroamidate-containing nucleic acid; and osmium tetroxideand piperidine treatment of nucleic acid.

As used herein, the term “complementary cleavage reactions” refers tocleavage reactions that are carried out on the same nucleic acid usingdifferent cleavage reagents or by altering the cleavage specificity ofthe same cleavage reagent such that alternate cleavage patterns of thesame target or reference nucleic acid or protein are generated. Incertain embodiments, nucleic acids of interest may be treated with oneor more specific cleavage agents (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ormore specific cleavage agents) in one or more reaction vessels (e.g.,nucleic acid of interest is treated with each specific cleavage agent ina separate vessel).

A nucleic acid suitable for use in the embodiments described hereinsometimes is amplified by any amplification process known in the art(e.g., PCR, RT-PCR and the like). Nucleic acid amplification may beparticularly beneficial when using organisms that are typicallydifficult to culture (e.g., slow growing, require specialize cultureconditions and the like). The terms “amplify”, “amplification”,“amplification reaction”, or “amplifying” as used herein, refer to anyin vitro processes for multiplying the copies of a target sequence ofnucleic acid. Amplification sometimes refers to an “exponential”increase in target nucleic acid. However, “amplifying” as used hereincan also refer to linear increases in the numbers of a select targetsequence of nucleic acid, but is different than a one-time, singleprimer extension step. In some embodiments, a limited amplificationreaction, also known as pre-amplification, can be performed.Pre-amplification is a method in which a limited amount of amplificationoccurs due to a small number of cycles, for example 10 cycles, beingperformed. Pre-amplification can allow some amplification, but stopsamplification prior to the exponential phase, and typically producesabout 500 copies of the desired nucleotide sequence(s). Use ofpre-amplification may also limit inaccuracies associated with depletedreactants in standard PCR reactions.

In some embodiments, a nucleic acid reagent sometimes is stablyintegrated into the chromosome of the host organism, or a nucleic acidreagent can be a deletion of a portion of the host chromosome, incertain embodiments (e.g., genetically modified organisms, wherealteration of the host genome confers the ability to selectively orpreferentially maintain the desired organism carrying the geneticmodification). Such nucleic acid reagents (e.g., nucleic acids orgenetically modified organisms whose altered genome confers a selectabletrait to the organism) can be selected for their ability to guideproduction of a desired protein or nucleic acid molecule. When desired,the nucleic acid reagent can be altered such that codons encode for (i)the same amino acid, using a different tRNA than that specified in thenative sequence, or (ii) a different amino acid than is normal,including unconventional or unnatural amino acids (including detectablylabeled amino acids). As described herein, the term “native sequence”refers to an unmodified nucleotide sequence as found in its naturalsetting (e.g., a nucleotide sequence as found in an organism).

A nucleic acid or nucleic acid reagent can comprise certain elementsoften selected according to the intended use of the nucleic acid. Any ofthe following elements can be included in or excluded from a nucleicacid reagent. A nucleic acid reagent, for example, may include one ormore or all of the following nucleotide elements: one or more promoterelements, one or more 5′ untranslated regions (5′UTRs), one or moreregions into which a target nucleotide sequence may be inserted (an“insertion element”), one or more target nucleotide sequences, one ormore 3′ untranslated regions (3′UTRs), and one or more selectionelements. A nucleic acid reagent can be provided with one or more ofsuch elements and other elements may be inserted into the nucleic acidbefore the nucleic acid is introduced into the desired organism. In someembodiments, a provided nucleic acid reagent comprises a promoter, 5′UTR, optional 3′ UTR and insertion element(s) by which a targetnucleotide sequence is inserted (i.e., cloned) into the nucleotide acidreagent. In certain embodiments, a provided nucleic acid reagentcomprises a promoter, insertion element(s) and optional 3′ UTR, and a 5′UTR/target nucleotide sequence is inserted with an optional 3′UTR. Theelements can be arranged in any order suitable for expression in thechosen expression system (e.g., expression in a chosen organism, orexpression in a cell free system, for example), and in some embodimentsa nucleic acid reagent comprises the following elements in the 5′ to 3′direction: (1) promoter element, 5′UTR, and insertion element(s); (2)promoter element, 5′UTR, and target nucleotide sequence; (3) promoterelement, 5′UTR, insertion element(s) and 3′ UTR; and (4) promoterelement, 5′ UTR, target nucleotide sequence and 3′ UTR.

A promoter element typically is required for DNA synthesis and/or RNAsynthesis. A promoter element often comprises a region of DNA that canfacilitate the transcription of a particular gene, by providing a startsite for the synthesis of RNA corresponding to a gene. Promotersgenerally are located near the genes they regulate, are located upstreamof the gene (e.g., 5′ of the gene), and are on the same strand of DNA asthe sense strand of the gene, in some embodiments.

A promoter often interacts with a RNA polymerase. A polymerase is anenzyme that catalyses synthesis of nucleic acids using a preexistingnucleic acid reagent. When the template is a DNA template, an RNAmolecule is transcribed before protein is synthesized. Enzymes havingpolymerase activity suitable for use in the present methods include anypolymerase that is active in the chosen system with the chosen templateto synthesize protein. In some embodiments, a promoter (e.g., aheterologous promoter) also referred to herein as a promoter element,can be operably linked to a nucleotide sequence or an open reading frame(ORF). Transcription from the promoter element can catalyze thesynthesis of an RNA corresponding to the nucleotide sequence or ORFsequence operably linked to the promoter, which in turn leads tosynthesis of a desired peptide, polypeptide or protein. The term“operably linked” as used herein with respect to promoters refers to anucleic acid sequence (e.g., a coding sequence) present on the samenucleic acid molecule as a promoter element and whose expression isunder the control of said promoter element.

Promoter elements sometimes exhibit responsiveness to regulatorycontrol. Promoter elements also sometimes can be regulated by aselective agent. That is, transcription from promoter elements sometimescan be turned on, turned off, up-regulated or down-regulated, inresponse to a change in environmental, nutritional or internalconditions or signals (e.g., heat inducible promoters, light regulatedpromoters, feedback regulated promoters, hormone influenced promoters,tissue specific promoters, oxygen and pH influenced promoters, promotersthat are responsive to selective agents (e.g., kanamycin) and the like,for example). Promoters influenced by environmental, nutritional orinternal signals frequently are influenced by a signal (direct orindirect) that binds at or near the promoter and increases or decreasesexpression of the target sequence under certain conditions.

Non-limiting examples of selective or regulatory agents that caninfluence transcription from a promoter element used in embodimentsdescribed herein include, without limitation, (1) nucleic acid segmentsthat encode products that provide resistance against otherwise toxiccompounds (e.g., antibiotics); (2) nucleic acid segments that encodeproducts that are otherwise lacking in the recipient cell (e.g.,essential products, tRNA genes, auxotrophic markers); (3) nucleic acidsegments that encode products that suppress the activity of a geneproduct; (4) nucleic acid segments that encode products that can bereadily identified (e.g., phenotypic markers such as antibiotics (e.g.,β-lactamase), β-galactosidase, green fluorescent protein (GFP), yellowfluorescent protein (YFP), red fluorescent protein (RFP), cyanfluorescent protein (CFP), and cell surface proteins); (5) nucleic acidsegments that bind products that are otherwise detrimental to cellsurvival and/or function; (6) nucleic acid segments that otherwiseinhibit the activity of any of the nucleic acid segments described inNos. 1-5 above (e.g., antisense oligonucleotides); (7) nucleic acidsegments that bind products that modify a substrate (e.g., restrictionendonucleases); (8) nucleic acid segments that can be used to isolate oridentify a desired molecule (e.g., specific protein binding sites); (9)nucleic acid segments that encode a specific nucleotide sequence thatcan be otherwise non-functional (e.g., for PCR amplification ofsubpopulations of molecules); (10) nucleic acid segments that, whenabsent, directly or indirectly confer resistance or sensitivity toparticular compounds; (11) nucleic acid segments that encode productsthat either are toxic or convert a relatively non-toxic compound to atoxic compound (e.g., Herpes simplex thymidine kinase, cytosinedeaminase) in recipient cells; (12) nucleic acid segments that inhibitreplication, partition or heritability of nucleic acid molecules thatcontain them; and/or (13) nucleic acid segments that encode conditionalreplication functions, e.g., replication in certain hosts or host cellstrains or under certain environmental conditions (e.g., temperature,nutritional conditions, and the like). In some embodiments, theregulatory or selective agent can be added to change the existing growthconditions to which the organism is subjected (e.g., growth in liquidculture, growth in a fermentor, growth on solid nutrient plates and thelike for example).

In some embodiments, regulation of a promoter element can be used toalter (e.g., increase, add, decrease or substantially eliminate) theactivity of a peptide, polypeptide or protein (e.g., enzyme activity forexample). For example, a microorganism can be engineered by geneticmodification to express a nucleic acid reagent that can add a novelactivity (e.g., an activity not normally found in the host organism) orincrease the expression of an existing activity by increasingtranscription from a homologous or heterologous promoter operably linkedto a nucleotide sequence of interest (e.g., homologous or heterologousnucleotide sequence of interest), in certain embodiments. In someembodiments, a microorganism can be engineered by genetic modificationto express a nucleic acid reagent that can decrease expression of anactivity by decreasing or substantially eliminating transcription from ahomologous or heterologous promoter operably linked to a nucleotidesequence of interest, in certain embodiments.

In some embodiments the activity can be altered using recombinant DNAand genetic techniques known to the artisan. Methods for engineeringmicroorganisms are further described herein. Tables herein providenon-limiting lists of yeast promoters that are up-regulated by oxygen,yeast promoters that are down-regulated by oxygen, yeast transcriptionalrepressors and their associated genes, DNA binding motifs as determinedusing the MEME sequence analysis software. Potential regulator bindingmotifs can be identified using the program MEME to search intergenicregions bound by regulators for overrepresented sequences. For eachregulator, the sequences of intergenic regions bound with p-values lessthan 0.001 were extracted to use as input for motif discovery. The MEMEsoftware was run using the following settings: a motif width rangingfrom 6 to 18 bases, the “zoops” distribution model, a 6th order Markovbackground model and a discovery limit of 20 motifs. The discoveredsequence motifs were scored for significance by two criteria: an E-valuecalculated by MEME and a specificity score. The motif with the bestscore using each metric is shown for each regulator. All motifspresented are derived from datasets generated in rich growth conditionswith the exception of a previously published dataset for epitope-taggedGal4 grown in galactose.

In some embodiments, the altered activity can be found by screening theorganism under conditions that select for the desired change inactivity. For example, certain microorganisms can be adapted to increaseor decrease an activity by selecting or screening the organism inquestion on a media containing substances that are poorly metabolized oreven toxic. An increase in the ability of an organism to grow asubstance that is normally poorly metabolized would result in anincrease in the growth rate on that substance, for example. A decreasein the sensitivity to a toxic substance might be manifested by growth onhigher concentrations of the toxic substance, for example. Geneticmodifications that are identified in this manner sometimes are referredto as naturally occurring mutations or the organisms that carry them cansometimes be referred to as naturally occurring mutants. Modificationsobtained in this manner are not limited to alterations in promotersequences. That is, screening microorganisms by selective pressure, asdescribed above, can yield genetic alterations that can occur innon-promoter sequences, and sometimes also can occur in sequences thatare not in the nucleotide sequence of interest, but in a relatednucleotide sequences (e.g., a gene involved in a different step of thesame pathway, a transport gene, and the like). Naturally occurringmutants sometimes can be found by isolating naturally occurring variantsfrom unique environments, in some embodiments.

In addition to the regulated promoter sequences, regulatory sequences,and coding polynucleotides provided herein, a nucleic acid reagent mayinclude a polynucleotide sequence 70% or more identical to the foregoing(or to the complementary sequences). That is, a nucleotide sequence thatis at least 70% or more, 71% or more, 72% or more, 73% or more, 74% ormore, 75% or more, 76% or more, 77% or more, 78% or more, 79% or more,80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% ormore, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more,91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% ormore, 97% or more, 98% or more, or 99% or more identical to a nucleotidesequence described herein can be utilized. The term “identical” as usedherein refers to two or more nucleotide sequences having substantiallythe same nucleotide sequence when compared to each other. One test fordetermining whether two nucleotide sequences or amino acids sequencesare substantially identical is to determine the percent of identicalnucleotide sequences or amino acid sequences shared.

Calculations of sequence identity can be performed as follows. Sequencesare aligned for optimal comparison purposes (e.g., gaps can beintroduced in one or both of a first and a second amino acid or nucleicacid sequence for optimal alignment and non-homologous sequences can bedisregarded for comparison purposes). The length of a reference sequencealigned for comparison purposes is sometimes 30% or more, 40% or more,50% or more, often 60% or more, and more often 70% or more, 80% or more,90% or more, or 100% of the length of the reference sequence. Thenucleotides or amino acids at corresponding nucleotide or polypeptidepositions, respectively, are then compared among the two sequences. Whena position in the first sequence is occupied by the same nucleotide oramino acid as the corresponding position in the second sequence, thenucleotides or amino acids are deemed to be identical at that position.The percent identity between the two sequences is a function of thenumber of identical positions shared by the sequences, taking intoaccount the number of gaps, and the length of each gap, introduced foroptimal alignment of the two sequences.

Comparison of sequences and determination of percent identity betweentwo sequences can be accomplished using a mathematical algorithm.Percent identity between two amino acid or nucleotide sequences can bedetermined using the algorithm of Meyers & Miller, CABIOS 4: 11-17(1989), which has been incorporated into the ALIGN program (version2.0), using a PAM120 weight residue table, a gap length penalty of 12and a gap penalty of 4. Also, percent identity between two amino acidsequences can be determined using the Needleman & Wunsch, J. Mol. Biol.48: 444-453 (1970) algorithm which has been incorporated into the GAPprogram in the GCG software package (available at the http address atworld wide web uniform resource locator gcg.com), using either a Blossum62 matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6,or 4 and a length weight of 1, 2, 3, 4, 5, or 6. Percent identitybetween two nucleotide sequences can be determined using the GAP programin the GCG software package (available at http address at world wide webuniform resource locator gcg.com), using a NWSgapdna.CMP matrix and agap weight of 40, 50, 60, 70, or 80 and a length weight of 1, 2, 3, 4,5, or 6. A set of parameters often used is a Blossum 62 scoring matrixwith a gap open penalty of 12, a gap extend penalty of 4, and aframeshift gap penalty of 5.

Sequence identity can also be determined by hybridization assaysconducted under stringent conditions. As use herein, the term “stringentconditions” refers to conditions for hybridization and washing.Stringent conditions are known to those skilled in the art and can befound in Current Protocols in Molecular Biology, John Wiley & Sons,N.Y., 6.3.1-6.3.6 (1989). Aqueous and non-aqueous methods are describedin that reference and either can be used. An example of stringenthybridization conditions is hybridization in 6× sodium chloride/sodiumcitrate (SSC) at about 45° C., followed by one or more washes in0.2×SSC, 0.1% SDS at 50° C. Another example of stringent hybridizationconditions are hybridization in 6× sodium chloride/sodium citrate (SSC)at about 45° C., followed by one or more washes in 0.2×SSC, 0.1% SDS at55° C. A further example of stringent hybridization conditions ishybridization in 6× sodium chloride/sodium citrate (SSC) at about 45°C., followed by one or more washes in 0.2×SSC, 0.1% SDS at 60° C. Often,stringent hybridization conditions are hybridization in 6× sodiumchloride/sodium citrate (SSC) at about 45° C., followed by one or morewashes in 0.2×SSC, 0.1% SDS at 65° C. More often, stringency conditionsare 0.5M sodium phosphate, 7% SDS at 65° C., followed by one or morewashes at 0.2×SSC, 1% SDS at 65° C.

As noted above, nucleic acid reagents may also comprise one or more 5′UTR's, and one or more 3′UTR's. A 5′ UTR may comprise one or moreelements endogenous to the nucleotide sequence from which it originates,and sometimes includes one or more exogenous elements. A 5′ UTR canoriginate from any suitable nucleic acid, such as genomic DNA, plasmidDNA, RNA or mRNA, for example, from any suitable organism (e.g., virus,bacterium, yeast, fungi, plant, insect or mammal). The artisan mayselect appropriate elements for the 5′ UTR based upon the chosenexpression system (e.g., expression in a chosen organism, or expressionin a cell free system, for example). A 5′ UTR sometimes comprises one ormore of the following elements known to the artisan: enhancer sequences(e.g., transcriptional or translational), transcription initiation site,transcription factor binding site, translation regulation site,translation initiation site, translation factor binding site, accessoryprotein binding site, feedback regulation agent binding sites, Pribnowbox, TATA box, −35 element, E-box (helix-loop-helix binding element),ribosome binding site, replicon, internal ribosome entry site (IRES),silencer element and the like. In some embodiments, a promoter elementmay be isolated such that all 5′ UTR elements necessary for properconditional regulation are contained in the promoter element fragment,or within a functional subsequence of a promoter element fragment.

A 5′UTR in the nucleic acid reagent can comprise a translationalenhancer nucleotide sequence. A translational enhancer nucleotidesequence often is located between the promoter and the target nucleotidesequence in a nucleic acid reagent. A translational enhancer sequenceoften binds to a ribosome, sometimes is an 18S rRNA-bindingribonucleotide sequence (i.e., a 40S ribosome binding sequence) andsometimes is an internal ribosome entry sequence (IRES). An IRESgenerally forms an RNA scaffold with precisely placed RNA tertiarystructures that contact a 40S ribosomal subunit via a number of specificintermolecular interactions. Examples of ribosomal enhancer sequencesare known and can be identified by the artisan (e.g., Mignone et al.,Nucleic Acids Research 33: D141-D146 (2005); Paulous et al., NucleicAcids Research 31: 722-733 (2003); Akbergenov et al., Nucleic AcidsResearch 32: 239-247 (2004); Mignone et al., Genome Biology 3(3):reviews 0004.1-0001.10 (2002); Gallie, Nucleic Acids Research 30:3401-3411 (2002); Shaloiko et al., http address at world wide webuniform resource locator interscience.wiley.com, DOI: 10.1002/bit.20267;and Gallie et al., Nucleic Acids Research 15: 3257-3273 (1987)).

A translational enhancer sequence sometimes is a eukaryotic sequence,such as a Kozak consensus sequence or other sequence (e.g., hydroidpolyp sequence, GenBank accession no. U07128). A translational enhancersequence sometimes is a prokaryotic sequence, such as a Shine-Dalgarnoconsensus sequence. In certain embodiments, the translational enhancersequence is a viral nucleotide sequence. A translational enhancersequence sometimes is from a 5′ UTR of a plant virus, such as TobaccoMosaic Virus (TMV), Alfalfa Mosaic Virus (AMV); Tobacco Etch Virus(ETV); Potato Virus Y (PVY); Turnip Mosaic (poty) Virus and Pea SeedBorne Mosaic Virus, for example. In certain embodiments, an omegasequence about 67 bases in length from TMV is included in the nucleicacid reagent as a translational enhancer sequence (e.g., devoid ofguanosine nucleotides and includes a 25 nucleotide long poly (CAA)central region).

A 3′ UTR may comprise one or more elements endogenous to the nucleotidesequence from which it originates and sometimes includes one or moreexogenous elements. A 3′ UTR may originate from any suitable nucleicacid, such as genomic DNA, plasmid DNA, RNA or mRNA, for example, fromany suitable organism (e.g., a virus, bacterium, yeast, fungi, plant,insect or mammal). The artisan can select appropriate elements for the3′ UTR based upon the chosen expression system (e.g., expression in achosen organism, for example). A 3′ UTR sometimes comprises one or moreof the following elements known to the artisan: transcription regulationsite, transcription initiation site, transcription termination site,transcription factor binding site, translation regulation site,translation termination site, translation initiation site, translationfactor binding site, ribosome binding site, replicon, enhancer element,silencer element and polyadenosine tail. A 3′ UTR often includes apolyadenosine tail and sometimes does not, and if a polyadenosine tailis present, one or more adenosine moieties may be added or deleted fromit (e.g., about 5, about 10, about 15, about 20, about 25, about 30,about 35, about 40, about 45 or about 50 adenosine moieties may be addedor subtracted).

In some embodiments, modification of a 5′ UTR and/or a 3′ UTR can beused to alter (e.g., increase, add, decrease or substantially eliminate)the activity of a promoter. Alteration of the promoter activity can inturn alter the activity of a peptide, polypeptide or protein (e.g.,enzyme activity for example), by a change in transcription of thenucleotide sequence(s) of interest from an operably linked promoterelement comprising the modified 5′ or 3′ UTR. For example, amicroorganism can be engineered by genetic modification to express anucleic acid reagent comprising a modified 5′ or 3′ UTR that can add anovel activity (e.g., an activity not normally found in the hostorganism) or increase the expression of an existing activity byincreasing transcription from a homologous or heterologous promoteroperably linked to a nucleotide sequence of interest (e.g., homologousor heterologous nucleotide sequence of interest), in certainembodiments. In some embodiments, a microorganism can be engineered bygenetic modification to express a nucleic acid reagent comprising amodified 5′ or 3′ UTR that can decrease the expression of an activity bydecreasing or substantially eliminating transcription from a homologousor heterologous promoter operably linked to a nucleotide sequence ofinterest, in certain embodiments.

A nucleotide reagent sometimes can comprise a target nucleotidesequence. A “target nucleotide sequence” as used herein encodes anucleic acid, peptide, polypeptide or protein of interest, and may be aribonucleotide sequence or a deoxyribonucleotide sequence.

A target nucleic acid sometimes can comprise a chimeric nucleic acid (orchimeric nucleotide sequence), which can encode a chimeric protein (orchimeric amino acid sequence). The term “chimeric” as used herein refersto a nucleic acid or nucleotide sequence, or encoded product thereof,containing sequences from two or more different sources. Any suitablesource can be selected, including, but not limited to, a sequence from anucleic acid, nucleotide sequence, ribosomal nucleic acid, RNA, DNA,regulatory nucleotide sequence (e.g., promoter, URL, enhancer, repressorand the like), coding nucleic acid, gene, nucleic acid linker, nucleicacid tag, amino acid sequence, peptide, polypeptide, protein,chromosome, and organism. A chimeric molecule can include a sequence ofcontiguous nucleotides or amino acids from a source including, but notlimited to, a virus, prokaryote, eukaryote, genus, species, homolog,ortholog, paralog and isozyme, nucleic acid linkers, nucleic acid tags,the like and combinations thereof). A chimeric molecule can be generatedby placing in juxtaposition fragments of related or unrelated nucleicacids, nucleotide sequences or DNA segments, in some embodiments. Incertain embodiments the nucleic acids, nucleotide sequences or DNAsegments can be native or wild type sequences, mutant sequences orengineered sequences (completely engineered or engineered to a point,for example).

In some embodiments, a chimera includes about 1, 2, 3, 4 or 5 sequences(e.g., contiguous nucleotides, contiguous amino acids) from one organismand 1, 2, 3, 4 or 5 sequences (e.g., contiguous nucleotides, contiguousamino acids) from another organism. The organisms sometimes are amicrobe, such as a bacterium (e.g., gram positive, gram negative), yeastor fungus (e.g., aerobic fungus, anaerobic fungus), for example. In someembodiments, the organisms are bacteria, the organisms are yeast or theorganisms are fungi (e.g., different species), and sometimes oneorganism is a bacterium or yeast and another is a fungus. A chimericmolecule may contain up to about 99% of sequences from one organism(e.g., about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45,50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99%) and the balancepercentage from one or more other organisms. In certain embodiments, achimeric molecule includes altered codons (in the case of a chimericnucleic acid) and one or more mutations (e.g., point mutations,nucleotide substitutions, amino acid substitutions).

A chimera sometimes is the result of recombination between two or morenucleic acids, nucleotide sequences or genes, and sometimes is theresult of genetic manipulation (e.g., designed and/or generated by thehand of a human being). Any suitable nucleic acid or nucleotide sequenceand method for combining nucleic acids or nucleotide sequences can beused to generate a chimeric nucleic acid or nucleotide sequence.Non-limiting examples of nucleic acid and nucleotide sequence sourcesand methods for generating chimeric nucleic acids and nucleotidesequences are presented herein.

In some embodiments, fragments used to generate a chimera can bejuxtaposed as units (e.g., nucleic acid from the sources are combinedend to end and not interspersed. In embodiments where a chimera includesone stretch of contiguous nucleotides for each organism, nucleotidesequence combinations can be noted as DNA source 1 DNA source 2 or DNAsource 1/DNA source 2/DNA source 3, the like and combinations thereof,for example. In certain embodiments, fragments used to generate achimera can be juxtaposed such that one or more fragments from one ormore sources can be interspersed with other fragments used to generatethe chimera (e.g., DNA source 1/DNA source 2/DNA source 1/DNA source3/DNA source 2/DNA source 1). In some embodiments, the nucleotidesequence length of the fragments used to generate a chimera can be inthe range from about 5 base pairs to about 5,000 base pairs (e.g., about5 base pairs (bp), about 10 bp, about 15 bp, about 20 bp, about 25 bp,about 30 bp, about 35 bp, about 40 bp, about 45 bp, about 50 bp, about55 bp, about 60 bp, about bp, about 65 bp, about 70 bp, about 75 bp,about 80 bp, about 85 bp, about 90 bp, about 95 bp, about 100 bp, about125 bp, about 150 bp, about 175 bp, about 200 bp, about 250 bp, about300 bp, about 350 bp, about 400 bp, about 450 bp, about 500 bp, about550 bp, about 600 bp, about 650 bp, about 700 bp, about 750 bp, about800 bp, about 850 bp, about 900 bp, about 950 bp, about 1000 bp, about1500 bp, about 2000 bp, about 2500 bp, about 3000 bp, about 3500 bp,about 4000 bp, about 4500 bp, or about 5000 bp).

In certain embodiments, a chimeric nucleic acid or nucleotide sequenceencodes the same activity as the activity encoded by the source nucleicacids or nucleotide sequences. In some embodiments, a chimeric nucleicacid or nucleotide sequence has a similar or the same activity, but theamount of the activity, or kinetics of the activity, are altered (e.g.,increased, decreased). In certain embodiments, a chimeric nucleic acidor nucleotide sequence encodes a different activity, and in someembodiments a chimeric nucleic acid or nucleotide sequences encodes achimeric activity (e.g., a combination of two or more activities).

A target nucleic acid sometimes is an untranslated ribonucleic acid andsometimes is a translated ribonucleic acid. An untranslated ribonucleicacid may include, but is not limited to, a small interfering ribonucleicacid (siRNA), a short hairpin ribonucleic acid (shRNA), otherribonucleic acid capable of RNA interference (RNAi), an antisenseribonucleic acid, or a ribozyme. A translatable target nucleotidesequence (e.g., a target ribonucleotide sequence) sometimes encodes apeptide, polypeptide or protein, which are sometimes referred to hereinas “target peptides,” “target polypeptides” or “target proteins.”

Any peptides, polypeptides or proteins, or an activity catalyzed by oneor more peptides, polypeptides or proteins may be encoded by a targetnucleotide sequence and may be selected by a person of ordinary skill inthe art. Representative proteins include enzymes (e.g.,phosphofructokinase activity, phosphogluconate dehydratase activity,2-keto-3-deoxygluconate-6-phosphate aldolase activity, xylose isomeraseactivity, phosphoenolpyruvate carboxylase activity, alcoholdehydrogenase 2 activity and thymidylate synthase activity and the like,for example), antibodies, serum proteins (e.g., albumin), membrane boundproteins, hormones (e.g., growth hormone, erythropoietin, insulin,etc.), cytokines, etc., and include both naturally occurring andexogenously expressed polypeptides. Representative activities (e.g.,enzymes or combinations of enzymes which are functionally associated toprovide an activity) include phosphofructokinase activity,phosphogluconate dehydratase activity,2-keto-3-deoxygluconate-6-phosphate aldolase activity, xylose isomeraseactivity, phosphoenolpyruvate carboxylase activity, alcoholdehydrogenase 2 activity and thymidylate synthase activity and the likefor example. The term “enzyme” as used herein refers to a protein whichcan act as a catalyst to induce a chemical change in other compounds,thereby producing one or more products from one or more substrates.

Specific polypeptides (e.g., enzymes) useful for embodiments describedherein are listed hereafter. The term “protein” as used herein refers toa molecule having a sequence of amino acids linked by peptide bonds.This term includes fusion proteins, oligopeptides, peptides, cyclicpeptides, polypeptides and polypeptide derivatives, whether native orrecombinant, and also includes fragments, derivatives, homologs, andvariants thereof. A protein or polypeptide sometimes is of intracellularorigin (e.g., located in the nucleus, cytosol, or interstitial space ofhost cells in vivo) and sometimes is a cell membrane protein in vivo. Insome embodiments (described above, and in further detail below inEngineering and Alteration Methods), a genetic modification can resultin a modification (e.g., increase, substantially increase, decrease orsubstantially decrease) of a target activity.

A translatable nucleotide sequence generally is located between a startcodon (AUG in ribonucleic acids and ATG in deoxyribonucleic acids) and astop codon (e.g., UAA (ochre), UAG (amber) or UGA (opal) in ribonucleicacids and TAA, TAG or TGA in deoxyribonucleic acids), and sometimes isreferred to herein as an “open reading frame” (ORF). A nucleic acidreagent sometimes comprises one or more ORFs. An ORF may be from anysuitable source, sometimes from genomic DNA, mRNA, reverse transcribedRNA or complementary DNA (cDNA) or a nucleic acid library comprising oneor more of the foregoing, and is from any organism species that containsa nucleic acid sequence of interest, protein of interest, or activity ofinterest. Non-limiting examples of organisms from which an ORF can beobtained include bacteria, yeast, fungi, human, insect, nematode,bovine, equine, canine, feline, rat or mouse, for example.

A nucleic acid reagent sometimes comprises a nucleotide sequenceadjacent to an ORF that is translated in conjunction with the ORF andencodes an amino acid tag. The tag-encoding nucleotide sequence islocated 3′ and/or 5′ of an ORF in the nucleic acid reagent, therebyencoding a tag at the C-terminus or N-terminus of the protein or peptideencoded by the ORF. Any tag that does not abrogate in vitrotranscription and/or translation may be utilized and may beappropriately selected by the artisan. Tags may facilitate isolationand/or purification of the desired ORF product from culture orfermentation media.

A tag sometimes specifically binds a molecule or moiety of a solid phaseor a detectable label, for example, thereby having utility forisolating, purifying and/or detecting a protein or peptide encoded bythe ORF. In some embodiments, a tag comprises one or more of thefollowing elements: FLAG (e.g., DYKDDDDKG (SEQ ID NO: 79)), V5 (e.g.,GKPIPNPLLGLDST (SEQ ID NO: 80)), c-MYC (e.g., EQKLISEEDL (SEQ ID NO:81)), HSV (e.g., QPELAPEDPED (SEQ ID NO: 82)), influenza hemaglutinin,HA (e.g., YPYDVPDYA (SEQ ID NO: 83)), VSV-G (e.g., YTDIEMNRLGK (SEQ IDNO: 182)), bacterial glutathione-S-transferase, maltose binding protein,a streptavidin- or avidin-binding tag (e.g., pcDNA™6 BioEase™ Gateway®Biotinylation System (Invitrogen)), thioredoxin, β-galactosidase,VSV-glycoprotein, a fluorescent protein (e.g., green fluorescent proteinor one of its many color variants (e.g., yellow, red, blue)), apolylysine or polyarginine sequence, a polyhistidine sequence (e.g.,His6 (SEQ ID NO: 84)) or other sequence that chelates a metal (e.g.,cobalt, zinc, copper), and/or a cysteine-rich sequence that binds to anarsenic-containing molecule. In certain embodiments, a cysteine-rich tagcomprises the amino acid sequence CC-Xn-CC (SEQ ID NO: 85), wherein X isany amino acid and n is 1 to 3, and the cysteine-rich sequence sometimesis CCPGCC (SEQ ID NO: 86). In certain embodiments, the tag comprises acysteine-rich element and a polyhistidine element (e.g., CCPGCC (SEQ IDNO: 87) and His6 (SEQ ID NO: 88)).

A tag often conveniently binds to a binding partner. For example, sometags bind to an antibody (e.g., FLAG) and sometimes specifically bind toa small molecule. For example, a polyhistidine tag specifically chelatesa bivalent metal, such as copper, zinc and cobalt; a polylysine orpolyarginine tag specifically binds to a zinc finger; a glutathioneS-transferase tag binds to glutathione; and a cysteine-rich tagspecifically binds to an arsenic-containing molecule. Arsenic-containingmolecules include LUMIO™ agents (Invitrogen, California), such as FIAsH™(EDT2[4′,5′-bis(1,3,2-dithioarsolan-2-yl)fluorescein-(1,2-ethanedithiol)2])and ReAsH reagents (e.g., U.S. Pat. No. 5,932,474 to Tsien et al.,entitled “Target Sequences for Synthetic Molecules;” U.S. Pat. No.6,054,271 to Tsien et al., entitled “Methods of Using SyntheticMolecules and Target Sequences;” U.S. Pat. Nos. 6,451,569 and 6,008,378;published U.S. Patent Application 2003/0083373, and published PCT PatentApplication WO 99/21013, all to Tsien et al. and all entitled “SyntheticMolecules that Specifically React with Target Sequences”). Suchantibodies and small molecules sometimes are linked to a solid phase forconvenient isolation of the target protein or target peptide.

A tag sometimes comprises a sequence that localizes a translated proteinor peptide to a component in a system, which is referred to as a “signalsequence” or “localization signal sequence” herein. A signal sequenceoften is incorporated at the N-terminus of a target protein or targetpeptide, and sometimes is incorporated at the C-terminus. Examples ofsignal sequences are known to the artisan, are readily incorporated intoa nucleic acid reagent, and often are selected according to the organismin which expression of the nucleic acid reagent is performed. A signalsequence in some embodiments localizes a translated protein or peptideto a cell membrane. Examples of signal sequences include, but are notlimited to, a nucleus targeting signal (e.g., steroid receptor sequenceand N-terminal sequence of SV40 virus large T antigen); mitochondrialtargeting signal (e.g., amino acid sequence that forms an amphipathichelix); peroxisome targeting signal (e.g., C-terminal sequence in YFGfrom S. cerevisiae); and a secretion signal (e.g., N-terminal sequencesfrom invertase, mating factor alpha, PHO5 and SUC2 in S. cerevisiae;multiple N-terminal sequences of B. subtilis proteins (e.g., Tjalsma etal., Microbiol. Molec. Biol. Rev. 64: 515-547 (2000)); alpha amylasesignal sequence (e.g., U.S. Pat. No. 6,288,302); pectate lyase signalsequence (e.g., U.S. Pat. No. 5,846,818); precollagen signal sequence(e.g., U.S. Pat. No. 5,712,114); OmpA signal sequence (e.g., U.S. Pat.No. 5,470,719); lam beta signal sequence (e.g., U.S. Pat. No.5,389,529); B. brevis signal sequence (e.g., U.S. Pat. No. 5,232,841);and P. pastoris signal sequence (e.g., U.S. Pat. No. 5,268,273)).

A tag sometimes is directly adjacent to the amino acid sequence encodedby an ORF (i.e., there is no intervening sequence) and sometimes a tagis substantially adjacent to an ORF encoded amino acid sequence (e.g.,an intervening sequence is present). An intervening sequence sometimesincludes a recognition site for a protease, which is useful for cleavinga tag from a target protein or peptide. In some embodiments, theintervening sequence is cleaved by Factor Xa (e.g., recognition site I(E/D)GR), thrombin (e.g., recognition site LVPRGS (SEQ ID NO: 89)),enterokinase (e.g., recognition site DDDDK (SEQ ID NO: 90)), TEVprotease (e.g., recognition site ENLYFQG (SEQ ID NO: 91)) orPreScission™ protease (e.g., recognition site LEVLFQGP (SEQ ID NO: 92)),for example.

An intervening sequence sometimes is referred to herein as a “linkersequence,” and may be of any suitable length selected by the artisan. Alinker sequence sometimes is about 1 to about 20 amino acids in length,and sometimes about 5 to about 10 amino acids in length. The artisan mayselect the linker length to substantially preserve target protein orpeptide function (e.g., a tag may reduce target protein or peptidefunction unless separated by a linker), to enhance disassociation of atag from a target protein or peptide when a protease cleavage site ispresent (e.g., cleavage may be enhanced when a linker is present), andto enhance interaction of a tag/target protein product with a solidphase. A linker can be of any suitable amino acid content, and oftencomprises a higher proportion of amino acids having relatively shortside chains (e.g., glycine, alanine, serine and threonine).

A nucleic acid reagent sometimes includes a stop codon between a tagelement and an insertion element or ORF, which can be useful fortranslating an ORF with or without the tag. Mutant tRNA molecules thatrecognize stop codons (described above) suppress translation terminationand thereby are designated “suppressor tRNAs.” Suppressor tRNAs canresult in the insertion of amino acids and continuation of translationpast stop codons (e.g., U.S. Patent Application No. 60/587,583, filedJul. 14, 2004, entitled “Production of Fusion Proteins by Cell-FreeProtein Synthesis,”; Eggertsson, et al., (1988) Microbiological Review52(3):354-374, and Engleerg-Kukla, et al. (1996) in Escherichia coli andSalmonella Cellular and Molecular Biology, Chapter 60, pps 909-921,Neidhardt, et al. eds., ASM Press, Washington, D.C.). A number ofsuppressor tRNAs are known, including but not limited to, supE, supP,supD, supF and supZ suppressors, which suppress the termination oftranslation of the amber stop codon; supB, glT, supL, supN, supC andsupM suppressors, which suppress the function of the ochre stop codonand glyT, trpT and Su-9 suppressors, which suppress the function of theopal stop codon. In general, suppressor tRNAs contain one or moremutations in the anti-codon loop of the tRNA that allows the tRNA tobase pair with a codon that ordinarily functions as a stop codon. Themutant tRNA is charged with its cognate amino acid residue and thecognate amino acid residue is inserted into the translating polypeptidewhen the stop codon is encountered. Mutations that enhance theefficiency of termination suppressors (i.e., increase stop codonread-through) have been identified. These include, but are not limitedto, mutations in the uar gene (also known as the prfA gene), mutationsin the ups gene, mutations in the sueA, sueB and sueC genes, mutationsin the rpsD (ramA) and rpsE (spcA) genes and mutations in the rplL gene.

Thus, a nucleic acid reagent comprising a stop codon located between anORF and a tag can yield a translated ORF alone when no suppressor tRNAis present in the translation system, and can yield a translated ORF-tagfusion when a suppressor tRNA is present in the system. Suppressor tRNAcan be generated in cells transfected with a nucleic acid encoding thetRNA (e.g., a replication incompetent adenovirus containing the humantRNA-Ser suppressor gene can be transfected into cells, or a YACcontaining a yeast or bacterial tRNA suppressor gene can be transfectedinto yeast cells, for example). Vectors for synthesizing suppressor tRNAand for translating ORFs with or without a tag are available to theartisan (e.g., Tag-On-Demand™ kit (Invitrogen Corporation, California);Tag-On-Demand™ Suppressor Supernatant Instruction Manual, Version B, 6Jun. 2003, at http address at world wide web uniform resource locatorinvitrogen.com/content/sfs/manuals/tagondemand_supernatant_man.pdf;Tag-On-Demand™ Gateway® Vector Instruction Manual, Version B, 20 Jun.2003 at http address at world wide web uniform resource locatorinvitrogen.com/content/sfs/manuals/tagondemand_vectors_man.pdf; andCapone et al., Amber, ochre and opal suppressor tRNA genes derived froma human serine tRNA gene. EMBO J. 4:213, 1985).

Any convenient cloning strategy known in the art may be utilized toincorporate an element, such as an ORF, into a nucleic acid reagent.Known methods can be utilized to insert an element into the templateindependent of an insertion element, such as (1) cleaving the templateat one or more existing restriction enzyme sites and ligating an elementof interest and (2) adding restriction enzyme sites to the template byhybridizing oligonucleotide primers that include one or more suitablerestriction enzyme sites and amplifying by polymerase chain reaction(described in greater detail herein). Other cloning strategies takeadvantage of one or more insertion sites present or inserted into thenucleic acid reagent, such as an oligonucleotide primer hybridizationsite for PCR, for example, and others described hereafter. In someembodiments, a cloning strategy can be combined with geneticmanipulation such as recombination (e.g., recombination of a nucleicacid reagent with a nucleic acid sequence of interest into the genome ofthe organism to be modified, as described further below). In someembodiments, the cloned ORF(s) can produce (directly or indirectly) adesired product, by engineering a microorganism with one or more ORFs ofinterest, which microorganism comprises one or more altered activitiesselected from the group consisting of phosphofructokinase activity,phosphogluconate dehydratase activity,2-keto-3-deoxygluconate-6-phosphate aldolase activity, xylose isomeraseactivity, phosphoenolpyruvate carboxylase activity, alcoholdehydrogenase 2 activity, sugar transport activity,phosphoglucoisomerase activity, transaldolase activity, transketolaseactivity, glucose-6-phosphate dehydrogenase activity,6-phosphogluconolactonase activity, 6-phosphogluconate dehydrogenase(decarboxylating) activity, and thymidylate synthase activity.

In some embodiments, the nucleic acid reagent includes one or morerecombinase insertion sites. A recombinase insertion site is arecognition sequence on a nucleic acid molecule that participates in anintegration/recombination reaction by recombination proteins. Forexample, the recombination site for Cre recombinase is IoxP, which is a34 base pair sequence comprised of two 13 base pair inverted repeats(serving as the recombinase binding sites) flanking an 8 base pair coresequence (e.g., FIG. 1 of Sauer, B., Curr. Opin. Biotech. 5:521-527(1994)). Other examples of recombination sites include attB, attP, attL,and attR sequences, and mutants, fragments, variants and derivativesthereof, which are recognized by the recombination protein λ Int and bythe auxiliary proteins integration host factor (IHF), FIS andexcisionase (Xis) (e.g., U.S. Pat. Nos. 5,888,732; 6,143,557; 6,171,861;6,270,969; 6,277,608; and 6,720,140; U.S. patent application Ser. No.09/517,466, filed Mar. 2, 2000, and Ser. No. 09/732,914, filed Aug. 14,2003, and in U.S. patent publication no. 2002-0007051-A1; Landy, Curr.Opin. Biotech. 3:699-707 (1993)).

Examples of recombinase cloning nucleic acids are in Gateway® systems(Invitrogen, California), which include at least one recombination sitefor cloning a desired nucleic acid molecules in vivo or in vitro. Insome embodiments, the system utilizes vectors that contain at least twodifferent site-specific recombination sites, often based on thebacteriophage lambda system (e.g., att1 and att2), and are mutated fromthe wild-type (att0) sites. Each mutated site has a unique specificityfor its cognate partner att site (i.e., its binding partnerrecombination site) of the same type (for example attB1 with attP1, orattL1 with attR1) and will not cross-react with recombination sites ofthe other mutant type or with the wild-type att0 site. Different sitespecificities allow directional cloning or linkage of desired moleculesthus providing desired orientation of the cloned molecules. Nucleic acidfragments flanked by recombination sites are cloned and subcloned usingthe Gateway® system by replacing a selectable marker (for example, ccdB)flanked by att sites on the recipient plasmid molecule, sometimes termedthe Destination Vector. Desired clones are then selected bytransformation of a ccdB sensitive host strain and positive selectionfor a marker on the recipient molecule. Similar strategies for negativeselection (e.g., use of toxic genes) can be used in other organisms suchas thymidine kinase (TK) in mammals and insects.

A recombination system useful for engineering yeast is outlined briefly.The system makes use of the ura3 gene (e.g., for S. cerevisiae and C.albicans, for example) or ura4 and ura5 genes (e.g., for S. pombe, forexample) and toxicity of the nucleotide analogue 5-Fluoroorotic acid(5-FOA). The ura3 or ura4 and ura5 genes encode orotine-5′-monophosphate(OMP) dicarboxylase. Yeast with an active ura3 or ura4 and ura5 gene(phenotypically Ura+) convert 5-FOA to fluorodeoxyuridine, which istoxic to yeast cells. Yeast carrying a mutation in the appropriategene(s) or having a knock out of the appropriate gene(s) can grow in thepresence of 5-FOA, if the media is also supplemented with uracil.

A nucleic acid engineering construct can be made which may comprise theURA3 gene or cassette (for S. cerevisiae), flanked on either side by thesame nucleotide sequence in the same orientation. The ura3 cassettecomprises a promoter, the ura3 gene and a functional transcriptionterminator. Target sequences which direct the construct to a particularnucleic acid region of interest in the organism to be engineered areadded such that the target sequences are adjacent to and abut theflanking sequences on either side of the ura3 cassette. Yeast can betransformed with the engineering construct and plated on minimal mediawithout uracil. Colonies can be screened by PCR to determine thosetransformants that have the engineering construct inserted in the properlocation in the genome. Checking insertion location prior to selectingfor recombination of the ura3 cassette may reduce the number ofincorrect clones carried through to later stages of the procedure.Correctly inserted transformants can then be replica plated on minimalmedia containing 5-FOA to select for recombination of the ura3 cassetteout of the construct, leaving a disrupted gene and an identifiablefootprint (e.g., nucleic acid sequence) that can be use to verify thepresence of the disrupted gene. The technique described is useful fordisrupting or “knocking out” gene function, but also can be used toinsert genes or constructs into a host organisms genome in a targeted,sequence specific manner. Further detail will be described below in theengineering section and in the example section.

In certain embodiments, a nucleic acid reagent includes one or moretopoisomerase insertion sites. A topoisomerase insertion site is adefined nucleotide sequence recognized and bound by a site-specifictopoisomerase. For example, the nucleotide sequence 5′-(C/T)CCTT-3′ is atopoisomerase recognition site bound specifically by most poxvirustopoisomerases, including vaccinia virus DNA topoisomerase I. Afterbinding to the recognition sequence, the topoisomerase cleaves thestrand at the 3′-most thymidine of the recognition site to produce anucleotide sequence comprising 5′-(C/T)CCTT-PO4-TOPO, a complex of thetopoisomerase covalently bound to the 3′ phosphate via a tyrosine in thetopoisomerase (e.g., Shuman, J. Biol. Chem. 266:11372-11379, 1991;Sekiguchi and Shuman, Nucl. Acids Res. 22:5360-5365, 1994; U.S. Pat. No.5,766,891; PCT/US95/16099; and PCT/US98/12372). In comparison, thenucleotide sequence 5′-GCAACTT-3′ is a topoisomerase recognition sitefor type IA E. coli topoisomerase III. An element to be inserted oftenis combined with topoisomerase-reacted template and thereby incorporatedinto the nucleic acid reagent (e.g., http address at world wide webuniform resource locatorinvitrogen.com/downloads/F-13512_Topo_Flyer.pdf; http address at worldwide web uniform resource locatorinvitrogen.com/content/sfs/brochures/710_021849%20_B_TOPOCloning_bro.pdf;TOPO TA Cloning® Kit and Zero Blunt® TOPO® Cloning Kit productinformation).

A nucleic acid reagent sometimes contains one or more origin ofreplication (ORI) elements. In some embodiments, a template comprisestwo or more ORIs, where one functions efficiently in one organism (e.g.,a bacterium) and another functions efficiently in another organism(e.g., a eukaryote, like yeast for example). In some embodiments, an ORImay function efficiently in one species (e.g., S. cerevisiae, forexample) and another ORI may function efficiently in a different species(e.g., S. pombe, for example). A nucleic acid reagent also sometimesincludes one or more transcription regulation sites.

A nucleic acid reagent can include one or more selection elements (e.g.,elements for selection of the presence of the nucleic acid reagent, andnot for activation of a promoter element which can be selectivelyregulated). Selection elements often are utilized using known processesto determine whether a nucleic acid reagent is included in a cell. Insome embodiments, a nucleic acid reagent includes two or more selectionelements, where one functions efficiently in one organism and anotherfunctions efficiently in another organism. Examples of selectionelements include, but are not limited to, (1) nucleic acid segments thatencode products that provide resistance against otherwise toxiccompounds (e.g., antibiotics); (2) nucleic acid segments that encodeproducts that are otherwise lacking in the recipient cell (e.g.,essential products, tRNA genes, auxotrophic markers); (3) nucleic acidsegments that encode products that suppress the activity of a geneproduct; (4) nucleic acid segments that encode products that can bereadily identified (e.g., phenotypic markers such as antibiotics (e.g.,β-lactamase), β-galactosidase, green fluorescent protein (GFP), yellowfluorescent protein (YFP), red fluorescent protein (RFP), cyanfluorescent protein (CFP), and cell surface proteins); (5) nucleic acidsegments that bind products that are otherwise detrimental to cellsurvival and/or function; (6) nucleic acid segments that otherwiseinhibit the activity of any of the nucleic acid segments described inNos. 1-5 above (e.g., antisense oligonucleotides); (7) nucleic acidsegments that bind products that modify a substrate (e.g., restrictionendonucleases); (8) nucleic acid segments that can be used to isolate oridentify a desired molecule (e.g., specific protein binding sites); (9)nucleic acid segments that encode a specific nucleotide sequence thatcan be otherwise non-functional (e.g., for PCR amplification ofsubpopulations of molecules); (10) nucleic acid segments that, whenabsent, directly or indirectly confer resistance or sensitivity toparticular compounds; (11) nucleic acid segments that encode productsthat either are toxic or convert a relatively non-toxic compound to atoxic compound (e.g., Herpes simplex thymidine kinase, cytosinedeaminase) in recipient cells; (12) nucleic acid segments that inhibitreplication, partition or heritability of nucleic acid molecules thatcontain them; and/or (13) nucleic acid segments that encode conditionalreplication functions, e.g., replication in certain hosts or host cellstrains or under certain environmental conditions (e.g., temperature,nutritional conditions, and the like).

A nucleic acid reagent is of any form useful for in vivo transcriptionand/or translation. A nucleic acid sometimes is a plasmid, such as asupercoiled plasmid, sometimes is a yeast artificial chromosome (e.g.,YAC), sometimes is a linear nucleic acid (e.g., a linear nucleic acidproduced by PCR or by restriction digest), sometimes is single-strandedand sometimes is double-stranded. A nucleic acid reagent sometimes isprepared by an amplification process, such as a polymerase chainreaction (PCR) process or transcription-mediated amplification process(TMA). In TMA, two enzymes are used in an isothermal reaction to produceamplification products detected by light emission (see, e.g.,Biochemistry 1996 Jun. 25; 35(25):8429-38 and http address world wideweb uniform resource locatordevicelink.com/ivdt/archive/00/11/007.html). Standard PCR processes areknown (e.g., U.S. Pat. Nos. 4,683,202; 4,683,195; 4,965,188; and5,656,493), and generally are performed in cycles. Each cycle includesheat denaturation, in which hybrid nucleic acids dissociate; cooling, inwhich primer oligonucleotides hybridize; and extension of theoligonucleotides by a polymerase (i.e., Taq polymerase). An example of aPCR cyclical process is treating the sample at 95° C. for 5 minutes;repeating forty-five cycles of 95° C. for 1 minute, 59° C. for 1 minute,10 seconds, and 72° C. for 1 minute 30 seconds; and then treating thesample at 72° C. for 5 minutes. Multiple cycles frequently are performedusing a commercially available thermal cycler. PCR amplificationproducts sometimes are stored for a time at a lower temperature (e.g.,at 4° C.) and sometimes are frozen (e.g., at −20° C.) before analysis.

In some embodiments, a nucleic acid reagent, protein reagent, proteinfragment reagent or other reagent described herein is isolated orpurified. The term “isolated” as used herein refers to material removedfrom its original environment (e.g., the natural environment if it isnaturally occurring, or a host cell if expressed exogenously), and thusis altered “by the hand of man” from its original environment. The term“purified” as used herein with reference to molecules does not refer toabsolute purity. Rather, “purified” refers to a substance in acomposition that contains fewer substance species in the same class(e.g., nucleic acid or protein species) other than the substance ofinterest in comparison to the sample from which it originated.“Purified,” if a nucleic acid or protein for example, refers to asubstance in a composition that contains fewer nucleic acid species orprotein species other than the nucleic acid or protein of interest incomparison to the sample from which it originated. Sometimes, a proteinor nucleic acid is “substantially pure,” indicating that the protein ornucleic acid represents at least 50% of protein or nucleic acid on amass basis of the composition. Often, a substantially pure protein ornucleic acid is at least 75% on a mass basis of the composition, andsometimes at least 95% on a mass basis of the composition.

Engineering and Alteration Methods

Methods and compositions (e.g., nucleic acid reagents) described hereincan be used to generate engineered microorganisms. As noted above, theterm “engineered microorganism” as used herein refers to a modifiedorganism that includes one or more activities distinct from an activitypresent in a microorganism utilized as a starting point for modification(e.g., host microorganism or unmodified organism). Engineeredmicroorganisms typically arise as a result of a genetic modification,usually introduced or selected for, by one of skill in the art usingreadily available techniques. Non-limiting examples of methods usefulfor generating an altered activity include, introducing a heterologouspolynucleotide (e.g., nucleic acid or gene integration, also referred toas “knock in”), removing an endogenous polynucleotide, altering thesequence of an existing endogenous nucleic acid sequence (e.g.,site-directed mutagenesis), disruption of an existing endogenous nucleicacid sequence (e.g., knock outs and transposon or insertion elementmediated mutagenesis), selection for an altered activity where theselection causes a change in a naturally occurring activity that can bestably inherited (e.g., causes a change in a nucleic acid sequence inthe genome of the organism or in an epigenetic nucleic acid that isreplicated and passed on to daughter cells), PCR-based mutagenesis, andthe like. The term “mutagenesis” as used herein refers to anymodification to a nucleic acid (e.g., nucleic acid reagent, or hostchromosome, for example) that is subsequently used to generate a productin a host or modified organism. Non-limiting examples of mutagenesisinclude, deletion, insertion, substitution, rearrangement, pointmutations, suppressor mutations and the like. Mutagenesis methods areknown in the art and are readily available to the artisan. Non-limitingexamples of mutagenesis methods are described herein and can also befound in Maniatis, T., E. F. Fritsch and J. Sambrook (1982) MolecularCloning: a Laboratory Manual; Cold Spring Harbor Laboratory, Cold SpringHarbor, N.Y.

The term “genetic modification” as used herein refers to any suitablenucleic acid addition, removal or alteration that facilitates productionof a target product (e.g., phosphogluconate dehydratase activity,2-keto-3-deoxygluconate-6-phosphate aldolase activity, xylose isomeraseactivity, or phosphoenolpyruvate carboxylase activity, for example). inan engineered microorganism. Genetic modifications include, withoutlimitation, insertion of one or more nucleotides in a native nucleicacid of a host organism in one or more locations, deletion of one ormore nucleotides in a native nucleic acid of a host organism in one ormore locations, modification or substitution of one or more nucleotidesin a native nucleic acid of a host organism in one or more locations,insertion of a non-native nucleic acid into a host organism (e.g.,insertion of an autonomously replicating vector), and removal of anon-native nucleic acid in a host organism (e.g., removal of a vector).

The term “heterologous polynucleotide” as used herein refers to anucleotide sequence not present in a host microorganism in someembodiments. In certain embodiments, a heterologous polynucleotide ispresent in a different amount (e.g., different copy number) than in ahost microorganism, which can be accomplished, for example, byintroducing more copies of a particular nucleotide sequence to a hostmicroorganism (e.g., the particular nucleotide sequence may be in anucleic acid autonomous of the host chromosome or may be inserted into achromosome). A heterologous polynucleotide is from a different organismin some embodiments, and in certain embodiments, is from the same typeof organism but from an outside source (e.g., a recombinant source).

The term “altered activity” as used herein refers to an activity in anengineered microorganism that is added or modified relative to the hostmicroorganism (e.g., added, increased, reduced, inhibited or removedactivity). An activity can be altered by introducing a geneticmodification to a host microorganism that yields an engineeredmicroorganism having added, increased, reduced, inhibited or removedactivity.

An added activity often is an activity not detectable in a hostmicroorganism. An increased activity generally is an activity detectablein a host microorganism that has been increased in an engineeredmicroorganism. An activity can be increased to any suitable level forproduction of a target product (e.g., adipic acid, 6-hydroxyhexanoicacid), including but not limited to less than 2-fold (e.g., about 10%increase to about 99% increase; about 20%, 30%, 40%, 50%, 60%, 70%, 80%,90% increase), 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold,9-fold, of 10-fold increase, or greater than about 10-fold increase. Areduced or inhibited activity generally is an activity detectable in ahost microorganism that has been reduced or inhibited in an engineeredmicroorganism. An activity can be reduced to undetectable levels in someembodiments, or detectable levels in certain embodiments. An activitycan be decreased to any suitable level for production of a targetproduct (e.g., adipic acid, 6-hydroxyhexanoic acid), including but notlimited to less than 2-fold (e.g., about 10% decrease to about 99%decrease; about 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% decrease),2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, of10-fold decrease, or greater than about 10-fold decrease.

An altered activity sometimes is an activity not detectable in a hostorganism and is added to an engineered organism. An altered activityalso may be an activity detectable in a host organism and is increasedin an engineered organism. An activity may be added or increased byincreasing the number of copies of a polynucleotide that encodes apolypeptide having a target activity, in some embodiments. In certainembodiments an activity can be added or increased by inserting into ahost microorganism a heterologous polynucleotide that encodes apolypeptide having the added activity. In certain embodiments, anactivity can be added or increased by inserting into a hostmicroorganism a heterologous polynucleotide that is (i) operably linkedto another polynucleotide that encodes a polypeptide having the addedactivity, and (ii) up regulates production of the polynucleotide. Thus,an activity can be added or increased by inserting or modifying aregulatory polynucleotide operably linked to another polynucleotide thatencodes a polypeptide having the target activity. In certainembodiments, an activity can be added or increased by subjecting a hostmicroorganism to a selective environment and screening formicroorganisms that have a detectable level of the target activity.Examples of a selective environment include, without limitation, amedium containing a substrate that a host organism can process and amedium lacking a substrate that a host organism can process.

An altered activity sometimes is an activity detectable in a hostorganism and is reduced, inhibited or removed (i.e., not detectable) inan engineered organism. An activity may be reduced or removed bydecreasing the number of copies of a polynucleotide that encodes apolypeptide having a target activity, in some embodiments. In someembodiments, an activity can be reduced or removed by (i) inserting apolynucleotide within a polynucleotide that encodes a polypeptide havingthe target activity (disruptive insertion), and/or (ii) removing aportion of or all of a polynucleotide that encodes a polypeptide havingthe target activity (deletion or knock out, respectively). In certainembodiments, an activity can be reduced or removed by inserting into ahost microorganism a heterologous polynucleotide that is (i) operablylinked to another polynucleotide that encodes a polypeptide having thetarget activity, and (ii) down regulates production of thepolynucleotide. Thus, an activity can be reduced or removed by insertingor modifying a regulatory polynucleotide operably linked to anotherpolynucleotide that encodes a polypeptide having the target activity.

An activity also can be reduced or removed by (i) inhibiting apolynucleotide that encodes a polypeptide having the activity or (ii)inhibiting a polynucleotide operably linked to another polynucleotidethat encodes a polypeptide having the activity. A polynucleotide can beinhibited by a suitable technique known in the art, such as bycontacting an RNA encoded by the polynucleotide with a specificinhibitory RNA (e.g., RNAi, siRNA, ribozyme). An activity also can bereduced or removed by contacting a polypeptide having the activity witha molecule that specifically inhibits the activity (e.g., enzymeinhibitor, antibody). In certain embodiments, an activity can be reducedor removed by subjecting a host microorganism to a selective environmentand screening for microorganisms that have a reduced level or removal ofthe target activity.

In some embodiments, an untranslated ribonucleic acid, or a cDNA can beused to reduce the expression of a particular activity or enzyme. Forexample, a microorganism can be engineered by genetic modification toexpress a nucleic acid reagent that reduces the expression of anactivity by producing an RNA molecule that is partially or substantiallyhomologous to a nucleic acid sequence of interest which encodes theactivity of interest. The RNA molecule can bind to the nucleic acidsequence of interest and inhibit the nucleic acid sequence fromperforming its natural function, in certain embodiments. In someembodiments, the RNA may alter the nucleic acid sequence of interestwhich encodes the activity of interest in a manner that the nucleic acidsequence of interest is no longer capable of performing its naturalfunction (e.g., the action of a ribozyme for example).

In certain embodiments, nucleotide sequences sometimes are added to,modified or removed from one or more of the nucleic acid reagentelements, such as the promoter, 5′UTR, target sequence, or 3′UTRelements, to enhance, potentially enhance, reduce, or potentially reducetranscription and/or translation before or after such elements areincorporated in a nucleic acid reagent. In some embodiments, one or moreof the following sequences may be modified or removed if they arepresent in a 5′UTR: a sequence that forms a stable secondary structure(e.g., quadruplex structure or stem loop stem structure (e.g., EMBLsequences X12949, AF274954, AF139980, AF152961, 595936, U194144,AF116649 or substantially identical sequences that form such stem loopstem structures)); a translation initiation codon upstream of the targetnucleotide sequence start codon; a stop codon upstream of the targetnucleotide sequence translation initiation codon; an ORF upstream of thetarget nucleotide sequence translation initiation codon; an ironresponsive element (IRE) or like sequence; and a 5′ terminaloligopyrimidine tract (TOP, e.g., consisting of 5-15 pyrimidinesadjacent to the cap). A translational enhancer sequence and/or aninternal ribosome entry site (IRES) sometimes is inserted into a 5′UTR(e.g., EMBL nucleotide sequences J04513, X87949, M95825, M12783,AF025841, AF013263, AF006822, M17169, M13440, M22427, D14838 and M17446and substantially identical nucleotide sequences).

An AU-rich element (ARE, e.g., AUUUA repeats) and/or splicing junctionthat follows a non-sense codon sometimes is removed from or modified ina 3′ UTR. A polyadenosine tail sometimes is inserted into a 3′ UTR ifnone is present, sometimes is removed if it is present, and adenosinemoieties sometimes are added to or removed from a polyadenosine tailpresent in a 3′ UTR. Thus, some embodiments are directed to a processcomprising: determining whether any nucleotide sequences that increase,potentially increase, reduce or potentially reduce translationefficiency are present in the elements, and adding, removing ormodifying one or more of such sequences if they are identified. Certainembodiments are directed to a process comprising: determining whetherany nucleotide sequences that increase or potentially increasetranslation efficiency are not present in the elements, andincorporating such sequences into the nucleic acid reagent.

In some embodiments, an activity can be altered by modifying thenucleotide sequence of an ORF. An ORF sometimes is mutated or modified(for example, by point mutation, deletion mutation, insertion mutation,PCR based mutagenesis and the like) to alter, enhance or increase,reduce, substantially reduce or eliminate the activity of the encodedprotein or peptide. The protein or peptide encoded by a modified ORFsometimes is produced in a lower amount or may not be produced atdetectable levels, and in other embodiments, the product or proteinencoded by the modified ORF is produced at a higher level (e.g., codonssometimes are modified so they are compatible with tRNA's preferentiallyused in the host organism or engineered organism). To determine therelative activity, the activity from the product of the mutated ORF (orcell containing it) can be compared to the activity of the product orprotein encoded by the unmodified ORF (or cell containing it).

In some embodiments, an ORF nucleotide sequence sometimes is mutated ormodified to alter the triplet nucleotide sequences used to encode aminoacids (e.g., amino acid codon triplets, for example). Modification ofthe nucleotide sequence of an ORF to alter codon triplets sometimes isused to change the codon found in the original sequence to better matchthe preferred codon usage of the organism in which the ORF or nucleicacid reagent will be expressed. For example, the codon usage, andtherefore the codon triplets encoded by a nucleic acid sequence frombacteria may be different from the preferred codon usage in eukaryoteslike yeast or plants. Preferred codon usage also may be differentbetween bacterial species. In certain embodiments an ORF nucleotidesequences sometimes is modified to eliminate codon pairs and/oreliminate mRNA secondary structures that can cause pauses duringtranslation of the mRNA encoded by the ORF nucleotide sequence.Translational pausing sometimes occurs when nucleic acid secondarystructures exist in an mRNA, and sometimes occurs due to the presence ofcodon pairs that slow the rate of translation by causing ribosomes topause. In some embodiments, the use of lower abundance codon tripletscan reduce translational pausing due to a decrease in the pause timeneeded to load a charged tRNA into the ribosome translation machinery.Therefore, to increase transcriptional and translational efficiency inbacteria (e.g., where transcription and translation are concurrent, forexample) or to increase translational efficiency in eukaryotes (e.g.,where transcription and translation are functionally separated), thenucleotide sequence of a nucleotide sequence of interest can be alteredto better suit the transcription and/or translational machinery of thehost and/or genetically modified microorganism. In certain embodiment,slowing the rate of translation by the use of lower abundance codons,which slow or pause the ribosome, can lead to higher yields of thedesired product due to an increase in correctly folded proteins and areduction in the formation of inclusion bodies.

Codons can be altered and optimized according to the preferred usage bya given organism by determining the codon distribution of the nucleotidesequence donor organism and comparing the distribution of codons to thedistribution of codons in the recipient or host organism. Techniquesdescribed herein (e.g., site directed mutagenesis and the like) can thenbe used to alter the codons accordingly. Comparisons of codon usage canbe done by hand, or using nucleic acid analysis software commerciallyavailable to the artisan.

Modification of the nucleotide sequence of an ORF also can be used tocorrect codon triplet sequences that have diverged in differentorganisms. For example, certain yeast (e.g., C. tropicalis and C.maltosa) use the amino acid triplet CUG (e.g., CTG in the DNA sequence)to encode serine. CUG typically encodes leucine in most organisms. Inorder to maintain the correct amino acid in the resultant polypeptide orprotein, the CUG codon must be altered to reflect the organism in whichthe nucleic acid reagent will be expressed. Thus, if an ORF from abacterial donor is to be expressed in either Candida yeast strainmentioned above, the heterologous nucleotide sequence must first bealtered or modified to the appropriate leucine codon. Therefore, in someembodiments, the nucleotide sequence of an ORF sometimes is altered ormodified to correct for differences that have occurred in the evolutionof the amino acid codon triplets between different organisms. In someembodiments, the nucleotide sequence can be left unchanged at aparticular amino acid codon, if the amino acid encoded is a conservativeor neutral change in amino acid when compared to the originally encodedamino acid.

In some embodiments, an activity can be altered by modifyingtranslational regulation signals, like a stop codon for example. A stopcodon at the end of an ORF sometimes is modified to another stop codon,such as an amber stop codon described above. In some embodiments, a stopcodon is introduced within an ORF, sometimes by insertion or mutation ofan existing codon. An ORF comprising a modified terminal stop codonand/or internal stop codon often is translated in a system comprising asuppressor tRNA that recognizes the stop codon. An ORF comprising a stopcodon sometimes is translated in a system comprising a suppressor tRNAthat incorporates an unnatural amino acid during translation of thetarget protein or target peptide. Methods for incorporating unnaturalamino acids into a target protein or peptide are known, which include,for example, processes utilizing a heterologous tRNA/synthetase pair,where the tRNA recognizes an amber stop codon and is loaded with anunnatural amino acid (e.g., World Wide Web URLiupac.org/news/prize/2003/wang.pdf).

Depending on the portion of a nucleic acid reagent (e.g., Promoter, 5′or 3′ UTR, ORI, ORF, and the like) chosen for alteration (e.g., bymutagenesis, introduction or deletion, for example) the modificationsdescribed above can alter a given activity by (i) increasing ordecreasing feedback inhibition mechanisms, (ii) increasing or decreasingpromoter initiation, (iii) increasing or decreasing translationinitiation, (iv) increasing or decreasing translational efficiency, (v)modifying localization of peptides or products expressed from nucleicacid reagents described herein, or (vi) increasing or decreasing thecopy number of a nucleotide sequence of interest, (vii) expression of ananti-sense RNA, RNAi, siRNA, ribozyme and the like. In some embodiments,alteration of a nucleic acid reagent or nucleotide sequence can alter aregion involved in feedback inhibition (e.g., 5′ UTR, promoter and thelike). A modification sometimes is made that can add or enhance bindingof a feedback regulator and sometimes a modification is made that canreduce, inhibit or eliminate binding of a feedback regulator.

In certain embodiments, alteration of a nucleic acid reagent ornucleotide sequence can alter sequences involved in transcriptioninitiation (e.g., promoters, 5′ UTR, and the like). A modificationsometimes can be made that can enhance or increase initiation from anendogenous or heterologous promoter element. A modification sometimescan be made that removes or disrupts sequences that increase or enhancetranscription initiation, resulting in a decrease or elimination oftranscription from an endogenous or heterologous promoter element.

In some embodiments, alteration of a nucleic acid reagent or nucleotidesequence can alter sequences involved in translational initiation ortranslational efficiency (e.g., 5′ UTR, 3′ UTR, codon triplets of higheror lower abundance, translational terminator sequences and the like, forexample). A modification sometimes can be made that can increase ordecrease translational initiation, modifying a ribosome binding site forexample. A modification sometimes can be made that can increase ordecrease translational efficiency. Removing or adding sequences thatform hairpins and changing codon triplets to a more or less preferredcodon are non-limiting examples of genetic modifications that can bemade to alter translation initiation and translation efficiency.

In certain embodiments, alteration of a nucleic acid reagent ornucleotide sequence can alter sequences involved in localization ofpeptides, proteins or other desired products (e.g., adipic acid, forexample). A modification sometimes can be made that can alter, add orremove sequences responsible for targeting a polypeptide, protein orproduct to an intracellular organelle, the periplasm, cellularmembranes, or extracellularly. Transport of a heterologous product to adifferent intracellular space or extracellularly sometimes can reduce oreliminate the formation of inclusion bodies (e.g., insoluble aggregatesof the desired product).

In some embodiments, alteration of a nucleic acid reagent or nucleotidesequence can alter sequences involved in increasing or decreasing thecopy number of a nucleotide sequence of interest. A modificationsometimes can be made that increases or decreases the number of copiesof an ORF stably integrated into the genome of an organism or on anepigenetic nucleic acid reagent. Non-limiting examples of alterationsthat can increase the number of copies of a sequence of interestinclude, adding copies of the sequence of interest by duplication ofregions in the genome (e.g., adding additional copies by recombinationor by causing gene amplification of the host genome, for example),cloning additional copies of a sequence onto a nucleic acid reagent, oraltering an ORI to increase the number of copies of an epigeneticnucleic acid reagent. Non-limiting examples of alterations that candecrease the number of copies of a sequence of interest include,removing copies of the sequence of interest by deletion or disruption ofregions in the genome, removing additional copies of the sequence fromepigenetic nucleic acid reagents, or altering an ORI to decrease thenumber of copies of an epigenetic nucleic acid reagent.

In certain embodiments, increasing or decreasing the expression of anucleotide sequence of interest can also be accomplished by altering,adding or removing sequences involved in the expression of an anti-senseRNA, RNAi, siRNA, ribozyme and the like. The methods described above canbe used to modify expression of anti-sense RNA, RNAi, siRNA, ribozymeand the like.

Engineered microorganisms can be prepared by altering, introducing orremoving nucleotide sequences in the host genome or in stably maintainedepigenetic nucleic acid reagents, as noted above. The nucleic acidreagents use to alter, introduce or remove nucleotide sequences in thehost genome or epigenetic nucleic acids can be prepared using themethods described herein or available to the artisan.

Nucleic acid sequences having a desired activity can be isolated fromcells of a suitable organism using lysis and nucleic acid purificationprocedures available in Maniatis, T., E. F. Fritsch and J. Sambrook(1982) Molecular Cloning: a Laboratory Manual; Cold Spring HarborLaboratory, Cold Spring Harbor, N.Y. or with commercially available celllysis and DNA purification reagents and kits. In some embodiments,nucleic acids used to engineer microorganisms can be provided forconducting methods described herein after processing of the organismcontaining the nucleic acid. For example, the nucleic acid of interestmay be extracted, isolated, purified or amplified from a sample (e.g.,from an organism of interest or culture containing a plurality oforganisms of interest, like yeast or bacteria for example). The term“isolated” as used herein refers to nucleic acid removed from itsoriginal environment (e.g., the natural environment if it is naturallyoccurring, or a host cell if expressed exogenously), and thus is altered“by the hand of man” from its original environment. An isolated nucleicacid generally is provided with fewer non-nucleic acid components (e.g.,protein, lipid) than the amount of components present in a sourcesample. A composition comprising isolated sample nucleic acid can besubstantially isolated (e.g., about 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99% or greater than 99% free of non-nucleic acid components).The term “purified” as used herein refers to sample nucleic acidprovided that contains fewer nucleic acid species than in the samplesource from which the sample nucleic acid is derived. A compositioncomprising sample nucleic acid may be substantially purified (e.g.,about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater than99% free of other nucleic acid species). The term “amplified” as usedherein refers to subjecting nucleic acid of a cell, organism or sampleto a process that linearly or exponentially generates amplicon nucleicacids having the same or substantially the same nucleotide sequence asthe nucleotide sequence of the nucleic acid in the sample, or portionthereof. As noted above, the nucleic acids used to prepare nucleic acidreagents as described herein can be subjected to fragmentation orcleavage.

Amplification of nucleic acids is sometimes necessary when dealing withorganisms that are difficult to culture. Where amplification may bedesired, any suitable amplification technique can be utilized.Non-limiting examples of methods for amplification of polynucleotidesinclude, polymerase chain reaction (PCR); ligation amplification (orligase chain reaction (LCR)); amplification methods based on the use ofQ-beta replicase or template-dependent polymerase (see US PatentPublication Number US20050287592); helicase-dependent isothermalamplification (Vincent et al., “Helicase-dependent isothermal DNAamplification”. EMBO reports 5 (8): 795-800 (2004)); strand displacementamplification (SDA); thermophilic SDA nucleic acid sequence basedamplification (3SR or NASBA) and transcription-associated amplification(TAA). Non-limiting examples of PCR amplification methods includestandard PCR, AFLP-PCR, Allele-specific PCR, Alu-PCR, Asymmetric PCR,Colony PCR, Hot start PCR, Inverse PCR (IPCR), In situ PCR (ISH),Intersequence-specific PCR (ISSR-PCR), Long PCR, Multiplex PCR, NestedPCR, Quantitative PCR, Reverse Transcriptase PCR (RT-PCR), Real TimePCR, Single cell PCR, Solid phase PCR, combinations thereof, and thelike. Reagents and hardware for conducting PCR are commerciallyavailable.

Protocols for conducting the various type of PCR listed above arereadily available to the artisan. PCR conditions can be dependent uponprimer sequences, target abundance, and the desired amount ofamplification, and therefore, one of skill in the art may choose from anumber of PCR protocols available (see, e.g., U.S. Pat. Nos. 4,683,195and 4,683,202; and PCR Protocols: A Guide to Methods and Applications,Innis et al., eds, 1990. PCR often is carried out as an automatedprocess with a thermostable enzyme. In this process, the temperature ofthe reaction mixture is cycled through a denaturing region, aprimer-annealing region, and an extension reaction region automatically.Machines specifically adapted for this purpose are commerciallyavailable. A non-limiting example of a PCR protocol that may be suitablefor embodiments described herein is, treating the sample at 95° C. for 5minutes; repeating forty-five cycles of 95° C. for 1 minute, 59° C. for1 minute, 10 seconds, and 72° C. for 1 minute 30 seconds; and thentreating the sample at 72° C. for 5 minutes. Additional PCR protocolsare described in the example section. Multiple cycles frequently areperformed using a commercially available thermal cycler. Suitableisothermal amplification processes known and selected by the person ofordinary skill in the art also may be applied, in certain embodiments.In some embodiments, nucleic acids encoding polypeptides with a desiredactivity can be isolated by amplifying the desired sequence from anorganism having the desired activity using oligonucleotides or primersdesigned based on sequences described herein

Amplified, isolated and/or purified nucleic acids can be cloned into therecombinant DNA vectors described in Figures herein or into suitablecommercially available recombinant DNA vectors. Cloning of nucleic acidsequences of interest into recombinant DNA vectors can facilitatefurther manipulations of the nucleic acids for preparation of nucleicacid reagents, (e.g., alteration of nucleotide sequences by mutagenesis,homologous recombination, amplification and the like, for example).Standard cloning procedures (e.g., enzymic digestion, ligation, and thelike) are readily available to the artisan and can be found in Maniatis,T., E. F. Fritsch and J. Sambrook (1982) Molecular Cloning: a LaboratoryManual; Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

In some embodiments, nucleic acid sequences prepared by isolation oramplification can be used, without any further modification, to add anactivity to a microorganism and thereby generate a genetically modifiedor engineered microorganism. In certain embodiments, nucleic acidsequences prepared by isolation or amplification can be geneticallymodified to alter (e.g., increase or decrease, for example) a desiredactivity. In some embodiments, nucleic acids, used to add an activity toan organism, sometimes are genetically modified to optimize theheterologous polynucleotide sequence encoding the desired activity(e.g., polypeptide or protein, for example). The term “optimize” as usedherein can refer to alteration to increase or enhance expression bypreferred codon usage. The term optimize can also refer to modificationsto the amino acid sequence to increase the activity of a polypeptide orprotein, such that the activity exhibits a higher catalytic activity ascompared to the “natural” version of the polypeptide or protein.

Nucleic acid sequences of interest can be genetically modified usingmethods known in the art. Mutagenesis techniques are particularly usefulfor small scale (e.g., 1, 2, 5, 10 or more nucleotides) or large scale(e.g., 50, 100, 150, 200, 500, or more nucleotides) geneticmodification. Mutagenesis allows the artisan to alter the geneticinformation of an organism in a stable manner, either naturally (e.g.,isolation using selection and screening) or experimentally by the use ofchemicals, radiation or inaccurate DNA replication (e.g., PCRmutagenesis). In some embodiments, genetic modification can be performedby whole scale synthetic synthesis of nucleic acids, using a nativenucleotide sequence as the reference sequence, and modifying nucleotidesthat can result in the desired alteration of activity. Mutagenesismethods sometimes are specific or targeted to specific regions ornucleotides (e.g., site-directed mutagenesis, PCR-based site-directedmutagenesis, and in vitro mutagenesis techniques such as transplacementand in vivo oligonucleotide site-directed mutagenesis, for example).Mutagenesis methods sometimes are non-specific or random with respect tothe placement of genetic modifications (e.g., chemical mutagenesis,insertion element (e.g., insertion or transposon elements) andinaccurate PCR based methods, for example).

Site directed mutagenesis is a procedure in which a specific nucleotideor specific nucleotides in a DNA molecule are mutated or altered. Sitedirected mutagenesis typically is performed using a nucleic acidsequence of interest cloned into a circular plasmid vector.Site-directed mutagenesis requires that the wild type sequence be knownand used a platform for the genetic alteration. Site-directedmutagenesis sometimes is referred to as oligonucleotide-directedmutagenesis because the technique can be performed usingoligonucleotides which have the desired genetic modificationincorporated into the complement a nucleotide sequence of interest. Thewild type sequence and the altered nucleotide are allowed to hybridizeand the hybridized nucleic acids are extended and replicated using a DNApolymerase. The double stranded nucleic acids are introduced into a host(e.g., E. coli, for example) and further rounds of replication arecarried out in vivo. The transformed cells carrying the mutated nucleicacid sequence are then selected and/or screened for those cells carryingthe correctly mutagenized sequence. Cassette mutagenesis and PCR-basedsite-directed mutagenesis are further modifications of the site-directedmutagenesis technique. Site-directed mutagenesis can also be performedin vivo (e.g., transplacement “pop-in pop-out”, In vivo site-directedmutagenesis with synthetic oligonucleotides and the like, for example).

PCR-based mutagenesis can be performed using PCR with oligonucleotideprimers that contain the desired mutation or mutations. The techniquefunctions in a manner similar to standard site-directed mutagenesis,with the exception that a thermocycler and PCR conditions are used toreplace replication and selection of the clones in a microorganism host.As PCR-based mutagenesis also uses a circular plasmid vector, theamplified fragment (e.g., linear nucleic acid molecule) containing theincorporated genetic modifications can be separated from the plasmidcontaining the template sequence after a sufficient number of rounds ofthermocycler amplification, using standard electrophoretic procedures. Amodification of this method uses linear amplification methods and a pairof mutagenic primers that amplify the entire plasmid. The proceduretakes advantage of the E. coli Dam methylase system which causes DNAreplicated in vivo to be sensitive to the restriction endonucleasesDpnI. PCR synthesized DNA is not methylated and is therefore resistantto DpnI. This approach allows the template plasmid to be digested,leaving the genetically modified, PCR synthesized plasmids to beisolated and transformed into a host bacteria for DNA repair andreplication, thereby facilitating subsequent cloning and identificationsteps. A certain amount of randomness can be added to PCR-based siteddirected mutagenesis by using partially degenerate primers.

Recombination sometimes can be used as a tool for mutagenesis.Homologous recombination allows the artisan to specifically targetregions of known sequence for insertion of heterologous nucleotidesequences using the host organisms natural DNA replication and repairenzymes. Homologous recombination methods sometimes are referred to as“pop in pop out” mutagenesis, transplacement, knock out mutagenesis orknock in mutagenesis. Integration of a nucleic acid sequence into a hostgenome is a single cross over event, which inserts the entire nucleicacid reagent (e.g., pop in). A second cross over event excises all but aportion of the nucleic acid reagent, leaving behind a heterologoussequence, often referred to as a “footprint” (e.g., pop out).Mutagenesis by insertion (e.g., knock in) or by double recombinationleaving behind a disrupting heterologous nucleic acid (e.g., knock out)both server to disrupt or “knock out” the function of the gene ornucleic acid sequence in which insertion occurs. By combining selectablemarkers and/or auxotrophic markers with nucleic acid reagents designedto provide the appropriate nucleic acid target sequences, the artisancan target a selectable nucleic acid reagent to a specific region, andthen select for recombination events that “pop out” a portion of theinserted (e.g., “pop in”) nucleic acid reagent.

Such methods take advantage of nucleic acid reagents that have beenspecifically designed with known target nucleic acid sequences at ornear a nucleic acid or genomic region of interest. Popping out typicallyleaves a “foot print” of left over sequences that remain after therecombination event. The left over sequence can disrupt a gene andthereby reduce or eliminate expression of that gene. In someembodiments, the method can be used to insert sequences, upstream ordownstream of genes that can result in an enhancement or reduction inexpression of the gene. In certain embodiments, new genes can beintroduced into the genome of a host organism using similarrecombination or “pop in” methods. An example of a yeast recombinationsystem using the ura3 gene and 5-FOA were described briefly above andfurther detail is presented herein.

A method for modification is described in Alani et al., “A method forgene disruption that allows repeated use of URA3 selection in theconstruction of multiply disrupted yeast strains”, Genetics116(4):541-545 August 1987. The original method uses a Ura3 cassettewith 1000 base pairs (bp) of the same nucleotide sequence cloned in thesame orientation on either side of the URA3 cassette. Targetingsequences of about 50 bp are added to each side of the construct. Thedouble stranded targeting sequences are complementary to sequences inthe genome of the host organism. The targeting sequences allowsite-specific recombination in a region of interest. The modification ofthe original technique replaces the two 1000 bp sequence direct repeatswith two 200 bp direct repeats. The modified method also uses 50 bptargeting sequences. The modification reduces or eliminatesrecombination of a second knock out into the 1000 bp repeat left behindin a first mutagenesis, therefore allowing multiply knocked out yeast.Additionally, the 200 bp sequences used herein are uniquely designed,self-assembling sequences that leave behind identifiable footprints. Thetechnique used to design the sequences incorporate design features suchas low identity to the yeast genome, and low identity to each other.Therefore a library of the self-assembling sequences can be generated toallow multiple knockouts in the same organism, while reducing oreliminating the potential for integration into a previous knockout.

In yeast the cassettes are typically of two different overallstructures, as follows:

<5′ homology region-promoter-coding sequence-terminator-3′ homologyregion>

<5′ homology region-promoter-coding sequence-terminator-marker-3′homology region>

The parts of the DNA transformation cassette possess the followingproperties:

5′ and 3′ homology regions—these DNA sequences dictate the specificlocation in the chromosome where the DNA transformation cassette willinsert through homologous recombination. The 5′ homology regionindicates the upstream boundary for insertion while the 3′ homologyindicates the downstream boundary. The homology regions may constitute agene that rescues auxotrophy in an engineered microorganism, i.e. thehomology regions mediate insertion into a non-functional gene thatresults in an auxotrophic phenotype and insertion of the cassetterestores function to the gene. For example, the 5′ and 3′ homologyregions may represent the two halves of the URA3 gene and directhomologous recombination in a mutant or loss-of-function ura3 gene,which rescues the loss-of-function.

Promoter—this DNA sequence drives transcription of the coding sequenceimmediately downstream of the promoter. A promoter will often be turnedon or off when the microorganism is exposed to specific compounds orgrown under certain conditions.

Coding sequence—the sequence of codons that are translated into thedesired protein. The codons can be optimized to reflect the endogenouscodon frequency of the engineered microorganism.

Terminator—this DNA sequence marks the end of the sequence to betranscribed, as indicated by the promoter. It may or may not containsequences that positively or negatively regulate the activity of thepromoter.

Marker—this DNA sequence encodes information that will confer propertiesto a yeast cell that mediate growth under selective or auxotrophicconditions. For example, if the initial cell line is auxotrophic foruracil and is transformed with a cassette containing a URA3 marker, anytransformant that contains the URA3 marker will now be able to grow inthe absence of uracil.

The DNA transformation cassette is generated through conventionalmolecular biology methods such as PCR, restriction enzyme digestion andDNA ligation and/or Gibson assembly. The cassette is transformed intothe yeast and clones of interest are identified as colonies that grow onthe appropriate selective or auxotrophic media, e.g. synthetic completeyeast media lacking uracil.

As noted above, the URA3 cassette makes use of the toxicity of 5-FOA inyeast carrying a functional URA3 gene. Uracil synthesis deficient yeastare transformed with the modified URA3 cassette, using standard yeasttransformation protocols, and the transformed cells are plated onminimal media minus uracil. In some embodiments, PCR can be used toverify correct insertion into the region of interest in the host genome,and certain embodiments the PCR step can be omitted. Inclusion of thePCR step can reduce the number of transformants that need to be counterselected to “pop out” the URA3 cassette. The transformants (e.g., all orthe ones determined to be correct by PCR, for example) can then becounter-selected on media containing 5-FOA, which will select forrecombination out (e.g., popping out) of the URA3 cassette, thusrendering the yeast ura3 deficient again, and resistant to 5-FOAtoxicity. Targeting sequences used to direct recombination events tospecific regions are presented herein. A modification of the methoddescribed above can be used to integrate genes in to the chromosome,where after recombination a functional gene is left in the chromosomenext to the 200 bp footprint.

In some embodiments, other auxotrophic or dominant selection markers canbe used in place of URA3 (e.g., an auxotrophic selectable marker), withthe appropriate change in selection media and selection agents.Auxotrophic selectable markers are used in strains deficient forsynthesis of a required biological molecule (e.g., amino acid ornucleoside, for example). Non-limiting examples of additionalauxotrophic markers include; HIS3, TRP1, LEU2, LEU2-d, and LYS2. Certainauxotrophic markers (e.g., URA3 and LYS2) allow counter selection toselect for the second recombination event that pops out all but one ofthe direct repeats of the recombination construct. HIS3 encodes anactivity involved in histidine synthesis. TRP1 encodes an activityinvolved in tryptophan synthesis. LEU2 encodes an activity involved inleucine synthesis. LEU2-d is a low expression version of LEU2 thatselects for increased copy number (e.g., gene or plasmid copy number,for example) to allow survival on minimal media without leucine. LYS2encodes an activity involved in lysine synthesis, and allows counterselection for recombination out of the LYS2 gene using alpha-aminoadipate (α-amino adipate).

Dominant selectable markers are useful because they also allowindustrial and/or prototrophic strains to be used for geneticmanipulations. Additionally, dominant selectable markers provide theadvantage that rich medium can be used for plating and culture growth,and thus growth rates are markedly increased. Non-limiting examples ofdominant selectable markers include; Tn903 kan^(r), Cm^(r), Hyg^(r),CUP1, and DHFR. Tn903 kan^(r) encodes an activity involved in kanamycinantibiotic resistance (e.g., typically neomycin phosphotransferase II orNPTII, for example). Cm^(r) encodes an activity involved inchloramphenicol antibiotic resistance (e.g., typically chloramphenicolacetyl transferase or CAT, for example). Hyg^(r) encodes an activityinvolved in hygromycin resistance by phosphorylation of hygromycin B(e.g., hygromycin phosphotransferase, or HPT). CUP1 encodes an activityinvolved in resistance to heavy metal (e.g., copper, for example)toxicity. DHFR encodes a dihydrofolate reductase activity which confersresistance to methotrexate and sulfanilamide compounds.

In contrast to site-directed or specific mutagenesis, random mutagenesisdoes not require any sequence information and can be accomplished by anumber of widely different methods. Random mutagenesis often is used togenerate mutant libraries that can be used to screen for the desiredgenotype or phenotype. Non-limiting examples of random mutagenesisinclude; chemical mutagenesis, UV-induced mutagenesis, insertion elementor transposon-mediated mutagenesis, DNA shuffling, error-prone PCRmutagenesis, and the like.

Chemical mutagenesis often involves chemicals like ethylmethanesulfonate (EMS), nitrous acid, mitomycin C,N-methyl-N-nitrosourea (MNU), diepoxybutane (DEB), 1,2,7,8-diepoxyoctane(DEO), methyl methane sulfonate (MMS),N-methyl-N′-nitro-N-nitrosoguanidine (MNNG), 4-nitroquinoline 1-oxide(4-NQO),2-methyloxy-6-chloro-9β-[ethyl-2-chloroethyl]aminopropylamino)-acridinedihydrochloride(ICR-170), 2-amino purine (2AP), and hydroxylamine (HA), provided hereinas non-limiting examples. These chemicals can cause base-pairsubstitutions, frameshift mutations, deletions, transversion mutations,transition mutations, incorrect replication, and the like. In someembodiments, the mutagenesis can be carried out in vivo. Sometimes themutagenic process involves the use of the host organism's DNAreplication and repair mechanisms to incorporate and replicate themutagenized base or bases.

Another type of chemical mutagenesis involves the use of base-analogs.The use of base-analogs cause incorrect base pairing which in thefollowing round of replication is corrected to a mismatched nucleotidewhen compared to the starting sequence. Base analog mutagenesisintroduces a small amount of non-randomness to random mutagenesis,because specific base analogs can be chosen which can be incorporated atcertain nucleotides in the starting sequence. Correction of themispairing typically yields a known substitution. For example,Bromo-deoxyuridine (BrdU) can be incorporated into DNA and replaces T inthe sequence. The host DNA repair and replication machinery can sometimecorrect the defect, but sometimes will mispair the BrdU with a G. Thenext round of replication then causes a G-C transversion from theoriginal A-T in the native sequence.

Ultra violet (UV) induced mutagenesis is caused by the formation ofthymidine dimers when UV light irradiates chemical bonds between twoadjacent thymine residues. Excision repair mechanism of the hostorganism correct the lesion in the DNA, but occasionally the lesion isincorrectly repaired typically resulting in a C to T transition.

Insertion element or transposon-mediated mutagenesis makes use ofnaturally occurring or modified naturally occurring mobile geneticelements. Transposons often encode accessory activities in addition tothe activities necessary for transposition (e.g., movement using atransposase activity, for example). In many examples, transposonaccessory activities are antibiotic resistance markers (e.g., see Tn903kan^(r) described above, for example). Insertion elements typically onlyencode the activities necessary for movement of the nucleic acidsequence. Insertion element and transposon mediated mutagenesis oftencan occur randomly, however specific target sequences are known for sometransposons. Mobile genetic elements like IS elements or Transposons(Tn) often have inverted repeats, direct repeats or both inverted anddirect repeats flanking the region coding for the transposition genes.Recombination events catalyzed by the transposase cause the element toremove itself from the genome and move to a new location, leaving behinda portion of an inverted or direct repeat. Classic examples oftransposons are the “mobile genetic elements” discovered in maize.Transposon mutagenesis kits are commercially available which aredesigned to leave behind a 5 codon insert (e.g., Mutation GenerationSystem kit, Finnzymes, World Wide Web URL finnzymes.us, for example).This allows the artisan to identify the insertion site, without fullydisrupting the function of most genes.

DNA shuffling is a method which uses DNA fragments from members of amutant library and reshuffles the fragments randomly to generate newmutant sequence combinations. The fragments are typically generatedusing DNasel, followed by random annealing and re-joining usingself-priming PCR. The DNA overhanging ends, from annealing of randomfragments, provide “primer” sequences for the PCR process. Shuffling canbe applied to libraries generated by any of the above mutagenesismethods.

Error prone PCR and its derivative rolling circle error prone PCR usesincreased magnesium and manganese concentrations in conjunction withlimiting amounts of one or two nucleotides to reduce the fidelity of theTaq polymerase. The error rate can be as high as 2% under appropriateconditions, when the resultant mutant sequence is compared to the wildtype starting sequence. After amplification, the library of mutantcoding sequences must be cloned into a suitable plasmid. Although pointmutations are the most common types of mutation in error prone PCR,deletions and frameshift mutations are also possible. There are a numberof commercial error-prone PCR kits available, including those fromStratagene and Clontech (e.g., World Wide Web URL strategene.com andWorld Wide Web URL clontech.com, respectively, for example). Rollingcircle error-prone PCR is a variant of error-prone PCR in whichwild-type sequence is first cloned into a plasmid, the whole plasmid isthen amplified under error-prone conditions.

As noted above, organisms with altered activities can also be isolatedusing genetic selection and screening of organisms challenged onselective media or by identifying naturally occurring variants fromunique environments. For example, 2-Deoxy-D-glucose is a toxic glucoseanalog. Growth of yeast on this substance yields mutants that areglucose-deregulated. A number of mutants have been isolated using2-Deoxy-D-glucose including transport mutants, and mutants that fermentglucose and galactose simultaneously instead of glucose first thengalactose when glucose is depleted. Similar techniques have been used toisolate mutant microorganisms that can metabolize plastics (e.g., fromlandfills), petrochemicals (e.g., from oil spills), and the like, eitherin a laboratory setting or from unique environments.

Similar methods can be used to isolate naturally occurring mutations ina desired activity when the activity exists at a relatively low ornearly undetectable level in the organism of choice, in someembodiments. The method generally consists of growing the organism to aspecific density in liquid culture, concentrating the cells, and platingthe cells on various concentrations of the substance to which anincrease in metabolic activity is desired. The cells are incubated at amoderate growth temperature, for 5 to 10 days. To enhance the selectionprocess, the plates can be stored for another 5 to 10 days at a lowtemperature. The low temperature sometimes can allow strains that havegained or increased an activity to continue growing while other strainsare inhibited for growth at the low temperature. Following the initialselection and secondary growth at low temperature, the plates can bereplica plated on higher or lower concentrations of the selectionsubstance to further select for the desired activity.

A native, heterologous or mutagenized polynucleotide can be introducedinto a nucleic acid reagent for introduction into a host organism,thereby generating an engineered microorganism. Standard recombinant DNAtechniques (restriction enzyme digests, ligation, and the like) can beused by the artisan to combine the mutagenized nucleic acid of interestinto a suitable nucleic acid reagent capable of (i) being stablymaintained by selection in the host organism, or (ii) being integratinginto the genome of the host organism. As noted above, sometimes nucleicacid reagents comprise two replication origins to allow the same nucleicacid reagent to be manipulated in bacterial before final introduction ofthe final product into the host organism (e.g., yeast or fungus forexample). Standard molecular biology and recombinant DNA methodsavailable to one of skill in the art can be found in Maniatis, T., E. F.Fritsch and J. Sambrook (1982) Molecular Cloning: a Laboratory Manual;Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

Nucleic acid reagents can be introduced into microorganisms usingvarious techniques. Non-limiting examples of methods used to introduceheterologous nucleic acids into various organisms include;transformation, transfection, transduction, electroporation,ultrasound-mediated transformation, particle bombardment and the like.In some instances, the addition of carrier molecules (e.g.,bis-benzimdazolyl compounds, for example, see U.S. Pat. No. 5,595,899)can increase the uptake of DNA in cells typically though to be difficultto transform by conventional methods. Conventional methods oftransformation are readily available to the artisan and can be found inManiatis, T., E. F. Fritsch and J. Sambrook (1982) Molecular Cloning: aLaboratory Manual; Cold Spring Harbor Laboratory, Cold Spring Harbor,N.Y.

Usually a DNA piece is constructed (called cassette) for the integrationof the gene of interest into the genome.

Culture, Production and Process Methods

Engineered microorganisms often are cultured under conditions thatoptimize yield of a target molecule. A non-limiting example of such atarget molecule is ethanol. Culture conditions often can alter (e.g.,add, optimize, reduce or eliminate, for example) activity of one or moreof the following activities: phosphofructokinase activity,phosphogluconate dehydratase activity,2-keto-3-deoxygluconate-6-phosphate aldolase activity, xylose isomeraseactivity, phosphoenolpyruvate carboxylase activity, alcoholdehydrogenase 2 activity and thymidylate synthase activities. Ingeneral, conditions that may be optimized include the type and amount ofcarbon source, the type and amount of nitrogen source, thecarbon-to-nitrogen ratio, the oxygen level, growth temperature, pH,length of the biomass production phase, length of target productaccumulation phase, and time of cell harvest.

The term “fermentation conditions” as used herein refers to any cultureconditions suitable for maintaining a microorganism (e.g., in a staticor proliferative state). Fermentation conditions can include severalparameters, including without limitation, temperature, oxygen content,nutrient content (e.g., glucose content), pH, agitation level (e.g.,revolutions per minute), gas flow rate (e.g., air, oxygen, nitrogengas), redox potential, cell density (e.g., optical density), cellviability and the like. A change in fermentation conditions (e.g.,switching fermentation conditions) is an alteration, modification orshift of one or more fermentation parameters. For example, one canchange fermentation conditions by increasing or decreasing temperature,increasing or decreasing pH (e.g., adding or removing an acid, a base orcarbon dioxide), increasing or decreasing oxygen content (e.g.,introducing air, oxygen, carbon dioxide, nitrogen) and/or adding orremoving a nutrient (e.g., one or more sugars or sources of sugar,biomass, vitamin and the like), or combinations of the foregoing.Examples of fermentation conditions are described herein. Aerobicconditions often comprise greater than about 50% dissolved oxygen (e.g.,about 52%, 54%, 56%, 58%, 60%, 62%, 64%, 66%, 68%, 70%, 72%, 74%, 76%,78%, 80%, 82%, 84%, 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98% or 99%, or greater than any one of the foregoing). Anaerobicconditions often comprise less than about 50% dissolved oxygen (e.g.,about 1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 22%, 24%, 26%,28%, 30%, 32%, 34%, 36%, 38%, 40%, 42%, 44%, 46%, 48%, or less than anyone of the foregoing).

Culture media generally contain a suitable carbon source. Carbon sourcesmay include, but are not limited to, monosaccharides (e.g., glucose,fructose, xylose), disaccharides (e.g., lactose, sucrose),oligosaccharides, polysaccharides (e.g., starch, cellulose,hemicellulose, other lignocellulosic materials or mixtures thereof),sugar alcohols (e.g., glycerol), and renewable feedstocks (e.g., cheesewhey permeate, corn steep liquor, sugar beet molasses, barley malt).Carbon sources also can be selected from one or more of the followingnon-limiting examples: linear or branched alkanes (e.g., hexane), linearor branched alcohols (e.g., hexanol), fatty acids (e.g., about 10carbons to about 22 carbons), esters of fatty acids, monoglycerides,diglycerides, triglycerides, phospholipids and various commercialsources of fatty acids including vegetable oils (e.g., soybean oil) andanimal fats. A carbon source may include one-carbon sources (e.g.,carbon dioxide, methanol, formaldehyde, formate and carbon-containingamines) from which metabolic conversion into key biochemicalintermediates can occur. It is expected that the source of carbonutilized may encompass a wide variety of carbon-containing sources andwill only be limited by the choice of the engineered microorganism(s).

Nitrogen may be supplied from an inorganic (e.g.,(NH.sub.4).sub.2SO.sub.4) or organic source (e.g., urea or glutamate).In addition to appropriate carbon and nitrogen sources, culture mediaalso can contain suitable minerals, salts, cofactors, buffers, vitamins,metal ions (e.g., Mn.sup.+2, Co.sup.+2, Zn.sup.+2, Mg.sup.+2) and othercomponents suitable for culture of microorganisms. Engineeredmicroorganisms sometimes are cultured in complex media (e.g., yeastextract-peptone-dextrose broth (YPD)). In some embodiments, engineeredmicroorganisms are cultured in a defined minimal media that lacks acomponent necessary for growth and thereby forces selection of a desiredexpression cassette (e.g., Yeast Nitrogen Base (DIFCO Laboratories,Detroit, Mich.)). Culture media in some embodiments are commoncommercially prepared media, such as Yeast Nitrogen Base (DIFCOLaboratories, Detroit, Mich.). Other defined or synthetic growth mediamay also be used and the appropriate medium for growth of the particularmicroorganism are known.

A variety of host organisms can be selected for the production ofengineered microorganisms. Non-limiting examples include yeast andfungi. In specific embodiments, yeast are cultured in YPD media (10 g/LBacto Yeast Extract, 20 g/L Bacto Peptone, and 20 g/L Dextrose).Filamentous fungi, in particular embodiments, are grown in CM (CompleteMedium) containing 10 g/L Dextrose, 2 g/L Bacto Peptone, 1 g/L BactoYeast Extract, 1 g/L Casamino acids, 50 mL/L 20× Nitrate Salts (120 g/LNaNO₃, 10.4 g/L KCl, 10.4 g/L MgSO₄.7 H₂O), 1 mL/L 1000× Trace Elements(22 g/L ZnSO₄.7 H₂O, 11 g/L H₃BO₃, 5 g/L MnCl₂.7H₂O, 5 g/L FeSO₄.7 H₂O,1.7 g/L CoCl₂.6 H₂O, 1.6 g/L CuSO₄.5 H₂O, 1.5 g/L Na₂MoO₄.2H₂O, and 50g/L Na₄EDTA), and 1 mL/L Vitamin Solution (100 mg each of Biotin,pyridoxine, thiamine, riboflavin, p-aminobenzoic acid, and nicotinicacid in 100 mL water).

A suitable pH range for the fermentation often is between about pH 4.0to about pH 8.0, where a pH in the range of about pH 5.5 to about pH 7.0sometimes is utilized for initial culture conditions. Culturing may beconducted under aerobic or anaerobic conditions, where microaerobicconditions sometimes are maintained. A two-stage process may beutilized, where one stage promotes microorganism proliferation andanother state promotes production of target molecule. In a two-stageprocess, the first stage may be conducted under aerobic conditions(e.g., introduction of air and/or oxygen) and the second stage may beconducted under anaerobic conditions (e.g., air or oxygen are notintroduced to the culture conditions).

A variety of fermentation processes may be applied for commercialbiological production of a target product. In some embodiments,commercial production of a target product from a recombinant microbialhost is conducted using a batch, fed-batch or continuous fermentationprocess, for example.

A batch fermentation process often is a closed system where the mediacomposition is fixed at the beginning of the process and not subject tofurther additions beyond those required for maintenance of pH and oxygenlevel during the process. At the beginning of the culturing process themedia is inoculated with the desired organism and growth or metabolicactivity is permitted to occur without adding additional sources (i.e.,carbon and nitrogen sources) to the medium. In batch processes themetabolite and biomass compositions of the system change constantly upto the time the culture is terminated. In a typical batch process, cellsproceed through a static lag phase to a high-growth log phase andfinally to a stationary phase, wherein the growth rate is diminished orhalted. Left untreated, cells in the stationary phase will eventuallydie.

A variation of the standard batch process is the fed-batch process,where the carbon source is continually added to the fermentor over thecourse of the fermentation process. Fed-batch processes are useful whencatabolite repression is apt to inhibit the metabolism of the cells orwhere it is desirable to have limited amounts of carbon source in themedia at any one time. Measurement of the carbon source concentration infed-batch systems may be estimated on the basis of the changes ofmeasurable factors such as pH, dissolved oxygen and the partial pressureof waste gases (e.g., CO.sub.2). Batch and fed-batch culturing methodsare known in the art. Examples of such methods may be found in Thomas D.Brock in Biotechnology: A Textbook of Industrial Microbiology, 2.sup.nded., (1989) Sinauer Associates Sunderland, Mass. and Deshpande, MukundV., Appl. Biochem. Biotechnol., 36:227 (1992).

In continuous fermentation process a defined media often is continuouslyadded to a bioreactor while an equal amount of culture volume is removedsimultaneously for product recovery. Continuous cultures generallymaintain cells in the log phase of growth at a constant cell density.Continuous or semi-continuous culture methods permit the modulation ofone factor or any number of factors that affect cell growth or endproduct concentration. For example, an approach may limit the carbonsource and allow all other parameters to moderate metabolism. In somesystems, a number of factors affecting growth may be alteredcontinuously while the cell concentration, measured by media turbidity,is kept constant. Continuous systems often maintain steady state growthand thus the cell growth rate often is balanced against cell loss due tomedia being drawn off the culture. Methods of modulating nutrients andgrowth factors for continuous culture processes, as well as techniquesfor maximizing the rate of product formation, are known and a variety ofmethods are detailed by Brock, supra.

In various embodiments ethanol may be purified from the culture media orextracted from the engineered microorganisms. Culture media may betested for ethanol concentration and drawn off when the concentrationreaches a predetermined level. Detection methods are known in the art,including but not limited to the use of a hydrometer and infraredmeasurement of vibrational frequency of dissolved ethanol using the CHband at 2900 cm⁻¹. Ethanol may be present at a range of levels asdescribed herein.

A target product sometimes is retained within an engineeredmicroorganism after a culture process is completed, and in certainembodiments, the target product is secreted out of the microorganisminto the culture medium. For the latter embodiments, (i) culture mediamay be drawn from the culture system and fresh medium may besupplemented, and/or (ii) target product may be extracted from theculture media during or after the culture process is completed.Engineered microorganisms may be cultured on or in solid, semi-solid orliquid media. In some embodiments media is drained from cells adheringto a plate. In certain embodiments, a liquid-cell mixture is centrifugedat a speed sufficient to pellet the cells but not disrupt the cells andallow extraction of the media, as known in the art. The cells may thenbe resuspended in fresh media. Target product may be purified fromculture media according to methods known in the art.

In certain embodiments, target product is extracted from the culturedengineered microorganisms. The microorganism cells may be concentratedthrough centrifugation at speed sufficient to shear the cell membranes.In some embodiments, the cells may be physically disrupted (e.g., shearforce, sonication) or chemically disrupted (e.g., contacted withdetergent or other lysing agent).

The phases may be separated by centrifugation or other method known inthe art and target product may be isolated according to known methods.

Commercial grade target product sometimes is provided in substantiallypure form (e.g., 90% pure or greater, 95% pure or greater, 99% pure orgreater or 99.5% pure or greater). In some embodiments, target productmay be modified into any one of a number of downstream products. Forexample, cannabidiolic acid may be derivatized or further processed tobe an ingredient in food, drinks, vape pens, gum, skin lotions,pharmaceuticals, and supplements.

Target product may be provided within cultured microbes containingtarget product, and cultured microbes may be supplied fresh or frozen ina liquid media or dried. Fresh or frozen microbes may be contained inappropriate moisture-proof containers that may also be temperaturecontrolled as necessary. Target product sometimes is provided in culturemedium that is substantially cell-free. In some embodiments targetproduct or modified target product purified from microbes is provided,and target product sometimes is provided in substantially pure form. Incertain embodiments, ethanol can be provided in anhydrous or hydrousforms. Ethanol may be transported in a variety of containers includingpints, quarts, liters, gallons, drums (e.g., 10 gallon or 55 gallon, forexample) and the like.

EXAMPLES

The examples set forth below illustrate certain embodiments and do notlimit the technology. Certain examples set forth below utilize standardrecombinant DNA and other biotechnology protocols known in the art. Manysuch techniques are described in detail in Maniatis, T., E. F. Fritschand J. Sambrook (1982) Molecular Cloning: a Laboratory Manual; ColdSpring Harbor Laboratory, Cold Spring Harbor, N.Y. DNA mutagenesis canbe accomplished using the Stratagene (San Diego, Calif.) “QuickChange”kit according to the manufacturer's instructions, or by one of the othertypes of mutagenesis described above. 5,000 bp DNA pieces can also bemanufactured to order by companies such as Twist Biosciences.

Example 1 Construction of Plasmids for Candida viswanathii

Protein sequence was reverse translated into DNA sequence to reflect theuse of yeast alternative genetic code and codon usage in Candidaviswanathii, reduction of secondary structure, and absence of certainrestriction enzyme recognition sites. Other DNA sequences that encodethe same protein may also be used. The following sequences were used asopen reading frames for genes used to genetically modify Candidaviswanathii.

CvACO1P Gene (SEQ ID NO: 93)ATGACAGAAGTAGTAGATAGAGCAAGTTCCCCAGCAAGTCCAGGATCTACGACCGCCGCCGCAGACGGTGCTAAGGTGGCGGTGGAGCCACGCGTAGATGTAGCGGCCCTTGGCGAGCAGTTGCTAGGGCGATGGGCTGACATCAGATTGCACGCACGAGACTTAGCAGGCCGCGAAGTGGTCCAAAAGGTTGAAGGACTTACGCACACTGAGCATCGGAGTAGAGTCTTTGGACAGTTGAAGTACTTGGTAGACAACAATGCTGTTCACAGAGCTTTTCCCTCCAGGCTAGGTGGATCAGATGACCATGGCGGTAATATAGCTGGATTCGAGGAATTAGTTACTGCTGATCCATCATTGCAAATAAAGGCCGGCGTTCAGTGGGGTTTGTTTGGTTCTGCAGTGATGCACTTGGGAACCCGTGAACATCATGACAAGTGGTTGCCAGGTATTATGTCGTTAGAAATACCGGGGTGTTTCGCGATGACAGAAACCGGGCACGGTAGCGACGTGGCCTCTATTGCTACAACAGCAACTTATGATGAGGAAACCCAAGAGTTTGTTATTGATACCCCGTTCAGAGCCGCTTGGAAAGATTATATCGGTAATGCAGCGAACGATGGTTTGGCGGCAGTTGTTTTCGCACAATTAATCACGAGGAAAGTGAACCATGGTGTACACGCCTTTTACGTGGATCTCAGAGATCCTGCGACTGGAGACTTCCTACCCGGAATAGGAGGAGAGGACGATGGAATCAAGGGGGGATTGAATGGCATTGACAACGGTAGACTACATTTTACGAACGTACGCATTCCTAGAACTAATCTTCTTAACAGATATGGCGATGTGGCGGTCGACGGCACATACCTGTCGACCATCGAATCACCAGGGCGCCGGTTCTTTACGATGCTTGGTACTCTAGTCCAGGGTAGAGTTAGTCTCGATGGAGCAGCTGTCGCTGCACTGAAGGTCGCATTGCAAAGTGCAATTCACTACGCTGCGGAGAGGAGACAATTTAATGCGACTTCACCTACTGAAGAAGAGGTCCTTCTTGATTATCAGAGGCATCAAAGGAGACTCTTTACACGACTTGCAACGACGTACGCCGCATCTTTCGCCCACGAGCAGCTATTGCAAAAGTTCGATGATGTCTTTTCAGGGGCACATGATACCGACGCCGACCGGCAGGACTTGGAAACCCTAGCCGCCGCTTTGAAGCCATTGAGCACATGGCATGCACTTGACACGTTACAAGAATGCAGAGAGGCCTGTGGGGGGGCCGGATTTTTGATAGAAAACCGTTTCGCGAGCTTGCGTGCTGACTTGGACGTTTACGTCACATTCGAGGGTGATAACACAGTTTTATTGCAATTGGTTGCTAAACGGCTCTTGGCAGACTACGCAAAAGAGTTCAGAGGGGCCAACTTCGGCGTTCTTGCCAGGTATGTGGTTGACCAAGCCGCGGGAGTGGCGCTCCACCGAACAGGACTAAGGCAAGTCGCTCAATTTGTTGCAGACAGCGGGTCCGTTCAGAAGTCGGCTCTTGCGCTTCGCGATGAAGAGGGTCAACGAACATTGTTAACGGACAGAGTACAGAGCATGGTTGCCGAAGTGGGGGCTGCCTTGAAAGGCGCAGGCAAATTACCCCAACATCAAGCAGCTGCATTGTTCAACCAACACCAGAACGAACTTATTGAGGCTGCCCAGGCCCATGCAGAACTCCTCCAATGGGAGGCATTTACAGAAGCTCTCGCTAAAGTCGACGATGCTGGTACAAAGGAAGTGCTTACTCGATTGCGAGATCTCTTTGGTTTGTCCTTGATTGAAAAACACTTGCTGTGGTATCTTATGAATGGACGTTTGTCCATGCAAAGAGGCAGGACAGTTGGAACTTACATTAATCGTTTACTTGTCAAGATCCGTCCACACGCACTAGACTTGGTTGATGCCTTCGGTTACGGCGCGGAGCATTTGCGTGCTGCTATCGCCACCGGAGCGGAAGCAACCCGACAGGATGAAGCCCGAACGTATTTTAGACAACAACGGGCATCGGGACTGGCCCCGGCCGATGAAAAGACCTTACTCGCTATCAAAGCTGGTAAATCAAGAGGGCGAAGGGCAAAGCTATGA CvHXS1 Gene (SEQ ID NO: 94)ATGGGAAAAAATTATAAATCTTTGGACTCAGTTGTGGCTAGTGACTTCATTGCACTTGGGATCACATCAGAAGTTGCTGAGACATTGCACGGACGCTTGGCAGAGATAGTTTGCAACTACGGCGCCGCAACACCTCAGACCTGGATTAACATCGCAAACCATATTCTAAGTCCAGATCTTCCATTTAGTCTCCATCAGATGTTGTTCTACGGTTGTTATAAGGACTTTGGTCCAGCACCCCCAGCTTGGATACCAGACCCCGAAAAAGTAAAGTCCACGAACTTAGGTGCCTTGTTAGAAAAGCGGGGAAAGGAGTTTCTAGGCGTTAAGTATAAGGACCCAATAAGTCTGTTTTCTCACTTCCAGGAGTTTAGCGTTCGAAATCCGGAAGTCTACTGGCGGACGGTACTTATGGATGAAATGAAGATACTGTTCAGCAAAGATCCCGAATGTATCCTCAGACGCGACGACATTAACAACCCAGGGGGCTCTGAGTGGCTACCAGGTGGATATCTCAACCTGGCCAAGAACTGTTTGAATGTAAATAGTAACAAAAAACTTAACGACACTATGATAGTGTGGAGAGATGAAGGAAATGACGATCTCCCATTGAATAAATTGACTCTTGATCAATTACGAAAACGAGTCTGGTTGGTTGGATACGCCCTAGAAGAGATGGGCCTTGAGAAGGGATGTGCGATTGCAATTGACATGCCCATGCACGTAGATGCGGTTGTGATCTATTTAGCTATCGTCTTGGCAGGCTACGTCGTTGTCTCCATTGCAGATTCATTCTCAGCACCGGAAATTTCCACAAGATTGCGTCTATCAAAGGCTAAGGCTATTTTTACACAAGATCATATCATCCGAGGGAAAAAGCGTATACCTTTGTACCTGCGTGTCGTCGAGGCCAAGTCTCCGATGGCAATAGTTATCCCGTGTTCGGGTTCAAATATTGGTGCGGAATTGCGGGATGGTGATATTCTGTGGGATTACTTCTTAGAACGCGCAAAGGAATTTAAGAACTGCGAATTTACAGCCCGTGAACAGCCAGTGGACGCGTACACAAATATTTTGTTCTCATCGGGAACCACCGGAGAGCCAAAGGCGATACCATGGACTCAAGCTACGCCTCTCAAGGCGGCTGCTGATGGTTGGTCACACTTGGACATTAGAAAGGGTGACGTAATTGTATGGCCTACCAATTTGGGGTGGATGATGGGGCCTTGGTTGGTCTATGCTTCACTCCTTAACGGGGCAAGCATCGCATTGTATAACGGATCTCCACTAGTGTCCGGCTTTGCCAAATTCGTTCAAGATGCGAAAGTTACTATGCTAGGAGTTGTCCCCTCCATCGTACGAAGCTGGAAAAGCACTAATTGCGTTAGTGGGTACGATTGGTCTACAATCAGATGCTTCTCCTCATCGGGTGAGGCATCGAATGTCGATGAATACTTATGGCTAATGGGAAGGGCTAACTACAAACCGGTCATCGAAATGTGCGGTGGCACAGAGATCGGGGGTGCCTTCAGCGCCGGTTCGTTTTTACAAGCCCAATCTTTGAGTAGCTTCTCATCCCAATGTATGGGATGCACCTTGTACATTCTCGACAAGAATGGCTACCCGATGCCAAAGAACAAGCCGGGTATAGGTGAATTGGCCTTGGGACCCGTGATGTTCGGTGCTTCCAAGACTTTACTTAACGGAAACCATCATGACGTTTATTTCAAAGGCATGCCCACCTTGAACGGAGAAGTCTTGAGGAGACACGGAGATATCTTCGAACTCACTTCGAACGGCTATTATCACGCTCATGGTAGAGCAGATGACACGATGAATATCGGGGGGATTAAAATTTCCTCAATCGAGATTGAAAGGGTGTGTAATGAAGTTGACGATAGAGTGTTTGAGACTACGGCCATTGGAGTGCCTCCATTGGGCGGAGGTCCAGAGCAGCTCGTTATCTTTTTTGTTCTTAAGGACAGCAATGATACGACCATCGACCTAAACCAATTGCGACTTAGTTTTAATCTTGGGTTACAAAAGAAATTGAACCCACTTTTTAAGGTGACGAGGGTTGTGCCACTTTCGCTGTTGCCTAGGACAGCCACCAACAAAATAATGAGAAGAGTGCTTAGACAGCAATTTAGTCATTT CGAGTGACyTKS1 Gene (SEQ ID NO: 95)ATGAATCATTTAAGAGCAGAAGGACCCGCATCAGTGTTAGCGATAGGTACAGCTAACCCAGAGAATATCTTAATCCAAGATGAATTTCCTGACTACTATTTCCGTGTTACTAAATCGGAACATATGACTCAACTTAAAGAGAAGTTCCGGAAAATCTGCGATAAATCCATGATCCGAAAGAGAAACTGTTTCCTTAACGAAGAACATCTCAAGCAAAACCCGAGGTTGGTAGAGCACGAAATGCAGACCTTGGATGCTAGGCAGGACATGTTGGTGGTCGAAGTGCCAAAACTCGGCAAGGACGCGTGCGCTAAGGCAATCAAGGAGTGGGGTCAACCGAAGTCTAAAATCACGCATCTAATATTTACATCTGCACTGACAACCGACATGCCGGGTGCCGATTATCACTGCGCCAAGCTACTTGGATTGAGTCCACTGGTTAAGAGAGTTATGATGTATCAATTGGGGTGTTACGGAGGGGGCACAGTCCTCAGAATTGCTAAGGATATTGCGGAAAATAACAAGGGCGCGAGGGTCCTTGCTGTATGTTGTGATATTATGGCCTGTTTGTTTCGCGGGCCCTCGGATTCAGATTTGGAATTGCTTGTCGGACAGGCAATTTTTGGTGACGGGGCCGCAGCAGTCATAGTGGGAGCCGAACCAGACGAAAGCGTGGGTGAAAGACCAATCTTTGAGTTGGTTCTGACCGGACAAACGATCTTACCTAACTCGGAAGGTACGATTGGAGGACATATTAGAGAAGCCGGCCTAATTTTCGATCTTCACAAAGACGTTCCAATGTTAATCTCCAATAACATAGAAAAGTGCTTGATAGAAGCATTTACTCCCATTGGTATTAGTGACTGGAACAGCATTTTCTGGATCACCCACCCTGGAGGAAAAGCTATACTCGATAAGGTTGAAGAGAAACTCGACTTGAAAAAGGAGAAATTCGTTGACTCACGACATGTGTTATCAGAGCACGGGAATATGAGTTCATCCACAGTCTTGTTCGTAATGGATGAATTGCGAAAACGCTCTCTTGAGGAGGGAAAGAGCACAACCGGTGACGGGTTTGAGTGGGGCGTGCTATTCGGTTTTGGCCCAGGTTTGACTGTCGAGCGGGTTGTTGTTCGTAGTGTACCAATTAAGTACTGA CvTKS1P Gene (SEQ ID NO: 96)ATGAATCATTTAAGAGCAGAAGGACCCGCATCAGTGTTAGCGATAGGTACAGCTAACCCAGAGAATATCTTAATCCAAGATGAATTTCCTGACTACTATTTCCGTGTTACTAAATCGGAACATATGACTCAACTTAAAGAGAAGTTCCGGAAAATCTGCGATAAATCCATGATCCGAAAGAGAAACTGTTTCCTTAACGAAGAACATCTCAAGCAAAACCCGAGGTTGGTAGAGCACGAAATGCAGACCTTGGATGCTAGGCAGGACATGTTGGTGGTCGAAGTGCCAAAACTCGGCAAGGACGCGTGCGCTAAGGCAATCAAGGAGTGGGGTCAACCGAAGTCTAAAATCACGCATCTAATATTTACATCTGCACTGACAACCGACATGCCGGGTGCCGATTATCACTGCGCCAAGCTACTTGGATTGAGTCCACTGGTTAAGAGAGTTATGATGTATCAATTGGGGTGTTACGGAGGGGGCACAGTCCTCAGAATTGCTAAGGATATTGCGGAAAATAACAAGGGCGCGAGGGTCCTTGCTGTATGTTGTGATATTATGGCCTGTTTGTTTCGCGGGCCCTCGGATTCAGATTTGGAATTGCTTGTCGGACAGGCAATTTTTGGTGACGGGGCCGCAGCAGTCATAGTGGGAGCCGAACCAGACGAAAGCGTGGGTGAAAGACCAATCTTTGAGTTGGTTCTGACCGGACAAACGATCTTACCTAACTCGGAAGGTACGATTGGAGGACATATTAGAGAAGCCGGCCTAATTTTCGATCTTCACAAAGACGTTCCAATGTTAATCTCCAATAACATAGAAAAGTGCTTGATAGAAGCATTTACTCCCATTGGTATTAGTGACTGGAACAGCATTTTCTGGATCACCCACCCTGGAGGAAAAGCTATACTCGATAAGGTTGAAGAGAAACTCGACTTGAAAAAGGAGAAATTCGTTGACTCACGACATGTGTTATCAGAGCACGGGAATATGAGTTCATCCACAGTCTTGTTCGTAATGGATGAATTGCGAAAACGCTCTCTTGAGGAGGGAAAGAGCACAACCGGTGACGGGTTTGAGTGGGGCGTGCTATTCGGTTTTGGCCCAGGTTTGACTGTCGAGCGGGTTGTTGTTCGTAGTGTACCAATTAAGTACGGAAGAAGGGCAAAGTTGTGA CvOAC1 Gene (SEQ ID NO: 97)ATGGCAGTCAAACACCTAATAGTTCTCAAATTTAAAGACGAGATTACTGAAGCTCAGAAGGAAGAGTTCTTTAAGACATATGTTAACTTAGTCAACATCATCCCCGCGATGAAGGACGTCTACTGGGGCAAGGATGTGACGCAAAAAAATAAGGAAGAAGGATACACACATATCGTTGAGGTGACCTTTGAGAGTGTGGAAACTATTCAAGATTATATTATTCACCCAGCCCATGTAGGGTTCGGTGACGTTTATCGATCATTCTGGGAAAAGTTGCTTATATTTGATTACACCCCAAGAAAATTGAAGCCTAAGTGA CvOACP1 Gene (SEQ ID NO: 98)ATGGCAGTCAAACACCTAATAGTTCTCAAATTTAAAGACGAGATTACTGAAGCTCAGAAGGAAGAGTTCTTTAAGACATATGTTAACTTAGTCAACATCATCCCCGCGATGAAGGACGTCTACTGGGGCAAGGATGTGACGCAAAAAAATAAGGAAGAAGGATACACACATATCGTTGAGGTGACCTTTGAGAGTGTGGAAACTATTCAAGATTATATTATTCACCCAGCCCATGTAGGGTTCGGTGACGTTTATCGATCATTCTGGGAAAAGTTGCTTATATTTGATTACACCCCAAGAAAATTGAAGCCTAAGGGAAGACGAGCTAAGTTGTGA CvPTS1 Gene(SEQ ID NO: 99)ATGGGTTTATCGTCAGTGTGCACTTTTTCTTTTCAAACAAACTACCACACCCTCCTAAACCCTCACAATAATAACCCAAAAACCTCCTTGCTATGTTACAGACATCCAAAGACACCGATCAAGTATTCATACAACAATTTTCCCAGTAAACATTGCTCAACGAAGTCCTTCCACTTGCAAAACAAATGCAGCGAATCATTGTCGATAGCTAAAAACTCGATACGTGCGGCAACCACTAACCAAACTGAGCCACCAGAGAGCGATAATCATTCAGTCGCCACCAAGATTTTGAACTTTGGAAAAGCCTGTTGGAAACTTCAAAGGCCTTACACCATTATCGCATTTACCAGTTGCGCATGTGGTTTGTTCGGGAAGGAATTATTACACAACACAAATTTGATCAGCTGGAGCCTAATGTTTAAGGCATTTTTCTTCTTAGTTGCAATTTTGTGTATAGCTTCGTTTACAACGACCATTAATCAGATTTACGACCTTCACATCGATCGGATCAATAAACCAGACTTGCCCCTTGCCTCTGGGGAAATCTCTGTAAATACTGCATGGATCATGCTGATAATCGTGGCTTTGTTTGGATTGATTATTACAATTAAGATGAAGGGGGGTCCATTATATATATTCGGGTACTGCTTCGGCATTTTCGGTGGTATCGTTTACTCCGTCCCACCCTTTAGATGGAAACAGAACCCCAGTACGGCCTTTCTACTCAATTTCTTGGCTCATATCATCACAAACTTCACATTCTATTATGCAAGCCGAGCGGCGCTTGGTTTGCCGTTCGAACTCAGACCGAGTTTTACATTTCTCCTTGCCTTCATGAAACTGATGGGACTGGCCCTTGCATTGATCAAGGATGCGTCAGATGTCGAAGGCGACACTAAGTTCGGCATTCTGACGCTTGCTTCCAAGTATGGAAGTAGAAATCTAACGCTTTTTTGTTCAGGAATAGTGCTACTTAGTTATGTTGCTGCTATACTCGCTGGCATTATTTGGCCTCAGGCCTTCAACTCTAACGTAATGTTGTTATCCCATGCTATTTTGGCGTTCTGGTTGATCTTGCAAACGCGAGATTTTGCACTCACTAACTACGACCCAGAGGCAGGAAGGCGCTTTTACGAGTTTATGTGGAAGTTGTATTATGCCGAATACTTGGTTTATGTTTTCATTTGA CVPTS1dN Gene(SEQ ID NO: 100)ATGGCGGCAACCACTAACCAAACTGAGCCACCAGAGAGCGATAATCATTCAGTCGCCACCAAGATTTTGAACTTTGGAAAAGCCTGTTGGAAACTTCAAAGGCCTTACACCATTATCGCATTTACCAGTTGCGCATGTGGTTTGTTCGGGAAGGAATTATTACACAACACAAATTTGATCAGCTGGAGCCTAATGTTTAAGGCATTTTTCTTCTTAGTTGCAATTTTGTGTATAGCTTCGTTTACAACGACCATTAATCAGATTTACGACCTTCACATCGATCGGATCAATAAACCAGACTTGCCCCTTGCCTCTGGGGAAATCTCTGTAAATACTGCATGGATCATGCTGATAATCGTGGCTTTGTTTGGATTGATTATTACAATTAAGATGAAGGGGGGTCCATTATATATATTCGGGTACTGCTTCGGCATTTTCGGTGGTATCGTTTACTCCGTCCCACCCTTTAGATGGAAACAGAACCCCAGTACGGCCTTTCTACTCAATTTCTTGGCTCATATCATCACAAACTTCACATTCTATTATGCAAGCCGAGCGGCGCTTGGTTTGCCGTTCGAACTCAGACCGAGTTTTACATTTCTCCTTGCCTTCATGAAACTGATGGGACTGGCCCTTGCATTGATCAAGGATGCGTCAGATGTCGAAGGCGACACTAAGTTCGGCATTCTGACGCTTGCTTCCAAGTATGGAAGTAGAAATCTAACGCTTTTTTGTTCAGGAATAGTGCTACTTAGTTATGTTGCTGCTATACTCGCTGGCATTATTTGGCCTCAGGCCTTCAACTCTAACGTAATGTTGTTATCCCATGCTATTTTGGCGTTCTGGTTGATCTTGCAAACGCGAGATTTTGCACTCACTAACTACGACCCAGAGGCAGGAAGGCGCTTTTACGAGTTTATGTGGAAGTTGTATTATGCCGAATACTTGGTTTATGTTTTCATTTGA CvPTS2 Gene(SEQ ID NO: 101)ATGGGGTTGTCCTTAGTTTGTACGTTCAGTTTCCAAACTAACTACCACACACTACTAAATCCGCACAACAAAAACCCGAAAAATTCATTGCTCTCCTATCAGCACCCAAAAACACCCATTATCAAGTCTAGTTACGACAACTTTCCATCAAAATACTGTCTAACGAAAAACTTTCATTTGTTGGGCTTAAATTCTCATAATCGTATTTCCAGTCAGTCCCGATCGATCAGGGCCGGGAGTGACCAAATTGAAGGTTCTCCACATCATGAAAGTGACAATTCAATTGCTACGAAGATTTTAAACTTTGGGCATACATGCTGGAAGCTACAGCGACCGTATGTAGTTAAGGGGATGATCAGCATTGCCTGCGGCCTATTCGGAAGGGAACTCTTCAATAATAGACATCTTTTTTCTTGGGGTTTAATGTGGAAAGCTTTTTTCGCTTTGGTTCCTATCCTTAGTTTTAACTTCTTCGCCGCTATTATGAATCAAATTTACGATGTTGACATCGACCGTATTAACAAACCCGATCTCCCCCTTGTTTCAGGCGAGATGTCCATTGAAACGGCATGGATTTTGTCCATCATTGTTGCGCTTACTGGCTTGATTGTTACCATTAAGCTTAAAAGCGCTCCCTTGTTCGTTTTTATATACATTTTCGGCATTTTTGCCGGATTCGCATACAGTGTCCCGCCTATACGTTGGAAACAATATCCATTCACGAACTTCTTGATCACGATCTCATCACATGTTGGATTGGCCTTTACGTCCTACAGTGCTACCACATCTGCCCTTGGATTGCCTTTCGTTTGGAGGCCTGCCTTCTCGTTTATCATTGCATTTATGACAGTGATGGGAATGACTATCGCATTTGCTAAAGATATCAGCGACATAGAGGGCGATGCAAAATATGGGGTGAGTACTGTTGCGACGAAGTTGGGCGCCCGAAATATGACCTTCGTTGTTTCCGGCGTTCTTTTACTTAACTATTTAGTATCGATTAGCATCGGGATCATCTGGCCACAGGTGTTTAAATCAAATATTATGATCTTGTCGCATGCCATCCTAGCTTTCTGTCTTATATTTCAAACAAGAGAATTAGCCCTAGCGAACTACGCCTCAGCACCAAGTCGTCAGTTCTTCGAATTTATATGGCTACTCTACTACGCCGAATACTTCGTCTATGTCTTCATTTAG CvCBD1 Gene(SEQ ID NO: 102)ATGAAGTGTTCTACGTTTAGTTTTTGGTTTGTTTGTAAAATTATATTCTTCTTTTTTTCCTTCAACATTCAGACATCAATCGCCAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACTGA CBD1dNS1 (SEQ ID NO: 103)ATGTTCTTGAAACACATTTTTGTTGCTCTCGCTTTTGCCTTGTTAGCTGACGCTACCCCAGCCCAGAAGAGATCTCCCGGCTTCGTTGCTTTAGACTTTGACATCGTCAAGGTTCAAAAGAACGTGACTGCCAACGACGACGCCGCTGCCATTGTTGCCAAGAGACAGACCAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACTGA CDB1dNS2 (SEQ ID NO: 104)ATGCAATTGTCATTGTCAGTTTTGTCAACAGTTGCAACAGCATTGTTGTCATTGACAACAGCAGTTGATGCAAAGTCACATAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACTGA CBD1dNV1 (SEQ ID NO: 105)ATGCAATTGTCCTTGTCGGTTTTATCAACCGTTGCCACGGCCTTGTTGTCCCTAACCACCGCCGTCGATGCTAAGTCCCACAACATCAAGTTGTCCAAGTTGTCCAACGAAGAAACATTGGACGCCTCCACATTCCAAGAATACACGAGCTCCTTGGCCAACAAGTACATGAACTTGTTCAACGCCGCTCACGGTAACCCAACCAGCTTTGGCTTGCAACACGTCTTGTCCAACCAAGAAGCTGAAGTCCCATTCGTTACCCCACAAAAGGGTGGCAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCAT AGACACTGACvCBD1dNP1 (SEQ ID NO: 106)ATGAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACGGAAGAAGGGCAAAGTTGTAA CvTHC1 Gene (SEQ ID NO: 107)ATGAATTGTTCAGCATTTAGTTTTTGGTTTGTTTGTAAGATTATTTTCTTCTTTTTGTCATTTAACATTCAAATTTCAATTGCAAACCCACAAGAAAACTTTTTGAAGTGTTTTTCAGAATACATTCCAAACAATCCAGCTAACCCAAAGTTTATTTACACACAACATGATCAATTGTACATGTCAGTTTTGAACTCAACAATTCAAAACTTGAGATTTACATCAGATACCACACCAAAGCCATTGGTTATTGTTACACCATCAAACGTTTCCCATATTCAAGCATCAATCTTGTGTTCAAAGAAGGTTGGATTGCAAATTAGAACCAGATCAGGAGGACACGATGCAGAAGGAATGTCATACATTTCACAAGTTCCATTCGTTGTTGTTGATTTGAGAAACATGCACTCAATTAAGATTGATGTTCATTCACAAACAGCATGGGTTGAAGCAGGAGCAACATTGGGTGAAGTTTACTACTGGATTAACGAAAAGAACGAAAACTTCAGTTTTCCAGGAGGTTACTGTCCAACAGTTGGAGTTGGAGGACATTTTTCAGGTGGAGGATACGGAGCATTGATGAGAAACTACGGATTGGCAGCAGATAACATTATTGATGCACACTTGGTTAACGTTGATGGAAAGGTTTTGGATAGAAAGTCAATGGGAGAAGATTTGTTTTGGGCAATTAGAGGAGGTGGTGGAGAGAACTTTGGAATTATTGCAGCATGGAAGATCAAGTTGGTTGCAGTTCCATCAAAGTCAACAATCTTTTCAGTTAAGAAGAACATGGAAATTCATGGTTTGGTTAAGTTGTTTAACAAGTGGCAAAACATTGCATACAAGTACGATAAGGATTTGGTTTTGATGACACATTTTATTACAAAGAACATTACAGATAACCATGGAAAGAACAAGACAACAGTTCACGGATACTTTTCATCAATTTTTCACGGAGGAGTTGATTCATTGGTTGACTTGATGAACAAGTCATTTCCAGAATTGGGAATCAAGAAGACAGATTGTAAGGAATTTTCATGGATTGATACAACAATTTTCTACTCAGGAGTTGTTAACTTTAACACAGCAAACTTTAAGAAGGAAATTTTGTTGGACAGATCAGCAGGAAAGAAGACCGCATTTTCCATTAAGTTGGATTACGTTAAGAAACCAATTCCAGAAACAGCAATGGTTAAGATTTTGGAAAAGTTGTACGAAGAAGATGTTGGTGTTGGAATGTACGTTTTGTACCCATACGGAGGAATTATGGAAGAAATCTCAGAATCAGCAATTCCATTTCCACATAGAGCAGGTATTATGTACGAATTGTGGTACACAGCATCATGGGAAAAGCAAGAAGATAATGAAAAGCATATTAACTGGGTTAGATCAGTTTACAACTTTACAACACCATACGTTTCACAAAACCCAAGATTGGCATACTTGAACTACAGAGATTTGGATTTGGGAAAGACAAACCCAGAATCACCAAACAACTATACACAAGCTAGAATTTGGGGAGAAAAGTACTTTGGTAAGAACTTCAACAGATTGGTTAAAGTTAAGACAAAGGCAGATCCAAATAACTTCTTTAGAAACGAACAATCAATTCCACCATTGCCACCACATCATCATTAA THC1dNS1 Gene(SEQ ID NO: 108)ATGTTCTTGAAACACATTTTTGTTGCTCTCGCTTTTGCCTTGTTAGCTGACGCTACCCCAGCCCAGAAGAGATCTCCCGGCTTCGTTGCTTTAGACTTTGACATCGTCAAGGTTCAAAAGAACGTGACTGCCAACGACGACGCCGCTGCCATTGTTGCCAAGAGACAGACCAACCCACAAGAAAACTTTTTGAAGTGTTTTTCAGAATACATTCCAAACAATCCAGCTAACCCAAAGTTTATTTACACACAACATGATCAATTGTACATGTCAGTTTTGAACTCAACAATTCAAAACTTGAGATTTACATCAGATACCACACCAAAGCCATTGGTTATTGTTACACCATCAAACGTTTCCCATATTCAAGCATCAATCTTGTGTTCAAAGAAGGTTGGATTGCAAATTAGAACCAGATCAGGAGGACACGATGCAGAAGGAATGTCATACATTTCACAAGTTCCATTCGTTGTTGTTGATTTGAGAAACATGCACTCAATTAAGATTGATGTTCATTCACAAACAGCATGGGTTGAAGCAGGAGCAACATTGGGTGAAGTTTACTACTGGATTAACGAAAAGAACGAAAACTTCAGTTTTCCAGGAGGTTACTGTCCAACAGTTGGAGTTGGAGGACATTTTTCAGGTGGAGGATACGGAGCATTGATGAGAAACTACGGATTGGCAGCAGATAACATTATTGATGCACACTTGGTTAACGTTGATGGAAAGGTTTTGGATAGAAAGTCAATGGGAGAAGATTTGTTTTGGGCAATTAGAGGAGGTGGTGGAGAGAACTTTGGAATTATTGCAGCATGGAAGATCAAGTTGGTTGCAGTTCCATCAAAGTCAACAATCTTTTCAGTTAAGAAGAACATGGAAATTCATGGTTTGGTTAAGTTGTTTAACAAGTGGCAAAACATTGCATACAAGTACGATAAGGATTTGGTTTTGATGACACATTTTATTACAAAGAACATTACAGATAACCATGGAAAGAACAAGACAACAGTTCACGGATACTTTTCATCAATTTTTCACGGAGGAGTTGATTCATTGGTTGACTTGATGAACAAGTCATTTCCAGAATTGGGAATCAAGAAGACAGATTGTAAGGAATTTTCATGGATTGATACAACAATTTTCTACTCAGGAGTTGTTAACTTTAACACAGCAAACTTTAAGAAGGAAATTTTGTTGGACAGATCAGCAGGAAAGAAGACCGCATTTTCCATTAAGTTGGATTACGTTAAGAAACCAATTCCAGAAACAGCAATGGTTAAGATTTTGGAAAAGTTGTACGAAGAAGATGTTGGTGTTGGAATGTACGTTTTGTACCCATACGGAGGAATTATGGAAGAAATCTCAGAATCAGCAATTCCATTTCCACATAGAGCAGGTATTATGTACGAATTGTGGTACACAGCATCATGGGAAAAGCAAGAAGATAATGAAAAGCATATTAACTGGGTTAGATCAGTTTACAACTTTACAACACCATACGTTTCACAAAACCCAAGATTGGCATACTTGAACTACAGAGATTTGGATTTGGGAAAGACAAACCCAGAATCACCAAACAACTATACACAAGCTAGAATTTGGGGAGAAAAGTACTTTGGTAAGAACTTCAACAGATTGGTTAAAGTTAAGACAAAGGCAGATCCAAATAACTTCTTTAGAAACGAACAATCAATTCCACCATTGCCACCACATCATCATTAATAA THC1dNS2 (SEQ ID NO: 109)ATGCAATTGTCATTGTCAGTTTTGTCAACAGTTGCAACAGCATTGTTGTCATTGACAACAGCAGTTGATGCAAAGTCACATAACCCACAAGAAAACTTTTTGAAGTGTTTTTCAGAATACATTCCAAACAATCCAGCTAACCCAAAGTTTATTTACACACAACATGATCAATTGTACATGTCAGTTTTGAACTCAACAATTCAAAACTTGAGATTTACATCAGATACCACACCAAAGCCATTGGTTATTGTTACACCATCAAACGTTTCCCATATTCAAGCATCAATCTTGTGTTCAAAGAAGGTTGGATTGCAAATTAGAACCAGATCAGGAGGACACGATGCAGAAGGAATGTCATACATTTCACAAGTTCCATTCGTTGTTGTTGATTTGAGAAACATGCACTCAATTAAGATTGATGTTCATTCACAAACAGCATGGGTTGAAGCAGGAGCAACATTGGGTGAAGTTTACTACTGGATTAACGAAAAGAACGAAAACTTCAGTTTTCCAGGAGGTTACTGTCCAACAGTTGGAGTTGGAGGACATTTTTCAGGTGGAGGATACGGAGCATTGATGAGAAACTACGGATTGGCAGCAGATAACATTATTGATGCACACTTGGTTAACGTTGATGGAAAGGTTTTGGATAGAAAGTCAATGGGAGAAGATTTGTTTTGGGCAATTAGAGGAGGTGGTGGAGAGAACTTTGGAATTATTGCAGCATGGAAGATCAAGTTGGTTGCAGTTCCATCAAAGTCAACAATCTTTTCAGTTAAGAAGAACATGGAAATTCATGGTTTGGTTAAGTTGTTTAACAAGTGGCAAAACATTGCATACAAGTACGATAAGGATTTGGTTTTGATGACACATTTTATTACAAAGAACATTACAGATAACCATGGAAAGAACAAGACAACAGTTCACGGATACTTTTCATCAATTTTTCACGGAGGAGTTGATTCATTGGTTGACTTGATGAACAAGTCATTTCCAGAATTGGGAATCAAGAAGACAGATTGTAAGGAATTTTCATGGATTGATACAACAATTTTCTACTCAGGAGTTGTTAACTTTAACACAGCAAACTTTAAGAAGGAAATTTTGTTGGACAGATCAGCAGGAAAGAAGACCGCATTTTCCATTAAGTTGGATTACGTTAAGAAACCAATTCCAGAAACAGCAATGGTTAAGATTTTGGAAAAGTTGTACGAAGAAGATGTTGGTGTTGGAATGTACGTTTTGTACCCATACGGAGGAATTATGGAAGAAATCTCAGAATCAGCAATTCCATTTCCACATAGAGCAGGTATTATGTACGAATTGTGGTACACAGCATCATGGGAAAAGCAAGAAGATAATGAAAAGCATATTAACTGGGTTAGATCAGTTTACAACTTTACAACACCATACGTTTCACAAAACCCAAGATTGGCATACTTGAACTACAGAGATTTGGATTTGGGAAAGACAAACCCAGAATCACCAAACAACTATACACAAGCTAGAATTTGGGGAGAAAAGTACTTTGGTAAGAACTTCAACAGATTGGTTAAAGTTAAGACAAAGGCAGATCCAAATAACTTCTTTAGAAACGAACAATCAATTCCACCATTGCCACCACATCATCATTAATAA THC1dNV1(SEQ ID NO: 110)ATGCAATTGTCCTTGTCGGTTTTATCAACCGTTGCCACGGCCTTGTTGTCCCTAACCACCGCCGTCGATGCTAAGTCCCACAACATCAAGTTGTCCAAGTTGTCCAACGAAGAAACATTGGACGCCTCCACATTCCAAGAATACACGAGCTCCTTGGCCAACAAGTACATGAACTTGTTCAACGCCGCTCACGGTAACCCAACCAGCTTTGGCTTGCAACACGTCTTGTCCAACCAAGAAGCTGAAGTCCCATTCGTTACCCCACAAAAGGGTGGCAACCCACAAGAAAACTTTTTGAAGTGTTTTTCAGAATACATTCCAAACAATCCAGCTAACCCAAAGTTTATTTACACACAACATGATCAATTGTACATGTCAGTTTTGAACTCAACAATTCAAAACTTGAGATTTACATCAGATACCACACCAAAGCCATTGGTTATTGTTACACCATCAAACGTTTCCCATATTCAAGCATCAATCTTGTGTTCAAAGAAGGTTGGATTGCAAATTAGAACCAGATCAGGAGGACACGATGCAGAAGGAATGTCATACATTTCACAAGTTCCATTCGTTGTTGTTGATTTGAGAAACATGCACTCAATTAAGATTGATGTTCATTCACAAACAGCATGGGTTGAAGCAGGAGCAACATTGGGTGAAGTTTACTACTGGATTAACGAAAAGAACGAAAACTTCAGTTTTCCAGGAGGTTACTGTCCAACAGTTGGAGTTGGAGGACATTTTTCAGGTGGAGGATACGGAGCATTGATGAGAAACTACGGATTGGCAGCAGATAACATTATTGATGCACACTTGGTTAACGTTGATGGAAAGGTTTTGGATAGAAAGTCAATGGGAGAAGATTTGTTTTGGGCAATTAGAGGAGGTGGTGGAGAGAACTTTGGAATTATTGCAGCATGGAAGATCAAGTTGGTTGCAGTTCCATCAAAGTCAACAATCTTTTCAGTTAAGAAGAACATGGAAATTCATGGTTTGGTTAAGTTGTTTAACAAGTGGCAAAACATTGCATACAAGTACGATAAGGATTTGGTTTTGATGACACATTTTATTACAAAGAACATTACAGATAACCATGGAAAGAACAAGACAACAGTTCACGGATACTTTTCATCAATTTTTCACGGAGGAGTTGATTCATTGGTTGACTTGATGAACAAGTCATTTCCAGAATTGGGAATCAAGAAGACAGATTGTAAGGAATTTTCATGGATTGATACAACAATTTTCTACTCAGGAGTTGTTAACTTTAACACAGCAAACTTTAAGAAGGAAATTTTGTTGGACAGATCAGCAGGAAAGAAGACCGCATTTTCCATTAAGTTGGATTACGTTAAGAAACCAATTCCAGAAACAGCAATGGTTAAGATTTTGGAAAAGTTGTACGAAGAAGATGTTGGTGTTGGAATGTACGTTTTGTACCCATACGGAGGAATTATGGAAGAAATCTCAGAATCAGCAATTCCATTTCCACATAGAGCAGGTATTATGTACGAATTGTGGTACACAGCATCATGGGAAAAGCAAGAAGATAATGAAAAGCATATTAACTGGGTTAGATCAGTTTACAACTTTACAACACCATACGTTTCACAAAACCCAAGATTGGCATACTTGAACTACAGAGATTTGGATTTGGGAAAGACAAACCCAGAATCACCAAACAACTATACACAAGCTAGAATTTGGGGAGAAAAGTACTTTGGTAAGAACTTCAACAGATTGGTTAAAGTTAAGACAAAGGCAGATCCAAATAACTTCTTTAGAAACGAACAATCAATTCCACCATTGCCACCACATCATCATTAATAA CvCBC1 Gene (SEQ ID NO: 111)ATGAATTGTAGCACTTTCTCATTCTGGTTTGTTTGTAAGATTATTTTCTTTTTCTTGTCATTTAACATTCAAATTTCAATTGCAAACCCACAAGAGAACTTTTTGAAGTGTTTCTCAGAATACATTCCAAACAACCCAGCTAACCCAAAGTTTATTTACACCCAACACGATCAATTGTACATGTCAGTTTTGAACTCAACAATTCAAAACTTGAGATTTACATCAGATACAACACCAAAGCCATTGGTTATTGTTACACCATCAAACGTTAGTCATATTCAAGCATCAATCTTGTGTTCAAAGAAGGTTGGATTGCAAATTAGAACTAGATCAGGAGGACATGATGCAGAAGGATTGTCATACATTTCACAAGTTCCATTTGCAATTGTTGATTTGAGAAACATGCACACAGTTAAGGTTGATATTCATTCACAAACAGCATGGGTTGAAGCAGGAGCAACATTGGGTGAAGTTTACTACTGGATTAACGAAATGAACGAAAACTTCTCATTTCCAGGAGGATACTGTCCAACAGTTGGTGTTGGAGGACACTTTTCAGGTGGTGGATACGGAGCATTGATGAGAAACTACGGATTGGCAGCAGATAACATTATTGATGCACATTTGGTTAACGTTGATGGAAAGGTTTTGGATAGAAAGTCAATGGGAGAAGATTTGTTTTGGGCAATTAGAGGAGGTGGAGGAGAAAACTTTGGAATCATTGCAGCATGTAAGATCAAGTTGGTTGTTGTTCCATCAAAGGCAACAATCTTTTCAGTTAAGAAGAACATGGAAATCCATGGATTGGTTAAGTTGTTTAACAAGTGGCAAAACATTGCATACAAGTACGATAAGGATTTGATGTTGACAACACATTTTAGAACAAGAAACATTACAGATAACCACGGAAAGAATAAGACAACAGTTCATGGATACTTTTCATCAATTTTCTTGGGAGGAGTTGATTCATTGGTTGACTTGATGAACAAGAGTTTTCCAGAATTGGGAATCAAGAAGACAGATTGTAAGGAATTGTCATGGATCGATACAACCATTTTCTACTCAGGAGTTGTTAACTACAACACAGCTAACTTTAAGAAGGAAATTTTGTTGGACAGATCAGCAGGTAAAAAGACAGCATTTTCAATTAAGTTGGATTACGTTAAGAAATTGATTCCAGAAACAGCAATGGTTAAGATTTTGGAAAAGTTGTACGAAGAAGAAGTTGGAGTTGGAATGTACGTTTTGTACCCATACGGAGGAATTATGGATGAAATTTCAGAATCAGCAATTCCATTTCCACATAGAGCAGGTATTATGTACGAATTGTGGTACACAGCAACATGGGAAAAGCAAGAAGATAACGAAAAGCATATTAACTGGGTTAGATCAGTTTACAACTTTACAACCCCATACGTTTCACAAAACCCAAGATTGGCATACTTGAACTACAGAGATTTGGATTTGGGAAAGACAAACCCAGAATCACCAAATAACTACACACAAGCTAGAATTTGGGGAGAAAAGTACTTTGGTAAGAACTTTAACAGATTGGTGAAGGTTAAGACAAAGGCAGACCCAAACAATTTCTTTAGAAACGAACAATCAATTCCACCATTGCCACCAAGACATCATTAA

The following plasmids were constructed using modern molecular biologytechniques described herein.

TABLE 1 Important Plasmid Seq ID Features pLD1 157 Empty URA3 multiintegration pLD10 158 PPOX4-CvTKS1 URA3 multi integration pLD12 159PPOX4-CvOAC1 URA3 multi integration pLD14 160 PPOX4-CvOAC1P URA3 multiintegration pLD16 161 PPOX4-CvHXS1 URA3 multi integration pLD19 180PPOX4-PTS1 URA3 multi integration pLD20 162 PPOX4-CvCBD1 URA3 multiintegration pLD22 163 PPOX4-CvACO1P URA3 multi integration pLD24 164PPOX4-CvTKS1P URA3 multi integration pLD26 181 PPOX4-PTS1dN URA3 multiintegration pLD56 165 PPOX4-CvPTS2 URA3 multi integration pLD111 169PPOX4-CvTHC1 URA3 multi integration pLD112 170 PPOX4-CvCBC1 URA3 multiintegration pLD125 172 PPOX4-CvCBD1dNS1 URA3 multi integration pLD127173 PPOX4-CvCBD1dNV1 URA3 multi integration pLD139 179 PPOX4-CvCBD1dNP1URA3 multi integration

Example 2 Construction of Plasmids for Yarrowia lipolytica

Protein sequence was reverse translated into DNA sequence to reflect theuse of a universal genetic code and codon usage in Yarrowia lipolytica,reduction of secondary structure, and absence of certain restrictionenzyme recognition sites. Other DNA sequences that encode the sameprotein may also be used. The following sequences were used as openreading frames for genes used to genetically modify Yarrowia lipolytica.

Y1ACO1P Gene (SEQ ID NO: 112)ATGACCGAAGTAGTTGACAGAGCCTCATCCCCCGCATCCCCTGGCTCAACTACGGCCGCCGCAGACGGTGCTAAGGTGGCCGTCGAGCCCCGAGTAGATGTGGCTGCGCTGGGAGAGCAGCTGCTGGGCCGATGGGCTGATATCCGTCTCCACGCCCGGGACCTTGCGGGACGAGAGGTAGTTCAGAAGGTGGAGGGTCTGACTCATACAGAGCACCGCTCTCGCGTCTTTGGCCAGCTCAAGTACTTGGTCGATAACAACGCAGTTCACCGAGCCTTTCCTTCTCGACTGGGTGGTAGTGACGACCACGGCGGAAACATCGCTGGTTTTGAGGAGCTTGTCACGGCGGACCCCTCCCTCCAGATCAAGGCCGGCGTCCAGTGGGGACTGTTCGGCTCCGCTGTTATGCACTTGGGAACTAGGGAGCACCACGACAAGTGGCTCCCAGGCATCATGTCTCTGGAAATCCCTGGTTGCTTTGCCATGACTGAGACTGGCCATGGCTCCGATGTCGCTTCCATTGCTACAACGGCCACCTATGATGAGGAAACCCAGGAGTTCGTTATTGACACCCCGTTCCGAGCCGCCTGGAAGGACTACATTGGAAACGCCGCTAACGACGGTTTGGCCGCTGTCGTGTTTGCCCAACTGATTACTCGAAAGGTTAACCATGGAGTGCACGCCTTCTACGTCGATCTGAGAGATCCCGCCACCGGAGACTTTCTCCCTGGTATTGGTGGAGAGGACGACGGTATTAAGGGGGGACTAAACGGAATTGATAACGGACGTCTCCATTTCACCAATGTTCGCATTCCCCGAACCAACCTGCTTAACCGTTACGGCGATGTTGCCGTCGATGGCACCTACAGCTCAACCATCGAATCTCCGGGGCGAAGATTCTTTACAATGCTAGGTACGCTGGTCCAGGGCCGAGTCAGCCTGGACGGTGCTGCAGTGGCTGCATCGAAGGTTGCTCTGCAATCCGCCATCCACTACGCCGCTGAGCGAAGACAGTTCAACGCCACTTCGCCCACAGAGGAGGAGGTGCTCCTGGATTACCAGCGACACCAGCGGCGCCTCTTTACCCGACTCGCCACCACCTACGCCGCATCGTTCGCCCATGAGCAACTGCTGCAGAAATTCGACGACGTGTTCTCGGGTGCTCATGATACTGACGCCGACCGTCAGGACCTTGAGACACTGGCTGCTGCTCTGAAGCCCCTTTCTACCTGGCATGCTCTCGATACCCTACAAGAGTGCCGAGAAGCGTGTGGGGGTGCAGGTTTTCTGATTGAGAACCGATTCGCTTCTCTCCGGGCCGATCTCGACGTCTACGTGACCTTCGAAGGAGACAACACCGTGCTTCTTCAGTTGGTGGCCAAGAGGCTGCTCGCTGACTATGCTAAGGAGTTCCGAGGTGCCAACTTCGGCGTGCTCGCGCGGTACGTCGTGGACCAGGCTGCCGGAGTCGCGCTACACCGAACCGGACTGCGACAGGTCGCTCAGTTCGTGGCCGACAGTGGATCTGTCCAGAAATCTGCTCTTGCCCTCCGAGACGAAGAAGGTCAGCGAACTCTGCTGACCGACAGAGTCCAGTCCATGGTTGCAGAGGTTGGCGCTGCTCTCAAAGGCGCGGGCAAGCTCCCCCAGCACCAGGCGGCAGCACTGTTCAATCAGCATCAAAACGAACTGATCGAGGCTGCCCAGGCCCACGCTGAGCTTTTACAGTGGGAGGCCTTTACTGAGGCTTTGGCCAAGGTGGACGACGCTGGCACTAAGGAAGTGTTGACCCGATTGCGTGACCTTTTTGGTCTGTCCCTTATCGAGAAGCACCTCAGCTGGTATCTGATGAACGGTAGGCTCTCGATGCAGAGAGGCCGAACGGTCGGCACTTACATTAATCGTCTTCTCGTTAAGATCCGACCACACGCACTTGATCTGGTTGATGCCTTCGGCTACGGAGCCGAGCACCTTCGGGCCGCTATCGCCACCGGCGCTGAGGCCACCCGACAGGACGAGGCCCGAACCTACTTCAGACAGCAACGAGCCTCCGGTAGCGCCCCTGCTGACGAGAAGACACTCCTCGCTATCAAGGCCGGCAAGTCTCGGGGACGACGAGCCAAACTGTAA Y1HXS1 Gene (SEQ ID NO: 113)ATGGGAAAGAATTACAAAAGTCTAGATTCTGTCGTTGCCAGTGACTTCATCGCGTTAGGCATTACATCCGAGGTCGCTGAGACTCTGCACGGACGGCTTGCCGAGATTGTGTGCAACTACGGAGCCGCTACCCCTCAGACTTGGATTAACATCGCCAACCACATTCTGTCGCCGGACCTCCCCTTCTCTTTGCACCAGATGTTATTCTACGGATGCTACAAGGATTTTGGCCCTGCACCTCCTGCCTGGATTCCGGACCCCGAAAAAGTCAAGTCCACCAACCTAGGTGCCCTGCTGGAAAAGCGAGGAAAGGAGTTCCTTGGTGTCAAGTACAAGGACCCCATTTCTTCTTTTTCTCATTTCCAGGAATTTTCGGTGCGTAATCCTGAGGTGTATTGGCGAACTGTGCTCATGGACGAGATGAAAATCTCCTTCAGCAAGGACCCAGAGTGTATCCTGCGACGAGACGACATTAACAACCCAGGAGGCTCGGAGTGGCTTCCCGGCGGATACCTAAACTCAGCTAAGAATTGTCTCAACGTGAACTCTAACAAGAAGTTGAACGACACCATGATCGTGTGGCGTGACGAAGGCAACGACGACCTGCCCCTGAACAAGTTGACTCTGGACCAGCTGCGAAAGAGGGTCTGGTTGGTTGGCTACGCCCTCGAAGAGATGGGCTTAGAGAAGGGTTGCGCTATTGCTATTGATATGCCCATGCACGTCGATGCTGTAGTGATCTACCTTGCCATTGTGTTAGCCGGTTACGTGGTCGTATCGATTGCCGATTCGTTCTCCGCTCCGGAGATTTCCACCCGACTCAGACTTAGCAAGGCCAAGGCAATCTTTACTCAAGATCACATCATCCGAGGTAAGAAGAGAATCCCTCTCTATTCTCGCGTGGTTGAGGCCAAGTCCCCAATGGCTATCGTCATACCTTGCAGCGGATCAAACATCGGGGCTGAGCTACGGGACGGTGATATCTCCTGGGATTACTTCCTGGAGCGAGCCAAAGAGTTCAAGAACTGCGAGTTTACAGCGCGTGAGCAGCCCGTCGATGCCTACACGAACATTCTATTCTCATCGGGCACAACGGGAGAGCCCAAGGCCATCCCCTGGACCCAAGCTACCCCCTTGAAAGCTGCCGCTGATGGTTGGTCCCATCTCGACATCAGAAAAGGCGATGTGATCGTTTGGCCCACTAACCTGGGCTGGATGATGGGTCCTTGGCTGGTATATGCCAGCCTACTGAACGGCGCTTCAATCGCACTGTACAACGGATCTCCACTCGTCAGCGGCTTTGCCAAGTTTGTTCAAGACGCCAAAGTCACCATGCTGGGTGTTGTTCCTTCAATCGTGCGAAGTTGGAAGAGTACCAACTGTGTCTCTGGATACGACTGGAGCACCATTCGATGCTTCAGTTCCTCCGGCGAGGCTTCCAACGTTGATGAGTACCTCTGGCTTATGGGTCGTGCGAATTACAAGCCTGTGATCGAGATGTGTGGTGGAACAGAAATTGGTGGTGCTTTTTCGGCCGGGTCCTTTCTTCAGGCTCAGTCTCTCTCCTCTTTCTCTTCCCAGTGTATGGGATGCACCCTGTATATTCTCGACAAGAACGGTTACCCCATGCCGAAGAATAAACCCGGTATTGGGGAGCTTGCTCTTGGCCCCGTCATGTTTGGTGCATCGAAGACCCTCCTGAACGGAAACCATCACGACGTCTACTTCAAGGGCATGCCCACACTTAACGGCGAAGTTCTTCGGCGACATGGAGACATTTTCGAACTTACATCGAACGGATACTACCACGCCCACGGGCGAGCAGATGATACGATGAACATCGGGGGCATCAAGATATCTTCTATCGAGATTGAAAGAGTGTGTAACGAGGTAGACGACCGCGTCTTCGAGACTACTGCGATCGGCGTCCCCCCCCTGGGCGGTGGCCCGGAGCAGCTAGTCATTTTTTTTGTGCTCAAGGACTCTAACGACACGACCATCGACCTCAATCAGCTGCGACTCTCCTTCAACCTTGGATTGCAGAAGAAGCTGAACCCTCTCTTCAAGGTCACTCGGGTTGTTCCCTTGTCCTCTCTTCCTCGAACCGCCACCAACAAGATTATGCGACGAGTGCTCCGACAGCAGTTCTCCCACTTCGAG TAAY1TKS1 Gene (SEQ ID NO: 114)ATGAATCATCTAAGAGCCGAAGGACCAGCAAGTGTACTCGCTATTGGTACTGCTAACCCCGAGAACATTCTTATTCAGGATGAGTTCCCGGACTACTATTTCAGGGTTACCAAGAGCGAGCATATGACCCAGCTTAAAGAGAAGTTCCGCAAGATATGCGACAAGTCCATGATCCGAAAGCGGAACTGCTTTCTCAATGAGGAGCACTTGAAGCAAAACCCCCGACTGGTTGAGCACGAGATGCAGACCTTGGACGCGCGACAAGACATGCTCGTCGTCGAGGTGCCCAAACTCGGTAAGGATGCTTGCGCTAAGGCCATTAAGGAGTGGGGTCAGCCCAAGTCGAAGATTACCCACCTAATCTTCACCTCCGCAAGCACTACAGACATGCCCGGTGCAGACTACCACTGTGCCAAGCTGCTCGGACTGTCACCGTCGGTCAAGCGAGTGATGATGTACCAGCTCGGCTGTTACGGGGGTGGAACCGTTCTCCGTATCGCCAAGGATATCGCTGAGAACAACAAAGGAGCTCGTGTCCTGGCTGTGTGTTGCGACATCATGGCCTGCTTGTTCAGAGGCCCTAGTGATTCCGATCTGGAATTACTTGTCGGTCAGGCCATCTTTGGAGATGGCGCCGCCGCTGTCATCGTGGGTGCCGAACCCGACGAGTCTGTTGGAGAAAGACCCATCTTTGAGCTTGTCTCCACGGGCCAGACCATCCTCCCTAACAGCGAGGGCACAATTGGAGGCCATATTCGAGAGGCCGGTCTGATTTTTGACCTGCATAAGGACGTGCCTATGCTGATTTCGAACAACATCGAGAAGTGTCTCATCGAGGCCTTCACTCCCATCGGCATTTCGGACTGGAACTCAATCTTCTGGATCACCCACCCAGGAGGCAAGGCGATTCTGGATAAAGTTGAGGAAAAGCTCGACCTTAAGAAGGAGAAGTTTGTGGATTCTCGACACGTCCTGTCTGAACACGGTAACATGTCTTCCTCTACTGTCCTGTTCGTAATGGACGAGCTTCGAAAGCGATCTCTGGAGGAAGGAAAGTCCACGACCGGCGACGGTTTTGAGTGGGGCGTGCTGTTCGGGTTCGGTCCTGGCCTCACTGTGGAGCGAGTTGTTGTCCGGTCCGTGCCTATTAAGTACTAA Y1TKS1P Gene (SEQ ID NO: 115)ATGAATCATCTAAGAGCCGAAGGACCAGCAAGTGTACTCGCTATTGGTACTGCTAACCCCGAGAACATTCTTATTCAGGATGAGTTCCCGGACTACTATTTCAGGGTTACCAAGAGCGAGCATATGACCCAGCTTAAAGAGAAGTTCCGCAAGATATGCGACAAGTCCATGATCCGAAAGCGGAACTGCTTTCTCAATGAGGAGCACTTGAAGCAAAACCCCCGACTGGTTGAGCACGAGATGCAGACCTTGGACGCGCGACAAGACATGCTCGTCGTCGAGGTGCCCAAACTCGGTAAGGATGCTTGCGCTAAGGCCATTAAGGAGTGGGGTCAGCCCAAGTCGAAGATTACCCACCTAATCTTCACCTCCGCAAGCACTACAGACATGCCCGGTGCAGACTACCACTGTGCCAAGCTGCTCGGACTGTCACCGTCGGTCAAGCGAGTGATGATGTACCAGCTCGGCTGTTACGGGGGTGGAACCGTTCTCCGTATCGCCAAGGATATCGCTGAGAACAACAAAGGAGCTCGTGTCCTGGCTGTGTGTTGCGACATCATGGCCTGCTTGTTCAGAGGCCCTAGTGATTCCGATCTGGAATTACTTGTCGGTCAGGCCATCTTTGGAGATGGCGCCGCCGCTGTCATCGTGGGTGCCGAACCCGACGAGTCTGTTGGAGAAAGACCCATCTTTGAGCTTGTCTCCACGGGCCAGACCATCCTCCCTAACAGCGAGGGCACAATTGGAGGCCATATTCGAGAGGCCGGTCTGATTTTTGACCTGCATAAGGACGTGCCTATGCTGATTTCGAACAACATCGAGAAGTGTCTCATCGAGGCCTTCACTCCCATCGGCATTTCGGACTGGAACTCAATCTTCTGGATCACCCACCCAGGAGGCAAGGCGATTCTGGATAAAGTTGAGGAAAAGCTCGACCTTAAGAAGGAGAAGTTTGTGGATTCTCGACACGTCCTGTCTGAACACGGTAACATGTCTTCCTCTACTGTCCTGTTCGTAATGGACGAGCTTCGAAAGCGATCTCTGGAGGAAGGAAAGTCCACGACCGGCGACGGTTTTGAGTGGGGCGTGCTGTTCGGGTTCGGTCCTGGCCTCACTGTGGAGCGAGTTGTTGTCCGGTCCGTGCCTATTAAGTACGGAAGAAGGGCAAAGTTGTAA Y1OAC1 Gene (SEQ ID NO: 116)ATGGCCGTCAAACACCTTATTGTCCTCAAGTTCAAAGATGAGATCACTGAAGCCCAGAAGGAGGAGTTTTTCAAGACCTACGTCAATTTGGTCAACATCATTCCAGCAATGAAGGATGTGTACTGGGGCAAGGACGTGACCCAGAAGAACAAGGAAGAGGGTTATACCCATATCGTTGAGGTTACGTTCGAGTCTGTGGAGACAATCCAAGACTACATCATTCACCCCGCTCACGTGGGCTTTGGAGACGTTTACAGATCCTTCTGGGAGAAGCTCCTGATTTTTGACTACACTCCTCGAAAGCTGAAGCCCAAGTAA Y1OAC1P Gene (SEQ ID NO: 117)ATGGCCGTCAAACACCTTATTGTCCTCAAGTTCAAAGATGAGATCACTGAAGCCCAGAAGGAGGAGTTTTTCAAGACCTACGTCAATTTGGTCAACATCATTCCAGCAATGAAGGATGTGTACTGGGGCAAGGACGTGACCCAGAAGAACAAGGAAGAGGGTTATACCCATATCGTTGAGGTTACGTTCGAGTCTGTGGAGACAATCCAAGACTACATCATTCACCCCGCTCACGTGGGCTTTGGAGACGTTTACAGATCCTTCTGGGAGAAGCTCCTGATTTTTGACTACACTCCTCGAAAGCTGAAGCCCAAGGGAAGAAGGGCAAAGTTGTAA Y1PTS2 Gene(SEQ ID NO: 118)ATGGGCCTCTCTCTAGTATGTACCTTCTCTTTCCAGACCAACTATCACACTCTACTGAACCCCCATAACAAGAACCCTAAAAATTCTCTTCTCAGTTACCAGCACCCCAAGACGCCTATCATTAAGTCCTCCTACGACAACTTTCCCTCTAAGTACTGCCTGACCAAAAACTTCCATCTCCTGGGACTGAACTCTCATAACAGAATTAGTAGCCAGTCCCGATCTATCCGAGCTGGCTCTGACCAGATTGAGGGCTCCCCTCACCATGAATCCGACAACAGCATCGCTACCAAGATTTTGAATTTTGGTCACACATGCTGGAAGCTCCAGCGACCGTACGTCGTGAAGGGTATGATCTCGATTGCCTGTGGACTGTTCGGACGTGAGCTTTTTAATAATCGACACTTGTTTTCATGGGGCCTCATGTGGAAGGCTTTTTTCGCCCTCGTGCCCATTCTGTCTTTCAACTTCTTTGCCGCTATTATGAACCAAATCTACGACGTTGATATTGATAGGATCAACAAGCCTGACCTGCCGCTCGTCTCGGGGGAGATGTCTATCGAGACAGCGTGGATTCTTTCGATTATCGTCGCGCTGACTGGCCTTATCGTTACCATAAAGTTGAAGTCTGCACCCCTCTTCGTGTTTATCTACATTTTCGGTATTTTTGCTGGATTCGCGTACTCCGTTCCCCCTATCAGATGGAAGCAGTACCCCTTTACTAACTTTCTGATTACTATCAGCAGCCACGTCGGTTTAGCCTTTACCTCATATTCGGCCACCACCAGTGCACTGGGCCTCCCCTTCGTCTGGCGACCTGCATTTTCATTCATCATCGCCTTCATGACTGTGATGGGTATGACCATCGCTTTCGCTAAGGACATCTCCGACATCGAGGGTGATGCTAAATATGGAGTGTCCACCGTGGCCACTAAGCTGGGAGCCCGGAACATGACGTTCGTCGTCTCTGGTGTTCTGCTCCTTAACTACTTGGTTTCGATCTCCATTGGCATTATCTGGCCACAAGTCTTCAAGTCCAACATTATGATTCTGTCCCACGCCATTCTTGCCTTTTGCCTGATCTTCCAGACACGCGAACTCGCTCTCGCTAACTACGCCTCCGCCCCATCGCGACAGTTCTTCGAGTTCATCTGGCTGCTTTACTACGCCGAGTACTTCGTTTACGTGTTCATCTAA Y1CBD1 Gene(SEQ ID NO: 119)ATGAAGTGTTCGACGTTTTCTTTTTGGTTTGTTTGTAAAATCATTTTCTTTTTCTTTTCTTTCAACATCCAAACGTCGATCGCAAACCCTAGAGAGAACTTTCTTAAGTGCTTCTCGCAGTACATCCCTAATAACGCTACCAACCTTAAGCTGGTGTACACCCAGAACAACCCTCTTTACATGTCTGTTCTAAACAGCACCATCCACAATCTTAGATTCACATCAGACACCACTCCCAAGCCGCTCGTCATCGTGACCCCGAGTCATGTGTCCCATATCCAAGGCACTATCCTGTGCTCTAAAAAGGTCGGTCTGCAGATTCGGACTCGCTCCGGTGGACATGATTCGGAGGGCATGTCCTACATTAGCCAGGTCCCCTTTGTGATCGTGGACCTGAGGAACATGCGGTCTATTAAGATTGATGTGCACTCACAGACCGCTTGGGTCGAGGCTGGTGCGACATTGGGTGAGGTGTACTACTGGGTGAACGAGAAGAACGAGAACCTGAGCCTCGCCGCTGGCTACTGTCCCACCGTTTGTGCCGGTGGACACTTCGGCGGAGGCGGATACGGTCCACTTATGCGAAACTACGGGCTCGCAGCTGATAATATCATCGACGCACACCTTGTTAACGTTCACGGCAAGGTGCTGGACCGAAAAAGCATGGGTGAGGACCTATTTTGGGCCTTGCGAGGCGGTGGTGCCGAATCCTTCGGAATTATCGTGGCCTGGAAGATCCGACTGGTCGCTGTGCCAAAGTCCACTATGTTCTCCGTCAAGAAAATTATGGAGATCCACGAACTCGTAAAGCTCGTCAATAAGTGGCAGAACATCGCCTACAAGTATGACAAGGATCTGCTGCTCATGACTCACTTCATCACGCGAAACATTACAGACAACCAGGGAAAGAACAAGACCGCTATCCATACCTACTTCTCCTCTGTCTTCCTTGGGGGTGTCGATTCCCTCGTTGATCTCATGAACAAATCTTTTCCAGAGCTCGGAATCAAGAAGACCGACTGCCGACAGCTCTCTTGGATCGACACCATTATTTTCTACTCAGGAGTCGTAAACTACGATACTGACAACTTTAACAAGGAGATTCTGTTAGATCGATCGGCCGGCCAGAACGGTGCCTTCAAGATCAAGCTCGACTATGTCAAAAAGCCCATTCCTGAATCCGTCTTCGTTCAAATTCTTGAAAAGTTGTACGAGGAGGATATCGGCGCCGGAATGTACGCGCTGTACCCCTACGGTGGCATTATGGACGAGATTTCTGAAAGTGCTATTCCCTTCCCCCACCGTGCTGGCATTCTGTATGAGCTGTGGTACATTTGCTCCTGGGAAAAGCAGGAGGACAACGAGAAGCACTTGAACTGGATACGAAACATTTACAATTTCATGACCCCCTATGTTTCGAAGAACCCTCGACTGGCCTACCTGAATTACCGCGACCTCGACATCGGAATTAACGACCCTAAGAACCCCAATAACTATACTCAGGCCAGAATCTGGGGCGAGAAGTACTTCGGCAAGAACTTTGACCGTCTGGTTAAGGTCAAGACCCTCGTGGACCCTAACAACTTCTTCCGAAACGAGCAGTCTATCCCCCCTCTGCCCCGACACCGGCATTAA Y1THC1 Gene (SEQ ID NO: 120)ATGAATTGTTCAGCTTTCTCTTTTTGGTTTGTCTGTAAGATCATTTTCTTCTTTCTATCCTTTCACATCCAAATTTCCATAGCCAACCCTCGTGAGAACTTCCTTAAGTGCTTTTCCAAGCACATTCCAAATAACGTCGCCAATCCCAAGCTGGTGTACACGCAGCATGACCAGCTCTACATGTCGATCCTCAATTCCACCATTCAAAACCTTAGATTCATTAGTGACACCACTCCCAAGCCCCTAGTCATTGTCACCCCTTCGAACAACTCGCATATTCAGGCAACTATTCTCTGCTCCAAGAAGGTTGGTTTACAGATCCGAACCCGGTCAGGTGGTCACGACGCTGAGGGCATGTCTTACATTTCCCAGGTCCCCTTTGTGGTGGTCGATCTGCGCAACATGCACTCCATTAAAATCGACGTCCACTCGCAGACTGCCTGGGTCGAGGCTGGAGCCACCCTTGGCGAGGTCTACTACTGGATTAACGAGAAGAACGAAAACCTGTCGTTCCCTGGCGGCTACTGTCCGACTGTTGGAGTCGGCGGACACTTTTCTGGTGGCGGATATGGTGCTCTCATGCGAAACTACGGACTGGCGGCAGACAACATCATCGATGCCCACCTTGTGAACGTTGACGGTAAGGTACTGGACCGAAAGTCTATGGGCGAGGACTTGTTTTGGGCCATCCGAGGTGGAGGTGGTGAGAACTTCGGGATCATCGCCGCCTGGAAGATCAAGCTGGTGGATGTGCCCAGTAAGTCTACCATTTTTAGCGTGAAGAAGAACATGGAGATCCACGGGCTGGTGAAGCTGTTCAACAAGTGGCAGAATATTGCGTACAAATACGACAAGGACCTGGTGCTTATGACCCATTTCATCACCAAGAACATCACGGATAACCACGGTAAAAACAAGACTACTGTTCACGGTTACTTCTCTTCAATTTTCCATGGTGGTGTGGATTCCCTCGTTGATTTGATGAACAAGTCCTTCCCAGAGCTGGGCATTAAGAAGACAGACTGCAAGGAATTTAGCTGGATTGATACCACCATCTTCTACTCTGGAGTTGTCAACTTCAACACCGCAAACTTCAAGAAGGAAATCCTCTTGGACCGATCTGCCGGCAAGAAGACAGCTTTTTCGATTAAACTGGATTACGTGAAGAAGCCCATCCCTGAGACAGCTATGGTCAAGATCCTTGAAAAACTTTATGAGGAGGACGTCGGAGCCGGAATGTACGTTCTCTATCCTTACGGCGGCATCATGGAGGAAATTTCTGAGTCTGCTATCCCCTTCCCCCATCGAGCCGGAATCATGTACGAGCTGTGGTACACCGCTAGTTGGGAGAAGCAGGAGGATAACGAGAAACATATCAATTGGGTCCGTAGCGTATACAATTTCACGACACCCTACGTGTCCCAGAACCCTCGACTCGCTTACCTGAACTATAGGGACCTGGACCTCGGCAAGACTAACCACGCTAGCCCGAACAACTACACCCAGGCCAGAATTTGGGGCGAAAAGTACTTCGGAAAGAACTTCAACCGACTCGTTAAGGTTAAGACCAAAGTTGACCCCAACAACTTTTTCCGGAACGAGCAGTCCATCCCTCCACTCCCTCCCCACCATCACTGA

The following plasmids were constructed using modern molecular biologytechniques described herein.

TABLE 2 Important Plasmid Seq ID Features pLD87 166 KU70 Disruptioncassette with LoxP-URA3-LoxP pLD101 167 POX5 Disruption cassette withLoxP-URA3-LoxP pLD102 168 POX3 Disruption cassette with LoxP-URA3-LoxPpLD131 174 CEN-ARS LEU2 PPOX2-PTS2 pLD132 175 CEN-ARS URA3 PPOX-CBD1pLD135 176 POX3 Disruption cassette URA3 ACO1P pLD137 177 CEN-ARS LEUpLD138 178 CEN-ARS URA

Example 3 Transformation of Candida viswanathii

A starting Candida viswanathii strain, such as the uracil auxotrophproduced in Example 2, is propagated in a 5 mL YPD culture that isincubated overnight at 30° C., 250 rpm. The next day, a 50 mL culture isinitiated with part of the 5 mL YPD overnight culture and grown for afew hours to an OD (600 nm) absorbance of 1.0-2.0. The resulting cellsare pelleted by centrifugation at 1000×g for 10 minutes. The cells arewashed by resuspension in sterile water, centrifuged (10000×g, 1 min)and resuspended in 1 mL sterile TE/LiOAC solution, pH 7.5. The cellswere centrifuged (10000×g, 1 min) again and resuspended in 500 ul ofTE/LiOAC solution and incubated with shaking at 30° C. for 30 minutes.

For each transformation reaction, 50 uL aliquots of cell suspension areto be used. To 50 ul of cells, add 5 uL of carrier DNA (boiled andcooled salmon sperm DNA, 10 mg/mL) and incubate for 1-2 minutes at roomtemperature. The DNA that is to be used to transform the yeast isoptimally inserted into the yeast genome as linearized DNA. Therefore,2-5 ug of linearized DNA for integration is added to the mixture ofcells and salmon sperm DNA. To this mixture, 300 uL of sterile PEGsolution (40% PEG 3500, 1×TE, 1×LiOAC) is added and the final mixture isincubated at 30° C. for 30-60 minutes while being gently agitated. Thecells are then pelleted by centrifugation at 1000×g 30 seconds,resuspended in 500 uL of YPD media and incubated at 30° C., 250 rpm for1-2 hours.

After recovery in YPD the cells are then pelleted by centrifugation andwashed twice with 1 mL of 1×TE before plating cells on the appropriateauxotrophic or selective media to identify transformants.

Example 4 Transformation of Yarrowia lipolytica

A starting Yarrowia lipolytica strain is propagated in 2 mL YPD culturethat is incubated overnight (˜20 hrs) at 30° C., 250 rpm. the resultingcells are pelleted by centrifugation at 6000×g. The cells are washed byresuspension in 250 ul of 0.3 M Li Acetate 10 mM Tris-HCl pH 8.0. Thecells are then pelleted and resuspended in 100 ul of 0.3 M Li Acetate 10mM Tris-HCl pH 8.0. To the cells 5 ul of salmon sperm DNA solution (8mg/ml ssDNA 10 mM Tris-HCL pH 8.01 mM EDTA) is added, 1 to 10 ul of DNA(up to 1 ug) and 15 ul of triacetic solution (95 ul of triacetin+5 ulbeta-mercaptoethanol). Cells are mix by pipetting and incubated 30 minat room temperature.

150 ul of PEG solution is added (40% PEG 3500, 1×TE, 1×LiOAC) and mixvia pipetting. Incubate at 30 min at 30 min at room temperature. Heatshock at 37 C for 15 to 25 minutes in water batch. Add 1 ml water, mixwell and then pellet at 6000×g. Decant, resuspend in 100 ul of TE (10 mMTris-HCl pH 8.0+1 mM EDTA and plate in desired media.

Example 5 Production of an Uracil Auxotroph of ATCC 20962

ATCC 20962 is a prototrophic yeast strain that is able to grow in theabsence of supplemented uracil. In order to utilize this strain forexperiments, it must first be made auxotrophic for uracil. In the caseof ATCC 20962, the URA3 gene must be inactivated to make the strainauxotrophic. This will allow for uracil auxotrophy to be rescued by theintroduction of a functional URA3 gene via transformation, as describedin Example 3.

To convert ATCC 20962 to a uracil auxotroph, an individual colony of thestrain was grown in 5 mL of YPD overnight at 30 C, shaken at 250 rpm.From the overnight culture, 20 and 100 ul of culture were plated onplates containing 5-FOA (recipe). The chemical 5-FOA is converted into atoxic compound, fluorodeoxyuridine, by the enzyme encoded by the URA3gene. Therefore, growth on 5-FOA selects for uracil auxotrophs that havespontaneously produced loss-of-function ura3 mutants. The plate wasplaced at 30 C for 3-6 days to produce colonies. The resulting colonieswere tested for growth on media lacking uracil, e.g. synthetic completeyeast media lacking uracil and 5-FOA plates. One of these colonies didnot grew on media lacking uracil but grew on 5-FOA plates, it wasconfirmed as uracil auxotrophs and named LCV32.

Example 6 Genomic DNA Extraction for PCR Analysis

An overnight culture in YPD or selective media was grown at 30 C 225rpm. Cells were pelleted in an screw-cap 1.5 ml microcentrifuge tube.Supernatant was decanted and cells resuspended in 250 ul of extractionbuffer (100 mM NaCl, 2% Triton X-100, 1% SDS, 10 mM Tris-Cl, 1 mM EDTApH 8.0). 200 ul of acid washed glass-beads (425-600), and 300 ul ofphenol:chorofom:isoamyl alcohol solution (25:24:1 ratio) that has beenequilibrated with 100 mM Tris Cl pH 8.0 is added and vortexed for 5 min.The microcentrifuge is then centrifuge and the supernatant is removed.The supernatant then is extracted with 300 ul of chloroform. The aqueoussolution is then transferred to a new microcentrifuge tube. 1.2 ml ofice-cold ethanol is added to the microcentrifuge tube. The tube is thenmixed and placed at −20 C or colder for 1 hr. The DNA is then pelletedby centrifugation at 10,000×G. The pellets are then air-dried andresuspended in 500 ul of TE (10 mM Tris-HCl 1 mM EDTA pH 8.0).

Example 7 Verification of Integrations in Candida viswanathii

To verify the integration of exogenous genes into the genome of Candidaviswanathii a PCR based method was developed where one or two ofdifferent exogenous genes were amplified in the same reaction as asection of the actin gene that serves as a control.

TABLE 3 Forward Reverse Gene Primer Primer Length CvACT1 4 5 859 CvHXS16 7 612 CvTKS1 8 9 617 CvOAC1 10 11 461 CvPTS1 12 13 611 CvCBD1 14 15411 CvACO1 16 17 414 CvPTS2 41 42 616 CvTHC1 168 169 397

For a 25 ul reaction, 12.5 ul of the 2× Master Mix, 0.5 ul of primers(10 μM of each), 1 ul of DNA template, and 11 ul of water. Standardrunning reactions are 95 C for 2 min, 30 cycles of 95 C for 30 sec, 55 Cfor 30 sec, and 72 C for 1 min, and a final step of 72 C for 2 min. 10ul to 20 ul is loaded in a 1.4 to 2.0% agarose TAE gel.

TABLE 4 Primer number Sequence 4 CCCAATTCCTGTGGTGGGTTGATTCG(SEQ ID NO: 121) 5 CTCTCAATTCGTTGTAGAAGGTGTGGTGC (SEQ ID NO: 122) 6CTTTGGACTCAGTTGTGGCTAGTGACTTC (SEQ ID NO: 123) 7GATCAAGAGTCAATTTATTCAATGGGAGATCGTC (SEQ ID NO: 124) 8GAGCAGAAGGACCCGCATCAGTG (SEQ ID NO: 125) 9 GTCACCAAAAATTGCCTGTCCGACAAGC(SEQ ID NO: 126) 10 CACGACATAATGGCAGTCAAACACCTAATAG (SEQ ID NO: 127) 11CTAGTTTTGTGTTCGGAGTATGCATACAACG (SEQ ID NO: 128) 12CTACCACACCCTCCTAAACCCTCAC (SEQ ID NO: 129) 13CGAAGCAGTACCCGAATATATATAATGGACC (SEQ ID NO: 130) 14CCTTCAACATTCAGACATCAATCGCCAAC (SEQ ID NO: 131) 15 CACCCAAGGTTGCCCCTGCTTC(SEQ ID NO: 132) 16 GAGCAAGTTCCCCAGCAAGTCCAG (SEQ ID NO: 133) 17CATGATGTTCACGGGTTCCCAAGTGC (SEQ ID NO: 134) 41 CATACATGCTGGAAGCTACAGCGAC(SEQ ID NO: 135) 42 CAGTACTCACCCCATATTTTGCATCGC (SEQ ID NO: 136) 168GTTAAGTTGTTTAACAAGTGGCAAAACATTGCATAC (SEQ ID NO: 137) 169CCAAAATCTTAACCATTGCTGTTTCTGGAATTGG (SEQ ID NO: 138) 170GATTTGTTTTGGGCAATTAGAGGAGGTGG (SEQ ID NO: 139) 171CAACTCCTGAGTAGAAAATGGTTGTATCGATC (SEQ ID NO: 140)

Example 8 Construction of Yeast Strains in Candida viswanathii

The following strains were constructed by transformation as described inthe previous example with a PacI digested plasmid as shown in Table 5.Ura+ strains were tested for successful integration of the gene or genesof interest by using the PCR-based method described above. A correctstrain was named according to the Table 5.

TABLE 5 Strain Parental Strain Plasmid Transformed LCV13 ATCC20913 pLD1LCV14 ATCC20913 pLD1 LCV22 ATCC20913 pLD10, pLD12, pLD16 LCV34 and LCV35LCV32 pLD22 LCV36 LCV32 pLD14, pLD22, pLD24 LCV38 LCV32 pLD10, pLD12,pLD116, pLD22 LCV40 LCV32 pLD1 LCV49 LCV32 pLD14, pLD22, pLD24, pLD26LCV50 ATCC20913 pLD56, pLD111 LCV51 ATCC20913 pLD19 LCV55 ATCC20913pLD56 LCV59 ATCC20913 pLD20, pLD56 LCV61 ATCC20913 pLD56, pLD111 LCV63ATCC20913 pLD56, pLD126 LCV67 ATCC20913 pLD56, pLD140 LCV70 ATCC20913pLD56, pLD139

Example 9 Construction of Yeast Strains in Yarrowia lipolytica

MYA-2613 (ATCC) was transformed with PacI digested pLD87 and Ura+transformants selected by growth in ScD-ura plates. Genomic DNA from theura+ strains was purified as described above. To identify the disruptionof the KU70 gene a four oligo PCR method was designed. Two primers(61+87) amplifies a 796 bp piece of the actin gene, and primers 63 and64 amplifies a 558 bp piece that is replaced by the URA3 gene if theKU70 gene is disrupted.

Using genomic DNA as the template for the method described allowed toidentify if the strain still had the KU70 gene (presence of both PCRfragments) or if the strain had a disrupted KU70 (presence of only theactin PCR fragment). One strain was identified with the correct PCRprofile and named YYL2.

YYL2 was transformed with pLD113 and Leu+ transformants selected bygrowth in ScD-leu plates. Leu+ transformant was then streaked in ScD+FOAplates. FOA resistant strains were isolated and its genomic DNApurified. To identify loss of the URA3 a four oligo PCR method wasdesigned. Two primers (61+87) amplifies a 796 bp piece of the actingene, and primers 115 and 116 amplifies a 594 bp piece ku70-URA3 piecethat is lost if the URA3 piece is removed from the KU70 loci.

Using genomic DNA as the template for the method described allowed toidentify if the strain still had the URA3 at the KU70 loci (presence ofboth PCR fragments) or if the strain had lost the URA3 at the KU70 loci(presence of only the actin PCR fragment). One strain was identifiedwith the correct PCR profile and named YYL4.

TABLE 6 Parental Plasmid Strain Strain Transform YYL2 MYA-2613 Pac1(pLD87) YYL2L YYL2 pLD113 YYL4 YYL2L YYL6 YYL4 pLD101 YYL27 YYL25 pLD102YYL29 YYL25 pLD135

TABLE 7 Strain Background Plasmid YYL7 MYA-2613 pLD131 YYL9 MYA-2613pLD132 YYL11 MYA-2613 pLD137 YYL13 MYA-2613 pLD138 YYL17 MYA-2613pLD131, pLD132 YYL19 MYA-2613 pLD131, pLD138 YYL21 MYA-2613 pLD137,pLD138

TABLE 8 Primer number Sequence 61 TTGTTACCAACTGGGATGACATGGAGAAG(SEQ ID NO: 141) 63 CTGATGGACGTGTTTTTCGACATGAACC (SEQ ID NO: 142) 64GAAAGGAACATAGTCATTTCCAAACTTGAAAGTC (SEQ ID NO: 143) 87CAGACGGAGTACTTTCGCTCGAGG (SEQ ID NO: 144) 115CCCAAATTTAGCTGCATCATTCATCAACC (SEQ ID NO: 145) 116CCGTGCTTAAGAGCAAGTTCCTTGAGG (SEQ ID NO: 146) 177 CTACGACATGCCCAAGGAGCAGC(SEQ ID NO: 147) 178 GGATTCGCACATTGGTGAACTGGATC (SEQ ID NO: 148) 179CCAAGCGACGACAAGCTGTTGAGC (SEQ ID NO: 149) 180 CGTGTGGGTAGCAGAGTGGGC(SEQ ID NO: 150) 181 CTTTGCCATGACTGAGACTGGCCATG (SEQ ID NO: 151) 182GAGGCGCCGCTGGTGTCG (SEQ ID NO: 152) 183 TCCGAAAGCGGAACTGCTTTCTCAATG(SEQ ID NO: 153) 184 CAGACCGGCCTCTCGAATATGGC (SEQ ID NO: 154) 185CTAGACTACACGGGCAACCTTAACCC (SEQ ID NO: 155) 186CTTGGGCTTCAGCTTTCGAGGAGTG (SEQ ID NO: 156)

YYL4 was transformed with PacI digested pLD101 and Ura+ transformantsselected by growth in ScD-ura plates. Genomic DNA from the ura+ strainswas purified as described above. To identify the disruption of the POX5gene a four oligo PCR method was designed. Two primers (61+87) amplifiesa 796 bp piece of the actin gene, and primers 179 and 180 amplifies a395 bp POX5 segment that is replaced by the URA3 gene.

Using genomic DNA as the template for the method described allowed toidentify if the strain still had the PO5 gene (presence of both PCRfragments) or if the strain had been disrupted for POX5 (presence ofonly the actin PCR fragment). One strain was identified with the correctPCR profile and named YYL6.

YYL6 is transformed with pLD113 and Leu+ transformants are selected bygrowth in ScD-leu plates. Leu+ transformant was then streaked in ScD+FOAplates. FOA resistant strains will be isolated and its genomic DNApurified. To identify loss of the URA3 a four oligo PCR method wasdesigned. Two primers (61+87) amplifies a 796 bp piece of the actingene, and primers 116 and 237 amplifies a 598 bp piece POX5-URA3 piecethat is lost if the URA3 piece is removed from the URA loci. A strainwith the correct PCR products was named YYL0025.

YYL25 is transformed with Pac 1 digested pLD102 or pLD135, and Ura+transformants selected by growth in ScD-ura plates. Genomic DNA from theura+ strains is purified as described above. To identify the disruptionof the POX4 gene a four oligo PCR method was designed. Two primers(61+87) amplifies a 796 bp piece of the actin gene, and primers 177 and178 amplifies a 596 bp POX3 segment that is replaced by the URA3 gene.One strain transformed with either pLD102 or pLD135 is identified withthe correct PCR profile and named YYL27 and YYL29, respectively.

Strain with plasmids were either transformed once (if containing oneplasmid) or sequentially (if containing more than one plasmid).

Example 10 Quantification of Olivetolic Acid and Cannabinoids

To a 100 to 500 mg wet yeast pellet 50 ul of HCl was added and vortexedfor 30 seconds. 400 ul of dichloromethane:ethyl ether (1:2) was addedand vortexed for 1 min and centrifuged for 2 min at 10 k rpm. The toplayer was removed, and the pellet was reextracted. The top layers werecombined and dried under vacuum. The powder was reconstituted in 200 ulof acetonitrile and sonicated for 1 min. The solution was centrifuge for2 min at 10 k rpm. Solution was then used for LC MS MS analysis.

For 0.5 ml of supernatant, 0.5 ml 1 M HCl was added and vortexed for 30s. 500 ul of dichloromethane was added, vortexed for 30 sec andcentrifuged for 2 min at 10 k rpm. The bottom layer was removed and theaqueous layer re-extracted. Both organic layer samples were combined anddry under vacuum. The powder was reconstituted in 200 ul of acetonitrileand sonicated for 1 min. The solution was centrifuge for 2 min at 10 krpm. Solution was then used for LC MS MS analysis.

Example 11 Quantification of Hexanoic Acid and Fatty Acids

To 1 ml of supernatant, 0.8 ml of 6N HCl was added. 400 ul ofdichloromethane:ethyl ether (1:2) was added, vortexed for 2 min andcentrifuge for 2 min. The top layer was removed the extraction wasrepeated. The top layers were combined and dried under vacuum. Thepowder was reconstituted in 167 ul acetonitrile and 33 ul ofacetonitrile with 20 mg/ml isopropyl alcohol and sonicated for 1 min.The solution was centrifuged for 2 m in at 10 k rpm. Solution was thenused for GC FID analysis.

Example 12 Yeast Media

ScD-ura

1 L of liquid media was made by making a 100 ml solution of 20% dextroseand a 900 ml solution with 1.7 g of Yeast Nitrogen Base without ammoniumsulfate and amino acids, 5 g of ammonium sulfate, and 2 g of dropoutamino acid mix without uracil (Sunrise Science Products). Both solutionswere combined, and filter sterilized or were autoclaved separately andcombined.

1 L worth of plates (˜40 plates) was made by making a 100 ml solution of20% dextrose, a 450 ml solution with 1.7 g of Yeast Nitrogen Basewithout ammonium sulfate and amino acids, 5 g of ammonium sulfate, and 2g of amino acid mix without uracil, and a 450 ml solution with 20 g ofagar. The solutions were autoclaved separately and combined.

ScD-leu

1 L of liquid media was made by making a 100 ml solution of 20% dextroseand a 900 ml solution with 1.7 g of Yeast Nitrogen Base without ammoniumsulfate and amino acids, 5 g of ammonium sulfate, and 2 g of dropoutamino acid mix without leucine (Sunrise Science Products). Bothsolutions were combined, and filter sterilized or were autoclavedseparately and combined.

1 L worth of plates (˜40 plates) was made by making a 100 ml solution of20% dextrose, a 450 ml solution with 1.7 g of Yeast Nitrogen Basewithout ammonium sulfate and amino acids, 5 g of ammonium sulfate, and 2g of amino acid mix without leucine and a 450 ml solution with 20 g ofagar. Both solutions were combined, and filter sterilized or autoclavedseparately and combined.

ScD-ura-leu

1 L of liquid media was made by making a 100 ml solution of 20% dextroseand a 900 ml solution with 1.7 1.7 g of Yeast Nitrogen Base withoutammonium sulfate and amino acids, 5 g of ammonium sulfate, and 2 g ofdropout amino acid mix without leucine and uracil (Sunrise ScienceProducts). Both solutions were combined, and filter sterilized orautoclaved separately and combined.

1 L worth of plates (˜40 plates) was made by making a 100 ml solution of20% dextrose, a 450 ml solution with 1.7 g of Yeast Nitrogen Basewithout ammonium sulfate and amino acids, 5 g of ammonium sulfate, and 2g of amino acid mix without leucine and uracil, and a 450 ml solutionwith 20 g of agar were made. The solutions were autoclaved separatelyand combined.

ScG-ura, ScG-leu, ScG-ura-leu was made the same as ScD-ura, ScD-leu orScD-ura-leu respectively except the dextrose was replaced with glycerolat a 40 g/L concentration. ScGP-ura, ScGP-leu, ScGP-ura-leu was the sameis the same as ScG-ura, ScG-leu or ScG-ura-leu, except, monopotassiumand dipotassium phosphate was added to a final concentration of 1 g/L.

YPD

1 L of liquid media was made by making a 100 ml solution of 20% dextroseand a 900 ml solution with 10 g yeast extract and 20 g of peptone. Bothsolutions were combined, and filter sterilized or autoclaved separatelyand combined.

1 L worth of plates (˜40 plates) was made by making a 100 ml solution of20% dextrose, a 450 ml solution with 10 g yeast extract and 20 g ofpeptone, and a 450 ml solution with 20 g of agar. The solutions wereautoclaved separately and combine afterwards.

SD+FOA

1 L worth of plates (˜40 plates) was made by making a 100 ml solution of20% dextrose, a 450 ml solution with 1.7 g of yeast nitrogen basewithout ammonium sulfate and amino acids, 5 g of ammonium sulfate, and 2g of amino acid mix without uracil, 0.5 g 5-FOA, 250 mg uracil, and a450 ml solution with 20 g of agar. The solutions were autoclavedseparately and combined.

SmP

1 L of liquid media was made by dissolving 1.7 g of yeast nitrogen basewithout ammonium sulfate and amino acids, 5 g of ammonium sulfate, 1 gpotassium phosphate, monobasic and 1 g potassium phosphate, bibasic. Thesolution was then filter sterilized.

YNEP Media

1 L of YNEP was made by dissolving 3 g yeast extract, 1.7 g of yeastnitrogen base without ammonium sulfate and amino acids, 5 g of ammoniumsulfate, 1 g potassium phosphate, monobasic and 1 g/l of dextrose orglycerol per liter. The solution was then filter sterilized.

MLM Media

1 L of MLM media was made by dissolving 3 g yeast extract, 1.7 g ofyeast nitrogen base without ammonium sulfate and amino acids, 1 gpotassium phosphate, monobasic and 1 g/1 of dextrose or glycerol. Filtersterilized

ScP-ura, ScP-leu, ScP-ura-leu was the same as Sc-ura, Sc-leu,Sc-ura-leu, respectively except monopotassium and dipotassium phosphatewas added to a final concentration of 1 g/L.

For Yarrowia media a supplement of thiamine, biotin and Myo-inositol canbe added to the media to a final concentration of 300 μg/L, 8 μg/L and 4μg/L.

Example 13 Shake Flask Fermentation Candida

A shake flask fermentation is a small-scale culture to test forproduction of a cannabinoid or cannabinoid precursor. A yeast strain tobe tested is grown on ScD-ura, or YPD for 2-3 days. Individual coloniesfrom those plates are propagated overnight in 5 mL of YPD or ScD-ura (30C, shaking at 250 rpm). The resulting culture is propagated overnight in50 mL of YPD or 25 ml of YNEP media (30 C, shaking at 250 rpm). Thebiomass from the 50 mL culture is spun down and washed with water, thenresuspended in 15 mL of 1×SMP or MLM media with 300 ul of oleic acid(technical grade, 90%). Yeast cells, media and oleic acid are placedinto a 250 mL culture flask (it may be a baffled flask for increasedaeration of the culture) and incubated at 30 C while shaking (250 rpm)for a 48-72 hours. The contents of the shake flask are spun down toproduce a cell pellet and a supernatant, which is the culture media. Thecell pellet and/or supernatant are analyzed for their contents by theappropriate method(s) as needed for the analyte(s) of interest.

Example 14 Shake Flask Fermentation Yarrowia

A shake flask fermentation is a small-scale culture to test forproduction of a cannabinoid or cannabinoid precursor. A yeast strain tobe tested is grown on ScD-ura, ScD-leu, ScD-ura-leu or YPD for 2-3 days.Individual colonies from those plates are propagated overnight in 5 mLof YPD, ScD-ura, ScD-leu, or ScD-ura-leu (30 C, shaking at 250 rpm). Theresulting culture is propagated overnight in 25 mL ScGP, ScGP-ura,ScGP-leu, or ScGP-ura-leu (30 C, shaking at 250 rpm). The biomass fromthe 25 mL culture is spun down and washed with water, then resuspendedin 20 mL of ScP, ScP-ura, ScP-leu or ScP-ura-leu media with 800 ul ofoleic acid (technical grade, 90%). Yeast cells, media and oleic acid areplaced into a 250 mL culture flask (it may be a baffled flask forincreased aeration of the culture) and incubated at 30 C while shaking(250 rpm) for a 24-72 hours. The contents of the shake flask are spundown to produce a cell pellet and a supernatant, which is the culturemedia. The cell pellet and/or supernatant are analyzed for theircontents by the appropriate method(s) as needed for the analyte(s) ofinterest.

Example 15 Production of Olivetolic Acid From Hexanoic Acid orHexanoate-Esters in Candida

Strain LCV22 (HXS1 TKS1 OAC) was grown overnight in 25 ml of YPD in a250 ml flask at 225 rpm and 30 C. 3 ml of the overnight culture was usedto inoculate 50 ml of YPD and grown overnight in a 250 ml flask at 225rpm and 30 C. A total of seven flasks were started. The biomass from the50 mL culture was spun down and washed with water, then resuspended in15 mL of 1×SMP media with 300 ul of oleic acid (technical grade, 90%).Yeast cells, media and oleic acid are placed into a baffled 250 mLculture flask. Different amounts of hexanoic acid, ethyl hexanoate, andgeranyl hexanoate were added to different flask as described in Table 9.and incubated at room temperature while shaking (250 rpm) for 72 hours.The contents of the shake flask were spun down to produce a cell pelletand a supernatant, which is the culture media. The cell pellets wereanalyzed for olivetolic acid using an LC-MS MS method.

As shown in Table 9, there was an increase in olivetolic productionusing hexanoate ester as opposed to hexanoic acid. This is consistentwith hexanoic acid being more toxic per mole than geranyl hexanoate andethyl hexanoate.

TABLE 9 Amount Olivetolic acid Flask Addition (ul) (Area per mg) 1 — — 52 Hexanoic acid 15 13 3 Ethyl hexanoate 20 56 4 Geranyl hexanoate 34 1795 Hexanoic acid 30 101 6 Ethyl hexanoate 40 62 7 Geranyl hexanoate 68344

Example 16 Production of Hexanoic Acid From Oleic Acid in Candida

Strain LCV14 (wildtype) and LCV35 (Δpox+ACO1P) were grown in 3 ml ofYPD. These overnight cultures were used to inoculate 50 ml of YPD andgrown overnight in a 250 ml flask at 225 rpm and 30 C. The biomass fromthe 50 mL culture was spun down and washed with water, then resuspendedin 15 mL of 1×SMP media with 300 ul of oleic acid (technical grade,90%). Yeast cells, media and oleic acid were placed into a 250 mLculture flask and incubated at 30 C while shaking (250 rpm) for 48hours. The contents of the shake flask were spun down to produce a cellpellet and a supernatant, which is the culture media. The cell pelletswere analyzed for hexanoic using an LC-MS MS method. As shown in Table10, LCV35 produced more hexanoic acid than LCV35, which is consistentwith the presence of an active pathway making hexanoic acid from oleicacid.

TABLE 10 Hexanoic Acid Strain (mg/L) LCV14 9.7 LCV35 61.2

Example 17 Production of Hexanoic Acid From Soybean Oil in Candida

Strain LCV14 (wildtype) and LCV34 (Δpox+ACO1P) were grown in 3 ml ofYPD. These overnight cultures were used to inoculate 50 ml of YPD andgrown overnight in a 250 ml flask at 225 rpm and 30 C. The biomass fromthe 50 mL culture was spun down and washed with water, then resuspendedin 15 mL of 1×SMP media with 300 ul of soybean oil. Yeast cells, mediaand soybean oil were placed into a 250 mL culture flask and incubated at30 C while shaking (250 rpm) for 48 hours. The contents of the shakeflask were spun down to produce a cell pellet and a supernatant, whichis the culture media. The cell pellets were analyzed for hexanoic acidusing an LC-MS MS method. As shown in Table 11, LCV34 produced morehexanoic acid than LCV14 when using soybean and palm oil, consistentwith the presence of an active pathway making hexanoic acid from soybeanoil and palm oil.

Example 18 Production of Hexanoic Acid From Alkane in Candida

Strain LCV14 (wildtype) and LCV34 (Δpox+ACO1P) were grown in 3 ml ofYPD. These overnight cultures were used to inoculate 50 ml of YPD andgrown overnight in a 250 ml flask at 225 rpm and 30 C. The biomass fromthe 50 mL culture was spun down and washed with water, then resuspendedin 15 mL of 1×SMP media with 300 ul of hexadecane or octadecane. Yeastcells, media and alkane were placed into a 250 mL culture flask andincubated at 30 C while shaking (250 rpm) for 48 hours. The contents ofthe shake flask were spun down to produce a cell pellet and asupernatant, which is the culture media. The cell pellets were analyzedfor hexanoic acid using an LC-MS MS method. As shown in Table 11, LCV34produced more hexanoic acid than LCV14 from hexadecane, which isconsistent with the presence of an active pathway making hexanoic acidfrom hexadecane. Octadecane may not be utilized effectively by the yeaststrains.

TABLE 11 Hexanoic Acid Strain Substrate (mg/L) LCV14 Soybean Oil 70LCV34 Soybean Oil 190 LCV14 Palm Oil 47 LCV34 Palm Oil 222 LCV14Octadecane 10 LCV34 Octadecane 3 LCV14 Hexadecane 2 LCV34 Hexadecane 174

Example 19 Production of Olivetolic Acid From Oleic Acid in Candida

Strain LCV14 (wildtype), LCV36 (Δpox+ACO1P+TKS1P+OAC1P), and LCV38(Δpox+ACO1P+HKS1+TKS1+OAC1) were grown in 3 ml of YPD. These overnightcultures were used to inoculate 50 ml of YPD and grown overnight in a250 ml flask at 225 rpm and 30 C. The biomass from the 50 mL culture wasspun down and washed with water, then resuspended in 15 mL of 1×SMPmedia with 300 ul of oleic acid (technical grade, 90%). Yeast cells,media and oleic acid were placed into a 250 mL culture flask andincubated at 30 C while shaking (250 rpm) for 48 hours. The contents ofthe shake flask were spun down to produce a cell pellet and asupernatant, which is the culture media. The supernatants were analyzedfor olivetolic acid using an LC-MS MS method. As shown in Table 12,LCV36 and LCV38 produced more olivetolic acid than LCV14, which isconsistent with the presence of an active pathway making olivetolic acidfrom oleic acid with either a peroxisomal TKS1P and OAC1P or anon-peroxisomal HKS1, TKS1 and OAC1.

TABLE 12 Strain Olivetolic Acid (Area/g) LCV14 611 LCV36 1094 LCV38 1026

Example 20 Production of Olivetolic Acid From Soybean Oil and Palm Oilin Candida

Strain LCV14 (wildtype) and LCV36 (Δpox+ACO1P+TKS1P+OAC1P) are grown in3 ml of YPD. These overnights are used to inoculate 50 ml of YPD andgrown overnight in a 250 ml flask at 225 rpm and 30 C. The biomass fromthe 50 mL culture is spun down and washed with water. It is resuspendedin 15 mL of 1×SMP media with 300 ul of soybean oil or 300 ul of palmoil. Yeast cells, media and soybean oil are placed into a 250 mL cultureflask. and incubated at 30 C while shaking (250 rpm) for 48 hours. Thecontents of the shake flask str spun down to produce a cell pellet and asupernatant, which is the culture media. The cell pellets andsupernatants are analyzed for olivetolic acid using an LC-MS MS method.

Example 21 Production of Olivetolic Acid From Alkanes in Candida

Strain LCV14 (wildtype) and LCV36 (Δpox+ACO1P+TKS1P+OAC1P) are grown in3 ml of YPD. These overnights are used to inoculate 50 ml of YPD andgrown overnight in a 250 ml flask at 225 rpm and 30 C. The biomass fromthe 50 mL culture is spun down and washed with water. It is resuspendedin 15 mL of 1×SMP media with 300 ul of hexadecane or octadecane. Yeastcells, media and alkane is placed into a 250 mL culture flask. andincubated at 30 C while shaking (250 rpm) for 48 hours. The contents ofthe shake flask are spun down to produce a cell pellet and asupernatant, which is the culture media. The cell pellets andsupernatant are analyzed for olivetolic acid using an LC-MS MS method.

Example 22 Production of CBGA From Olivetolic Acid in Candida

Strain LCV51 (PTS1), LCV55 (PTS2) and LCV13 (wildtype) were grown in 3ml of YPD. These overnight cultures were used to inoculate 2× (forLCV55) or 1× (for LCV13 and LCV5150 ml cultures of YPD and grownovernight in a 250 ml flask at 225 rpm and 30 C. The biomass from the 50mL cultures were spun down and washed with water, then resuspended in 15mL of 1×SMP media with 300 ul of oleic acid. Yeast cells, media andoleic acid were placed into a 250 mL culture flask. To one of the LCV55flasks and the LCV13 flask, olivetolic acid was added to a finalconcentration of 1 mM. The flasks were then incubated at 30 C whileshaking (250 rpm) for 48 hours. The contents of the shake flask werespun down to produce a cell pellet and a supernatant, which is theculture media. The cell supernatants were analyzed for CBGA using anLC-MS MS method. As shown in Table 13, LCV51 and LCV55 produced moreCBGA than LCV13 and LCV55 without olivetolic acid, which is consistentwith the presence of an active pathway making CBGA acid from oleic acidwhen either PTS1 or PTS2 is expressed.

TABLE 13 StrainStrain CBGA Area/ul LCV13 Yes 18,200 LCV51 Yes 21,920LCV55 No 0 LCV55 Yes 36,000

Example 23 Production of CBDA From Olivetolic Acid in Candida

Strain LCV55 (PTS2) and LCV59 (PTS2 CBD1) is grown in 3 ml of YPD. Theseovernights are used to inoculate 2× (for LCV59) or 1× (for LCV55) 50 mlof YPD and grown overnight in a 250 ml flask at 225 rpm and 30 C. Thebiomass from the 50 mL culture is spun down and washed with water, thenresuspended in 15 mL of 1×SMP media with 300 ul of oleic acid. Yeastcells, media and oleic acid are placed into a 250 mL culture flask. Toone of the LCV59 flasks and the LCV55 flask, olivetolic acid is added toa final concentration of 1 mM. The flasks are then incubated at 30 Cwhile shaking (250 rpm) for 48 hours. The contents of the shake flaskare spun down to produce a cell pellet and a supernatant, which is theculture media. The cell pellets and supernatants are analyzed for CBDAusing an LC-MS MS method.

Example 24 Production of THCA From Olivetolic Acid in Candida

Strain LCV55 (PTS2) and LC61 (PTS2 THC1) are grown in 3 ml of YPD. Theseovernight cultures are used to inoculate 2× (for LCV61) or 1× (forLCV155) 50 ml of YPD and grown overnight in a 250 ml flask at 225 rpmand 30 C. The biomass from the 50 mL culture is spun down and washedwith water, then resuspended in 15 mL of 1×SMP media with 300 ul ofoleic acid. Yeast cells, media and oleic acid are placed into a 250 mLculture flask. To one of the LCV61 flasks and the LCV55 flask,olivetolic acid is added to a final concentration of 1 mM. The flasksare then incubated at 30 C while shaking (250 rpm) for 48 hours. Thecontents of the shake flask are spun down to produce a cell pellet and asupernatant, which is the culture media. The cell pellets andsupernatants are analyzed for THCA using an LC-MS MS method.

Example 25 Production of CBGA From Fatty Acids in Candida

Strain LCV36 (Δpox+ACO1P+TKS1P+OAC1P) and LCV49(Δpox+ACO1P+TKS1P+OAC1P+PTS1dN), were grown in 3 ml of YPD. Theseovernight cultures were used to inoculate 50 ml of YPD and grownovernight in a 250 ml flask at 225 rpm and 30 C. The biomass from the 50mL culture was spun down and washed with water, then resuspended in 15mL of 1×SMP media with 300 ul of oleic acid (technical grade, 90%).Yeast cells, media and oleic acid were placed into a 250 mL cultureflask and incubated at 30 C while shaking (250 rpm) for 48 hours. Thecontents of the shake flask were spun down to produce a cell pellet anda supernatant, which is the culture media. The supernatants wereanalyzed for CBGA using an LC-MS MS method. As shown in Table, LCV49produced more CBGA than LCV36, which is consistent with the presence ofan active pathway making CBGA from oleic acid.

TABLE 14 Strain CBGA Area/ul LCV36 1,058 LCV49 2,000

Example 26 Production of CBDA From Fatty Acids in Candida

A strain is created that expresses ACO1P, TKS1P, AOC1P, PTS2 and CBD1 ina pox deleted background. This strain is grown overnight in 3 mol ofYPD. This overnight culture is used to inoculate 50 ml of YPD and grownovernight in a 250 ml flask at 225 rpm and 30 C. The biomass from the 50mL culture is spun down and washed with water. It is resuspended in 15mL of 1×SMP media supplemented with 300 ul of oleic acid. Yeast cells,media and oleic are placed into a 250 mL culture flask. The flasks arethen incubated at 30 C while shaking (250 rpm) for 48 hours. Thecontents of the shake flask are spun down to produce a cell pellet and asupernatant. The cell pellet and supernatants are analyzed for CBDA acidusing an LC-MS MS method.

Example 27 Production of THCA From Fatty Acids in Candida

A strain is created that expresses ACO1P, TKS1P, AOC1P, PTS2 and THC1 orACO1, HXS1, TKS1, AOC1, PTS2, and THC1 in a pox deleted background. Thisstrain is grown overnight in 3 mol of YPD. This overnight is used toinoculate 50 ml of YPD and grown overnight in a 250 ml flask at 225 rpmand 30 C. The biomass from the 50 mL culture is spun down and washedwith water. It is resuspended in 15 mL of 1×SMP media with 300 ul ofoleic acid. Yeast cells, media and oleic acid are placed into a 250 mLculture flask. The flask is then incubated at 30 C while shaking (250rpm) for 48 hours. The contents of the shake flask are spun down toproduce a cell pellet and a supernatant, which is the culture media. Thecell pellet and supernatant is analyzed for THCA acid using an LC-MS MSmethod.

Example 28 Enhanced Secretion of CBDA in Candida

Strain LCV59 (PTS2 CBD1), LCV63 (PTS2 CBD1dNS1), LCV67 (PTS2 CBDdNV1),and LCV70 (PTS2 CBD1dNP1) are grown in 3 ml of ScD-ura. These overnightcultures are used to inoculate 50 ml of YPD and grown overnight in 1 250ml flask at 225 rpm and 30 C. The biomass from the 50 mL culture is spundown and washed with water, then resuspended in 15 mL of 1×SMP mediawith 300 ul of oleic acid. Yeast cells, media and oleic acid is placedinto a 250 mL culture flask. Olivetolic acid is added to a finalconcentration of 1 mM. The flasks are then incubated at 30 C whileshaking (250 rpm) for 48 hours. The contents of the shake flask are spundown to produce a cell pellet and a supernatant, which is the culturemedia. The cell pellets and supernatants are analyzed for CBDA using anLC-MS MS method.

Example 29 Enhanced Secretion of THCA in Candida

Strains expressing either (PTS2 THC1), (PTS2 THC1dNS1), (PTS2 THCdNV1),or (PTS2 THC1dNP1) were grown in 3 ml of ScD-ura. These overnightcultures are used to inoculate 50 ml of YPD and grown overnight in a 250ml flask at 225 rpm and 30 C. The biomass from the 50 mL culture is spundown and washed with water, then resuspended in 15 mL of 1×SMP mediawith 300 ul of oleic acid. Yeast cells, media and oleic acid is placedinto a 250 mL culture flask. Olivetolic acid is added to a finalconcentration of 1 mM. The flasks are then incubated at 30 C whileshaking (250 rpm) for 48 hours. The contents of the shake flask are spundown to produce a cell pellet and a supernatant, which is the culturemedia. The cell pellets and supernatants are analyzed for THCA using anLC-MS MS method.

Example 30 Production of CBCA in Candida From Fatty Acids

A strain is created that expresses ACO1P, TKS1P, OAC1P, PTS2 and CBC1 orACO1P, HXS1, TKS1, OAC1, PTS2, and CBC1 in a pox deleted background.This strain is grown overnight in 3 mol of YPD. This overnight cultureis used to inoculate 50 ml of YPD and grown overnight in a 250 ml flaskat 225 rpm and 30 C. The biomass from the 50 mL culture is spun down andwashed with water, then resuspended in 15 mL of 1×SMP media with 300 ulof oleic acid. Yeast cells, media and oleic acid are placed into a 250mL culture flask. The flask is then incubated at 30 C while shaking (250rpm) for 48 hours. The contents of the shake flask are spun down toproduce a cell pellet and a supernatant, which is the culture media. Thecell pellet and supernatant are analyzed for CBCA acid using an LC-MS MSmethod.

Example 31 Production of Hexanoic Acid From Fatty Acids in Yarrowia

Strain YYL2 (wildtype), YYL6 (Δpox5), YYL27(Δpox3 Δpox5), andYYL29(Δpox3 Δpox5+ACO1P) are grown in 3 ml of YPD. These overnightcultures are used to inoculate 25 ml of ScGP and grown overnight in a250 ml flask at 225 rpm and 30 C. The biomass from the 25 mL culture wasspun down and washed with water, then resuspended in 20 mL of ScP mediawith 800 ul of oleic acid (technical grade, 90%). Yeast cells, media andoleic acid were placed into a 250 mL culture flask and incubated at 30 Cwhile shaking (250 rpm) for 48 hours. The fermentation is analyzed forhexanoic acid using an GC-FID method.

Example 32 Production of Hexanoic Acid From Soybean Oil and Palm Oil inYarrowia

Strain YYL2 (wildtype), YYL6 (Δpox5), YYL27(Δpox3 Δpox5), andYYL29(Δpox3 Δpox5+ACO1P) are grown in 3 ml of YPD. These overnightcultures are used to inoculate 25 ml of ScGP and grown overnight in a250 ml flask at 225 rpm and 30 C. The biomass from the 25 mL culture wasspun down and washed with water, then resuspended in 20 mL of ScP mediawith 800 ul of oleic acid (technical grade, 90%). Yeast cells, media andvegetable oil were placed into a 250 mL culture flask and incubated at30 C while shaking (250 rpm) for 48 hours. The fermentation is analyzedfor hexanoic acid using an GC-FID method.

Example 33 Production of Hexanoic Acid From Alkanes in Yarrowia

Strain YYL2 (wildtype), YYL6 (Δpox5), YYL27(Δpox3 Δpox5), andYYL29(Δpox3 Δpox5+ACO1P) are grown in 3 ml of YPD. These overnightcultures are used to inoculate 25 ml of ScGP and grown overnight in a250 ml flask at 225 rpm and 30 C. The biomass from the 25 mL culture isspun down and washed with water, then resuspended in 20 mL of ScP mediawith 800 ul of either hexadecane and octadecane. Yeast cells, media andoleic acid are placed into a 250 mL culture flask and incubated at 30 Cwhile shaking (250 rpm) for 48 hours. The fermentation is analyzed forhexanoic acid using an GC-FID method.

Example 34 Production of Olivetolic Acid From Hexanoic Acid orHexanoate-Esters in Yarrowia

A strain is created that expresses HXS1, TKS1 and OAC1 is grownovernight in 3 ml of YPD. This overnight culture is used to inoculate 25ml of ScGP and grown overnight in a 250 ml flask at 225 rpm and 30 C.The biomass from the 25 mL culture is spun down and washed with water,then resuspended in 20 mL of ScP media with 800 ul oleic acid. Yeastcells, media and oleic acid is placed into a 250 mL culture flask.Hexanoic acid, ethyl-hexanoate, geranyl hexanoate or other hexanoateester is added to the flask. The culture flask is incubated at 30 Cwhile shaking (250 rpm) for 48 hours. The contents of the shake flaskare spun down to produce a cell pellet and a supernatant. The cellpellets and supernatants are analyzed for olivetolic acid using an LC-MSMS method.

Example 35 Production of Olivetolic Acid From Fatty Acids in Yarrowia

A strain that produces hexanoic acid that expresses TKS1P and OAC1P orHXS1 TKS1 OAC1 is grown overnight in 3 ml of YPD. This overnight cultureis used to inoculate 25 ml of ScGP and grown overnight in a 250 ml flaskat 225 rpm and 30 C. The biomass from the 25 mL culture is spun down andis washed with water. It is resuspended in 20 mL of ScP media with 800ul oleic acid. Yeast cells, media and oleic acid is placed into a 250 mLculture flask. The culture flask is incubated at 30 C while shaking (250rpm) for 48 hours. The contents of the shake flask are spun down toproduce a cell pellet and a supernatant, which is the culture media. Thecell pellets and supernatants are analyzed for olivetolic acid using anLC-MS MS method.

Example 36 Production of Olivetolic Acid 1 From Soybean Oil or Palm Oilin Yarrowia

A strain that produces hexanoic acid that expresses TKS1P and OAC1P orHXS1 TKS1 OAC1 is grown overnight in 3 ml of YPD. This overnight cultureis used to inoculate 25 ml of ScGP and grown overnight in a 250 ml flaskat 225 rpm and 30 C. The biomass from the 25 mL culture is spun down andis washed with water, then resuspended in 20 mL of ScP media with 800 ulsoybean or palm oil. Yeast cells, media and vegetable oil is placed intoa 250 mL culture flask. The culture flask is incubated at 30 C whileshaking (250 rpm) for 48 hours. The contents of the shake flask are spundown to produce a cell pellet and a supernatant, which is the culturemedia. The cell pellets and supernatants are analyzed for olivetolicacid using an LC MS MS method.

Example 37 Production of Olivetolic Acid From Alkanes in Yarrowia

A strain that produces hexanoic acid that expresses TKS1P and OAC1P orHXS1 TKS1 OAC1 is grown overnight in 3 ml of YPD. This overnight cultureis used to inoculate 25 ml of ScGP and grown overnight in a 250 ml flaskat 225 rpm and 30 C. The biomass from the 25 mL culture is spun down andis washed with water. It is resuspended in 20 mL of ScP media with 800ul of hexadecane or octadecane. Yeast cells, media and alkane are placedinto a 250 mL culture flask. The culture flask is incubated at 30 Cwhile shaking (250 rpm) for 48 hours. The contents of the shake flaskare spun down to produce a cell pellet and a supernatant, which is theculture media. The cell pellets and supernatants are analyzed forolivetolic acid using an LC MS MS method.

Example 38 Production of CBGA From Olivetolic Acid in Yarrowia

YYL7 is grown overnight in 3 ml of ScD-leu. This overnight culture isused to inoculate 25 ml of ScGP-leu and grown overnight in a 250 mlflask at 225 rpm and 30 C. The biomass from the 25 mL culture is spundown and is washed with water, then resuspended in 20 mL of Sc-leu mediawith 800 ul oleic acid. Yeast cells, media and oleic are placed into a250 mL culture flask. Olivetolic acid is added to a final concentrationof 1 mM to the culture flask. The culture flask is incubated at 30 Cwhile shaking (250 rpm) for 48 hours. The contents of the shake flaskare spun down to produce a cell pellet and a supernatant, which is theculture media. The cell pellets and supernatants are analyzed for CBGAusing an LC-MS MS method.

Example 39 Production of CBDA From Olivetolic Acid in Yarrowia

YYL17 is grown overnight in 3 ml of ScD-leu-ura. This overnight cultureis used to inoculate 25 ml of ScGP-leu-ura and grown overnight in a 250ml flask at 225 rpm and 30 C. The biomass from the 25 mL culture is spundown and is washed with water, then resuspended in 20 mL of ScP-ura-leumedia with 800 ul oleic acid. Yeast cells, media and oleic are placedinto a 250 mL culture flask. Olivetolic acid is added to a finalconcentration of 1 mM to the culture flask. The culture flask isincubated at 30 C while shaking (250 rpm) for 48 hours. The contents ofthe shake flask are spun down to produce a cell pellet and asupernatant, which is the culture media. The cell pellets andsupernatants are analyzed for CBDA using an LC-MS MS method.

Example 40 Production of THCA From Olivetolic Acid in Yarrowia

A strain expressing PTS2 and THC1 is grown overnight in 3 ml ofScD-leu-ura (if genes are in a plasmid) or YPD (if genes areintegrated). This overnight is used to inoculate 25 ml of ScGP-leu-uraif genes are in a plasmid) or ScGP (if genes are integrated) and grownovernight in a 250 ml flask at 225 rpm and 30 C. The biomass from the 25mL culture is spun down and is washed with water, then resuspended in 20mL of ScP-ura-leu media with 800 ul oleic acid (if genes are in aplasmid) or ScP (if genes are integrated) media with 800 ul oleic acid.Yeast cells, media and oleic are placed into a 250 mL culture flask.Olivetolic acid is added to a final concentration of 1 mM to the cultureflask. The culture flask is incubated at 30 C while shaking (250 rpm)for 48 hours. The contents of the shake flask are spun down to produce acell pellet and a supernatant. The cell pellets and supernatants areanalyzed for THCA using an LC-MS MS method.

Example 41 Production of CBGA From Fatty Acids in Yarrowia

A strain that produces hexanoic acid that expresses TKS1P OAC1P PTS2 orHXS1 TKS1 OAC1 PTS2 is grown overnight in 3 ml of YPD. This overnightculture is used to inoculate 25 ml of ScGP and grown overnight in a 250ml flask at 225 rpm and 30 C. The biomass from the 25 mL culture is spundown and is washed with water, then resuspended in 20 mL of ScP mediawith 800 ul oleic acid. Yeast cells, media and oleic acid are placedinto a 250 mL culture flask. The culture flask is incubated at 30 Cwhile shaking (250 rpm) for 48 hours. The contents of the shake flaskare spun down to produce a cell pellet and a supernatant. The cellpellets and supernatants are analyzed for CBGA using an LC-MS MS method.

Example 42 Production of CBDA From Fatty Acids in Yarrowia

A strain that produces hexanoic acid that expresses TKS1P OAC1P PTS2CBD1 or HXS1 TKS1 OAC1 PTS2 CBD1 is grown overnight in 3 ml of YPD. Thisovernight culture is used to inoculate 25 ml of ScGP and grown overnightin a 250 ml flask at 225 rpm and 30 C. The biomass from the 25 mLculture is spun down and is washed with water, then resuspended in 20 mLof ScP media with 800 ul oleic acid. Yeast cells, media and oleic acidare placed into a 250 mL culture flask. The culture flask is incubatedat 30 C while shaking (250 rpm) for 48 hours. The contents of the shakeflask are spun down to produce a cell pellet and a supernatant. The cellpellets and supernatants are analyzed for CBDA using an LC-MS MS method

Example 43 Production of THCA From Fatty Acids in Yarrowia

A strain that produces hexanoic acid that expresses TKS1P OAC1P PTS2THC1 or HXS1 TKS1 OAC1 PTS2 THC1 is grown overnight in 3 ml of YPD. Thisovernight culture is used to inoculate 25 ml of ScGP and grown overnightin a 250 ml flask at 225 rpm and 30 C. The biomass from the 25 mLculture is spun down and is washed with water, then resuspended in 20 mLof ScP media with 800 ul oleic acid. Yeast cells, media and oleic acidare placed into a 250 mL culture flask. The culture flask is incubatedat 30 C while shaking (250 rpm) for 48 hours. The contents of the shakeflask are spun down to produce a cell pellet and a supernatant, which isthe culture media. The cell pellets and supernatants are analyzed forTHCA using an LC MS MS method

Example 44 Production of CBCA From Fatty Acids in Yarrowia

A strain that produces hexanoic acid that expresses TKS1P OAC1P PTS2CBC1 or HXS1 TKS1 OAC1 PTS2 CBC1 is grown overnight in 3 ml of YPD. Thisovernight culture is used to inoculate 25 ml of ScGP and grown overnightin a 250 ml flask at 225 rpm and 30 C. The biomass from the 25 mLculture is spun down and is washed with water, then resuspended in 20 mLof ScP media with 800 ul oleic acid. Yeast cells, media and oleic acidare placed into a 250 mL culture flask. The culture flask is incubatedat 30 C while shaking (250 rpm) for 48 hours. The contents of the shakeflask are spun down to produce a cell pellet and a supernatant, which isthe culture media. The cell pellets and supernatants are analyzed forCBC1 using an LC MS MS method

Sequences (Yarrowia)

pLD1 (SEQ ID NO: 157)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACATAAGAAGAGCCCGGGTCTAGATGTGTGCTCTTCCGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGA CCT pLD10(SEQ ID NO: 158)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGAATCATTTAAGAGCAGAAGGACCCGCATCAGTGTTAGCGATAGGTACAGCTAACCCAGAGAATATCTTAATCCAAGATGAATTTCCTGACTACTATTTCCGTGTTACTAAATCGGAACATATGACTCAACTTAAAGAGAAGTTCCGGAAAATCTGCGATAAATCCATGATCCGAAAGAGAAACTGTTTCCTTAACGAAGAACATCTCAAGCAAAACCCGAGGTTGGTAGAGCACGAAATGCAGACCTTGGATGCTAGGCAGGACATGTTGGTGGTCGAAGTGCCAAAACTCGGCAAGGACGCGTGCGCTAAGGCAATCAAGGAGTGGGGTCAACCGAAGTCTAAAATCACGCATCTAATATTTACATCTGCACTGACAACCGACATGCCGGGTGCCGATTATCACTGCGCCAAGCTACTTGGATTGAGTCCACTGGTTAAGAGAGTTATGATGTATCAATTGGGGTGTTACGGAGGGGGCACAGTCCTCAGAATTGCTAAGGATATTGCGGAAAATAACAAGGGCGCGAGGGTCCTTGCTGTATGTTGTGATATTATGGCCTGTTTGTTTCGCGGGCCCTCGGATTCAGATTTGGAATTGCTTGTCGGACAGGCAATTTTTGGTGACGGGGCCGCAGCAGTCATAGTGGGAGCCGAACCAGACGAAAGCGTGGGTGAAAGACCAATCTTTGAGTTGGTTCTGACCGGACAAACGATCTTACCTAACTCGGAAGGTACGATTGGAGGACATATTAGAGAAGCCGGCCTAATTTTCGATCTTCACAAAGACGTTCCAATGTTAATCTCCAATAACATAGAAAAGTGCTTGATAGAAGCATTTACTCCCATTGGTATTAGTGACTGGAACAGCATTTTCTGGATCACCCACCCTGGAGGAAAAGCTATACTCGATAAGGTTGAAGAGAAACTCGACTTGAAAAAGGAGAAATTCGTTGACTCACGACATGTGTTATCAGAGCACGGGAATATGAGTTCATCCACAGTCTTGTTCGTAATGGATGAATTGCGAAAACGCTCTCTTGAGGAGGGAAAGAGCACAACCGGTGACGGGTTTGAGTGGGGCGTGCTATTCGGTTTTGGCCCAGGTTTGACTGTCGAGCGGGTTGTTGTTCGTAGTGTACCAATTAAGTACTGATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD12(SEQ ID NO: 159)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGGCAGTCAAACACCTAATAGTTCTCAAATTTAAAGACGAGATTACTGAAGCTCAGAAGGAAGAGTTCTTTAAGACATATGTTAACTTAGTCAACATCATCCCCGCGATGAAGGACGTCTACTGGGGCAAGGATGTGACGCAAAAAAATAAGGAAGAAGGATACACACATATCGTTGAGGTGACCTTTGAGAGTGTGGAAACTATTCAAGATTATATTATTCACCCAGCCCATGTAGGGTTCGGTGACGTTTATCGATCATTCTGGGAAAAGTTGCTTATATTTGATTACACCCCAAGAAAATTGAAGCCTAAGTGATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAA CCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGC CTGACCT pLD14(SEQ ID NO: 160)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGGCAGTCAAACACCTAATAGTTCTCAAATTTAAAGACGAGATTACTGAAGCTCAGAAGGAAGAGTTCTTTAAGACATATGTTAACTTAGTCAACATCATCCCCGCGATGAAGGACGTCTACTGGGGCAAGGATGTGACGCAAAAAAATAAGGAAGAAGGATACACACATATCGTTGAGGTGACCTTTGAGAGTGTGGAAACTATTCAAGATTATATTATTCACCCAGCCCATGTAGGGTTCGGTGACGTTTATCGATCATTCTGGGAAAAGTTGCTTATATTTGATTACACCCCAAGAAAATTGAAGCCTAAGGGAAGACGAGCTAAGTTGTGATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD16 (SEQ ID NO: 161)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGGGAAAAAATTATAAATCTTTGGACTCAGTTGTGGCTAGTGACTTCATTGCACTTGGGATCACATCAGAAGTTGCTGAGACATTGCACGGACGCTTGGCAGAGATAGTTTGCAACTACGGCGCCGCAACACCTCAGACCTGGATTAACATCGCAAACCATATTCTAAGTCCAGATCTTCCATTTAGTCTCCATCAGATGTTGTTCTACGGTTGTTATAAGGACTTTGGTCCAGCACCCCCAGCTTGGATACCAGACCCCGAAAAAGTAAAGTCCACGAACTTAGGTGCCTTGTTAGAAAAGCGGGGAAAGGAGTTTCTAGGCGTTAAGTATAAGGACCCAATAAGTCTGTTTTCTCACTTCCAGGAGTTTAGCGTTCGAAATCCGGAAGTCTACTGGCGGACGGTACTTATGGATGAAATGAAGATACTGTTCAGCAAAGATCCCGAATGTATCCTCAGACGCGACGACATTAACAACCCAGGGGGCTCTGAGTGGCTACCAGGTGGATATCTCAACCTGGCCAAGAACTGTTTGAATGTAAATAGTAACAAAAAACTTAACGACACTATGATAGTGTGGAGAGATGAAGGAAATGACGATCTCCCATTGAATAAATTGACTCTTGATCAATTACGAAAACGAGTCTGGTTGGTTGGATACGCCCTAGAAGAGATGGGCCTTGAGAAGGGATGTGCGATTGCAATTGACATGCCCATGCACGTAGATGCGGTTGTGATCTATTTAGCTATCGTCTTGGCAGGCTACGTCGTTGTCTCCATTGCAGATTCATTCTCAGCACCGGAAATTTCCACAAGATTGCGTCTATCAAAGGCTAAGGCTATTTTTACACAAGATCATATCATCCGAGGGAAAAAGCGTATACCTTTGTACCTGCGTGTCGTCGAGGCCAAGTCTCCGATGGCAATAGTTATCCCGTGTTCGGGTTCAAATATTGGTGCGGAATTGCGGGATGGTGATATTCTGTGGGATTACTTCTTAGAACGCGCAAAGGAATTTAAGAACTGCGAATTTACAGCCCGTGAACAGCCAGTGGACGCGTACACAAATATTTTGTTCTCATCGGGAACCACCGGAGAGCCAAAGGCGATACCATGGACTCAAGCTACGCCTCTCAAGGCGGCTGCTGATGGTTGGTCACACTTGGACATTAGAAAGGGTGACGTAATTGTATGGCCTACCAATTTGGGGTGGATGATGGGGCCTTGGTTGGTCTATGCTTCACTCCTTAACGGGGCAAGCATCGCATTGTATAACGGATCTCCACTAGTGTCCGGCTTTGCCAAATTCGTTCAAGATGCGAAAGTTACTATGCTAGGAGTTGTCCCCTCCATCGTACGAAGCTGGAAAAGCACTAATTGCGTTAGTGGGTACGATTGGTCTACAATCAGATGCTTCTCCTCATCGGGTGAGGCATCGAATGTCGATGAATACTTATGGCTAATGGGAAGGGCTAACTACAAACCGGTCATCGAAATGTGCGGTGGCACAGAGATCGGGGGTGCCTTCAGCGCCGGTTCGTTTTTACAAGCCCAATCTTTGAGTAGCTTCTCATCCCAATGTATGGGATGCACCTTGTACATTCTCGACAAGAATGGCTACCCGATGCCAAAGAACAAGCCGGGTATAGGTGAATTGGCCTTGGGACCCGTGATGTTCGGTGCTTCCAAGACTTTACTTAACGGAAACCATCATGACGTTTATTTCAAAGGCATGCCCACCTTGAACGGAGAAGTCTTGAGGAGACACGGAGATATCTTCGAACTCACTTCGAACGGCTATTATCACGCTCATGGTAGAGCAGATGACACGATGAATATCGGGGGGATTAAAATTTCCTCAATCGAGATTGAAAGGGTGTGTAATGAAGTTGACGATAGAGTGTTTGAGACTACGGCCATTGGAGTGCCTCCATTGGGCGGAGGTCCAGAGCAGCTCGTTATCTTTTTTGTTCTTAAGGACAGCAATGATACGACCATCGACCTAAACCAATTGCGACTTAGTTTTAATCTTGGGTTACAAAAGAAATTGAACCCACTTTTTAAGGTGACGAGGGTTGTGCCACTTTCGCTGTTGCCTAGGACAGCCACCAACAAAATAATGAGAAGAGTGCTTAGACAGCAATTTAGTCATTTCGAGTGATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD20 (SEQ ID NO: 162)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGAAGTGTTCTACGTTTAGTTTTTGGTTTGTTTGTAAAATTATATTCTTCTTTTTTTCCTTCAACATTCAGACATCAATCGCCAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACTGATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCA TTCCGCCTGACCTpLD22 (SEQ ID NO: 163)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGACAGAAGTAGTAGATAGAGCAAGTTCCCCAGCAAGTCCAGGATCTACGACCGCCGCCGCAGACGGTGCTAAGGTGGCGGTGGAGCCACGCGTAGATGTAGCGGCCCTTGGCGAGCAGTTGCTAGGGCGATGGGCTGACATCAGATTGCACGCACGAGACTTAGCAGGCCGCGAAGTGGTCCAAAAGGTTGAAGGACTTACGCACACTGAGCATCGGAGTAGAGTCTTTGGACAGTTGAAGTACTTGGTAGACAACAATGCTGTTCACAGAGCTTTTCCCTCCAGGCTAGGTGGATCAGATGACCATGGCGGTAATATAGCTGGATTCGAGGAATTAGTTACTGCTGATCCATCATTGCAAATAAAGGCCGGCGTTCAGTGGGGTTTGTTTGGTTCTGCAGTGATGCACTTGGGAACCCGTGAACATCATGACAAGTGGTTGCCAGGTATTATGTCGTTAGAAATACCGGGGTGTTTCGCGATGACAGAAACCGGGCACGGTAGCGACGTGGCCTCTATTGCTACAACAGCAACTTATGATGAGGAAACCCAAGAGTTTGTTATTGATACCCCGTTCAGAGCCGCTTGGAAAGATTATATCGGTAATGCAGCGAACGATGGTTTGGCGGCAGTTGTTTTCGCACAATTAATCACGAGGAAAGTGAACCATGGTGTACACGCCTTTTACGTGGATCTCAGAGATCCTGCGACTGGAGACTTCCTACCCGGAATAGGAGGAGAGGACGATGGAATCAAGGGGGGATTGAATGGCATTGACAACGGTAGACTACATTTTACGAACGTACGCATTCCTAGAACTAATCTTCTTAACAGATATGGCGATGTGGCGGTCGACGGCACATACCTGTCGACCATCGAATCACCAGGGCGCCGGTTCTTTACGATGCTTGGTACTCTAGTCCAGGGTAGAGTTAGTCTCGATGGAGCAGCTGTCGCTGCACTGAAGGTCGCATTGCAAAGTGCAATTCACTACGCTGCGGAGAGGAGACAATTTAATGCGACTTCACCTACTGAAGAAGAGGTCCTTCTTGATTATCAGAGGCATCAAAGGAGACTCTTTACACGACTTGCAACGACGTACGCCGCATCTTTCGCCCACGAGCAGCTATTGCAAAAGTTCGATGATGTCTTTTCAGGGGCACATGATACCGACGCCGACCGGCAGGACTTGGAAACCCTAGCCGCCGCTTTGAAGCCATTGAGCACATGGCATGCACTTGACACGTTACAAGAATGCAGAGAGGCCTGTGGGGGGGCCGGATTTTTGATAGAAAACCGTTTCGCGAGCTTGCGTGCTGACTTGGACGTTTACGTCACATTCGAGGGTGATAACACAGTTTTATTGCAATTGGTTGCTAAACGGCTCTTGGCAGACTACGCAAAAGAGTTCAGAGGGGCCAACTTCGGCGTTCTTGCCAGGTATGTGGTTGACCAAGCCGCGGGAGTGGCGCTCCACCGAACAGGACTAAGGCAAGTCGCTCAATTTGTTGCAGACAGCGGGTCCGTTCAGAAGTCGGCTCTTGCGCTTCGCGATGAAGAGGGTCAACGAACATTGTTAACGGACAGAGTACAGAGCATGGTTGCCGAAGTGGGGGCTGCCTTGAAAGGCGCAGGCAAATTACCCCAACATCAAGCAGCTGCATTGTTCAACCAACACCAGAACGAACTTATTGAGGCTGCCCAGGCCCATGCAGAACTCCTCCAATGGGAGGCATTTACAGAAGCTCTCGCTAAAGTCGACGATGCTGGTACAAAGGAAGTGCTTACTCGATTGCGAGATCTCTTTGGTTTGTCCTTGATTGAAAAACACTTGCTGTGGTATCTTATGAATGGACGTTTGTCCATGCAAAGAGGCAGGACAGTTGGAACTTACATTAATCGTTTACTTGTCAAGATCCGTCCACACGCACTAGACTTGGTTGATGCCTTCGGTTACGGCGCGGAGCATTTGCGTGCTGCTATCGCCACCGGAGCGGAAGCAACCCGACAGGATGAAGCCCGAACGTATTTTAGACAACAACGGGCATCGGGACTGGCCCCGGCCGATGAAAAGACCTTACTCGCTATCAAAGCTGGTAAATCAAGAGGGCGAAGGGCAAAGCTATGATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCAT TCCGCCTGACCTpLD24 (SEQ ID NO: 164)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGAATCATTTAAGAGCAGAAGGACCCGCATCAGTGTTAGCGATAGGTACAGCTAACCCAGAGAATATCTTAATCCAAGATGAATTTCCTGACTACTATTTCCGTGTTACTAAATCGGAACATATGACTCAACTTAAAGAGAAGTTCCGGAAAATCTGCGATAAATCCATGATCCGAAAGAGAAACTGTTTCCTTAACGAAGAACATCTCAAGCAAAACCCGAGGTTGGTAGAGCACGAAATGCAGACCTTGGATGCTAGGCAGGACATGTTGGTGGTCGAAGTGCCAAAACTCGGCAAGGACGCGTGCGCTAAGGCAATCAAGGAGTGGGGTCAACCGAAGTCTAAAATCACGCATCTAATATTTACATCTGCACTGACAACCGACATGCCGGGTGCCGATTATCACTGCGCCAAGCTACTTGGATTGAGTCCACTGGTTAAGAGAGTTATGATGTATCAATTGGGGTGTTACGGAGGGGGCACAGTCCTCAGAATTGCTAAGGATATTGCGGAAAATAACAAGGGCGCGAGGGTCCTTGCTGTATGTTGTGATATTATGGCCTGTTTGTTTCGCGGGCCCTCGGATTCAGATTTGGAATTGCTTGTCGGACAGGCAATTTTTGGTGACGGGGCCGCAGCAGTCATAGTGGGAGCCGAACCAGACGAAAGCGTGGGTGAAAGACCAATCTTTGAGTTGGTTCTGACCGGACAAACGATCTTACCTAACTCGGAAGGTACGATTGGAGGACATATTAGAGAAGCCGGCCTAATTTTCGATCTTCACAAAGACGTTCCAATGTTAATCTCCAATAACATAGAAAAGTGCTTGATAGAAGCATTTACTCCCATTGGTATTAGTGACTGGAACAGCATTTTCTGGATCACCCACCCTGGAGGAAAAGCTATACTCGATAAGGTTGAAGAGAAACTCGACTTGAAAAAGGAGAAATTCGTTGACTCACGACATGTGTTATCAGAGCACGGGAATATGAGTTCATCCACAGTCTTGTTCGTAATGGATGAATTGCGAAAACGCTCTCTTGAGGAGGGAAAGAGCACAACCGGTGACGGGTTTGAGTGGGGCGTGCTATTCGGTTTTGGCCCAGGTTTGACTGTCGAGCGGGTTGTTGTTCGTAGTGTACCAATTAAGTACGGAAGAAGGGCAAAGTTGTGATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD56 (SEQ ID NO: 165)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGGGGTTGTCCTTAGTTTGTACGTTCAGTTTCCAAACTAACTACCACACACTACTAAATCCGCACAACAAAAACCCGAAAAATTCATTGCTCTCCTATCAGCACCCAAAAACACCCATTATCAAGTCTAGTTACGACAACTTTCCATCAAAATACTGTCTAACGAAAAACTTTCATTTGTTGGGCTTAAATTCTCATAATCGTATTTCCAGTCAGTCCCGATCGATCAGGGCCGGGAGTGACCAAATTGAAGGTTCTCCACATCATGAAAGTGACAATTCAATTGCTACGAAGATTTTAAACTTTGGGCATACATGCTGGAAGCTACAGCGACCGTATGTAGTTAAGGGGATGATCAGCATTGCCTGCGGCCTATTCGGAAGGGAACTCTTCAATAATAGACATCTTTTTTCTTGGGGTTTAATGTGGAAAGCTTTTTTCGCTTTGGTTCCTATCCTTAGTTTTAACTTCTTCGCCGCTATTATGAATCAAATTTACGATGTTGACATCGACCGTATTAACAAACCCGATCTCCCCCTTGTTTCAGGCGAGATGTCCATTGAAACGGCATGGATTTTGTCCATCATTGTTGCGCTTACTGGCTTGATTGTTACCATTAAGCTTAAAAGCGCTCCCTTGTTCGTTTTTATATACATTTTCGGCATTTTTGCCGGATTCGCATACAGTGTCCCGCCTATACGTTGGAAACAATATCCATTCACGAACTTCTTGATCACGATCTCATCACATGTTGGATTGGCCTTTACGTCCTACAGTGCTACCACATCTGCCCTTGGATTGCCTTTCGTTTGGAGGCCTGCCTTCTCGTTTATCATTGCATTTATGACAGTGATGGGAATGACTATCGCATTTGCTAAAGATATCAGCGACATAGAGGGCGATGCAAAATATGGGGTGAGTACTGTTGCGACGAAGTTGGGCGCCCGAAATATGACCTTCGTTGTTTCCGGCGTTCTTTTACTTAACTATTTAGTATCGATTAGCATCGGGATCATCTGGCCACAGGTGTTTAAATCAAATATTATGATCTTGTCGCATGCCATCCTAGCTTTCTGTCTTATATTTCAAACAAGAGAATTAGCCCTAGCGAACTACGCCTCAGCACCAAGTCGTCAGTTCTTCGAATTTATATGGCTACTCTACTACGCCGAATACTTCGTCTATGTCTTCATTTAGTAATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD87 (SEQ ID NO: 166)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTTTAATTAAGTCGACTTGATGTTTAGAGTGTCCAGATCCGCAAGATCGGCTCGCACTTGTGTTGTGTTGTTTCAAATCAGCCTGTCGTTTTGTGTCGTTTGAGATCATTCTGTCTCACTCTTAGGCTCGCTTAGAACCGACAACGGAGAATCCGGGCTCGGTTTTTCGGTCGGCCTTGATCTGGGCCTTGGACTTGTACTGGTCGGCCATCTCCACGTTGACCAGCTCCTTGACCTTGTAGAGCTGACCGGCGATACCAGGAGACACCTTGTAGTACTTCTGGGAGCCGACCTTGCCCAGACCGAGGGTCTTGAGCACGTCACGTGTTCTCCACGGCATTCGCAGGATAGATCGGACCTGTGTGACTTTGTAGAACATGGCGTTTCAGGTGGTTGCGTGAGTGTGTAAAATCGTGTCTTTCAGAAGTTACAAATTTCACCGCATTTAGAGTTTATGCAGATGGGCGGTGTGTGGTTGGGAGTTCGATTTCCGTGCGTGCATTTGATCTTGATGAATTGGATTTGTACATGGGGAATAGCACGTCAAGAACCGCCTACTGCAAACTCGTGAATATTGAGATTATTGAGGAAATTCAAGGAAAATTCAGATCAGATTTGAGAGCAAAGTCCAACAATACTACACAATCCCTTTCCTGTATTCTTCCACCATCGTCATCGTCGTCTGTCTTCTCTTCAGCTTTTTAATTTCACTCCCCACAAACCCAAATTTAGCTGCATCATTCATCAACCTCCAATTATAACTATACATCGCGACACGAACACGAAACACGAACCACGAACCGCCGCTTTGTCGACGGAGTGAGACGGGAGAGAGACCATGGTCTCTCGCTCGTCTCACGCTTAGCGGCCGCGTCGACATAACTTCGTATAGCATACATTATACGAAGTTATTTTCTAATTTGGACCGATAGCCGTATAGTCCAGTCTATCTATAAGTTCAACTAACTCGTAACTATTACCATAACATATACTTCACTGCCCCAGATAAGGTTCCGATAAAAAGTTGTGCAGACTAAATTTATTTCAGTCTCCTCTTCACCACCAAAATGCCCTCCTACGAAGCGCGAGCTAACGTCCACAAGTCCGCCTTTGCCGCCCGAGTGCTCAAGCTCGTGGCAGCCAAGAAAACCAACCTGTGTGCTTCTCTGGATGTTACCACCACCAAGGAGCTCATTGAGCTTGCCGATAAGGTCGGACCTTATGTGTGCATGATCAAGACCCATATCGACATCATTGACGACTTCACCTACGCCGGAACTGTGCTCCCCCTCAAGGAACTTGCTCTTAAGCACGGTTTCTTCCTGTTCGAGGACAGAAAGTTCGCAGATATTGGCAACACTGTCAAGCACCAGTACAAGAACGGTGTCTACCGAATCGCCGAGTGGTCCGATATCACCAACGCCCACGGTGTACCCGGAACCGGAATCATTGCTGGCCTGCGAGCTGGTGCCGAGGAAACTGTCTCTGAACAGAAGAAGGAGGATGTCTCTGACTACGAGAACTCCCAGTACAAGGAGTTCCTGGTCCCCTCTCCCAACGAGAAGCTGGCCAGAGGTCTGCTCATGCTGGCCGAGCTGTCTTGCAAGGGCTCTCTGGCCACTGGCGAGTACTCCAAGCAGACCATTGAGCTTGCCCGATCCGACCCCGAGTTTGTGGTTGGCTTCATTGCCCAGAACCGACCTAAGGGCGACTCTGAGGACTGGCTTATTCTGACCCCCGGGGTGGGTCTTGACGACAAGGGAGATGCTCTCGGACAGCAGTACCGAACTGTTGAGGATGTCATGTCTACCGGAACGGATATCATAATTGTCGGCCGAGGTCTGTACGGCCAGAACCGAGATCCTATTGAGGAGGCCAAGCGATACCAGAAGGCTGGCTGGGAGGCTTACCAGAAGATTAACTGTTAGAGGTTAGACTATGGATATGTCATTTAACTGTGTATATAGAGAGCGTGCAAGTATGGAGCGCTTGTTCAGCTTGTATGATGGTCAGACGACCTGTCTGATCGAGTATGTATGATACTGCACAACCTGATAACTTCGTATAGCATACATTATACGAAGTTATCTCGAGGGATCCCTAGGGAGGCACATCTAAACGAATAACGAATATTAATGATACCATCATATCTCAGAACATGTATGACTGCTGCTTCCAAACGATATGAGGATGAGTCCTCTTTCAGATTAAGATAGAGTACAAATATATTATCTATATACTGGTGTCTGTGCGATGTCGTATGAGCGGTGAATCATGTGACTGTCACGTGGTTTGGCCCAAGTTACACCGTAGCTACGCCTTTCTTGACCGACTCCATGGTCTTCTGGGCGGGTTGACAGTTTCCACTGGATGAGCGTCCGCCTCCTGTTCCTGTCGTTGTCCCTGCAGCTCAGCCTCAATCTTCTGACCGAGCTCGGAGTCCAGGGAAATGCCAACAGGTTGTCCAAGCAACATCATGGTTTGGTGGGCAGCCGTGATCTCATCGTCGTTGGATACCATTCGGTACTTGGCCTCAATCTGCACAAAGTAGCGGTACCACTGGTTTCGAGCAAACCGCTCCAATTGAGCCTCTCCGTCGAGAGAGAGAGTAGGTGATTGCTCCAACTTGCGGCCAAAATGAAGTTCTCGACTCACCTTTTTGAAGCGGTTCTTCTTGCCCATCTTGGTGGCGAAAGTAGTGGCTAGTGGTGGATGACTTTGTATAATGTACCGATGAAGAGGGTTGTATTTGCTCAGTAAGAAGTAGCGAGTGAAATCAGATCACTTAACGAGAGCAAAGGGCAATGGAATACCTGCTGCCTGATTAACAACAGCTTCTGTGTCGTTTCTCTCTTGTGAATGAGTGTGTTGCTAGAGGTAGGTTGGCACTCCAATGTTA CTTAATTAApLD101 (SEQ ID NO: 167)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCTCGTGATACCAATTCGGAGCCTGCTTTTTTGTACAAACTTGTTGATAATGGCAATTCAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAGCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTTTAATTAACGATCCGCGTAAATTCAGAGCAATGCCAAGATCCTTATTTCCGATAACAGCGAGATACACATCAGAAGAGGTGGAGACTCTGGCCCCGCACGACCACCACGTCGTCACTCAAAGCAAAGTCACGATGTAGAAATCACAATCGTCCCCATAAGCACGTGGATTCCCCTGGTTTTGTTTCGGCCTCGGCAGTGGCAATTCTGGGGTATATAAACCAGCAAGGTTATGACCTGATTGACCTGCTTGTGGCCTGATAAACCGCCTGACTTTTGTGATAAGGTTGGGAGCATGCGGCTCGGGCCATTGTGAGCATTTTCGTCAAGGACTGGCCAAGTCCAACTGGAAGAGACATGGGCAAAATGTCGACTTTACAGATGTACCCGAAATTGCTTCAATTGCTCTCAGCTGCCGGAACCGGATCTATCGGTGCAAGTATCGTACAGTAGACATGTGCTATTGGTAACCCTCGGTATTGGCTAGGTTTCGTATCAGGGATACAGTTCAACGCTGATCGCATATGGCATGATTCCGGCTCGACACAGCGACCAAGAACCAAGCGTGTATGTCGTAGACTTGCAAATCATGTGGGGCTTATCCCCGGATTTCCCCAAGTCACGTTTTCACAAAGGCTGTCTCCCGAATGCATGAGCCGAGGCAGGCTAAACTGGTTTGTTCATGTACCCCACACAACGTAAAGATGCACCCCATGTGCAGTGAAATACCACAAGTATATATATACCGACCTACCCGAGATAGCAAATTGATTCTACACTTACACTACCAATTCTTACATCAAACCAAACCGCTTGAGACCATCCGGTCTCTGATCATCCTCGAGATAACTTCGTATAATGTATGCTATACGAAGTTATCAGGTTGTGCAGTATCATACATACTCGATCAGACAGGTCGTCTGACCATCATACAAGCTGAACAAGCGCTCCATACTTGCACGCTCTCTATATACACAGTTAAATGACATATCCATAGTCTAACCTCTAACAGTTAATCTTCTGGTAAGCCTCCCAGCCAGCCTTCTGGTATCGCTTGGCCTCCTCAATAGGATCTCGGTTCTGGCCGTACAGACCTCGGCCGACAATTATGATATCCGTTCCGGTAGACATGACATCCTCAACAGTTCGGTACTGCTGTCCGAGAGCATCTCCCTTGTCGTCAAGACCCACCCCGGGGGTCAGAATAAGCCAGTCCTCAGAGTCGCCCTTAGGTCGGTTCTGGGCAATGAAGCCAACCACAAACTCGGGGTCGGATCGGGCAAGCTCAATGGTCTGCTTGGAGTACTCGCCAGTGGCCAGAGAGCCCTTGCAAGACAGCTCGGCCAGCATGAGCAGACCTCTGGCCAGCTTCTCGTTGGGAGAGGGGACCAGGAACTCCTTGTACTGGGAGTTCTCGTAGTCAGAGACATCCTCCTTCTTCTGTTCAGAGACAGTTTCCTCGGCACCAGCTCGCAGGCCAGCAATGATTCCGGTTCCGGGTACACCGTGGGCGTTGGTGATATCGGACCACTCGGCGATTCGGTAGACACCGTTCTTGTACTGGTGCTTGACAGTGTTGCCAATATCTGCGAACTTTCTGTCCTCGAACAGGAAGAAACCGTGCTTAAGAGCAAGTTCCTTGAGGGGGAGCACAGTTCCGGCGTAGGTGAAGTCGTCAATGATGTCGATATGGGTCTTGATCATGCACACATAAGGTCCGACCTTATCGGCAAGCTCAATGAGCTCCTTGGTGGTGGTAACATCCAGAGAAGCACACAGGTTGGTTTTCTTGGCTGCCACGAGCTTGAGCACTCGGGCGGCAAAGGCGGACTTGTGGACGTTAGCTCGCGCTTCGTAGGAGGGCATTTTGGTGGTGAAGAGGAGACTGAAATAAATTTAGTCTGCACAACTTTTTATCGGAACCTTATCTGGGGCAGTGAAGTATATGTTATGGTAATAGTTACGAGTTAGTTGAACTTATAGATAGACTGGACTATACGGCTATCGGTCCAAATTAGAAAATAACTTCGTATAATGTATGCTATACGAAGTTATGTCGACGCGGCCGCACAAGCACTACATGGACGAGGTCAAGGCTGCCAACAACCCTCGTAACACCCATGCTCCTTACTACGAGACAAAGCTGCGACCCTTCCTGTTCCGACCCGATGAGGACGAGGAGATTTGCGACCTGGACGAGTAGGTTGTTGTAATACTATGATTTATTGTGTTTATATGTTATTGATACTATTGAAAGAGTTATTGTGTAATTTTAGATGCTGTATGTTAACTAGAAGCTCAGATTCTACAAAGAGATCCTCAGATCTGAGGAATGATCTACGTTCTGCAATAGAAGGGACAACTGCAGCTCTGAATGACCACAAAAAGAATACACCACAAGCAGTTGTAACTGAGCTATTAGCCTTGCTTTCGCACCATTCGCTTTTCTGGATGGTAGCCCTTTACTACAAGTAGCTAATATGGAATGTACATTACCGTCTCATTACAATATGTATATGCAAGTTCATGGCACTTCATGCACACCAGCCCCTTCGTTAAGTACCTTCCAAAAAGTGATCAATGATAAGTGATATATCTAATTTAGAGATCTGGACACACGAACAAGTCGGGAACACAAATCCCGAGATGATTGCCTGCTCAGAGGAGTCCAATTAGTCTTTACACCATTCGTGCTAATGAAGGGCACAGAATATTCCACTTTGAAAGTTTAAGATTAAGCTCGGCTCGCAATTATGCATGAAAAATATGTAGGGAGAGAACGATCCCACGAGTTCTGTTTGGTTGCGAGAGTGTTCGGGTTTTCTCCTAAAAAGAATAGGGGAGGGAAAAATTATCGCCTAAGTCACCATTAATTAA pLD102 (SEQ ID NO: 168)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCTCGTGATACCAATTCGGAGCCTGCTTTTTTGTACAAACTTGTTGATAATGGCAATTCAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAGCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTTTAATTAATTGGCAAATTTTACTGTGGCCTTCAGAACGGTAAAAATAGACCAATCAGAATTCTGAAAAGCACATCTTGATCTCCTCATTGCGGGGAGTCCAACGGTGGTCTTATTCCCCCGAATTTCCCGCTCAATCTCGTTCCAGACCGACCCGGACACAGTGCTTAACGCCGTTCCGAAACTCTACCGCAGATATGCTCCAACGGACTGGGCTGCATAGATGTGATCCTCGGCTTGGAGAAATGGATAAAAGCCGGCCAAAAAAAAAGCGGAAAAAAGCGGAAAAAAAGAGAAAAAAAATCGCAAAATTTGAAAAATAGGGGGAAAAGACGCAAAAACGCAAGGAGGGGGGAGTATATGACACTGATAAGCAAGCTCACAACGGTTCCTCTTATTTTTTTCCTCATCTTCTGCCTAGGTTCCCAAAATCCCAGATGCTTCTCTCCAGTGCCAAAAGTAAGTACCCCACAGGTTTTCGGCCGAAAATTCCACGTGCAGCAACGTCGTGTGGGGTGTTAAAATGTGGGGGCGGGGAACCAGGACAAGAGGCTCTTGTGGGAGCCGAATGAGAGCACAAAGCGGGCGGGTGTGATAAGGGCATTTTTGCCCATTTTCCCTTCTCCTGTCTCTCCGACGGTGATGGCGTTGTGCGTCCTCTATCTATTTCTTTTTATTTCTTTTTGTTTTATTTCTCTGACTACCGATTTGGCTTGATTTCCTCAACCCCACACAAATAAGCTCGGGCCGAGGAATATATATATACACGGACACAGTCGCCCTGTGGACAACACGTCACTACCTCTACGACGCTTGAGACCATCCGGTCTCTGATCATCCTCGAGATAACTTCGTATAATGTATGCTATACGAAGTTATCAGGTTGTGCAGTATCATACATACTCGATCAGACAGGTCGTCTGACCATCATACAAGCTGAACAAGCGCTCCATACTTGCACGCTCTCTATATACACAGTTAAATGACATATCCATAGTCTAACCTCTAACAGTTAATCTTCTGGTAAGCCTCCCAGCCAGCCTTCTGGTATCGCTTGGCCTCCTCAATAGGATCTCGGTTCTGGCCGTACAGACCTCGGCCGACAATTATGATATCCGTTCCGGTAGACATGACATCCTCAACAGTTCGGTACTGCTGTCCGAGAGCATCTCCCTTGTCGTCAAGACCCACCCCGGGGGTCAGAATAAGCCAGTCCTCAGAGTCGCCCTTAGGTCGGTTCTGGGCAATGAAGCCAACCACAAACTCGGGGTCGGATCGGGCAAGCTCAATGGTCTGCTTGGAGTACTCGCCAGTGGCCAGAGAGCCCTTGCAAGACAGCTCGGCCAGCATGAGCAGACCTCTGGCCAGCTTCTCGTTGGGAGAGGGGACCAGGAACTCCTTGTACTGGGAGTTCTCGTAGTCAGAGACATCCTCCTTCTTCTGTTCAGAGACAGTTTCCTCGGCACCAGCTCGCAGGCCAGCAATGATTCCGGTTCCGGGTACACCGTGGGCGTTGGTGATATCGGACCACTCGGCGATTCGGTAGACACCGTTCTTGTACTGGTGCTTGACAGTGTTGCCAATATCTGCGAACTTTCTGTCCTCGAACAGGAAGAAACCGTGCTTAAGAGCAAGTTCCTTGAGGGGGAGCACAGTTCCGGCGTAGGTGAAGTCGTCAATGATGTCGATATGGGTCTTGATCATGCACACATAAGGTCCGACCTTATCGGCAAGCTCAATGAGCTCCTTGGTGGTGGTAACATCCAGAGAAGCACACAGGTTGGTTTTCTTGGCTGCCACGAGCTTGAGCACTCGGGCGGCAAAGGCGGACTTGTGGACGTTAGCTCGCGCTTCGTAGGAGGGCATTTTGGTGGTGAAGAGGAGACTGAAATAAATTTAGTCTGCACAACTTTTTATCGGAACCTTATCTGGGGCAGTGAAGTATATGTTATGGTAATAGTTACGAGTTAGTTGAACTTATAGATAGACTGGACTATACGGCTATCGGTCCAAATTAGAAAATAACTTCGTATAATGTATGCTATACGAAGTTATGTCGACGCGGCCGCATGGAGCGTGTGTTCTGAGTCGATGTTTTCTATGGAGTTGTGAGTGTTAGTAGACATGATGGGTTTATATATGATGAATGAATAGATGTGATTTTGATTTGCACGATGGAATTGAGAACTTTGTAAACGTACATGGGAATGTATGAATGTGGGGGTTTTGTGACTGGATAACTGACGGTCAGTGGACGCCGTTGTTCAAATATCCAAGAGATGCGAGAAACTTTGGGTCAAGTGAACATGTCCTCTCTGTTCAAGTAAACCATCAACTATGGGTAGTATATTTAGTAAGGACAAGAGTTGAGATTCTTTGGAGTCCTAGAAACGTATTTTCGCGTTCCAAGATCAAATTAGTAGAGTAATACGGGCACGGGAATCCATTCATAGTCTCAATTTTCCCATAGGTGTGCTACAAGGTGTTGAGATGTGGTACAGTACCACCATGATTCGAGGTAAAGAGCCCAGAAGTCATTGATGAGGTCAAGAAATACACAGATCTACAGCTCAATACAATGAATATCTTCTTTCATATTCTTCAGGTGACACCAAGGGTGTCTATTTTCCCCAGAAATGCGTGAAAAGGCGCGTGTGTAGCGTGGAGTATGGGTTCGGTTGGCGTATCCTTCATATATCGACGAAATAGTAGGGCAAGAGATGACAAAAAGTATCTATATGTAGACAGCGTAGAATATGGATTTGATTGGTATAAATTCATTTATTGCGTGTCTCACAAATACTCTCGATAAGTTGGGGTTAAACTGGAGATGGAACAATGTCGATATCTCGACATATTTTGATATTTGTTAATTAA pLD111 (SEQ ID NO: 169)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGAATTGTTCAGCATTTAGTTTTTGGTTTGTTTGTAAGATTATTTTCTTCTTTTTGTCATTTAACATTCAAATTTCAATTGCAAACCCACAAGAAAACTTTTTGAAGTGTTTTTCAGAATACATTCCAAACAATCCAGCTAACCCAAAGTTTATTTACACACAACATGATCAATTGTACATGTCAGTTTTGAACTCAACAATTCAAAACTTGAGATTTACATCAGATACCACACCAAAGCCATTGGTTATTGTTACACCATCAAACGTTTCCCATATTCAAGCATCAATCTTGTGTTCAAAGAAGGTTGGATTGCAAATTAGAACCAGATCAGGAGGACACGATGCAGAAGGAATGTCATACATTTCACAAGTTCCATTCGTTGTTGTTGATTTGAGAAACATGCACTCAATTAAGATTGATGTTCATTCACAAACAGCATGGGTTGAAGCAGGAGCAACATTGGGTGAAGTTTACTACTGGATTAACGAAAAGAACGAAAACTTCAGTTTTCCAGGAGGTTACTGTCCAACAGTTGGAGTTGGAGGACATTTTTCAGGTGGAGGATACGGAGCATTGATGAGAAACTACGGATTGGCAGCAGATAACATTATTGATGCACACTTGGTTAACGTTGATGGAAAGGTTTTGGATAGAAAGTCAATGGGAGAAGATTTGTTTTGGGCAATTAGAGGAGGTGGTGGAGAGAACTTTGGAATTATTGCAGCATGGAAGATCAAGTTGGTTGCAGTTCCATCAAAGTCAACAATCTTTTCAGTTAAGAAGAACATGGAAATTCATGGTTTGGTTAAGTTGTTTAACAAGTGGCAAAACATTGCATACAAGTACGATAAGGATTTGGTTTTGATGACACATTTTATTACAAAGAACATTACAGATAACCATGGAAAGAACAAGACAACAGTTCACGGATACTTTTCATCAATTTTTCACGGAGGAGTTGATTCATTGGTTGACTTGATGAACAAGTCATTTCCAGAATTGGGAATCAAGAAGACAGATTGTAAGGAATTTTCATGGATTGATACAACAATTTTCTACTCAGGAGTTGTTAACTTTAACACAGCAAACTTTAAGAAGGAAATTTTGTTGGACAGATCAGCAGGAAAGAAGACCGCATTTTCCATTAAGTTGGATTACGTTAAGAAACCAATTCCAGAAACAGCAATGGTTAAGATTTTGGAAAAGTTGTACGAAGAAGATGTTGGTGTTGGAATGTACGTTTTGTACCCATACGGAGGAATTATGGAAGAAATCTCAGAATCAGCAATTCCATTTCCACATAGAGCAGGTATTATGTACGAATTGTGGTACACAGCATCATGGGAAAAGCAAGAAGATAATGAAAAGCATATTAACTGGGTTAGATCAGTTTACAACTTTACAACACCATACGTTTCACAAAACCCAAGATTGGCATACTTGAACTACAGAGATTTGGATTTGGGAAAGACAAACCCAGAATCACCAAACAACTATACACAAGCTAGAATTTGGGGAGAAAAGTACTTTGGTAAGAACTTCAACAGATTGGTTAAAGTTAAGACAAAGGCAGATCCAAATAACTTCTTTAGAAACGAACAATCAATTCCACCATTGCCACCACATCATCATTAATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD112 (SEQ ID NO: 170)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGAATTGTAGCACTTTCTCATTCTGGTTTGTTTGTAAGATTATTTTCTTTTTCTTGTCATTTAACATTCAAATTTCAATTGCAAACCCACAAGAGAACTTTTTGAAGTGTTTCTCAGAATACATTCCAAACAACCCAGCTAACCCAAAGTTTATTTACACCCAACACGATCAATTGTACATGTCAGTTTTGAACTCAACAATTCAAAACTTGAGATTTACATCAGATACAACACCAAAGCCATTGGTTATTGTTACACCATCAAACGTTAGTCATATTCAAGCATCAATCTTGTGTTCAAAGAAGGTTGGATTGCAAATTAGAACTAGATCAGGAGGACATGATGCAGAAGGATTGTCATACATTTCACAAGTTCCATTTGCAATTGTTGATTTGAGAAACATGCACACAGTTAAGGTTGATATTCATTCACAAACAGCATGGGTTGAAGCAGGAGCAACATTGGGTGAAGTTTACTACTGGATTAACGAAATGAACGAAAACTTCTCATTTCCAGGAGGATACTGTCCAACAGTTGGTGTTGGAGGACACTTTTCAGGTGGTGGATACGGAGCATTGATGAGAAACTACGGATTGGCAGCAGATAACATTATTGATGCACATTTGGTTAACGTTGATGGAAAGGTTTTGGATAGAAAGTCAATGGGAGAAGATTTGTTTTGGGCAATTAGAGGAGGTGGAGGAGAAAACTTTGGAATCATTGCAGCATGTAAGATCAAGTTGGTTGTTGTTCCATCAAAGGCAACAATCTTTTCAGTTAAGAAGAACATGGAAATCCATGGATTGGTTAAGTTGTTTAACAAGTGGCAAAACATTGCATACAAGTACGATAAGGATTTGATGTTGACAACACATTTTAGAACAAGAAACATTACAGATAACCACGGAAAGAATAAGACAACAGTTCATGGATACTTTTCATCAATTTTCTTGGGAGGAGTTGATTCATTGGTTGACTTGATGAACAAGAGTTTTCCAGAATTGGGAATCAAGAAGACAGATTGTAAGGAATTGTCATGGATCGATACAACCATTTTCTACTCAGGAGTTGTTAACTACAACACAGCTAACTTTAAGAAGGAAATTTTGTTGGACAGATCAGCAGGTAAAAAGACAGCATTTTCAATTAAGTTGGATTACGTTAAGAAATTGATTCCAGAAACAGCAATGGTTAAGATTTTGGAAAAGTTGTACGAAGAAGAAGTTGGAGTTGGAATGTACGTTTTGTACCCATACGGAGGAATTATGGATGAAATTTCAGAATCAGCAATTCCATTTCCACATAGAGCAGGTATTATGTACGAATTGTGGTACACAGCAACATGGGAAAAGCAAGAAGATAACGAAAAGCATATTAACTGGGTTAGATCAGTTTACAACTTTACAACCCCATACGTTTCACAAAACCCAAGATTGGCATACTTGAACTACAGAGATTTGGATTTGGGAAAGACAAACCCAGAATCACCAAATAACTACACACAAGCTAGAATTTGGGGAGAAAAGTACTTTGGTAAGAACTTTAACAGATTGGTGAAGGTTAAGACAAAGGCAGACCCAAACAATTTCTTTAGAAACGAACAATCAATTCCACCATTGCCACCAAGACATCATTAATAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD113 (SEQ ID NO: 171)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTGATCCCAATATTACACCCAAGTAGCATGCATAAGCTAAAAGTAACTCGCAGCGCACACCGTGCAGATTCATAAGTCTATGATTAATTGAACGCCAATAACCCGGCTTACTACAAGTACAAGTAGGTATACATAGCGGTAATGAATCATTAGAAAAATAAAAAACAAAAAAAAACAAAACAAACTGTTGTGGATGCATCAACAGTAGTACATAGTTGTACGATGTACTTGTACTTGTAAAAGCAAAAATGTACAATATCTCAGGGAGCGCAACTTTTACGTTCGAAGAACAATGTACCGCATACCGCATTCTAGATTCTGCGGAACGTCTAACCTGGAAATACGATTTTTTATTTCTTTCATTTTTTTTGCTTCTTCAAAAGTATGGTAATTTCCTACCATTACAGTTGACACTGAACGAGGGGGGATTGAATTTAAGCAAAAAATTAAATCAAAATACCTTTATGTATCCAGCCCATGTAATAAACAAAAGGATTATATAACAAGAAATAAATATATACCTTTAATGGATCATTAGAATAAAAATAAATACGAGAAGCACACCAGAGAAGCTTTTTGATTGCCACTATACCGCTACTTTGGTATATCTTATTATAATTGTTGAATTTGCAAGATAGAATGTCATTCATTGGAGAGAAATCCAAGGAATATGTGGGATGAAATGACTAGAAGTATGAACAATGAGAATAGTACATACTTGTACCTGTATTTCTAGAAGAGAGAAAGACAGTTGAGTGTGTGATTCTCGTCCAATAATAATCTCAATAGTAACGTGTGAATAGCTGTTCTTTGATAGTTGATATTTCTCGATGACTATTTATGTTGTACAAGGGATTTTTTTCGTTGCTGTTGATTTCGAATTAGGCAATGCAGATATCATTTATGCTATCCATATTTAAGATTTCCCATACGCATTTATAACATTTATTCTACATAAATTGTTAAATGAACGAACTGCCATTATAAATTGTTTCCTAAATAGGAAGTGTTTTTCATAAAGCAAGTAAGTTGTCTAATAATACTAAGTAATAAAAATAAGTTCATACAATATATTTTGAGAACATCATTTGGAGGCGGTAGATGGAGTCTGTTTATTATTAAACAATGCGAGATGACCCCTTAAATATTGAGAACATCAGTTGGAGGCGGCAGATGGAGTCTGTCTATTTAGCAATGGGACATGACTGTCAGTATCATCATATGTATATATATAATACATATAATATTATATAACACGATTTTTTTAAATTATTGGCCCGAAAATTAATCAGTGTAGACTGGATCCTCGAGAACCATTTAATTAACAAGTCGAGAACGTACCACTGTCCTCCACTACAAACACACCCAATCTGCTTCTTCTAGTCAAGGTTGCTACACCGGTAAATTATAAATCATCATTTCATTAGCAGGGCTGGGCCCTTTTTATAGAGTCTTATACACTAGCGGACCCTGCCGGTAGACCAACCCGCAGGCGCGTCAGTTTGCTCCTTCCATCAATGCGTCGTAGAAACGACTTACTCCTTCTTGAGCAGCTCCTTGACCTTGTTGGCAACAAAGTCTCCGACCTCGGAGGTGGAGGAGGAGCCTCCGATATCGGCGGTAGTGATACCAGCCTCGACGGACTCCTTGACGGCAGCCTCAACAGCGTCACCGGCGGGCTTCATGTTAAGAGAGAACTTGAGCATCATGGCGGCAGACAGAATGGTGGCAATGGGGTTGACCTTCTGCTTGCCGAGATCGGGGGCAGATCCGTGACAGGGCTCGTACAGACCGAACGCCTCGTTGGTGTCGGGCAGAGAAGCCAGAGAGGCGGAGGGCAGCAGACCCAGAGAACCGGGGATGACGGAGGCCTCGTCGGAGATGATATCGCCAAACATGTTGGTGGTGATGATGATACCATTCATCTTGGAGGGCTGCTTGATGAGGATCATGGCGGCCGAGTCGATCAGCTGGTGGTTGAGCTCCAGCTGGGGGAATTCGTCCTTGAGGACTCGGGTGACGGTCTTTCGCCAAAGTCGAGAGGAGGCCAGCACGTTGGCCTTGTCAAGGGACCACACGGGAAGAGGGGGGTTGTGCTGAAGGGCCAGGAAGGCGGCCATTCGGGCAATTCGCTCAACCTCAGGAACGGAGTAAGTCTCAGTGTCGGAAGCGACGCCAGATCCGTCATCCTCCTTTCGCTCTCCAAAGTAGATACCTCCGACGAGCTCTCGGACAATGATGAAGTCGGTGCCCTCAACGTTTCGGATGGGGGAGAGATCGGCGAGCTTGGGCGACAGCAGCTGGCAGGGTCGCAGGTTGGCGTACAGGTTCAGGTCCTTTCGCAGCTTGAGAAGACCCTGCTCGGGTCGCACGTCGGTTCGTCCGTCGGGAGTGGTCCATACGGTGTTGGCAGCGCCTCCGACAGCACCGAGCATAATAGAGTCAGCCTTTCGGCAGATGTCGAGAGTAGCGTCGGTGATGGGCTCGCCCTCCTTCTCAATGGCAGCTCCTCCAATGAGTCGGTCCTCAAACACAAACTCGGTGCCGGAGGCCTCAGCAACAGACTTGAGCACCTTGACGGCCTCGGCAATCACCTCGGGGCCACAGAAGTCGCCGCCGAGAAGAACAATCTTCTTGGAGTCAGTCTTGGTCTTCTTAGTTTCGGGTTCCATTGTGGATGTGTGTGGTTGTATGTGTGATGTGGTGTGTGGAGTGAAAATCTGTGGCTGGCAAACGCTCTTGTATATATACGCACTTTTGCCCGTGCTATGTGGAAGACTAAACCTCCGAAGATTGTGACTCAGGTAGTGCGGTATCGGCTAGGGACCCAAACCTTGTCGATGCCGATAGCGCTATCGAACGTACCCCAGCCGGCCGGGAGTATGTCGGAGGGGACATACGAGATCGTCAAGGGTTTGTGGCCAACTGGTAAATAAATGATGACTCAGGCGACGACGGAATTCGACAGCAACTACTCCTTTCACCAACCATGTGCATTTTAGCTCGAATAACATTCACAGGCTTGGTGATCTACATCCATGGTGTCTGGCCGATTACCGTGGTGTTTTGGCAGTAACGAGAATATTGAGTGAACTCTTCCCATCACCAATAAAGACTCATACTACAATCACGAGCGCTTCAGCTGCCACTATAGTGTTGGTGACACAATACCCCTCGATGCTGGGCATTACTGTAGCAAGAGATATTATTTCATGGCGCATTTTCCAGTCTACCTGACTTTTTAGTGTGATTTCTTCTCCACATTTTATGCTCAGTGTGAAAAGTTGGAGTGCACACTTAATTATCGCCGGTTTTCGGAAAGTACTATGTGCTCAAGGTTGCACCCCACGTTACGTATGCAGCACATTGAGCAGCCTTTGGACCGTGGAGATAACGGTGTGGAGATAGCAACGGGTAGTCTTCGTATTAATTCAATGCATTGTTAGTTTTATATGATATGGTGTCGAGCGGCCGCGACCGGGTTGGCGGCGCATTTGTGTCCCAAAAAACAGCCCCAATTGCCCCAATTGACCCCAAATTGACCCAGTAGCGGGCCCAACCCCGGCGAGAGCCCCCTTCTCCCCACATATCAAACCTCCCCCGGTTCCCACACTTGCCGTTAAGGGCGTAGGGTACTGCAGTCTGGAATCTACGCTTGTTCAGACTTTGTACTAGTTTCTTTGTCTGGCCATCCGGGTAACCCATGCCGGACGCAAAATAGACTACTGAAAATTTTTTTGCTTTGTGGTTGGGACTTTAGCCAAGGGTATAAAAGACCACCGTCCCCGAATTACCTTTCCTCTTCTTTTCTCTCTCTCCTTGTCAACTCACACCCGAAATCGTTAAGCATTTCCTTCTGAGTATAAGAATCATTCAAAATGTCCAACCTCCTCACCGTCCACCAGAACCTTCCCGCCCTTCCCGTGGACGCCACCTCCGACGAGGTCCGAAAGAACCTCATGGACATGTTCCGAGATCGACAGGCCTTCTCCGAGCACACTTGGAAGATGCTCCTCTCCGTCTGCCGATCCTGGGCCGCCTGGTGCAAGCTCAACAACCGAAAGTGGTTCCCCGCCGAGCCCGAGGACGTCCGAGACTACCTCCTTTACCTCCAGGCCCGAGGCCTCGCCGTCAAGACCATCCAGCAGCACCTCGGCCAGCTCAACATGCTCCACCGACGATCCGGCCTCCCCCGACCCTCCGACTCCAACGCCGTGTCCCTCGTCATGCGACGAATCCGAAAGGAGAACGTGGACGCCGGCGAGCGAGCCAAGCAGGCCCTTGCCTTCGAGCGAACCGACTTCGACCAGGTCCGATCCCTCATGGAGAACTCCGACCGATGCCAGGACATCCGAAACCTCGCCTTCCTTGGCATCGCCTACAACACCCTCCTTCGAATCGCCGAGATCGCCCGAATCCGAGTCAAGGACATCTCCCGAACCGACGGCGGCCGAATGCTCATCCACATCGGCCGAACCAAGACCCTCGTGTCCACCGCCGGCGTCGAGAAGGCCCTCTCCCTCGGCGTCACCAAGCTCGTCGAGCGATGGATCTCCGTGTCCGGCGTCGCTGACGACCCCAACAACTACCTCTTCTGCCGAGTCCGAAAGAACGGCGTCGCTGCTCCCTCCGCCACCTCCCAGCTCTCCACCCGAGCCCTTGAGGGCATCTTCGAGGCCACCCACCGACTCATCTACGGCGCCAAGGACGACTCCGGCCAGCGATACCTCGCCTGGTCCGGCCACTCTGCTCGAGTCGGTGCCGCCCGAGACATGGCCCGAGCCGGTGTCTCCATCCCCGAGATCATGCAGGCCGGCGGCTGGACCAACGTCAACATCGTCATGAACTACATCCGAAACCTCGACTCCGAGACTGGCGCCATGGTCCGACTTCTTGAGGACGGCGACTGATGATCATATGATTACATTAATAGCTAATTACGTGTATCCGATATATATACTAATTACAATAGTACATATTAGAACATACAATA GTTTTAATTAApLD125 (SEQ ID NO: 172)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACATAATGTTCTTGAAACACATTTTTGTTGCTCTCGCTTTTGCCTTGTTAGCTGACGCTACCCCAGCCCAGAAGAGATCTCCCGGCTTCGTTGCTTTAGACTTTGACATCGTCAAGGTTCAAAAGAACGTGACTGCCAACGACGACGCCGCTGCCATTGTTGCCAAGAGACAGACCAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACTGAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD127 (SEQ ID NO: 173)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGCAATTGTCCTTGTCGGTTTTATCAACCGTTGCCACGGCCTTGTTGTCCCTAACCACCGCCGTCGATGCTAAGTCCCACAACATCAAGTTGTCCAAGTTGTCCAACGAAGAAACATTGGACGCCTCCACATTCCAAGAATACACGAGCTCCTTGGCCAACAAGTACATGAACTTGTTCAACGCCGCTCACGGTAACCCAACCAGCTTTGGCTTGCAACACGTCTTGTCCAACCAAGAAGCTGAAGTCCCATTCGTTACCCCACAAAAGGGTggcAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACTGAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT pLD131 (SEQ ID NO: 174)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTGATCCCAATATTACACCCAAGTAGCATGCATAAGCTAAAAGTAACTCGCAGCGCACACCGTGCAGATTCATAAGTCTATGATTAATTGAACGCCAATAACCCGGCTTACTACAAGTACAAGTAGGTATACATAGCGGTAATGAATCATTAGAAAAATAAAAAACAAAAAAAAACAAAACAAACTGTTGTGGATGCATCAACAGTAGTACATAGTTGTACGATGTACTTGTACTTGTAAAAGCAAAAATGTACAATATCTCAGGGAGCGCAACTTTTACGTTCGAAGAACAATGTACCGCATACCGCATTCTAGATTCTGCGGAACGTCTAACCTGGAAATACGATTTTTTATTTCTTTCATTTTTTTTGCTTCTTCAAAAGTATGGTAATTTCCTACCATTACAGTTGACACTGAACGAGGGGGGATTGAATTTAAGCAAAAAATTAAATCAAAATACCTTTATGTATCCAGCCCATGTAATAAACAAAAGGATTATATAACAAGAAATAAATATATACCTTTAATGGATCATTAGAATAAAAATAAATACGAGAAGCACACCAGAGAAGCTTTTTGATTGCCACTATACCGCTACTTTGGTATATCTTATTATAATTGTTGAATTTGCAAGATAGAATGTCATTCATTGGAGAGAAATCCAAGGAATATGTGGGATGAAATGACTAGAAGTATGAACAATGAGAATAGTACATACTTGTACCTGTATTTCTAGAAGAGAGAAAGACAGTTGAGTGTGTGATTCTCGTCCAATAATAATCTCAATAGTAACGTGTGAATAGCTGTTCTTTGATAGTTGATATTTCTCGATGACTATTTATGTTGTACAAGGGATTTTTTTCGTTGCTGTTGATTTCGAATTAGGCAATGCAGATATCATTTATGCTATCCATATTTAAGATTTCCCATACGCATTTATAACATTTATTCTACATAAATTGTTAAATGAACGAACTGCCATTATAAATTGTTTCCTAAATAGGAAGTGTTTTTCATAAAGCAAGTAAGTTGTCTAATAATACTAAGTAATAAAAATAAGTTCATACAATATATTTTGAGAACATCATTTGGAGGCGGTAGATGGAGTCTGTTTATTATTAAACAATGCGAGATGACCCCTTAAATATTGAGAACATCAGTTGGAGGCGGCAGATGGAGTCTGTCTATTTAGCAATGGGACATGACTGTCAGTATCATCATATGTATATATATAATACATATAATATTATATAACACGATTTTTTTAAATTATTGGCCCGAAAATTAATCAGTGTAGACTGGATCCTCGAGAACCATTTAATTAAGATCGTCGACGATTCCGCCAAGTGAGACTGGCGATCGGGAGAAGGGTTGGTGGTCATGGGGGATAGAATTTGTACAAGTGGAAAAACCACTACGAGTAGCGGATTTGATACCACAAGTAGCAGAGATATACAGCAATGGTGGGAGTGCAAGTATCGGAATGTACTGTACCTCCTGTACTCGTACTCGTACGGCACTCGTAGAAACGGGGCAATACGGGGGAGAAGCGATCGCCCGTCTGTTCAATCGCCACAAGTCCGAGTAATGCTTGAGTATCGAAGTCTTGTACCTCCCTGTCAATCATGGCACCACTGGTCTTGACTTGTCTATTCATACTGGACAAGCGCCAGAGTTAAGCTTGTAGCGAATTTCGCCCTCGGACATCACCCCATACGACGGACACACATGCCCGACAAACAGCCTCTCTTATTGTAGCTGAAAGTATATTGAATGTGAACGTGTACAATATCAGGTACCAGCGGGAGGTTACGGCCAAGGTGATACCGGAATAACCCTGGCTTGGAGATGGTCGGTCCATTGTACTGAAGTGTCCGTGTCGTTTCCGTCACTGCCCCAATTGGACATGTTTGTTTTTCCGATCTTTCGGGCGCCCTCTCCTTGTCTCCTTGTCTGTCTCCTGGACTGTTGCTACCCCATTTCTTTGGCCTCCATTGGTTCCTCCCCGTCTTTCACGTCGTCTATGGTTGCATGGTTTCCCTTATACTTTTCCCCACAGTCACATGTTATGGAGGGGTCTAGATGGAGGCCTAATTTTGACGTGCAAGGGGCGAATTGGGGCGAGAAACACGTCGTGGACATGGTGCAAGGCCCGCAGGGTTGATTCGACGCTTTTCCGCGAAAAAAACAAGTCCAAATACCCCCGTTTATTCTCCCTCGGCTCTCGGTATTTCACATGAAAACTATAACCTAGACTACACGGGCAACCTTAACCCCAGAGTATACTTATATACCAAAGGGATGGGTCCTCAAAAATCACACAAGCAACGACGCCATGGGCCTCTCTCTAGTATGTACCTTCTCTTTCCAGACCAACTATCACACTCTACTGAACCCCCATAACAAGAACCCTAAAAATTCTCTTCTCAGTTACCAGCACCCCAAGACGCCTATCATTAAGTCCTCCTACGACAACTTTCCCTCTAAGTACTGCCTGACCAAAAACTTCCATCTCCTGGGACTGAACTCTCATAACAGAATTAGTAGCCAGTCCCGATCTATCCGAGCTGGCTCTGACCAGATTGAGGGCTCCCCTCACCATGAATCCGACAACAGCATCGCTACCAAGATTTTGAATTTTGGTCACACATGCTGGAAGCTCCAGCGACCGTACGTCGTGAAGGGTATGATCTCGATTGCCTGTGGACTGTTCGGACGTGAGCTTTTTAATAATCGACACTTGTTTTCATGGGGCCTCATGTGGAAGGCTTTTTTCGCCCTCGTGCCCATTCTGTCTTTCAACTTCTTTGCCGCTATTATGAACCAAATCTACGACGTTGATATTGATAGGATCAACAAGCCTGACCTGCCGCTCGTCTCGGGGGAGATGTCTATCGAGACAGCGTGGATTCTTTCGATTATCGTCGCGCTGACTGGCCTTATCGTTACCATAAAGTTGAAGTCTGCACCCCTCTTCGTGTTTATCTACATTTTCGGTATTTTTGCTGGATTCGCGTACTCCGTTCCCCCTATCAGATGGAAGCAGTACCCCTTTACTAACTTTCTGATTACTATCAGCAGCCACGTCGGTTTAGCCTTTACCTCATATTCGGCCACCACCAGTGCACTGGGCCTCCCCTTCGTCTGGCGACCTGCATTTTCATTCATCATCGCCTTCATGACTGTGATGGGTATGACCATCGCTTTCGCTAAGGACATCTCCGACATCGAGGGTGATGCTAAATATGGAGTGTCCACCGTGGCCACTAAGCTGGGAGCCCGGAACATGACGTTCGTCGTCTCTGGTGTTCTGCTCCTTAACTACTTGGTTTCGATCTCCATTGGCATTATCTGGCCACAAGTCTTCAAGTCCAACATTATGATTCTGTCCCACGCCATTCTTGCCTTTTGCCTGATCTTCCAGACACGCGAACTCGCTCTCGCTAACTACGCCTCCGCCCCATCGCGACAGTTCTTCGAGTTCATCTGGCTGCTTTACTACGCCGAGTACTTCGTTTACGTGTTCATCTAATAAGAGTAGGCAATTAACAGATAGTTTGCCGGTGATAATTCTCTTAACCTCCCACACTCCTTTGACATAACGATTTATGTAACGAAACTGAAATTTGACCAGATATTGTTGTAAATAGAAAATCTGGCTTGTAGGTGGCAAAATGCGGCGTCTTTGTTCATCAATTCCCTCTGTGACTACTCGTCATCCCTTTATGTTCGACTGTCGTATTTCTTATTTTCCATACATATGCAAGTGAGATGCCCGTGTCCGAATTCGCTATGGATCCATAGCGTCGACACCATATCATATAAAACTAACAATGCATTGAATTAATACGAAGACTACCCGTTGCTATCTCCACACCGTTATCTCCACGGTCCAAAGGCTGCTCAATGTGCTGCATACGTAACGTGGGGTGCAACCTTGAGCACATAGTACTTTCCGAAAACCGGCGATAATTAAGTGTGCACTCCAACTTTTCACACTGAGCATAAAATGTGGAGAAGAAATCACACTAAAAAGTCAGGTAGACTGGAAAATGCGCCATGAAATAATATCTCTTGCTACAGTAATGCCCAGCATCGAGGGGTATTGTGTCACCAACACTATAGTGGCAGCTGAAGCGCTCGTGATTGTAGTATGAGTCTTTATTGGTGATGGGAAGAGTTCACTCAATATTCTCGTTACTGCCAAAACACCACGGTAATCGGCCAGACACCATGGATGTAGATCACCAAGCCTGTGAATGTTATTCGAGCTAAAATGCACATGGTTGGTGAAAGGAGTAGTTGCTGTCGAATTCCGTCGTCGCCTGAGTCATCATTTATTTACCAGTTGGCCACAAACCCTTGACGATCTCGTATGTCCCCTCCGACATACTCCCGGCCGGCTGGGGTACGTTCGATAGCGCTATCGGCATCGACAAGGTTTGGGTCCCTAGCCGATACCGCACTACCTGAGTCACAATCTTCGGAGGTTTAGTCTTCCACATAGCACGGGCAAAAGTGCGTATATATACAAGAGCGTTTGCCAGCCACAGATTTTCACTCCACACACCACATCACACATACAACCACACACATCCACAATGGAACCCGAAACTAAGAAGACCAAGACTGACTCCAAGAAGATTGTTCTTCTCGGCGGCGACTTCTGTGGCCCCGAGGTGATTGCCGAGGCCGTCAAGGTGCTCAAGTCTGTTGCTGAGGCCTCCGGCACCGAGTTTGTGTTTGAGGACCGACTCATTGGAGGAGCTGCCATTGAGAAGGAGGGCGAGCCCATCACCGACGCTACTCTCGACATCTGCCGAAAGGCTGACTCTATTATGCTCGGTGCTGTCGGAGGCGCTGCCAACACCGTATGGACCACTCCCGACGGACGAACCGACGTGCGACCCGAGCAGGGTCTTCTCAAGCTGCGAAAGGACCTGAACCTGTACGCCAACCTGCGACCCTGCCAGCTGCTGTCGCCCAAGCTCGCCGATCTCTCCCCCATCCGAAACGTTGAGGGCACCGACTTCATCATTGTCCGAGAGCTCGTCGGAGGTATCTACTTTGGAGAGCGAAAGGAGGATGACGGATCTGGCGTCGCTTCCGACACTGAGACTTACTCCGTTCCTGAGGTTGAGCGAATTGCCCGAATGGCCGCCTTCCTGGCCCTTCAGCACAACCCCCCTCTTCCCGTGTGGTCCCTTGACAAGGCCAACGTGCTGGCCTCCTCTCGACTTTGGCGAAAGACCGTCACCCGAGTCCTCAAGGACGAATTCCCCCAGCTGGAGCTCAACCACCAGCTGATCGACTCGGCCGCCATGATCCTCATCAAGCAGCCCTCCAAGATGAATGGTATCATCATCACCACCAACATGTTTGGCGATATCATCTCCGACGAGGCCTCCGTCATCCCCGGTTCTCTGGGTCTGCTGCCCTCCGCCTCTCTGGCTTCTCTGCCCGACACCAACGAGGCGTTCGGTCTGTACGAGCCCTGTCACGGATCTGCCCCCGATCTCGGCAAGCAGAAGGTCAACCCCATTGCCACCATTCTGTCTGCCGCCATGATGCTCAAGTTCTCTCTTAACATGAAGCCCGCCGGTGACGCTGTTGAGGCTGCCGTCAAGGAGTCCGTCGAGGCTGGTATCACTACCGCCGATATCGGAGGCTCCTCCTCCACCTCCGAGGTCGGAGACTTTGTTGCCAACAAGGTCAAGGAGCTGCTCAAGAAGGAGTAAGTCGTTTCTACGACGCATTGATGGAAGGAGCAAACTGACGCGCCTGCGGGTTGGTCTACCGGCAGGGTCCGCTAGTGTATAAGACTCTATAAAAAGGGCCCAGCCCTGCTAATGAAATGATGATTTATAATTTACCGGTGTAGCAACCTTGACTAGAAGAAGCAGATTGGGTGTGTTTGTAGTGGAGGACAGTGGTACGTTTTAATTAA pLD132 (SEQ ID NO: 175)TTAATTAAGATCGTCGACGATTCCGCCAAGTGAGACTGGCGATCGGGAGAAGGGTTGGTGGTCATGGGGGATAGAATTTGTACAAGTGGAAAAACCACTACGAGTAGCGGATTTGATACCACAAGTAGCAGAGATATACAGCAATGGTGGGAGTGCAAGTATCGGAATGTACTGTACCTCCTGTACTCGTACTCGTACGGCACTCGTAGAAACGGGGCAATACGGGGGAGAAGCGATCGCCCGTCTGTTCAATCGCCACAAGTCCGAGTAATGCTTGAGTATCGAAGTCTTGTACCTCCCTGTCAATCATGGCACCACTGGTCTTGACTTGTCTATTCATACTGGACAAGCGCCAGAGTTAAGCTTGTAGCGAATTTCGCCCTCGGACATCACCCCATACGACGGACACACATGCCCGACAAACAGCCTCTCTTATTGTAGCTGAAAGTATATTGAATGTGAACGTGTACAATATCAGGTACCAGCGGGAGGTTACGGCCAAGGTGATACCGGAATAACCCTGGCTTGGAGATGGTCGGTCCATTGTACTGAAGTGTCCGTGTCGTTTCCGTCACTGCCCCAATTGGACATGTTTGTTTTTCCGATCTTTCGGGCGCCCTCTCCTTGTCTCCTTGTCTGTCTCCTGGACTGTTGCTACCCCATTTCTTTGGCCTCCATTGGTTCCTCCCCGTCTTTCACGTCGTCTATGGTTGCATGGTTTCCCTTATACTTTTCCCCACAGTCACATGTTATGGAGGGGTCTAGATGGAGGCCTAATTTTGACGTGCAAGGGGCGAATTGGGGCGAGAAACACGTCGTGGACATGGTGCAAGGCCCGCAGGGTTGATTCGACGCTTTTCCGCGAAAAAAACAAGTCCAAATACCCCCGTTTATTCTCCCTCGGCTCTCGGTATTTCACATGAAAACTATAACCTAGACTACACGGGCAACCTTAACCCCAGAGTATACTTATATACCAAAGGGATGGGTCCTCAAAAATCACACAAGCAACGACGCCATGAAGTGTTCGACGTTTTCTTTTTGGTTTGTTTGTAAAATCATTTTCTTTTTCTTTTCTTTCAACATCCAAACGTCGATCGCAAACCCTAGAGAGAACTTTCTTAAGTGCTTCTCGCAGTACATCCCTAATAACGCTACCAACCTTAAGCTGGTGTACACCCAGAACAACCCTCTTTACATGTCTGTTCTAAACAGCACCATCCACAATCTTAGATTCACATCAGACACCACTCCCAAGCCGCTCGTCATCGTGACCCCGAGTCATGTGTCCCATATCCAAGGCACTATCCTGTGCTCTAAAAAGGTCGGTCTGCAGATTCGGACTCGCTCCGGTGGACATGATTCGGAGGGCATGTCCTACATTAGCCAGGTCCCCTTTGTGATCGTGGACCTGAGGAACATGCGGTCTATTAAGATTGATGTGCACTCACAGACCGCTTGGGTCGAGGCTGGTGCGACATTGGGTGAGGTGTACTACTGGGTGAACGAGAAGAACGAGAACCTGAGCCTCGCCGCTGGCTACTGTCCCACCGTTTGTGCCGGTGGACACTTCGGCGGAGGCGGATACGGTCCACTTATGCGAAACTACGGGCTCGCAGCTGATAATATCATCGACGCACACCTTGTTAACGTTCACGGCAAGGTGCTGGACCGAAAAAGCATGGGTGAGGACCTATTTTGGGCCTTGCGAGGCGGTGGTGCCGAATCCTTCGGAATTATCGTGGCCTGGAAGATCCGACTGGTCGCTGTGCCAAAGTCCACTATGTTCTCCGTCAAGAAAATTATGGAGATCCACGAACTCGTAAAGCTCGTCAATAAGTGGCAGAACATCGCCTACAAGTATGACAAGGATCTGCTGCTCATGACTCACTTCATCACGCGAAACATTACAGACAACCAGGGAAAGAACAAGACCGCTATCCATACCTACTTCTCCTCTGTCTTCCTTGGGGGTGTCGATTCCCTCGTTGATCTCATGAACAAATCTTTTCCAGAGCTCGGAATCAAGAAGACCGACTGCCGACAGCTCTCTTGGATCGACACCATTATTTTCTACTCAGGAGTCGTAAACTACGATACTGACAACTTTAACAAGGAGATTCTGTTAGATCGATCGGCCGGCCAGAACGGTGCCTTCAAGATCAAGCTCGACTATGTCAAAAAGCCCATTCCTGAATCCGTCTTCGTTCAAATTCTTGAAAAGTTGTACGAGGAGGATATCGGCGCCGGAATGTACGCGCTGTACCCCTACGGTGGCATTATGGACGAGATTTCTGAAAGTGCTATTCCCTTCCCCCACCGTGCTGGCATTCTGTATGAGCTGTGGTACATTTGCTCCTGGGAAAAGCAGGAGGACAACGAGAAGCACTTGAACTGGATACGAAACATTTACAATTTCATGACCCCCTATGTTTCGAAGAACCCTCGACTGGCCTACCTGAATTACCGCGACCTCGACATCGGAATTAACGACCCTAAGAACCCCAATAACTATACTCAGGCCAGAATCTGGGGCGAGAAGTACTTCGGCAAGAACTTTGACCGTCTGGTTAAGGTCAAGACCCTCGTGGACCCTAACAACTTCTTCCGAAACGAGCAGTCTATCCCCCCTCTGCCCCGACACCGGCATTAATAAGAGTAGGCAATTAACAGATAGTTTGCCGGTGATAATTCTCTTAACCTCCCACACTCCTTTGACATAACGATTTATGTAACGAAACTGAAATTTGACCAGATATTGTTGTAAATAGAAAATCTGGCTTGTAGGTGGCAAAATGCGGCGTCTTTGTTCATCAATTCCCTCTGTGACTACTCGTCATCCCTTTATGTTCGACTGTCGTATTTCTTATTTTCCATACATATGCAAGTGAGATGCCCGTGTCCGAATTCGCTATGGATCCATAGCGCAGGTTGTGCAGTATCATACATACTCGATCAGACAGGTCGTCTGACCATCATACAAGCTGAACAAGCGCTCCATACTTGCACGCTCTCTATATACACAGTTAAATGACATATCCATAGTCTAACCTCTAACAGTTAATCTTCTGGTAAGCCTCCCAGCCAGCCTTCTGGTATCGCTTGGCCTCCTCAATAGGATCTCGGTTCTGGCCGTACAGACCTCGGCCGACAATTATGATATCCGTTCCGGTAGACATGACATCCTCAACAGTTCGGTACTGCTGTCCGAGAGCATCTCCCTTGTCGTCAAGACCCACCCCGGGGGTCAGAATAAGCCAGTCCTCAGAGTCGCCCTTAGGTCGGTTCTGGGCAATGAAGCCAACCACAAACTCGGGGTCGGATCGGGCAAGCTCAATGGTCTGCTTGGAGTACTCGCCAGTGGCCAGAGAGCCCTTGCAAGACAGCTCGGCCAGCATGAGCAGACCTCTGGCCAGCTTCTCGTTGGGAGAGGGGACCAGGAACTCCTTGTACTGGGAGTTCTCGTAGTCAGAGACATCCTCCTTCTTCTGTTCAGAGACAGTTTCCTCGGCACCAGCTCGCAGGCCAGCAATGATTCCGGTTCCGGGTACACCGTGGGCGTTGGTGATATCGGACCACTCGGCGATTCGGTAGACACCGTTCTTGTACTGGTGCTTGACAGTGTTGCCAATATCTGCGAACTTTCTGTCCTCGAACAGGAAGAAACCGTGCTTAAGAGCAAGTTCCTTGAGGGGGAGCACAGTTCCGGCGTAGGTGAAGTCGTCAATGATGTCGATATGGGTCTTGATCATGCACACATAAGGTCCGACCTTATCGGCAAGCTCAATGAGCTCCTTGGTGGTGGTAACATCCAGAGAAGCACACAGGTTGGTTTTCTTGGCTGCCACGAGCTTGAGCACTCGGGCGGCAAAGGCGGACTTGTGGACGTTAGCTCGCGCTTCGTAGGAGGGCATTTTGGTGGTGAAGAGGAGACTGAAATAAATTTAGTCTGCACAACTTTTTATCGGAACCTTATCTGGGGCAGTGAAGTATATGTTATGGTAATAGTTACGAGTTAGTTGAACTTATAGATAGACTGGACTATACGGCTATCGGTCCAAATTAGAAATTAATTAAATGGTTCTCGAGGATCCAGTCTACACTGATTAATTTTCGGGCCAATAATTTAAAAAAATCGTGTTATATAATATTATATGTATTATATATATACATATGATGATACTGACAGTCATGTCCCATTGCTAAATAGACAGACTCCATCTGCCGCCTCCAACTGATGTTCTCAATATTTAAGGGGTCATCTCGCATTGTTTAATAATAAACAGACTCCATCTACCGCCTCCAAATGATGTTCTCAAAATATATTGTATGAACTTATTTTTATTACTTAGTATTATTAGACAACTTACTTGCTTTATGAAAAACACTTCCTATTTAGGAAACAATTTATAATGGCAGTTCGTTCATTTAACAATTTATGTAGAATAAATGTTATAAATGCGTATGGGAAATCTTAAATATGGATAGCATAAATGATATCTGCATTGCCTAATTCGAAATCAACAGCAACGAAAAAAATCCCTTGTACAACATAAATAGTCATCGAGAAATATCAACTATCAAAGAACAGCTATTCACACGTTACTATTGAGATTATTATTGGACGAGAATCACACACTCAACTGTCTTTCTCTCTTCTAGAAATACAGGTACAAGTATGTACTATTCTCATTGTTCATACTTCTAGTCATTTCATCCCACATATTCCTTGGATTTCTCTCCAATGAATGACATTCTATCTTGCAAATTCAACAATTATAATAAGATATACCAAAGTAGCGGTATAGTGGCAATCAAAAAGCTTCTCTGGTGTGCTTCTCGTATTTATTTTTATTCTAATGATCCATTAAAGGTATATATTTATTTCTTGTTATATAATCCTTTTGTTTATTACATGGGCTGGATACATAAAGGTATTTTGATTTAATTTTTTGCTTAAATTCAATCCCCCCTCGTTCAGTGTCAACTGTAATGGTAGGAAATTACCATACTTTTGAAGAAGCAAAAAAAATGAAAGAAATAAAAAATCGTATTTCCAGGTTAGACGTTCCGCAGAATCTAGAATGCGGTATGCGGTACATTGTTCTTCGAACGTAAAAGTTGCGCTCCCTGAGATATTGTACATTTTTGCTTTTACAAGTACAAGTACATCGTACAACTATGTACTACTGTTGATGCATCCACAACAGTTTGTTTTGTTTTTTTTTGTTTTTTATTTTTCTAATGATTCATTACCGCTATGTATACCTACTTGTACTTGTAGTAAGCCGGGTTATTGGCGTTCAATTAATCATAGACTTATGAATCTGCACGGTGTGCGCTGCGAGTTACTTTTAGCTTATGCATGCTACTTGGGTGTAATATTGGGATCAGGTCAGGCGGAATGGCACTTCCTTATTCCAGATGCGTGCGGATTATGCATGACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGCTTGTGGTGGATCACAGTTATTGGAGACTTCCTTGGCCGTACGATGGGTTTTGTTTCAGGTATCCCAACCTGGACGTCTCGTATAATGCGACAAACAACAGATAAAACGAAAGGCCCAGTCTTTCGACTGAGCCTTTCGTTTTATTTGGATCCACTAGTTCTAGAGCGGCGGGGGAAAGCCACGTTGTGTCTCAAAATCTCTGATGTTACATTGCACAAGATAAAAATATATCATCATGAACAATAAAACTGTCTGCTTACATAAACAGTAATACAAGGGGTGTTATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGCGATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCGACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCAATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTTATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAGAATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTTTGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGTTGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAGCTTTTGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAATTAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTGCCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAATTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATCAGAATTTGTTAATTGGTTGTAACACTGGCAGAGCGGACGATTTGAAGCCCCCTACCCATTTACGCTGACTTGACGGGACGGCGGCTTTGTTGAATAGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCTTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTTCCAGCGACATATGCCATACGCCGAACTGAACTCCACCTAATGTCTTGGAGATTGTCGGATAGCGCGGAATAGGATTGTGCCCTCTGAGCGGATAACAATTTCACACAGGAAACAGCTATGACCATGACACATGCATCCACCATCGCAGACTTATCATCACTGAGCCTCCACCTAGCCT pLD135 (SEQ ID NO: 176)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCTCGTGATACCAATTCGGAGCCTGCTTTTTTGTACAAACTTGTTGATAATGGCAATTCAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGAGCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTTTAATTAATTGGCAAATTTTACTGTGGCCTTCAGAACGGTAAAAATAGACCAATCAGAATTCTGAAAAGCACATCTTGATCTCCTCATTGCGGGGAGTCCAACGGTGGTCTTATTCCCCCGAATTTCCCGCTCAATCTCGTTCCAGACCGACCCGGACACAGTGCTTAACGCCGTTCCGAAACTCTACCGCAGATATGCTCCAACGGACTGGGCTGCATAGATGTGATCCTCGGCTTGGAGAAATGGATAAAAGCCGGCCAAAAAAAAAGCGGAAAAAAGCGGAAAAAAAGAGAAAAAAAATCGCAAAATTTGAAAAATAGGGGGAAAAGACGCAAAAACGCAAGGAGGGGGGAGTATATGACACTGATAAGCAAGCTCACAACGGTTCCTCTTATTTTTTTCCTCATCTTCTGCCTAGGTTCCCAAAATCCCAGATGCTTCTCTCCAGTGCCAAAAGTAAGTACCCCACAGGTTTTCGGCCGAAAATTCCACGTGCAGCAACGTCGTGTGGGGTGTTAAAATGTGGGGGCGGGGAACCAGGACAAGAGGCTCTTGTGGGAGCCGAATGAGAGCACAAAGCGGGCGGGTGTGATAAGGGCATTTTTGCCCATTTTCCCTTCTCCTGTCTCTCCGACGGTGATGGCGTTGTGCGTCCTCTATCTATTTCTTTTTATTTCTTTTTGTTTTATTTCTCTGACTACCGATTTGGCTTGATTTCCTCAACCCCACACAAATAAGCTCGGGCCGAGGAATATATATATACACGGACACAGTCGCCCTGTGGACAACACGTCACTACCTCTACGACGCTATGGATCCATAGCGAATTCGGACACGGGCATCTCACTTGCATATGTATGGAAAATAAGAAATACGACAGTCGAACATAAAGGGATGACGAGTAGTCACAGAGGGAATTGATGAACAAAGACGCCGCATTTTGCCACCTACAAGCCAGATTTTCTATTTACAACAATATCTGGTCAAATTTCAGTTTCGTTACATAAATCGTTATGTCAAAGGAGTGTGGGAGGTTAAGAGAATTATCACCGGCAAACTATCTGTTAATTGCCTACTCTTATTACAGTTTGGCTCGTCGTCCCCGAGACTTGCCGGCCTTGATAGCGAGGAGTGTCTTCTCGTCAGCAGGGGCGCTACCGGAGGCTCGTTGCTGTCTGAAGTAGGTTCGGGCCTCGTCCTGTCGGGTGGCCTCAGCGCCGGTGGCGATAGCGGCCCGAAGGTGCTCGGCTCCGTAGCCGAAGGCATCAACCAGATCAAGTGCGTGTGGTCGGATCTTAACGAGAAGACGATTAATGTAAGTGCCGACCGTTCGGCCTCTCTGCATCGAGAGCCTACCGTTCATCAGATACCAGCTGAGGTGCTTCTCGATAAGGGACAGACCAAAAAGGTCACGCAATCGGGTCAACACTTCCTTAGTGCCAGCGTCGTCCACCTTGGCCAAAGCCTCAGTAAAGGCCTCCCACTGTAAAAGCTCAGCGTGGGCCTGGGCAGCCTCGATCAGTTCGTTTTGATGCTGATTGAACAGTGCTGCCGCCTGGTGCTGGGGGAGCTTGCCCGCGCCTTTGAGAGCAGCGCCAACCTCTGCAACCATGGACTGGACTCTGTCGGTCAGCAGAGTTCGCTGACCTTCTTCGTCTCGGAGGGCAAGAGCAGATTTCTGGACAGATCCACTGTCGGCCACGAACTGAGCGACCTGTCGCAGTCCGGTTCGGTGTAGCGCGACTCCGGCAGCCTGGTCCACGACGTACCGCGCGAGCACGCCGAAGTTGGCACCTCGGAACTCCTTAGCATAGTCAGCGAGCAGCCTCTTGGCCACCAACTGAAGAAGCACGGTGTTGTCTCCTTCGAAGGTCACGTAGACGTCGAGATCGGCCCGGAGAGAAGCGAATCGGTTCTCAATCAGAAAACCTGCACCCCCACACGCTTCTCGGCACTCTTGTAGGGTATCGAGAGCATGCCAGGTAGAAAGGGGCTTCAGAGCAGCAGCCAGTGTCTCAAGGTCCTGACGGTCGGCGTCAGTATCATGAGCACCCGAGAACACGTCGTCGAATTTCTGCAGCAGTTGCTCATGGGCGAACGATGCGGCGTAGGTGGTGGCGAGTCGGGTAAAGAGGCGCCGCTGGTGTCGCTGGTAATCCAGGAGCACCTCCTCCTCTGTGGGCGAAGTGGCGTTGAACTGTCTTCGCTCAGCGGCGTAGTGGATGGCGGATTGCAGAGCAACCTTCGATGCAGCCACTGCAGCACCGTCCAGGCTGACTCGGCCCTGGACCAGCGTACCTAGCATTGTAAAGAATCTTCGCCCCGGAGATTCGATGGTTGAGCTGTAGGTGCCATCGACGGCAACATCGCCGTAACGGTTAAGCAGGTTGGTTCGGGGAATGCGAACATTGGTGAAATGGAGACGTCCGTTATCAATTCCGTTTAGTCCCCCCTTAATACCGTCGTCCTCTCCACCAATACCAGGGAGAAAGTCTCCGGTGGCGGGATCTCTCAGATCGACGTAGAAGGCGTGCACTCCATGGTTAACCTTTCGAGTAATCAGTTGGGCAAACACGACAGCGGCCAAACCGTCGTTAGCGGCGTTTCCAATGTAGTCCTTCCAGGCGGCTCGGAACGGGGTGTCAATAACGAACTCCTGGGTTTCCTCATCATAGGTGGCCGTTGTAGCAATGGAAGCGACATCGGAGCCATGGCCAGTCTCAGTCATGGCAAAGCAACCAGGGATTTCCAGAGACATGATGCCTGGGAGCCACTTGTCGTGGTGCTCCCTAGTTCCCAAGTGCATAACAGCGGAGCCGAACAGTCCCCACTGGACGCCGGCCTTGATCTGGAGGGAGGGGTCCGCCGTGACAAGCTCCTCAAAACCAGCGATGTTTCCGCCGTGGTCGTCACTACCACCCAGTCGAGAAGGAAAGGCTCGGTGAACTGCGTTGTTATCGACCAAGTACTTGAGCTGGCCAAAGACGCGAGAGCGGTGCTCTGTATGAGTCAGACCCTCCACCTTCTGAACTACCTCTCGTCCCGCAAGGTCCCGGGCGTGGAGACGGATATCAGCCCATCGGCCCAGCAGCTGCTCTCCCAGCGCAGCCACATCTACTCGGGGCTCGACGGCCACCTTAGCACCGTCTGCGGCGGCCGTAGTTGAGCCAGGGGATGCGGGGGATGAGGCTCTGTCAACTACTTCGGTCATGGCGTCGTTGCTTGTGTGATTTTTGAGGACCCATCCCTTTGGTATATAAGTATACTCTGGGGTTAAGGTTGCCCGTGTAGTCTAGGTTATAGTTTTCATGTGAAATACCGAGAGCCGAGGGAGAATAAACGGGGGTATTTGGACTTGTTTTTTTCGCGGAAAAGCGTCGAATCAACCCTGCGGGCCTTGCACCATGTCCACGACGTGTTTCTCGCCCCAATTCGCCCCTTGCACGTCAAAATTAGGCCTCCATCTAGACCCCTCCATAACATGTGACTGTGGGGAAAAGTATAAGGGAAACCATGCAACCATAGACGACGTGAAAGACGGGGAGGAACCAATGGAGGCCAAAGAAATGGGGTAGCAACAGTCCAGGAGACAGACAAGGAGACAAGGAGAGGGCGCCCGAAAGATCGGAAAAACAAACATGTCCAATTGGGGCAGTGACGGAAACGACACGGACACTTCAGTACAATGGACCGACCATCTCCAAGCCAGGGTTATTCCGGTATCACCTTGGCCGTAACCTCCCGCTGGTACCTGATATTGTACACGTTCACATTCAATATACTTTCAGCTACAATAAGAGAGGCTGTTTGTCGGGCATGTGTGTCCGTCGTATGGGGTGATGTCCGAGGGCGAAATTCGCTACAAGCTTAACTCTGGCGCTTGTCCAGTATGAATAGACAAGTCAAGACCAGTGGTGCCATGATTGACAGGGAGGTACAAGACTTCGATACTCAAGCATTACTCGGACTTGTGGCGATTGAACAGACGGGCGATCGCTTCTCCCCCGTATTGCCCCGTTTCTACGAGTGCCGTACGAGTACGAGTACAGGAGGTACAGTACATTCCGATACTTGCACTCCCACCATTGCTGTATATCTCTGCTACTTGTGGTATCAAATCCGCTACTCGTAGTGGTTTTTCCACTTGTACAAATTCTATCCCCCATGACCACCAACCCTTCTCCCGATCGCCAGTCTCACTTGGCGGAATCGTCGACGATCATCCTCGAGATGCGGCCGCGTCGACATAACTTCGTATAGCATACATTATACGAAGTTATTTTCTAATTTGGACCGATAGCCGTATAGTCCAGTCTATCTATAAGTTCAACTAACTCGTAACTATTACCATAACATATACTTCACTGCCCCAGATAAGGTTCCGATAAAAAGTTGTGCAGACTAAATTTATTTCAGTCTCCTCTTCACCACCAAAATGCCCTCCTACGAAGCGCGAGCTAACGTCCACAAGTCCGCCTTTGCCGCCCGAGTGCTCAAGCTCGTGGCAGCCAAGAAAACCAACCTGTGTGCTTCTCTGGATGTTACCACCACCAAGGAGCTCATTGAGCTTGCCGATAAGGTCGGACCTTATGTGTGCATGATCAAGACCCATATCGACATCATTGACGACTTCACCTACGCCGGAACTGTGCTCCCCCTCAAGGAACTTGCTCTTAAGCACGGTTTCTTCCTGTTCGAGGACAGAAAGTTCGCAGATATTGGCAACACTGTCAAGCACCAGTACAAGAACGGTGTCTACCGAATCGCCGAGTGGTCCGATATCACCAACGCCCACGGTGTACCCGGAACCGGAATCATTGCTGGCCTGCGAGCTGGTGCCGAGGAAACTGTCTCTGAACAGAAGAAGGAGGATGTCTCTGACTACGAGAACTCCCAGTACAAGGAGTTCCTGGTCCCCTCTCCCAACGAGAAGCTGGCCAGAGGTCTGCTCATGCTGGCCGAGCTGTCTTGCAAGGGCTCTCTGGCCACTGGCGAGTACTCCAAGCAGACCATTGAGCTTGCCCGATCCGACCCCGAGTTTGTGGTTGGCTTCATTGCCCAGAACCGACCTAAGGGCGACTCTGAGGACTGGCTTATTCTGACCCCCGGGGTGGGTCTTGACGACAAGGGAGATGCTCTCGGACAGCAGTACCGAACTGTTGAGGATGTCATGTCTACCGGAACGGATATCATAATTGTCGGCCGAGGTCTGTACGGCCAGAACCGAGATCCTATTGAGGAGGCCAAGCGATACCAGAAGGCTGGCTGGGAGGCTTACCAGAAGATTAACTGTTAGAGGTTAGACTATGGATATGTCATTTAACTGTGTATATAGAGAGCGTGCAAGTATGGAGCGCTTGTTCAGCTTGTATGATGGTCAGACGACCTGTCTGATCGAGTATGTATGATACTGCACAACCTGATAACTTCGTATAGCATACATTATACGAAGTTATCTCGAGGCGGCCGCATGGAGCGTGTGTTCTGAGTCGATGTTTTCTATGGAGTTGTGAGTGTTAGTAGACATGATGGGTTTATATATGATGAATGAATAGATGTGATTTTGATTTGCACGATGGAATTGAGAACTTTGTAAACGTACATGGGAATGTATGAATGTGGGGGTTTTGTGACTGGATAACTGACGGTCAGTGGACGCCGTTGTTCAAATATCCAAGAGATGCGAGAAACTTTGGGTCAAGTGAACATGTCCTCTCTGTTCAAGTAAACCATCAACTATGGGTAGTATATTTAGTAAGGACAAGAGTTGAGATTCTTTGGAGTCCTAGAAACGTATTTTCGCGTTCCAAGATCAAATTAGTAGAGTAATACGGGCACGGGAATCCATTCATAGTCTCAATTTTCCCATAGGTGTGCTACAAGGTGTTGAGATGTGGTACAGTACCACCATGATTCGAGGTAAAGAGCCCAGAAGTCATTGATGAGGTCAAGAAATACACAGATCTACAGCTCAATACAATGAATATCTTCTTTCATATTCTTCAGGTGACACCAAGGGTGTCTATTTTCCCCAGAAATGCGTGAAAAGGCGCGTGTGTAGCGTGGAGTATGGGTTCGGTTGGCGTATCCTTCATATATCGACGAAATAGTAGGGCAAGAGATGACAAAAAGTATCTATATGTAGACAGCGTAGAATATGGATTTGATTGGTATAAATTCATTTATTGCGTGTCTCACAAATACTCTCGATAAGTTGGGGTTAAACTGGAGATGGAACAATGTCGATATCTCGACATATTTTGATATTTGTTAATTAA pLD137 (SEQ ID NO: 177)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTGATCCCAATATTACACCCAAGTAGCATGCATAAGCTAAAAGTAACTCGCAGCGCACACCGTGCAGATTCATAAGTCTATGATTAATTGAACGCCAATAACCCGGCTTACTACAAGTACAAGTAGGTATACATAGCGGTAATGAATCATTAGAAAAATAAAAAACAAAAAAAAACAAAACAAACTGTTGTGGATGCATCAACAGTAGTACATAGTTGTACGATGTACTTGTACTTGTAAAAGCAAAAATGTACAATATCTCAGGGAGCGCAACTTTTACGTTCGAAGAACAATGTACCGCATACCGCATTCTAGATTCTGCGGAACGTCTAACCTGGAAATACGATTTTTTATTTCTTTCATTTTTTTTGCTTCTTCAAAAGTATGGTAATTTCCTACCATTACAGTTGACACTGAACGAGGGGGGATTGAATTTAAGCAAAAAATTAAATCAAAATACCTTTATGTATCCAGCCCATGTAATAAACAAAAGGATTATATAACAAGAAATAAATATATACCTTTAATGGATCATTAGAATAAAAATAAATACGAGAAGCACACCAGAGAAGCTTTTTGATTGCCACTATACCGCTACTTTGGTATATCTTATTATAATTGTTGAATTTGCAAGATAGAATGTCATTCATTGGAGAGAAATCCAAGGAATATGTGGGATGAAATGACTAGAAGTATGAACAATGAGAATAGTACATACTTGTACCTGTATTTCTAGAAGAGAGAAAGACAGTTGAGTGTGTGATTCTCGTCCAATAATAATCTCAATAGTAACGTGTGAATAGCTGTTCTTTGATAGTTGATATTTCTCGATGACTATTTATGTTGTACAAGGGATTTTTTTCGTTGCTGTTGATTTCGAATTAGGCAATGCAGATATCATTTATGCTATCCATATTTAAGATTTCCCATACGCATTTATAACATTTATTCTACATAAATTGTTAAATGAACGAACTGCCATTATAAATTGTTTCCTAAATAGGAAGTGTTTTTCATAAAGCAAGTAAGTTGTCTAATAATACTAAGTAATAAAAATAAGTTCATACAATATATTTTGAGAACATCATTTGGAGGCGGTAGATGGAGTCTGTTTATTATTAAACAATGCGAGATGACCCCTTAAATATTGAGAACATCAGTTGGAGGCGGCAGATGGAGTCTGTCTATTTAGCAATGGGACATGACTGTCAGTATCATCATATGTATATATATAATACATATAATATTATATAACACGATTTTTTTAAATTATTGGCCCGAAAATTAATCAGTGTAGACTGGATCCTCGAGAACCATTTAATTAAGATCAGAGACCGGATGGTCTCAAGCGTCGACACCATATCATATAAAACTAACAATGCATTGAATTAATACGAAGACTACCCGTTGCTATCTCCACACCGTTATCTCCACGGTCCAAAGGCTGCTCAATGTGCTGCATACGTAACGTGGGGTGCAACCTTGAGCACATAGTACTTTCCGAAAACCGGCGATAATTAAGTGTGCACTCCAACTTTTCACACTGAGCATAAAATGTGGAGAAGAAATCACACTAAAAAGTCAGGTAGACTGGAAAATGCGCCATGAAATAATATCTCTTGCTACAGTAATGCCCAGCATCGAGGGGTATTGTGTCACCAACACTATAGTGGCAGCTGAAGCGCTCGTGATTGTAGTATGAGTCTTTATTGGTGATGGGAAGAGTTCACTCAATATTCTCGTTACTGCCAAAACACCACGGTAATCGGCCAGACACCATGGATGTAGATCACCAAGCCTGTGAATGTTATTCGAGCTAAAATGCACATGGTTGGTGAAAGGAGTAGTTGCTGTCGAATTCCGTCGTCGCCTGAGTCATCATTTATTTACCAGTTGGCCACAAACCCTTGACGATCTCGTATGTCCCCTCCGACATACTCCCGGCCGGCTGGGGTACGTTCGATAGCGCTATCGGCATCGACAAGGTTTGGGTCCCTAGCCGATACCGCACTACCTGAGTCACAATCTTCGGAGGTTTAGTCTTCCACATAGCACGGGCAAAAGTGCGTATATATACAAGAGCGTTTGCCAGCCACAGATTTTCACTCCACACACCACATCACACATACAACCACACACATCCACAATGGAACCCGAAACTAAGAAGACCAAGACTGACTCCAAGAAGATTGTTCTTCTCGGCGGCGACTTCTGTGGCCCCGAGGTGATTGCCGAGGCCGTCAAGGTGCTCAAGTCTGTTGCTGAGGCCTCCGGCACCGAGTTTGTGTTTGAGGACCGACTCATTGGAGGAGCTGCCATTGAGAAGGAGGGCGAGCCCATCACCGACGCTACTCTCGACATCTGCCGAAAGGCTGACTCTATTATGCTCGGTGCTGTCGGAGGCGCTGCCAACACCGTATGGACCACTCCCGACGGACGAACCGACGTGCGACCCGAGCAGGGTCTTCTCAAGCTGCGAAAGGACCTGAACCTGTACGCCAACCTGCGACCCTGCCAGCTGCTGTCGCCCAAGCTCGCCGATCTCTCCCCCATCCGAAACGTTGAGGGCACCGACTTCATCATTGTCCGAGAGCTCGTCGGAGGTATCTACTTTGGAGAGCGAAAGGAGGATGACGGATCTGGCGTCGCTTCCGACACTGAGACTTACTCCGTTCCTGAGGTTGAGCGAATTGCCCGAATGGCCGCCTTCCTGGCCCTTCAGCACAACCCCCCTCTTCCCGTGTGGTCCCTTGACAAGGCCAACGTGCTGGCCTCCTCTCGACTTTGGCGAAAGACCGTCACCCGAGTCCTCAAGGACGAATTCCCCCAGCTGGAGCTCAACCACCAGCTGATCGACTCGGCCGCCATGATCCTCATCAAGCAGCCCTCCAAGATGAATGGTATCATCATCACCACCAACATGTTTGGCGATATCATCTCCGACGAGGCCTCCGTCATCCCCGGTTCTCTGGGTCTGCTGCCCTCCGCCTCTCTGGCTTCTCTGCCCGACACCAACGAGGCGTTCGGTCTGTACGAGCCCTGTCACGGATCTGCCCCCGATCTCGGCAAGCAGAAGGTCAACCCCATTGCCACCATTCTGTCTGCCGCCATGATGCTCAAGTTCTCTCTTAACATGAAGCCCGCCGGTGACGCTGTTGAGGCTGCCGTCAAGGAGTCCGTCGAGGCTGGTATCACTACCGCCGATATCGGAGGCTCCTCCTCCACCTCCGAGGTCGGAGACTTTGTTGCCAACAAGGTCAAGGAGCTGCTCAAGAAGGAGTAAGTCGTTTCTACGACGCATTGATGGAAGGAGCAAACTGACGCGCCTGCGGGTTGGTCTACCGGCAGGGTCCGCTAGTGTATAAGACTCTATAAAAAGGGCCCAGCCCTGCTAATGAAATGATGATTTATAATTTACCGGTGTAGCAACCTTGACTAGAAGAAGCAGATTGGGTGTGTTTGTAGTGGAGGACAGTGGTACGTTTTAATTAA pLD138 (SEQ ID NO: 178)AGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCTGATCCCAATATTACACCCAAGTAGCATGCATAAGCTAAAAGTAACTCGCAGCGCACACCGTGCAGATTCATAAGTCTATGATTAATTGAACGCCAATAACCCGGCTTACTACAAGTACAAGTAGGTATACATAGCGGTAATGAATCATTAGAAAAATAAAAAACAAAAAAAAACAAAACAAACTGTTGTGGATGCATCAACAGTAGTACATAGTTGTACGATGTACTTGTACTTGTAAAAGCAAAAATGTACAATATCTCAGGGAGCGCAACTTTTACGTTCGAAGAACAATGTACCGCATACCGCATTCTAGATTCTGCGGAACGTCTAACCTGGAAATACGATTTTTTATTTCTTTCATTTTTTTTGCTTCTTCAAAAGTATGGTAATTTCCTACCATTACAGTTGACACTGAACGAGGGGGGATTGAATTTAAGCAAAAAATTAAATCAAAATACCTTTATGTATCCAGCCCATGTAATAAACAAAAGGATTATATAACAAGAAATAAATATATACCTTTAATGGATCATTAGAATAAAAATAAATACGAGAAGCACACCAGAGAAGCTTTTTGATTGCCACTATACCGCTACTTTGGTATATCTTATTATAATTGTTGAATTTGCAAGATAGAATGTCATTCATTGGAGAGAAATCCAAGGAATATGTGGGATGAAATGACTAGAAGTATGAACAATGAGAATAGTACATACTTGTACCTGTATTTCTAGAAGAGAGAAAGACAGTTGAGTGTGTGATTCTCGTCCAATAATAATCTCAATAGTAACGTGTGAATAGCTGTTCTTTGATAGTTGATATTTCTCGATGACTATTTATGTTGTACAAGGGATTTTTTTCGTTGCTGTTGATTTCGAATTAGGCAATGCAGATATCATTTATGCTATCCATATTTAAGATTTCCCATACGCATTTATAACATTTATTCTACATAAATTGTTAAATGAACGAACTGCCATTATAAATTGTTTCCTAAATAGGAAGTGTTTTTCATAAAGCAAGTAAGTTGTCTAATAATACTAAGTAATAAAAATAAGTTCATACAATATATTTTGAGAACATCATTTGGAGGCGGTAGATGGAGTCTGTTTATTATTAAACAATGCGAGATGACCCCTTAAATATTGAGAACATCAGTTGGAGGCGGCAGATGGAGTCTGTCTATTTAGCAATGGGACATGACTGTCAGTATCATCATATGTATATATATAATACATATAATATTATATAACACGATTTTTTTAAATTATTGGCCCGAAAATTAATCAGTGTAGACTGGATCCTCGAGAACCATTTAATTAATTTCTAATTTGGACCGATAGCCGTATAGTCCAGTCTATCTATAAGTTCAACTAACTCGTAACTATTACCATAACATATACTTCACTGCCCCAGATAAGGTTCCGATAAAAAGTTGTGCAGACTAAATTTATTTCAGTCTCCTCTTCACCACCAAAATGCCCTCCTACGAAGCGCGAGCTAACGTCCACAAGTCCGCCTTTGCCGCCCGAGTGCTCAAGCTCGTGGCAGCCAAGAAAACCAACCTGTGTGCTTCTCTGGATGTTACCACCACCAAGGAGCTCATTGAGCTTGCCGATAAGGTCGGACCTTATGTGTGCATGATCAAGACCCATATCGACATCATTGACGACTTCACCTACGCCGGAACTGTGCTCCCCCTCAAGGAACTTGCTCTTAAGCACGGTTTCTTCCTGTTCGAGGACAGAAAGTTCGCAGATATTGGCAACACTGTCAAGCACCAGTACAAGAACGGTGTCTACCGAATCGCCGAGTGGTCCGATATCACCAACGCCCACGGTGTACCCGGAACCGGAATCATTGCTGGCCTGCGAGCTGGTGCCGAGGAAACTGTCTCTGAACAGAAGAAGGAGGATGTCTCTGACTACGAGAACTCCCAGTACAAGGAGTTCCTGGTCCCCTCTCCCAACGAGAAGCTGGCCAGAGGTCTGCTCATGCTGGCCGAGCTGTCTTGCAAGGGCTCTCTGGCCACTGGCGAGTACTCCAAGCAGACCATTGAGCTTGCCCGATCCGACCCCGAGTTTGTGGTTGGCTTCATTGCCCAGAACCGACCTAAGGGCGACTCTGAGGACTGGCTTATTCTGACCCCCGGGGTGGGTCTTGACGACAAGGGAGATGCTCTCGGACAGCAGTACCGAACTGTTGAGGATGTCATGTCTACCGGAACGGATATCATAATTGTCGGCCGAGGTCTGTACGGCCAGAACCGAGATCCTATTGAGGAGGCCAAGCGATACCAGAAGGCTGGCTGGGAGGCTTACCAGAAGATTAACTGTTAGAGGTTAGACTATGGATATGTCATTTAACTGTGTATATAGAGAGCGTGCAAGTATGGAGCGCTTGTTCAGCTTGTATGATGGTCAGACGACCTGTCTGATCGAGTATGTATGATACTGCACAACCTGCGCTTGAGACCATCCGGTCTCTGATCTTAAT TAA pLD139(SEQ ID NO: 179)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACATAATGAACCCAAGGGAAAACTTCCTTAAGTGTTTTCTGCAGTACATCCCTAACAATGCAACAAACCTCAAGTTGGTGTACACTCAAAACAATCCACTCTATATGAGCGTGCTTAATAGCACAATCCACAACTTGCGCTTCACGTCAGATACTACGCCTAAGCCACTAGTGATCGTTACACCATCACACGTCAGCCATATTCAAGGAACGATCCTATGTCTGAAAAAGGTCGGGTTGCAAATCAGGACTCGATCAGGAGGGCACGATAGTGAGGGAATGAGTTACATCTCGCAAGTACCCTTCGTGATAGTTGACTTGCGAAATATGCGGTCTATTAAAATTGACGTACATAGCCAGACCGCCTGGGTTGAAGCAGGGGCAACCTTGGGTGAAGTTTATTACTGGGTCAATGAAAAAAACGAAAACCTAAGTCTTGCTGCTGGATATTGCCCCACCGTTTGCGCGGGTGGTCATTTTGGAGGCGGCGGATATGGTCCGTTGATGAGAAATTATGGACTTGCAGCAGACAATATTATAGATGCCCACTTGGTGAACGTTCATGGAAAGGTCTTGGACCGTAAGTCCATGGGTGAAGATCTTTTCTGGGCCTTGAGAGGTGGTGGAGCGGAATCGTTTGGCATCATCGTTGCCTGGAAAATTAGGTTGGTTGCGGTCCCGAAGAGTACAATGTTCTCCGTGAAGAAGATTATGGAAATACATGAGCTTGTCAAGTTAGTTAACAAGTGGCAAAATATCGCTTATAAGTATGATAAAGACTTGCTTTTGATGACTCATTTTATTACGCGAAACATAACCGATAACCAGGGCAAGAACAAGACTGCTATTCACACGTACTTCTCCTCTGTATTTCTTGGAGGAGTAGACTCCTTAGTTGACTTGATGAACAAGAGTTTCCCAGAATTGGGGATTAAGAAGACAGATTGCAGACAATTATCGTGGATAGATACAATCATATTCTATAGCGGTGTCGTCAATTACGATACTGATAATTTTAATAAAGAAATCCTCCTAGATCGTTCAGCTGGGCAAAACGGGGCATTCAAAATTAAATTGGATTATGTGAAGAAACCAATTCCAGAGCTGGTGTTTGTTCAGATATTGGAAAAACTTTACGAAGAAGACATTGGCGCAGGTATGTACGCTTTGTATCCATATGGAGGCATTATGGACGAGATCTCAGAGCTGGCGATCCCCTTCCCGCACAGAGCTGGGATACTCTACGAGCTATGGTACATCTGCTCTTGGGAGAAACAAGAAGACAACGAGAAACATCTCAATTGGATTCGGAACATATACAACTTTATGACCCCATACGTATCAAAAAACCCGCGCTTAGCATACTTGAATTACAGAGACTTAGATATCGGTATCAATGATCCTAAGAATCCTAACAATTACACCCAAGCCCGTATTTGGGGTGAGAAATATTTCGGCAAGAATTTTGACAGATTAGTTAAGGTCAAAACACTCGTGGACCCCAACAACTTTTTCCGAAACGAGCAGTCGATTCCACCACTACCCAGGCATAGACACGGAAGAAGGGCAAAGTTGTAAGAGTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCA TTCCGCCTGACCTpLD19 (SEQ ID NO: 180)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGGGTTTATCGTCAGTGTGCACTTTTTCTTTTCAAACAAACTACCACACCCTCCTAAACCCTCACAATAATAACCCAAAAACCTCCTTGCTATGTTACAGACATCCAAAGACACCGATCAAGTATTCATACAACAATTTTCCCAGTAAACATTGCTCAACGAAGTCCTTCCACTTGCAAAACAAATGCAGCGAATCATTGTCGATAGCTAAAAACTCGATACGTGCGGCAACCACTAACCAAACTGAGCCACCAGAGAGCGATAATCATTCAGTCGCCACCAAGATTTTGAACTTTGGAAAAGCCTGTTGGAAACTTCAAAGGCCTTACACCATTATCGCATTTACCAGTTGCGCATGTGGTTTGTTCGGGAAGGAATTATTACACAACACAAATTTGATCAGCTGGAGCCTAATGTTTAAGGCATTTTTCTTCTTAGTTGCAATTTTGTGTATAGCTTCGTTTACAACGACCATTAATCAGATTTACGACCTTCACATCGATCGGATCAATAAACCAGACTTGCCCCTTGCCTCTGGGGAAATCTCTGTAAATACTGCATGGATCATGCTGATAATCGTGGCTTTGTTTGGATTGATTATTACAATTAAGATGAAGGGGGGTCCATTATATATATTCGGGTACTGCTTCGGCATTTTCGGTGGTATCGTTTACTCCGTCCCACCCTTTAGATGGAAACAGAACCCCAGTACGGCCTTTCTACTCAATTTCTTGGCTCATATCATCACAAACTTCACATTCTATTATGCAAGCCGAGCGGCGCTTGGTTTGCCGTTCGAACTCAGACCGAGTTTTACATTTCTCCTTGCCTTCATGAAACTGATGGGACTGGCCCTTGCATTGATCAAGGATGCGTCAGATGTCGAAGGCGACACTAAGTTCGGCATTCTGACGCTTGCTTCCAAGTATGGAAGTAGAAATCTAACGCTTTTTTGTTCAGGAATAGTGCTACTTAGTTATGTTGCTGCTATACTCGCTGGCATTATTTGGCCTCAGGCCTTCAACTCTAACGTAATGTTGTTATCCCATGCTATTTTGGCGTTCTGGTTGATCTTGCAAACGCGAGATTTTGCACTCACTAACTACGACCCAGAGGCAGGAAGGCGCTTTTACGAGTTTATGTGGAAGTTGTATTATGCCGAATACTTGGTTTATGTTTTCATTTGATAAgagTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCC ATTCCGCCTGACCTpLD26 (SEQ ID NO: 181)TTAATTAATTCCGCTTAATGGAGTCCAAAAAGACCAACCTCTGCGCCTCGATCGACGTGACCACAACCGCCGAGTTCCTTTCGCTCATCGACAAGCTCGGTCCCCACATCTGTCTCGTGAAGACGCACATCGATATCATCTCAGACTTCAGCTACGAGGGCACGATTGAGCCGTTGCTTGTGCTTGCAGAGCGCCACGGGTTCTTGATATTCGAGGACAGGAAGTTTGCTGATATCGGAAACACCGTGATGTTGCAGTACACCTCGGGGGTATACCGGATCGCGGCGTGGAGTGACATCACGAACGCGCACGGAGTGACTGGGAAGGGCGTCGTTGAAGGGTTGAAACGCGGTGCGGAGGGGGTAGAAAAGGAAAGGGGCGTGTTGATGTTGGCGGAGTTGTCGAGTAAAGGCTCGTTGGCGCATGGTGAATATACCCGTGAGACGATCGAGATTGCGAAGAGTGATCGGGAGTTCGTGATTGGGTTCATCGCGCAGCGGGACATGGGGGGTAGAGAAGAAGGGTTTGATTGGATCATCATGACGCCTGGTGTGGGGTTGGATGATAAAGGCGATGCGTTGGGCCAGCAGTATAGGACTGTTGATGAGGTGGTTCTGACTGGTACCGATGTGATTATTGTCGGGAGAGGGTTGTTTGGAAAAGGAAGAGACCCTGAGGTGGAGGGAAAGAGATACAGGGATGCTGGATGGAAGGCATACTTGAAGAGAACTGGTCAGTTAGAATAAATATTGTAATAAATAGGTCTATATACATACACTAAGCTTCTAGGACGTCATTGTAGTCTTCGAAGTTGTCTGCTAGTTTAGTTCTCATGATTTCGAAAACCAATAACGCAATGGATGTAGCAGGGATGGTGGTTAGTGCGTTCCTGACAAACCCAGAGTACGCCGCCTCAAACCACGTCACATTCGCCCTTTGCTTCATCCGCATCACTTGCTTGAAGGTATCCACGTACGAGTTGTAATACACCTTGAAGAACGGCTTCGTCTAGTTCGGCATGGCAGATCATCATGCCTGCAGGAGCTCCAATTGTAATATTTCGGGAGAAATATCGTTGGGGTAAAACAACAGAGAGAGAGAGGGAGAGATGGTTCTGGTAGAATTATAATCTGGTTGTTGCAAATGCTACTGATCGACTCTGGCAATGTCTGTAGCTCGCTAGTTGTATGCAACTTAGGTGTTATGCATACACACGGTTATTCGGTTGAATTGTGGAGTAAAAATTGTCTGAGTTGTGTCTTAGCTACTGGCTGGCCCCCCGCGAAAGATAATCAAAATTACACTTGTGAATTTTTGCACACACACCGATTAACATTTCCCTTTTTTGTCCACCGATACACGCTTGCCTCTTCTTATTTTCTCTGTGCTTCCCCCTCCTGTGACTTTTTCCACCATTGATATAAAATCAACTCCATTTCCCTAAAATCTCCCCAGATTCTAAAAACAACTTCTTCTCTTCTGCTTTTCCTTATTTTTGTTATATTTATTTACCATCCCTTATTTTGAATAGTTATTCCCCACTAACATTGTTCAAATCTTCACGACataATGGCGGCAACCACTAACCAAACTGAGCCACCAGAGAGCGATAATCATTCAGTCGCCACCAAGATTTTGAACTTTGGAAAAGCCTGTTGGAAACTTCAAAGGCCTTACACCATTATCGCATTTACCAGTTGCGCATGTGGTTTGTTCGGGAAGGAATTATTACACAACACAAATTTGATCAGCTGGAGCCTAATGTTTAAGGCATTTTTCTTCTTAGTTGCAATTTTGTGTATAGCTTCGTTTACAACGACCATTAATCAGATTTACGACCTTCACATCGATCGGATCAATAAACCAGACTTGCCCCTTGCCTCTGGGGAAATCTCTGTAAATACTGCATGGATCATGCTGATAATCGTGGCTTTGTTTGGATTGATTATTACAATTAAGATGAAGGGGGGTCCATTATATATATTCGGGTACTGCTTCGGCATTTTCGGTGGTATCGTTTACTCCGTCCCACCCTTTAGATGGAAACAGAACCCCAGTACGGCCTTTCTACTCAATTTCTTGGCTCATATCATCACAAACTTCACATTCTATTATGCAAGCCGAGCGGCGCTTGGTTTGCCGTTCGAACTCAGACCGAGTTTTACATTTCTCCTTGCCTTCATGAAACTGATGGGACTGGCCCTTGCATTGATCAAGGATGCGTCAGATGTCGAAGGCGACACTAAGTTCGGCATTCTGACGCTTGCTTCCAAGTATGGAAGTAGAAATCTAACGCTTTTTTGTTCAGGAATAGTGCTACTTAGTTATGTTGCTGCTATACTCGCTGGCATTATTTGGCCTCAGGCCTTCAACTCTAACGTAATGTTGTTATCCCATGCTATTTTGGCGTTCTGGTTGATCTTGCAAACGCGAGATTTTGCACTCACTAACTACGACCCAGAGGCAGGAAGGCGCTTTTACGAGTTTATGTGGAAGTTGTATTATGCCGAATACTTGGTTTATGTTTTCATTTGATAAgagTGACTCTTTTGATAAGAGTCGCAAATTTGATTTCATAAGTATATATTCATTATGTAAAGTAGTAAATGGAAAATTCATTAAAAAAAAAGCAAATTTCCGTTGTATGCATACTCCGAACACAAAACTAGCCCCGGAAAAACCCTTAGTTGATAGTTGCGAATTTAGGTCGACCATATGCGACGGGTACAACGAGAATTGTATTGAATTGATCAAGAACATGATCTTGGTGTTACAGAACATCAAGTTCTTGGACCAGACTGAGAATGCACAGATATACAAGGCGTCATGTGATAAAATGGATGAGATTTATCCACAATTGAAGAAAGAGTTTATGGAAAGTGGTCAACCAGAAGCTAAACAGGAAGAAGCAAACGAAGAGGTGAAACAAGAAGAAGAAGGTAAATAAGTATTTTGTATTATATAACAAACAAAGTAAGGAATACAGATTTATACAATAAATTGCCATACTAGTCACGTGAGATATCTCATCCATTCCCCAACTCCCAAGAAAATAAAAAAGTGAAAAATAAAATCAAACCCAAAGATCAACCTCCCCATCATCATCGTCATCAAACCCCCAGCTCAATTCGCAATGGTTAGCACAAAAACATACACAGAAAGGGCATCAGCACACCCCTCCAAGGTTGCCCAACGTTTATTAATTAAAGGCTAGGTGGAGGCTCAGTGATGATAAGTCTGCGATGGTGGATGCATGTGTCATGGTCATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCAGAGGGCACAATCCTATTCCGCGCTATCCGACAATCTCCAAGACATTAGGTGGAGTTCAGTTCGGCGTATGGCATATGTCGCTGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAAATGGGTAGGGGGCTTCAAATCGTCCGCTCTGCCAGTGTTACAACCAATTAACAAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTATCAATACCATATTTTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTTCCATAGGATGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCGTCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAGCTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAACCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAATTACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAATCAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATCAGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCATCTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCCCATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCAGCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCCTTGTATTACTGTTTATGTAAGCAGACAGTTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAACATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCGCCGCTCTAGAACTAGTGGATCCAAATAAAACGAAAGGCTCAGTCGAAAGACTGGGCCTTTCGTTTTATCTGTTGTTTGTCGCATTATACGAGACGTCCAGGTTGGGATACCTGAAACAAAACCCATCGTACGGCCAAGGAAGTCTCCAATAACTGTGATCCACCACAAGCGCCAGGGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTCATGCATAATCCGCACGCATCTGGAATAAGGAAGTGCCATTCCGCCTGACCT

References including disclosure related to compartmentalization of anenzyme through signal sequences include the following, each of which isincorporated by reference herein in its entirety: Agarwal et al. 2001“Gene isolation and characterization of two acyl CoA oxidases fromsoybean with broad substrate specificities and enhanced expression inthe growing seedling axis.” Plant Mol Biol. 2001 November; 47(4):519-31;Alconado and Juarez 2006. “Acyl-CoA oxidase activity from Beauveriabassiana, an entomopathogenic fungus”. J Basic Microbiol. 2006;46(6):435-43; Aizpurua-Olaizola et al. “Identification andquantification of cannabinoids in Cannabis sativa L. plants by highperformance liquid chromatography-mass spectrometry.” Anal Bioanal Chem.2014 November; 406(29):7549-60; Backer et al. “Innovative developmentand validation of an HPLC/DAD method for the qualitative andquantitative determination of major cannabinoids in Cannabis plantmaterial.” J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec. 15;877(32):4115-24; Bakke et al. “N-ethylmaleimide-resistant acyl-coenzymeA oxidase from Arthrobacter ureafaciens NBRC 12140: molecular cloning,gene expression and characterization of the recombinant enzyme.” BiochimBiophys Acta. 2007 January; 1774(1):65-71; Barth and Gaillardin.“Physiology and genetics of the dimorphic fungus Yarrowia lipolytica.”FEMS Microbiol Rev. 1997 April; 19(4):219-37; Beggah et al. “Intra- andintermolecular events direct the propeptide-mediated maturation of theCandida albicans secreted aspartic proteinase Sap1p.” Microbiology. 2000November; 146 (Pt 11):2765-73; Brocard and Hartig. “Peroxisome targetingsignal 1: is it really a simple tripeptide?” Biochim Biophys Acta. 2006December; 1763(12):1565-73; Brown et al. “Aspergillus has distinct fattyacid synthases for primary and secondary metabolism: Proc Natl Acad SciUSA. 1996 Dec. 10; 93(25):14873-7; Carbalho et al. “Designingmicroorganisms for heterologous biosynthesis of cannabinoids.” FEMSYeast Res. 2017 Jun. 1; 17(4); Gagne et al. “Identification ofolivetolic acid cyclase from Cannabis sativa reveals a unique catalyticroute to plant polyketides.” Proc Natl Acad Sci USA. 2012 Jul. 31;109(31):12811-6; Gajewski et al. “Engineering fungal de novo fatty acidsynthesis for short chain fatty acid production.” Nat Commun. 2017 Mar.10; 8:14650; Gao et al. “Iterative integration of multiple-copy pathwaygenes in Yarrowia lipolytica for heterologous β-carotene production”.Metab Eng. 2017 May; 41:192-201; Gietz and Woods “Transformation ofYeast by Lithium Acetate/Single-Stranded Carrier DNA/Polyethylene GlycolMethod”. Methods Enzymol. 2002; 350:87-96; Hong et al. “EngineeringYarrowia lipolytica to express secretory invertase with strong FBA1INpromoter”. Yeast. 2012 February; 29(2):59-72; Hooks et al. “Long-chainacyl-CoA oxidases of Arabidopsis.” Plant J. 1999 October; 20(1):1-13;Hunkova and Fenci. “Toxic effects of fatty acids on yeast cells:dependence of inhibitory effects on fatty acid concentration.”Biotechnol Bioeng. 1977 November; 19(11):1623-41; Kistler and Boz“Cellular compartmentalization of secondary metabolism” Front.Microbiology February 2015; Klionsky et al. “Intracellular sorting andprocessing of a yeast vacuolar hydrolase: proteinase A propeptidecontains vacuolar targeting information.” Mol Cell Biol. 1988 May;8(5):2105-16; Krink-Koutsoubelis et al.” Engineered Production ofShort-Chain Acyl-Coenzyme A Esters in Saccharomyces cerevisiae.” ACSSynth Biol. 2018 Apr. 20; 7(4):1105-1115; Lametschwandtner et al. “Thedifference in recognition of terminal tripeptides as peroxisomaltargeting signal 1 between yeast and human is due to differentaffinities of their receptor Pex5p to the cognate signal and to residuesadjacent to it.” J Biol Chem. 1998 Dec. 11; 273(50):33635-43;Ledesma-Amaro and Nicaud. “Yarrowia lipolytica as a biotechnologicalchassis to produce usual and unusual fatty acids.” Prog Lipid Res. 2016January; 61:40-50; Liang et al. “Structure, mechanism and function ofprenyltransferase.” Eur J Biochem. 2002 July; 269(14):3339-54; Lui etal. “Membrane stress caused by octanoic acid in Saccharomycescerevisiae” Appl Microbiol Biotechnol. 2013 April; 97(7):3239-51; Luoet. al 2002 “The acyl-CoA oxidases from the yeast Yarrowia lipolytica:characterization of Aox2p.” Arch Biochem Biophys. November 1;407(1):32-8; Luo et al 2019 “Complete biosynthesis of cannabinoids andtheir unnatural analogues in yeast.” Nature. 2019 March;567(7746):123-126; Pamplaniyi “Identification, isolation, and functionalcharacterization of prenyltransferases in Cannabis sativa” DissertationDortmund 2016; Reiser et. al 2009 “AoxA is a major peroxisomal longchain fattyacyl-CoA oxidase required for beta-oxidation in A. nidulans”.Curr Genet. 2010 April; 56(2):139-50; Setoyama et. al 1995 “Functionalexpression of two forms of rat acyl-CoA oxidase and their substratespecificities” December 14; 217(2):482-7; Shimiu et al. “Type IIIPolyketide Synthases: Functional Classification and Phylogenomics.Chembiochem. 2017 Jan. 3; 18(1):50-65; Stout et al. “The hexanoyl-CoAprecursor for cannabinoid biosynthesis is formed by an acyl-activatingenzyme in Cannabis sativa trichomes.” Plant J. 2012 August;71(3):353-65; Tan et al. “Synthetic Pathway for the Production ofOlivetolic Acid in Escherichia coli”. ACS Synth Biol. 2018 Aug. 17;7(8):1886-1896; Taura et al. “Characterization of olivetol synthase, apolyketide synthase putatively involved in cannabinoid biosyntheticpathway.” FEBS Lett. 2009 Jun. 18; 583(12):2061-6; Zirpel et al.“Production of Δ9-tetrahydrocannabinolic acid from cannabigerolic acidby whole cells of Pichia (Komagataella) pastoris expressingΔ9-tetrahydrocannabinolic acid synthase from Cannabis sativa L.”Biotechnol Lett. 2015 September; 37(9):1869-75; Zirpel et al.“Optimization of Δ9-tetrahydrocannabinolic acid synthase production inKomagataella phaffii via post-translational bottleneck identification.”J Biotechnol. 2018 Apr. 20; 272-273:40-47; Zirpel “RecombinantExpression and Functional Characterization of Cannabinoid ProducingEnzymes in Komagataella phaffii” Dissertation Dortmund 2018; Yang et al“Structural basis for olivetolic acid formation by a polyketide cyclasefrom Cannabis sativa.” FEBS J. 2016 March; 283(6):1088-106; U.S. Pat.Nos. 7,851,199; 8,884,100; 9,546,362; 9,611,460; 9,765,308; 9,822,384;10,059,971; 10,287,557; U.S. Pat. Publ. No. 2014/0228586 A1; U.S. Pat.Publ. No. 2016/0010126 A1; U.S. Pat. Publ. No. 2016/0298151 A1; U.S.Pat. Publ. No. 2017/0211049 A1; U.S. Pat. Publ. No. 2018/0073043 A1;U.S. Pat. Publ. No. 2018/0155748 A1; U.S. Pat. Publ. No. 2018/0334692A1;PCT Publ. No. WO2017139496A1; PCT Publ. No. WO2018200888A1; PCT Publ.No. WO2018219995A1; PCT Publ. No. WO2018148849A1; PCT Publ. No.WO2018148848A1; and PCT Publ. No. WO2019071000A1.

Exemplary Methods, Microorganisms, and Compositions (e.g., Polyketides)

Method 1: A method, comprising: providing a microorganism selected fromthe group consisting of a fungi and a yeast, wherein the microorganismhas been modified to produce a polyketide in fermentation, wherein atleast one of the enzymes that mediate the polyketide production havebeen targeted to at least one compartment within a secretory pathwayresulting in an increase in secretion of the polyketide.

Method 2: Method 1, wherein the polyketide is a cannabinoid.

Method 3: Method 2, wherein the poleketide is a cannabinoid that isselected from the group consisting of cannabigerolic acid,Δ9-tetrahydrocannabinolic acid, cannabidiolic acid, cannabichromenicacid, cannabigerovarinic acid, tetrahydrocannabivarin acid,cannabidivarinic acid, and cannabichromevarinic acid.

Method 4: Method 1, wherein the polyketide is olivetolic acid.

Method 5: Method 1, wherein the microorganism is a yeast.

Method 6: Method 5, wherein the yeast is from a genus selected from thegroup consisting of Candida, Arxula, Pichia, Scheffersomyces,Kluyveromyces, Saccharomyces, Yarrowia, or Schizosaccharomyces.

Method 7: Method 5, wherein the yeast is a Candida viswanathii.

Method 8: Method 5, wherein the yeast is Arxula adeninivorans.

Method 9: Method 5, wherein the yeast is Yarrowia lipolytica.

Method 10: Method 1, wherein the microorganism is a fungi.

Method 11: Method 10, wherein the fungi is from a genus selected fromthe group consisting of Aspergillus, Trichoderma or Myceliophthora.

Method 12: Method 10, wherein the fungi is Aspergillus niger.

Method 13: Method 10, wherein the fungi is Aspergillus terreus.

Method 14: Method 10, wherein the fungi is Trichoderma harzianum.

Method 15: Method 10, wherein the fungi is Myceliophthora thermophila.

Method 16: Method 1, wherein the compartment within the secretorypathway is an endoplasmic reticulum.

Method 17: Method 1, wherein the compartment within the secretorypathway is a Golgi apparatus.

Method 18: Method 1, wherein the compartment within the secretorypathway is a vacuole.

Method 19: Method 1, wherein the compartment within the secretorypathway is an endosome.

Method 20: Method 1, wherein the enzyme is removed of its endogenousamino-terminal localization sequence and/or carboxyl-terminallocalization sequence.

Method 21: Method 16, whereby the enzyme has been modified with theN-terminal addition of the N-terminal 24 amino acids(MMWKFLIAIGLIFSYCCNAQLLDS) from OST1 and a C-terminal addition of theamino acids HDEL to localize the enzyme to the endoplasmic reticulum.

Method 22: Method 18, whereby the enzyme has been modified by anN-terminal addition of N-terminal 73 amino acids(MGITNETQALLGGDSLSCLNKKKSNTKRNLSYLLNIITVSIIAYLCFFATHNHHNDSGIPKVDPHKKKNIIMM) of PHO8 to localize the enzyme to the vacuole.

Method 23: Method 18, whereby the enzyme has been modified with theN-terminal fusion with Sna4 to localize the enzyme to the vacuole.

Method 24: Method 18, whereby the enzyme has been modified with theN-terminal addition of N-terminal 92 amino acids(MQLSLSVLSTVATALLSLTTAVDAKSHNIKLSKLSNEETLDASTFQEYTSSLANKYMNLFNAAHGNPTSFGLQHVLSNQEAEVPFVTPQKGG) from vacuolar aspartic protease tolocalize the enzyme to the vacuole.

Method 25: Method 19, whereby the enzyme has been modified with theN-terminal addition of N-terminal 305 amino acids from DOA4(MTLLLKPTSELDATSRKIIERIQSNSPTFQHLFDLLLNLLPFFDKTVSLLGSIGYCDYEVAYVTYQTCIQVVGLMKPKTNSLNQDIFKGVQLQTRKRASTFKAILSYFAEPETQEEDPLLNRFKSLSGGGSKTKSSQDEVFHEWITSSELQRELSSKKVLLIDFRPRKDYLNNHIKYKDLNHIEPTQLETLLDSASDQDLETLVKKSAPYDQYHIFLERHKYDLIVVYNYNYGSESTDRLLGIIDVVSKPNPFTKLITILMNNKYISSRLKKPLFLSGGVLNWYKTFGIEYLERTLVQNGV AHT) tolocalize the enzyme to an endosomal compartment.

Method 26: Method 17, whereby the enzyme has been modified with theN-terminal addition of N-terminal 81 amino acids ofbeta-galactosyltransferase(MRLREPLLSGSAAMPGASLQRACRLLVAVCALHLGVTLVYYLAGRDLSRLPQLVGVSTPLQGGSNSAAAIGQSSGELRTGG) to localize the enzyme to a Golgi compartment.

Method 27: Method 17, whereby the enzyme has been modified withN-terminal 34 amino acids of rat liver alpha-2,6-sialyltransferase(MIHTNLKKKFSLFILVFLLFAVICVWKKGSDYEA) to localize the enzyme to a Golgicompartment.

Method 28: Method 16 whereby the enzyme has been modified the N-terminaladdition of the N-terminal 31 amino acids(MKFGVLFSVFAAIVSALPLQEGPLNKRAYPS) from glucoamylase and a C-terminaladdition of the amino acids HDEL to localize the enzyme to theendoplasmic reticulum.

Method 29: Method 1, wherein the fermentation uses a fatty acid and/orsugar as a carbon source.

Method 30: Method 1, wherein the fermentation uses dextrose or sucroseas a carbon source.

Method 31: Method 1, wherein the enzyme is prenyltransferase.

Method 32: Method 1, wherein the enzyme is cannabidiolic acid synthase.

Method 33: Method 32, wherein the microorganism has been modified toexpress the protein sequence SEQ. ID *53, 54, 55 or 56.

Method 34: Method 1, wherein the enzyme is tetrahydrocannabidiolic acidsynthase.

Method 35: Method 34, wherein the microorganism has been modified toexpress the protein sequence SEQ. ID *58, 59, 60 or 61.

Method 36: Method 1, wherein the enzyme is cannabichromenic acidsynthase.

Microorganism 37: A microorganism selected from the group consisting ofa fungi and a yeast, wherein the microorganism has been modified toproduce a polyketide in fermentation, wherein at least one of theenzymes that mediate the polyketide production have been targeted to atleast one compartment within a secretory pathway resulting in anincrease in secretion of the one polyketide.

Microorganism 38: Microorganism 37, wherein the microorganism is ayeast.

Microorganism 39: Microorganism 38, wherein the yeast is from a genusselected from the group consisting of Candida, Arxula, Pichia,Scheffersomyces, Kluyveromyces, Saccharomyces, Yarrowia, orSchizosaccharomyces.

Microorganism 40: Microorganism 38, wherein the yeast is a Candidaviswanathii.

Microorganism 41: Microorganism 38, wherein the yeast is Arxulaadeninivorans.

Microorganism 42: Microorganism 38, wherein the yeast is Yarrowialipolytica.

Microorganism 43: Microorganism 37, wherein the microorganism is afungi.

Microorganism 44: Microorganism 43, wherein the fungi is from a genusselected from the group consisting of Aspergillus, Trichoderma orMyceliophthora.

Microorganism 45: Microorganism 43, wherein the fungi is Aspergillusniger.

Microorganism 46: Microorganism 43, wherein the fungi is Aspergillusterreus.

Microorganism 47: Microorganism 43, wherein the fungi is Trichodermaharzianum.

Microorganism 48: Microorganism 43, wherein the fungi is Myceliophthorathermophila.

Microorganism 49: Microorganism 37, wherein the polyketide is acannabinoid.

Microorganism 50: Microorganism 37, wherein the polyketide is selectedfrom the group consisting of cannabigerolic acid,Δ9-tetrahydrocannabinolic acid, cannabidiolic acid, cannabichromenicacid, cannabigerovarinic acid, tetrahydrocannabivarin acid,cannabidivarinic acid, and cannabichromevarinic acid.

Microorganism 51: Microorganism 37, wherein the polyketide is olivetolicacid.

Microorganism 52: Microorganism 37, wherein the compartment within thesecretory pathway is an endoplasmic reticulum.

Microorganism 53: Microorganism 37, wherein the compartment within thesecretory pathway is a Golgi apparatus.

Microorganism 54: Microorganism 37, wherein the compartment within thesecretory pathway is a vacuole.

Microorganism 55: Microorganism 37, wherein the compartment within thesecretory pathway is an endosome.

Microorganism 56: Microorganism 37, wherein the enzyme is removed of itsendogenous amino-terminal localization sequence and/or carboxyl-terminallocalization sequence.

Microorganism 57: Microorganism 52, whereby the enzyme has been modifiedwith the N-terminal addition of the N-terminal 24 amino acids(MMWKFLIAIGLIFSYCCNAQLLDS) from OST1 and a C-terminal addition of theamino acids FIDEL to localize the enzyme to the endoplasmic reticulum.

Microorganism 58: Microorganism 54, whereby the enzyme has been modifiedby an N-terminal addition of N-terminal 73 amino acids(MGITNETQALLGGDSLSCLNKKKSNTKRNLSYLLNIITVSIIALCFFTHNHHNDSGIPKVDPHKKKNIIMM) of PHO8 to localize the enzyme to the vacuole.

Microorganism 59: Microorganism 54, whereby the enzyme has been modifiedwith the N-terminal fusion with Sna4 to localize the enzyme to thevacuole.

Microorganism 60: Microorganism 54, whereby the enzyme has been modifiedwith the N-terminal addition of N-terminal 92 amino acids(MQLSLSVLSTVATALLSLTTAVDAKSHNIKLSKLSNEETLDASTFQEYTSSLANKYMNLFNAAHGNPTSFGLQHVLSNQEAEVPFVTPQKGG) from vacuolar aspartic protease tolocalize the enzyme to the vacuole.

Microorganism 61: Microorganism 55, whereby the enzyme has been modifiedwith the N-terminal addition of N-terminal 305 amino acids from DOA4(MTLLLKPTSELDATSRKIIERIQSNSPTFQHLFDLLLNLLPFFDKTVSLLGSIGYCDYEVAYVTYQTCIQVVGLMKPKTNSLNQDIFKGNQLQTRKRASTKAILSYFAEPETQEEDPLLNRFKSLSGGGSKTKSSQDEVFHEWITSSELQRELSSKKVLLIDFRPRKDYLNNHIKYKDLVHIEPTQLETLLDSASDQDLETLVKKSAPYDQYHIFLERHKYDLIVVYNYNYGSESTDRLLGIIDVVSKPNPFTKLITILMNNKYISSRLKVKPLFLSGGVLNWYKTFGIEYLERTLVQNGV AHT) tolocalize the enzyme to an endosomal compartment.

Microorganism 62: Microorganism 53, whereby the enzyme has been modifiedwith the N-terminal addition of N-terminal 81 amino acids ofbeta-galactosyltransferase(MRLREPLLSGSAAMPGASLQRACRLLVAVCALHLGVTLVYYLAGRDLSRLPQLVGVSTPLQGGSNSAAAIGQSSGELRTGG) to localize the enzyme to a Golgi compartment.

Microorganism 63: Microorganism 53, whereby the enzyme has been modifiedwith N-terminal 34 amino acids of rat liver alpha-2,6-sialyltransferase(MIHTNLKKKFSLFILVFLLFAVICVWKKGSDYEA) to localize the enzyme to a Golgicompartment.

Microorganism 64: Microorganism 52, whereby the enzyme has been modifiedthe N-terminal addition of the N-terminal 31 amino acids(MKFGVLFSVFAAIVSALPLQEGPLNKRAYPS) from glucoamylase and a C-terminaladdition of the amino acids HDEL to localize the enzyme to theendoplasmic reticulum.

Microorganism 65: Microorganism 37, wherein the fermentation uses afatty acid and/or sugar as a carbon source.

Microorganism 66: Microorganism 37, wherein the fermentation usesdextrose or sucrose as a carbon source.

Microorganism 67: Microorganism 37, wherein the enzyme isprenyltransferase.

Microorganism 68: Microorganism 37, wherein the enzyme is cannabidiolicacid synthase.

Microorganism 69: Microorganism 68, wherein the microorganism has beenmodified to express the protein sequence SEQ. ID *53, 54, 55 or 56.

Microorganism 70: Microorganism 37, wherein the enzyme istetrahydrocannabidiolic acid synthase.

Microorganism 71: Microorganism 70, wherein the microorganism has beenmodified to express the protein sequence SEQ. ID *58, 59, 60 or 61.

Microorganism 72: Microorganism 37, wherein the enzyme iscannabichromenic acid synthase.

Polyketide 73: A polyketide produced by any one of Methods 1-36.

Polyketide 74: A polyketide produced by any one of Microorganisms 37-72.

Method 75: A method, comprising: providing as a feedstock at least oneof a fatty acid, vegetable oil, or an alkane to a microorganism whichhas a modified beta-oxidation pathway, wherein the beta-oxidationpathway has been modified by a modification to produce a fatty acid or afatty acid-CoA that is a substrate for an acyl-CoA synthase or apolyketide synthase, respectively, wherein the microorganism produces apolyketide.

Method 76: Method 75, wherein at least one of an acyl-coA oxidase, enoylCoA hydratase, 3-hydroxyacyl-CoA dehydrogenase, B-ketothiolase orthiolase has been modified and/or replaced in the microorganism.

Method 77: Method 75, wherein the modification is one or more of adeletion, a mutation, a replacement, or an expression of one of acyl-coAoxidase, enoyl CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase,B-ketholiase, or thiolase.

Method 78: Method 75, wherein the modification is of acyl-coA oxidase.

Method 79: Method 75, wherein the microorganism has been modified toinclude wherein the microorganism has been modified to express theprotein sequence SEQ. ID 10.

Method 80: Method 75, wherein the feedstock is a fatty acid or avegetable oil.

Method 81: Method 80, wherein the fatty acid is selected from the groupconsisting of oleic acid, palmitic acid, stearic acid, linoleic acid,alpha-linolenic acid, palmitoleic acid, tridecanoic acid, pentadecanoicacid, and nonanoic acid.

Method 82: Method 80, wherein the vegetable oil is selected from thegroup consisting of palm oil, soybean oil, corn oil, canola oil, coconutoil, sunflower oil, olive oil, palm kernel oil, lard, castor oil, peanutoil, sesame oil, grapeseed, avocado oil, and flaxseed oil.

Method 83: Method 75, wherein the fatty acid is in a form of a methylester or ethyl ester.

Method 84: Method 75, wherein the alkane is selected from the groupconsisting of octadecane, hetadecane, hexadecane, pentadecane,tetradecane, tridecane, dodecane, and undecane.

Method 85: Method 75, wherein the polyketide synthase is a tetraketydesynthase.

Method 86: Method 75, wherein the polyketide synthase is TKS1 or TKS1p.

Method 87: Method 75, wherein the polyketide synthase is targeted to theperoxisome.

Method 88: Method 75, wherein an olivetolic acid synthase is expressed.

Method 89: Method 88, wherein the olivetolic acid synthase is CsOAC1.

Method 90: Method 88, where the olivetolic acid synthase is targeted tothe peroxisome.

Method 91: Method 75, wherein an endogenous acyl-coA oxidase has beenmutated.

Method 92: Method 75, wherein an endogenous acyl-coA oxidase has beenreplaced with a non-native acyl-coA oxidase.

Method 93: Method 92, wherein the non-native acyl-coA oxidase isselected from the group consisting of ACO1P, ACO2, ACO3, ACO4, ACO5,ACO6, ACO7, ACO8, ACO9 and ACO10.

Method 94: Method 75, wherein the polyketide is a cannabinoid.

Method 95: Method 75, wherein the polyketide is selected from the groupconsisting of cannabigerolic acid, Δ9-tetrahydrocannabinolic acid,cannabidiolic acid, cannabichromenic acid, cannabigerovarinic acid,tetrahydrocannabivarin acid, cannabidivarinic acid, andcannabichromevarinic acid.

Method 96: Method 75, wherein the polyketide is olivetolic acid.

Method 97: Method 75, wherein a polyketide synthase is expressed.

Method 98: Method 97, wherein the polyketide synthase is a tetraketydesynthase.

Method 99: Method 97, wherein the polyketide synthase is TKS1 or TKS1p

Method 100: Method 97, wherein the polyketide synthase is targeted tothe peroxisome

Method 101: Method 75, wherein an olivetolic acid synthase is expressed.

Method 102: Method 101, wherein the olivetolic acid synthase is CsOAC1

Method 103: Method 101, where the olivetolic acid synthase is targetedto the peroxisome.

Method 104: Method 75, wherein beta-oxidation has been modified.

Method 105: Method 104, wherein an endogenous acyl-coA oxidase has beenmutated.

Method 106: Method 104, wherein an endogenous acyl-coA oxidase has beenreplaced with a non-native acyl-coA oxidase.

Method 107: Method 106, wherein the non-native acyl-coA oxidase isselected from the group consisting of ACO1P, ACO2, ACO3, ACO4, ACO5,ACO6, ACO7, ACO8, ACO9, and ACO10.

Method 108: Method 75, wherein the microorganism is a yeast.

Method 109: Method 108, wherein the yeast is from a genus selected fromthe group consisting of Candida, Arxula, Pichia, Scheffersomyces,Kluyveromyces, Saccharomyces, Yarrowia, or Schizosaccharomyces.

Method 110: Method 108, wherein the yeast is a Candida viswanathii.

Method 111: Method 108, wherein the yeast is Arxula adeninivorans.

Method 112: Method 108, wherein the yeast is Yarrowia lipolytica.

Method 113: Method 75, wherein the microorganism is a fungi.

Method 114: Method 113, wherein the fungi is from a genus selected fromthe group consisting of Aspergillus, Trichoderma or Myceliophthora.

Method 115: Method 113, wherein the fungi is Aspergillus niger.

Method 116: Method 113, wherein the fungi is Aspergillus terreus.

Method 117: Method 113, wherein the fungi is Trichoderma harzianum.

Method 118: Method 113, wherein the fungi is Myceliophthora thermophila.

Microorganism 119: A microorganism, wherein the microorganism is a yeastor a fungi having a modified beta-oxidation pathway, wherein thebeta-oxidation pathway has been modified by a modification to produce afatty acid or a fatty acid-CoA that is a substrate for an acyl-CoAsynthase or a polyketide synthase, respectively, wherein themicroorganism produces a polyketide

Microorganism 120: Microorganism 119, wherein the microorganism is ayeast.

Microorganism 121: Microorganism 120, wherein the yeast is from a genusselected from the group consisting of Candida, Arxula, Pichia,Scheffersomyces, Kluyveromyces, Saccharomyces, Yarrowia, orSchizosaccharomyces.

Microorganism 122: Microorganism 120, wherein the yeast is a Candidaviswanathii.

Microorganism 123: Microorganism 120, wherein the yeast is Arxulaadeninivorans.

Microorganism 124: Microorganism 120, wherein the yeast is Yarrowialipolytica.

Microorganism 125: Microorganism 119, wherein the microorganism is afungi.

Microorganism 126: Microorganism 125, wherein the fungi is from a genusselected from the group consisting of Aspergillus, Trichoderma orMyceliophthora.

Microorganism 127: Microorganism 125, wherein the fungi is Aspergillusniger.

Microorganism 128: Microorganism 125, wherein the fungi is Aspergillusterreus.

Microorganism 129: Microorganism 125, wherein the fungi is Trichodermaharzianum.

Microorganism 130: Microorganism 125, wherein the fungi isMyceliophthora thermophila.

Microorganism 131: Microorganism 119, wherein at least one of anacyl-coA oxidase, enoyl CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase,B-ketholiase or thiolase has been modified and/or replaced in themicroorganism.

Microorganism 132: Microorganism 119, wherein the modification is one ormore of a deletion, a mutation, a replacement, or an expression of oneof acyl-coA oxidase, enoyl CoA hydratase, 3-hydroxyacyl-CoAdehydrogenase, B-ketholiase, or thiolase.

Microorganism 133: Microorganism 119, wherein the modification is ofacyl-coA oxidase.

Microorganism 134: Microorganism 119, wherein the microorganism has beenmodified to include SEQ. ID 10.

Microorganism 135: Microorganism 119, wherein the polyketide synthase isa tetraketyde synthase.

Microorganism 136: Microorganism 119, wherein the polyketide synthase isTKS1 or TKS1p.

Microorganism 137: Microorganism 119, wherein the polyketide synthase istargeted to the peroxisome.

Microorganism 138: Microorganism 119, wherein an olivetolic acidsynthase is expressed.

Microorganism 139: Microorganism 138, wherein the olivetolic acidsynthase is CsOAC1.

Microorganism 140: Microorganism 119, where the olivetolic acid synthaseis targeted to the peroxisome.

Microorganism 141: Microorganism 119, wherein an endogenous acyl-coAoxidase has been mutated.

Microorganism 142: Microorganism 119, wherein an endogenous acyl-coAoxidase has been replaced with a non-native acyl-coA oxidase.

Microorganism 143: Microorganism 142, wherein the non-native acyl-coAoxidase is selected from the group consisting of of ACO1P, ACO2, ACO3,ACO4, ACO5, ACO6, ACO7, ACO8, ACO9, and ACO10.

Microorganism 144: Microorganism 119, wherein the polyketide is acannabinoid.

Microorganism 145: Microorganism 119, wherein the polyketide is selectedfrom the group consisting of cannabigerolic acid,Δ9-tetrahydrocannabinolic acid, cannabidiolic acid, cannabichromenicacid, cannabigerovarinic acid, tetrahydrocannabivarin acid,cannabidivarinic acid, and cannabichromevarinic acid.

Microorganism 146: Microorganism 119, wherein the polyketide isolivetolic acid.

Polyketide 147: A polyketide produced by any one of Methods 75-118.

Polyketide 148: A polyketide produced by any one of Microorganisms119-146.

Method 149: A method, comprising: providing a microorganism that hasbeen modified to produce a polyketide; and providing the microorganismwith a C5-11 fatty acid ester in fermentation to yield a correspondingC5-9 fatty acid, wherein the C5-9 fatty acid is activated by an Acyl-CoAsynthase and is used as a substrate for a polyketide synthase, fromwhich the polyketide is obtained.

Method 150: Method 149, wherein the microorganism has been geneticallymodified.

Method 151: Method 149, wherein the polyketide is a cannabinoid.

Method 152: Method 151, wherein the cannabinoid is selected from thegroup consisting of cannabigerolic acid, Δ9-tetrahydrocannabinolic acid,cannabidiolic acid, cannabichromenic acid, cannabigerovarinic acid,tetrahydrocannabivarin acid, cannabidivarinic acid, andcannabichromevarinic acid.

Method 153: Method 149, wherein the polyketide is olivetolic acid.

Method 154: Method 149, wherein the microorganism is a yeast.

Method 155: Method 154, wherein the yeast is from a genus selected fromthe group consisting of Candida, Arxula, Pichia, Scheffersomyces,Kluyveromyces, Saccharomyces, Yarrowia, or Schizosaccharomyces.

Method 156: Method 154, wherein the yeast is a Candida viswanathii.

Method 157: Method 154, wherein the yeast is Arxula adeninivorans.

Method 158: Method 154, wherein the yeast is Yarrowia lipolytica.

Method 159: Method 149, wherein the microorganism is a fungi.

Method 160: Method 159, wherein the fungi is from a genus selected fromthe group consisting of Aspergillus, Trichoderma or Myceliophthora.

Method 162: Method 159, wherein the fungi is Aspergillus niger.

Method 163: Method 159, wherein the fungi is Aspergillus terreus.

Method 164: Method 159, wherein the fungi is Trichoderma harzianum.

Method 164: Method 159, wherein the fungi is Myceliophthora thermophila.

Method 165: Method 159, wherein the C₅₋₁₁ fatty acid ester is a C6 fattyacid ester.

Method 166: Method 159, wherein the C₅₋₁₁ fatty acid ester is an esterof an acid selected from the group consisting of pentanoic acid,hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoicacid, and undecanoic acid.

Method 167: Method 159, wherein the C₅₋₁₁ fatty acid ester is an esterselected from the group consisting of methyl ester, ethyl ester, andgenaryl ester.

Polyketide 168: A polyketide produced by any one of Methods 149-167.

The above description presents the best mode contemplated for carryingout the present invention, and of the manner and process of making andusing it, in such full, clear, concise, and exact terms as to enable anyperson skilled in the art to which it pertains to make and use thisinvention. This invention is, however, susceptible to modifications andalternate constructions from that discussed above that are fullyequivalent. Consequently, this invention is not limited to theparticular embodiments disclosed. On the contrary, this invention coversall modifications and alternate constructions coming within the spiritand scope of the invention as generally expressed by the followingclaims, which particularly point out and distinctly claim the subjectmatter of the invention. While the disclosure has been illustrated anddescribed in detail in the drawings and foregoing description, suchillustration and description are to be considered illustrative orexemplary and not restrictive.

All references cited herein are incorporated herein by reference intheir entirety. To the extent publications and patents or patentapplications incorporated by reference contradict the disclosurecontained in the specification, the specification is intended tosupersede and/or take precedence over any such contradictory material.

Unless otherwise defined, all terms (including technical and scientificterms) are to be given their ordinary and customary meaning to a personof ordinary skill in the art, and are not to be limited to a special orcustomized meaning unless expressly so defined herein. It should benoted that the use of particular terminology when describing certainfeatures or aspects of the disclosure should not be taken to imply thatthe terminology is being re-defined herein to be restricted to includeany specific characteristics of the features or aspects of thedisclosure with which that terminology is associated. Terms and phrasesused in this application, and variations thereof, especially in theappended claims, unless otherwise expressly stated, should be construedas open ended as opposed to limiting. As examples of the foregoing, theterm ‘including’ should be read to mean ‘including, without limitation,’‘including but not limited to,’ or the like; the term ‘comprising’ asused herein is synonymous with ‘including,’ ‘containing,’ or‘characterized by,’ and is inclusive or open-ended and does not excludeadditional, unrecited elements or method steps; the term ‘having’ shouldbe interpreted as ‘having at least;’ the term ‘includes’ should beinterpreted as ‘includes but is not limited to;’ the term ‘example’ isused to provide exemplary instances of the item in discussion, not anexhaustive or limiting list thereof; adjectives such as ‘known’,‘normal’, ‘standard’, and terms of similar meaning should not beconstrued as limiting the item described to a given time period or to anitem available as of a given time, but instead should be read toencompass known, normal, or standard technologies that may be availableor known now or at any time in the future; and use of terms like‘preferably,’ ‘preferred,’ ‘desired,’ or ‘desirable,’ and words ofsimilar meaning should not be understood as implying that certainfeatures are critical, essential, or even important to the structure orfunction of the invention, but instead as merely intended to highlightalternative or additional features that may or may not be utilized in aparticular embodiment of the invention. Likewise, a group of itemslinked with the conjunction ‘and’ should not be read as requiring thateach and every one of those items be present in the grouping, but rathershould be read as ‘and/or’ unless expressly stated otherwise. Similarly,a group of items linked with the conjunction ‘or’ should not be read asrequiring mutual exclusivity among that group, but rather should be readas ‘and/or’ unless expressly stated otherwise.

Where a range of values is provided, it is understood that the upper andlower limit, and each intervening value between the upper and lowerlimit of the range is encompassed within the embodiments.

With respect to the use of substantially any plural and/or singularterms herein, those having skill in the art can translate from theplural to the singular and/or from the singular to the plural as isappropriate to the context and/or application. The varioussingular/plural permutations may be expressly set forth herein for sakeof clarity. The indefinite article ‘a’ or ‘an’ does not exclude aplurality. A single processor or other unit may fulfill the functions ofseveral items recited in the claims. The mere fact that certain measuresare recited in mutually different dependent claims does not indicatethat a combination of these measures cannot be used to advantage. Anyreference signs in the claims should not be construed as limiting thescope.

It will be further understood by those within the art that if a specificnumber of an introduced claim recitation is intended, such an intentwill be explicitly recited in the claim, and in the absence of suchrecitation no such intent is present. For example, as an aid tounderstanding, the following appended claims may contain usage of theintroductory phrases ‘at least one’ and ‘one or more’ to introduce claimrecitations. However, the use of such phrases should not be construed toimply that the introduction of a claim recitation by the indefinitearticles ‘a’ or ‘an’ limits any particular claim containing suchintroduced claim recitation to embodiments containing only one suchrecitation, even when the same claim includes the introductory phrases‘one or more’ or ‘at least one’ and indefinite articles such as ‘a’ or‘an’ (e.g., ‘a’ and/or ‘an’ should typically be interpreted to mean ‘atleast one’ or ‘one or more’); the same holds true for the use ofdefinite articles used to introduce claim recitations. In addition, evenif a specific number of an introduced claim recitation is explicitlyrecited, those skilled in the art will recognize that such recitationshould typically be interpreted to mean at least the recited number(e.g., the bare recitation of ‘two recitations,’ without othermodifiers, typically means at least two recitations, or two or morerecitations). Furthermore, in those instances where a conventionanalogous to ‘at least one of A, B, and C, etc.’ is used, in generalsuch a construction is intended in the sense one having skill in the artwould understand the convention (e.g., ‘a system having at least one ofA, B, and C’ would include but not be limited to systems that have Aalone, B alone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). In those instances where aconvention analogous to ‘at least one of A, B, or C, etc.’ is used, ingeneral such a construction is intended in the sense one having skill inthe art would understand the convention (e.g., ‘a system having at leastone of A, B, or C’ would include but not be limited to systems that haveA alone, B alone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). It will be furtherunderstood by those within the art that virtually any disjunctive wordand/or phrase presenting two or more alternative terms, whether in thedescription, claims, or drawings, should be understood to contemplatethe possibilities of including one of the terms, either of the terms, orboth terms. For example, the phrase ‘A or B’ will be understood toinclude the possibilities of ‘A’ or ‘B’ or ‘A and B.’

All numbers expressing quantities of ingredients, reaction conditions,and so forth used in the specification are to be understood as beingmodified in all instances by the term ‘about.’ Accordingly, unlessindicated to the contrary, the numerical parameters set forth herein areapproximations that may vary depending upon the desired propertiessought to be obtained. At the very least, and not as an attempt to limitthe application of the doctrine of equivalents to the scope of anyclaims in any application claiming priority to the present application,each numerical parameter should be construed in light of the number ofsignificant digits and ordinary rounding approaches.

Furthermore, although the foregoing has been described in some detail byway of illustrations and examples for purposes of clarity andunderstanding, it is apparent to those skilled in the art that certainchanges and modifications may be practiced. Therefore, the descriptionand examples should not be construed as limiting the scope of theinvention to the specific embodiments and examples described herein, butrather to also cover all modification and alternatives coming with thetrue scope and spirit of the invention.

What is claimed is:
 1. A method of isolating a polyketide, the methodcomprising: providing as a feedstock at least one of a fatty acid,vegetable oil, or an alkane to a genetically modified yeast, thegenetically modified yeast comprising modified enzymes for producing thepolyketide in the peroxisome, and the modified enzymes comprisingacyl-CoA oxidase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase,beta-ketothiolase, thiolase, acyl-CoA synthase, and Type III polyketidesynthase, wherein each modified enzyme comprises a peroxisomal targetingsequence, and wherein each modified enzyme is localized to theperoxisome; culturing the genetically modified yeast under conditionssufficient to produce in the peroxisome a fatty acid or a fatty acid-CoAthat is a substrate for an acyl-CoA synthase or a polyketide synthase,respectively; and isolating the polyketide from the genetically modifiedyeast.
 2. The method of claim 1, wherein the acyl-CoA oxidase comprisesthe protein sequence as set forth in SEQ ID NO:
 10. 3. The method ofclaim 1, wherein the Type III polyketide synthase is a tetraketidesynthase.
 4. The method of claim 1, wherein the Type III polyketidesynthase is TKS1 or TKS1p.
 5. The method of claim 1, wherein anolivetolic acid synthase is expressed in the peroxisome.
 6. The methodof claim 1, wherein an endogenous acyl-coA oxidase has been replacedwith a non-native acyl-coA oxidase.
 7. The method of claim 1, whereinthe polyketide is selected from the group consisting of cannabigerolicacid, Δ9-tetrahydrocannabinolic acid, cannabidiolic acid,cannabichromenic acid, cannabigerovarinic acid, tetrahydrocannabivarinacid, cannabidivarinic acid, and cannabichromevarinic acid.
 8. Themethod of claim 1, wherein the yeast is from a genus selected from thegroup consisting of Candida, Arxula, Pichia, Scheffersomyces,Kluyveromyces, Saccharomyces, Yarrowia, and Schizosaccharomyces.
 9. Themethod of claim 1, wherein the yeast is from a genus of Candida.
 10. Themethod of claim 1, wherein the polyketide is olivetolic acid or hexanoicacid.
 11. The method of claim 1, wherein the peroxisomal targetingsequence has a consensus sequence of [S/A/H/C/E/P/Q/V]-[K/R/H/Q]-[L/F]as set forth in SEQ ID NO:
 7. 12. The method of claim 1, wherein theperoxisomal targeting sequence is GRRAKL as set forth in SEQ ID NO: 6,added to the carboxyl-terminus of the modified enzyme.
 13. A method ofproducing olivetolic acid in a peroxisome, the method comprising:providing as a feedstock a fatty acid to a genetically modified yeast,the genetically modified yeast comprising modified enzymes comprisingacyl-CoA oxidase, enoyl-CoA hydratase, 3-hydroxyacyl-CoA dehydrogenase,beta-ketothiolase, thiolase, acyl-CoA synthase, and Type III polyketidesynthase, wherein each modified enzyme comprises a peroxisomal targetingsequence, and wherein each modified enzyme is localized to theperoxisome for producing the olivetolic acid in the peroxisome;culturing the microorganism under conditions sufficient to produce inthe peroxisome olivetolic acid; and isolating the olivetolic acid.